Professor John McMurray
- Professor of Cardiology (Cardiovascular & Metabolic Health)
telephone:
01413303479
email:
John.McMurray@glasgow.ac.uk
RC217Level C2, School of Cardiovascular and Metabolic Health, BHF Glasgow CRC, Glasgow G12 8TA
https://orcid.org/0000-0002-6317-3975Biography
John McMurray OBE, BSC (Hons), MB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FMedSci
Professor McMurray is currently Professor of Medical Cardiology and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.
Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011. He is a Past-President of the Heart Failure Association of the ESC.
He is a Highly Cited Researcher (https://recognition.webofscience.com/awards/highly-cited/2021/) and has a H-index of >200 (https://scholar.google.com/citations?user=n0ZdRMoAAAAJ&hl=en). He is and has been involved in many guideline committees, including chairing the Task Force for 2012 ESC Guidelines on heart failure and was a member of the 2016 and 2021 Task Forces. Professor McMurray is an Associate Editor for JACC-Heart Failure and is also a member of the editorial board of several journals including the European Journal of Heart Failure, Diabetes Care and the New England Journal of Medicine, and Guest Editor for Circulation & Circulation: Heart Failure. He is the Congress Programme Committee Chair for the European Society of Cardiology 2023/2024 and European Society of Cardiology Board Member.
Professor McMurray was a member of the recent European Society of Cardiology (ESC) Task Force that created a policy on gender https://www.escardio.org/static-file/Escardio/About%20the%20ESC/Documents/European%20Society%20of%20Cardiology%20Gender%20Policy.pdf and the NEJM policy group on diversity in research studies https://www.nejm.org/doi/full/10.1056/NEJMe2114651
He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases).
Professor McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognises outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition.
Professor McMurray was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”. In 2021 Professor McMurray received the Rigshospitalet’s International KFJ Award. In 2023 he was made an honorary fellow of the Japanese Circulation Society. Professor McMurray has been invited to lecture widely at many international congresses and delivered many several named lectures.
Research interests
Research Theme: Cardiac Diseases
Prof McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials. He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including the completed CHARM-Added, CORONA, I-Preserve, EMPHASIS-HF, PARADIGM-HF, ATMOSPHERE, Harmony-Outcomes, PARAGON-HF, GALACTIC-HF, DAPA-HF, DAPA-CKD, ASCEND-D and -ND trials, DELIVER, the ongoing FINEARTS-HF trial and the recently announced FINALITY trial.
DAPA-HF trial website: www.dapatrial.org
DELIVER trial website: www.delivertrial.org
He has been a member and chair of many guideline committees and the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition, he was a member of the 2008 ESC HF Guidelines Task Force, and Chair of the 2012 Task Force and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee and the 2014 National Institute for Health and Care Excellence (NICE) Acute HF Guideline Committee.
He is a member of NICE Appraisal Committee A and a member of the editorial board of the New England Journal of Medicine and sit on the editorial board of several leading cardiovascular journals, including the European Heart Journal (Associate Editor) and Circulation.
In 2013, Prof McMurray was identified as one of the 400 most influential biomedical researchers in the world and the only cardiovascular researcher on this list from the UK (Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers,1996-2011. Eur J Clin Invest. 2013; 43:1339-65). I have also been included in the 2014, 2016, 2017 and 2018 Highly Cited Researchers listing and one of The World's Most Influential Scientific Minds: 2014 by Thomson Reuters.
Google Scholar
https://www.webofscience.com/wos/author/record/B-2467-2013
https://research.com/scientists-rankings/best-scientists/gb
Research groups
Publications
2024
Osmanska, J., Petrie, M. C. , Docherty, K. F. , Lee, M. M.Y. , McMurray, J. J.V. and Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083) (Accepted for Publication)
Lu, H. et al. (2024) Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the PARADIGM‐HF and PARAGON‐HF trials. European Journal of Heart Failure, (doi: 10.1002/ejhf.3487) (PMID:39439294) (Early Online Publication)
Docherty, K. F. et al. (2024) Wearable accelerometer-derived measures of physical activity in heart failure: insights from the DETERMINE trials. Journal of Cardiac Failure, (Accepted for Publication)
Chatur, S. et al. (2024) Sacubitril/valsartan in patients with heart failure and deterioration in eGFR to <30 mL/min/1.73 m2. JACC: Heart Failure, 12(10), pp. 1692-1703. (doi: 10.1016/j.jchf.2024.03.014) (PMID:38842957)
Docherty, K. F. et al. (2024) Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials. Circulation: Heart Failure, 17(10), e012349. (doi: 10.1161/CIRCHEARTFAILURE.124.012349) (PMID:39212948) (PMCID:PMC11472896)
Wang, X. et al. (2024) Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE‐MI echocardiographic substudy. European Journal of Heart Failure, (doi: 10.1002/ejhf.3472) (PMID:39315586) (Early Online Publication)
Jhund, P. S. et al. (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet, 404(10458), pp. 1119-1131. (doi: 10.1016/S0140-6736(24)01733-1) (PMID:39232490)
Pabon, M. A. et al. (2024) In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3410) (PMID:39300780) (Early Online Publication)
Lu, H. et al. (2024) Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3414) (PMID:39217577) (Early Online Publication)
Abdin, A. et al. (2024) Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: an analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, 26(9), pp. 1952-1963. (doi: 10.1002/ejhf.3350) (PMID:39016033)
Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)
Butt, J. H. et al. (2024) Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. Circulation, (doi: 10.1161/circulationaha.124.071110) (PMID:39217458) (Accepted for Publication)
Mc Causland, F. R. et al. (2024) Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI. European Journal of Heart Failure, 26(9), pp. 1984-1992. (doi: 10.1002/ejhf.3386) (PMID:39056455)
Matsumoto, S. et al. (2024) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.3383) (PMID:39215677) (Early Online Publication)
Yang, M. et al. (2024) Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment. European Journal of Heart Failure, (doi: 10.1002/ejhf.3417) (PMID:39169481) (Early Online Publication)
Butt, J. H. et al. (2024) Anthropometric measures and long‐term mortality in non‐ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox. European Journal of Heart Failure, (doi: 10.1002/ejhf.3424) (PMID:39155576) (Early Online Publication)
Cleland, J. et al. (2024) The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Journal of the American College of Cardiology, (Accepted for Publication)
Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)
Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)
Kondo, T. et al. (2024) Low natriuretic peptide levels and outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 12(8), pp. 1442-1455. (doi: 10.1016/j.jchf.2024.04.027) (PMID:38904646)
Lam, C. S.P. et al. (2024) Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial. European Journal of Heart Failure, 26(8), pp. 1727-1735. (doi: 10.1002/ejhf.3294) (PMID:38783712)
Lassen, M. C.H. et al. (2024) Cardiovascular‐kidney‐metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON‐HF. European Journal of Heart Failure, 26(8), pp. 1762-1774. (doi: 10.1002/ejhf.3304) (PMID:38932589)
Matsumoto, S. et al. (2024) Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. Journal of Cardiology, 84(2), pp. 133-140. (doi: 10.1016/j.jjcc.2023.11.005) (PMID:38000538)
O'Hara, D. V., Lam, C. S.P., McMurray, J. J.V. , Yi, T. W., Hocking, S., Dawson, J., Raichand, S., Januszewski, A. S. and Jardine, M. J. (2024) Applications of SGLT2 inhibitors beyond glycaemic control. Nature Reviews Nephrology, 20(8), pp. 513-529. (doi: 10.1038/s41581-024-00836-y) (PMID:38671190)
Yang, M. et al. (2024) Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 26(8), pp. 1788-1803. (doi: 10.1002/ejhf.3352) (PMID:38923118)
Zahir Anjum, D. et al. (2024) Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study. European Journal of Heart Failure, 26(8), pp. 1717-1726. (doi: 10.1002/ejhf.3249) (PMID:38700461)
Espersen, C. et al. (2024) Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, 132036. (doi: 10.1016/j.ijcard.2024.132036) (PMID:38599465)
Ostrominski, J. W. et al. (2024) Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction a trial-level analysis. Journal of the American College of Cardiology, 84(2), pp. 223-228. (doi: 10.1016/j.jacc.2024.05.005) (PMID:38744407)
Yang, M. et al. (2024) Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, 26(7), pp. 1524-1538. (doi: 10.1002/ejhf.3263) (PMID:38700986)
Conrad, N. et al. (2024) Temporal trends and patterns in cardiovascular disease incidence: a population-based study in 22 million individuals. British Medical Journal, 385, e078523. (doi: 10.1136/bmj-2023-078523) (PMID:38925788) (PMCID:PMC11203392)
Shen, L. et al. (2024) Revisiting race and the benefit of RAS blockade in heart failure. A meta-analysis of randomized clinical trials. JAMA: Journal of the American Medical Association, 331(24), 2094. (doi: 10.1001/jama.2024.6774) (PMID:38809561)
Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)
Friday, J. M. et al. (2024) Loop diuretic utilisation with or without heart failure: impact on prognosis. European Heart Journal, (doi: 10.1093/eurheartj/ehae345) (PMID:38845446) (Early Online Publication)
Chatur, S. et al. (2024) Effects of sacubitril/valsartan across the spectrum of renal impairment in patients with heart failure. Journal of the American College of Cardiology, 83(22), pp. 2148-2159. (doi: 10.1016/j.jacc.2024.03.392) (PMID:38588927)
Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)
Pabón, M. A. et al. (2024) Sex differences in heart failure with improved ejection fraction. JACC: Heart Failure, 12(6), pp. 1119-1122. (doi: 10.1016/j.jchf.2024.03.011) (PMID:38661586)
Solomon, S. D. et al. (2024) Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial. European Journal of Heart Failure, 26(6), pp. 1334-1346. (doi: 10.1002/ejhf.3266) (PMID:38733212)
Vaduganathan, M. et al. (2024) Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial. European Journal of Heart Failure, 26(6), pp. 1324-1333. (doi: 10.1002/ejhf.3253) (PMID:38742248)
Kondo, T. et al. (2024) Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83(20), pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385) (PMID:38537918)
Davis, J. A., Booth, D., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2024) Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data. European Journal of Heart Failure, 26(3), pp. 664-673. (doi: 10.1002/ejhf.3197) (PMID:38509642)
Lassen, M. C. H. et al. (2024) Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: a pre‐specified analysis of the DELIVER trial. European Journal of Heart Failure, 26(7), pp. 1539-1548. (doi: 10.1002/ejhf.3269) (PMID:38745498)
Foà, A. et al. (2024) Sacubitril/Valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 83(18), pp. 1731-1739. (doi: 10.1016/j.jacc.2024.02.035) (PMID:38537919)
McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)
Gilbert, M. P., Skelly, J., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J.V. , Del Prato, S. and Pratley, R. E. (2024) Effect of albiglutide on cardiovascular outcomes in older adults: a post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 26(5), pp. 1714-1722. (doi: 10.1111/dom.15479) (PMID:38317618)
Kondo, T. et al. (2024) A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nature Medicine, 30(5), pp. 1432-1439. (doi: 10.1038/s41591-024-02941-8) (PMID:38710952) (PMCID:PMC11108780)
Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
Heerspink, H. J.L. et al. (2024) Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria. American Heart Journal, 270, pp. 125-135. (doi: 10.1016/j.ahj.2024.02.006) (PMID:38367893)
Minamisawa, M. et al. (2024) Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: the PARAGON‐HF study. European Journal of Heart Failure, 26(4), pp. 871-881. (doi: 10.1002/ejhf.3167) (PMID:38369856)
Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, 30(4), pp. 618-623. (doi: 10.1016/j.cardfail.2023.11.020) (PMID:38122924)
Peikert, A. et al. (2024) Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER Trial. JACC: Heart Failure, 12(4), pp. 631-644. (doi: 10.1016/j.jchf.2023.09.007) (PMID:37767674)
Peikert, A. et al. (2024) Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, 26(4), pp. 912-924. (doi: 10.1002/ejhf.3184) (PMID:38487939)
Knigge, P. et al. (2024) Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016. Journal of the American Heart Association, 13(6), e032539. (doi: 10.1161/JAHA.123.032539) (PMID:38471834) (PMCID:PMC11009989)
Bhatt, A. S. et al. (2024) Cost effectiveness of dapagliflozin for heart failure across the spectrum of ejection fraction: an economic evaluation based on pooled, individual participant data from the DELIVER and DAPA-HF trials. Journal of the American Heart Association, 13(5), e032279. (doi: 10.1161/JAHA.123.032279) (PMID:38390793) (PMCID:PMC10944049)
Mann, D. L. et al. (2024) Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI. Journal of the American College of Cardiology, 83(9), pp. 904-914. (doi: 10.1016/j.jacc.2024.01.002) (PMID:38418004)
Adamo, M. et al. (2024) Tricuspid regurgitation and clinical outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 12(3), pp. 552-563. (doi: 10.1016/j.jchf.2023.11.018) (PMID:38300212)
Dimond, M. G. et al. (2024) Left ventricular ejection fraction and the future of heart failure phenotyping. JACC: Heart Failure, 12(3), pp. 451-460. (doi: 10.1016/j.jchf.2023.11.005) (PMID:38099892)
Butt, J. H. et al. (2024) Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER. Journal of Cardiac Failure, 30(3), pp. 436-448. (doi: 10.1016/j.cardfail.2023.08.027) (PMID:38104937)
Ferguson, L. D. , Molenberghs, G., Verbeke, G., Rahimi, K., Rao, S., McInnes, I. B. , McMurray, J. J.V. , Sattar, N. and Conrad, N. (2024) Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatology, 6(3), e156-e167. (doi: 10.1016/S2665-9913(23)00338-7)
Wang, X. et al. (2024) Effects of dapagliflozin in patients in Asia: a post hoc subgroup analysis from the DELIVER trial. JACC: Asia, 4(2), pp. 108-118. (doi: 10.1016/j.jacasi.2023.10.005) (PMID:38371292) (PMCID:PMC10866733)
Brum, W. S., Docherty, K. F. , Ashton, N. J., Zetterberg, H., Hansson, O., McMurray, J. J. V. and Blennow, K. (2024) Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81(2), pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719) (PMID:38109077) (PMCID:PMC10728797)
Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)
Owen, R. et al. (2024) Sex differences in the clinical presentation and natural history of dilated cardiomyopathy. JACC: Heart Failure, 12(2), pp. 352-363. (doi: 10.1016/j.jchf.2023.10.009) (PMID:38032570) (PMCID:PMC10857810)
Vart, P. et al. (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 79(2), glad181. (doi: 10.1093/gerona/glad181) (PMID:37527836) (PMCID:PMC10809037)
Vardeny, O. et al. (2024) Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiology, 9(3), pp. 283-289. (doi: 10.1001/jamacardio.2023.5318) (PMID:38265835) (PMCID:PMC10809142)
Omerovic, E. et al. (2024) Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation. Trials, 25, 80. (doi: 10.1186/s13063-024-07935-y) (PMID:38263138) (PMCID:PMC10807265)
Petrie, M. C. et al. (2024) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, 149(4), pp. 335-38. (doi: 10.1161/CIRCULATIONAHA.123.066163) (PMID:38252738)
Docherty, K. F. et al. (2024) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, 30(1), pp. 26-35. (doi: 10.1016/j.cardfail.2023.08.020) (PMID:37683911)
Lala, A. et al. (2024) Standardized definitions for evaluation of acute decompensated heart failure therapies: HF-ARC expert panel paper. JACC: Heart Failure, 12(1), pp. 1-15. (doi: 10.1016/j.jchf.2023.09.030) (PMID:38069997)
Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)
McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)
Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)
Pellicori, P. et al. (2024) Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS‐986231). European Journal of Heart Failure, 26(1), pp. 142-151. (doi: 10.1002/ejhf.3077) (PMID:37990754)
Schou, M. et al. (2024) Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial. European Journal of Heart Failure, 26(1), pp. 130-139. (doi: 10.1002/ejhf.3079) (PMID:37933184)
2023
Jackson, A. M. et al. (2023) A 20-year population study of peripartum cardiomyopathy. European Heart Journal, 44(48), pp. 5128-5141. (doi: 10.1093/eurheartj/ehad626) (PMID:37804234) (PMCID:PMC10733720)
Ostrominski, J. W. et al. (2023) Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial. Circulation, 148(24), pp. 1945-1957. (doi: 10.1161/CIRCULATIONAHA.123.065254) (PMID:37830208)
McMurray, J. J.V. et al. (2023) Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, (doi: 10.1161/CIRCULATIONAHA.123.065061) (PMID:38059368) (Early Online Publication)
Bhatt, A. S. et al. (2023) Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal of Heart Failure, 25(12), pp. 2177-2188. (doi: 10.1002/ejhf.3043) (PMID:37771274)
Fletcher, R. A. et al. (2023) Effect of SGLT2 inhibitors on discontinuation of renin–angiotensin system blockade: A joint analysis of the CREDENCE and DAPA-CKD trials. Journal of the American Society of Nephrology, 34(12), pp. 1965-1975. (doi: 10.1681/ASN.0000000000000248) (PMID:37876229)
Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)
Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)
Pabon, M. et al. (2023) Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial. JACC: Heart Failure, 11(12), pp. 1729-1738. (doi: 10.1016/j.jchf.2023.07.029) (PMID:37831045)
Vardeny, O. et al. (2023) Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 29(12), p. 3269. (doi: 10.1038/s41591-023-02302-x) (PMID:36932245)
Zahir Anjum, D. et al. (2023) Initiation of medical therapy for heart failure patients according to kidney function: a Danish nationwide study. Clinical Epidemiology, 15, pp. 855-866. (doi: 10.2147/clep.s412787) (PMID:37489222) (PMCID:PMC10363354)
Chatur, S. et al. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793)
Mc Causland, F. R. et al. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176)
Chatur, S. et al. (2023) Dapagliflozin in patients with heart failure and deterioration in renal function. Journal of the American College of Cardiology, 82(19), pp. 1854-1863. (doi: 10.1016/j.jacc.2023.08.026) (PMID:37634707)
Leong, D. P. et al. (2023) Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries. European Heart Journal, 44(42), pp. 4435-4444. (doi: 10.1093/eurheartj/ehad595) (PMID:37639487) (PMCID:PMC10635666)
Ostrominski, J. W. et al. (2023) Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 11(11), pp. 1491-1503. (doi: 10.1016/j.jchf.2023.05.015) (PMID:37226448)
Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Heart Journal, 44(41), pp. 4310-4320. (doi: 10.1093/eurheartj/ehad476) (PMID:37632756)
Bhatt, A. S. et al. (2023) Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiology, 8(11), pp. 1041-1048. (doi: 10.1001/jamacardio.2023.3216) (PMID:37755814)
Burger, P. M. et al. (2023) Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. European Journal of Heart Failure, 25(11), pp. 1962-1975. (doi: 10.1002/ejhf.3028) (PMID:37691140)
Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)
Heerspink, H. J. L. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309)
Kondo, T. et al. (2023) Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials. NEJM Evidence, 2(11), (doi: 10.1056/EVIDoa2300042)
Ostrominski, J. W. et al. (2023) Duration of heart failure with preserved ejection fraction and outcomes with sacubitril/valsartan: insights from the PARAGON-HF trial. Journal of Cardiac Failure, 29(11), pp. 1494-1503. (doi: 10.1016/j.cardfail.2023.05.003) (PMID:37220823)
Vissing, C. R. et al. (2023) Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial. JAMA Cardiology, 8(11), pp. 1083-1088. (doi: 10.1001/jamacardio.2023.2808) (PMID:37672268)
McDonagh, T. A. et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 44(37), pp. 3627-3639. (doi: 10.1093/eurheartj/ehad195) (PMID:37622666)
Rohde, L. E. and McMurray, J. J.V. (2023) REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed. European Heart Journal, 44(37), pp. 3652-3654. (doi: 10.1093/eurheartj/ehad488) (PMID:37525996)
Bozkurt, B., Desai, A. S., Ahmad, T., Deswal, A., Heidenreich, P. A., Ibrahim, N. E., McMurray, J. , Pinney, S. P., Vaduganathan, M. and Walsh, M. N. (2023) As we embark on a second year. JACC: Heart Failure, 11(10), pp. 1466-1469. (doi: 10.1016/j.jchf.2023.09.001) (PMID:37793737)
Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)
Lam, C. S.P., Docherty, K. F. , Ho, J. E., McMurray, J. J.V. , Myhre, P. L. and Omland, T. (2023) Recent successes in heart failure treatment. Nature Medicine, 29(10), pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2) (PMID:37814060)
Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)
Peikert, A. et al. (2023) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC: Heart Failure, 11(10), pp. 1380-1393. (doi: 10.1016/j.jchf.2023.05.014) (PMID:37294244)
Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 25(10), pp. 1831-1839. (doi: 10.1002/ejhf.2944) (PMID:37369637) (PMCID:PMC10947165)
Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398)
Wang, X. et al. (2023) Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE‐MI. Journal of the American Heart Association, 12(17), e028942. (doi: 10.1161/JAHA.122.028942) (PMID:37609931) (PMCID:PMC10547323)
Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)
Bhatt, A. S. et al. (2023) Operational challenges and mitigation measures during the COVID-19 pandemic – lessons from DELIVER. American Heart Journal, 263, pp. 133-140. (doi: 10.1016/j.ahj.2023.05.013) (PMID:37220822) (PMCID:PMC10200275)
Pabon, M. et al. (2023) Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, 25(9), pp. 1663-1670. (doi: 10.1002/ejhf.3001) (PMID:37632711)
Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, 25(9), pp. 1606-1618. (doi: 10.1002/ejhf.2962) (PMID:37401511)
Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)
Chatur, S. et al. (2023) Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal, 44(31), pp. 2930-2943. (doi: 10.1093/eurheartj/ehad283) (PMID:37220093)
Ioannou, A. et al. (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 44(31), pp. 2893-2907. (doi: 10.1093/eurheartj/ehad347) (PMID:37216684) (PMCID:PMC10424879)
Vaduganathan, M. et al. (2023) Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal, 44(31), pp. 2982-2993. (doi: 10.1093/eurheartj/ehad344) (PMID:37210743) (PMCID:PMC10424880)
Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)
Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)
Inciardi, R. M. et al. (2023) Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 82(6), pp. 489-499. (doi: 10.1016/j.jacc.2023.05.010) (PMID:37225045)
Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422)
Foroutan, F. et al. (2023) Global comparison of readmission rates for patients with heart failure. Journal of the American College of Cardiology, 82(5), pp. 430-444. (doi: 10.1016/j.jacc.2023.05.040) (PMID:37495280)
Barat, A. et al. (2023) Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM-associated genes: a subgroup analysis of the PARADIGM-HF trial. European Journal of Heart Failure, 25(8), pp. 1256-1266. (doi: 10.1002/ejhf.2886) (PMID:37191081)
Booth, D., Davis, J. A., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2023) The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health‐economic analysis of the DELIVER trial. European Journal of Heart Failure, 25(8), pp. 1386-1395. (doi: 10.1002/ejhf.2940) (PMID:37344985)
Butt, J. H. et al. (2023) Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial. European Journal of Heart Failure, 25(8), pp. 1228-1242. (doi: 10.1002/ejhf.2851) (PMID:37042062)
Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Journal of Cardio-Thoracic Surgery, 64(2), ezad286. (doi: 10.1093/ejcts/ezad286) (PMID:37632766)
Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, 25(8), pp. 1364-1371. (doi: 10.1002/ejhf.2912) (PMID:37210608)
Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)
Heidenreich, P. A. and McMurray, J. J.V. (2023) Should beta-blockers be used in heart failure if the LVEF is not reduced? JACC: Heart Failure, 11(8), pp. 901-902. (doi: 10.1016/j.jchf.2023.05.023) (PMID:37452802)
Jankowska, E. A. et al. (2023) Optimizing outcomes in heart failure: 2022 and beyond. ESC Heart Failure, 10(4), pp. 2159-2169. (doi: 10.1002/ehf2.14363) (PMID:37060168) (PMCID:PMC10375115)
McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)
Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial. European Journal of Heart Failure, 25(8), pp. 1444-1449. (doi: 10.1002/ejhf.2952) (PMID:37370197)
Myhre, P. L. et al. (2023) Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan. European Journal of Heart Failure, 25(8), pp. 1396-1405. (doi: 10.1002/ejhf.2957) (PMID:37401523)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
Peikert, A. et al. (2023) Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(7), pp. 684-690. (doi: 10.1001/jamacardio.2023.1342) (PMID:37208998) (PMCID:PMC10200027)
Bhatt, A. S. et al. (2023) Effect of dapagliflozin on health status and quality-of-life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF & DELIVER trials. European Journal of Heart Failure, 25(7), pp. 981-988. (doi: 10.1002/ejhf.2909) (PMID:37211977)
Chatur, S. et al. (2023) Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. European Journal of Heart Failure, 25(7), pp. 1170-1175. (doi: 10.1002/ejhf.2915) (PMID:37212168)
Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)
Desai, A. S., Deswal, A., McMurray, J. J.V. , Pinney, S. P. and Vaduganathan, M. (2023) Optimizing background therapy for heart failure in clinical trials. JACC: Heart Failure, 11(7), pp. 806-809. (doi: 10.1016/j.jchf.2023.05.012) (PMID:37407155)
Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)
Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25(7), pp. 999-1009. (doi: 10.1002/ejhf.2864) (PMID:37062865)
Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)
Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)
Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2023) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, 12(12), e026844. (doi: 10.1161/JAHA.122.026844) (PMID:37301739) (PMCID:PMC10356033)
Sattar, N. et al. (2023) Years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation, 147(25), pp. 1872-1886. (doi: 10.1161/CIRCULATIONAHA.122.063374) (PMID:37154040)
Desai, A. S., Lam, C. S.P., McMurray, J. J.V. and Redfield, M. M. (2023) How to manage heart failure with preserved ejection fraction: Practical guidance for clinicians. JACC: Heart Failure, 11(6), pp. 619-636. (doi: 10.1016/j.jchf.2023.03.011) (PMID:37140514)
Conrad, N. et al. (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, 401(10391), pp. 1878-1890. (doi: 10.1016/S0140-6736(23)00457-9) (PMID:37156255)
McMurray, J. J.V. and Metra, M. (2023) Transcatheter repair of secondary mitral regurgitation. New England Journal of Medicine, 388(22), pp. 2097-2098. (doi: 10.1056/NEJMe2302924) (PMID:37256981)
Biering-Sørensen, T. et al. (2023) The effect of sacubitril/valsartan on left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). Journal of Cardiac Failure, 29(6), pp. 968-973. (doi: 10.1016/j.cardfail.2023.03.019) (PMID:37031887)
Curtain, J. P., Lee, M. M.Y. , McMurray, J. J.V. , Gardner, R. S., Petrie, M. C. and Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109(11), pp. 823-831. (doi: 10.1136/heartjnl-2022-321885) (PMID:36522146) (PMCID:PMC10314022)
Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)
Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)
Clephas, P.R.D., Radhoe, S.P., Boersma, E., Gregson, J., Jhund, P.S. , Abraham, W.T., McMurray, J.J.V. , de Boer, R.A. and Brugts, J.J. (2023) Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. European Heart Journal, (doi: 10.1093/eurheartj/ehad346) (PMID:37210750) (Early Online Publication)
Rasmussen, M. et al. (2023) Global variations in heart failure etiology, management, and outcomes. JAMA: Journal of the American Medical Association, 329(19), pp. 1650-1661. (doi: 10.1001/jama.2023.5942) (PMID:37191704) (PMCID:PMC10189564)
Chertow, G. M. et al. (2023) Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. Journal of the American Heart Association, 12(9), e028739. (doi: 10.1161/JAHA.122.028739) (PMID:37119064) (PMCID:PMC10227210)
Jering, K. S. et al. (2023) Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circulation: Heart Failure, (doi: 10.1161/CIRCHEARTFAILURE.122.010259) (PMID:37125529) (Early Online Publication)
Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)
Lanfear, D. E. et al. (2023) Omecamtiv mecarbil in Black patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF. JACC: Heart Failure, 11(5), pp. 569-579. (doi: 10.1016/j.jchf.2022.11.021) (PMID:36881396)
McEwan, P. et al. (2023) Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrology Dialysis Transplantation, 38(5), pp. 1260-1270. (doi: 10.1093/ndt/gfac280) (PMID:36301617) (PMCID:PMC10157747)
Chatur, S. et al. (2023) Variation in renal function following transition to sacubitril/valsartan in patients with heart failure. Journal of the American College of Cardiology, 81(15), pp. 1443-1455. (doi: 10.1016/j.jacc.2023.02.009) (PMID:36812948)
Biering-Sørensen, T. et al. (2023) Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction. European Heart Journal: Cardiovascular Imaging, (doi: 10.1093/ehjci/jead062) (PMID:37039073) (Early Online Publication)
Lee, M. M. Y. and McMurray, J. J. V. (2023) Lack of benefit of renin-angiotensin system inhibitors in COVID-19. JAMA: Journal of the American Medical Association, 329(14), pp. 1155-1156. (doi: 10.1001/jama.2023.4405) (PMID:37039803)
Butt, J. H., Solomon, S. D. and McMurray, J. J.V. (2023) Response by Butt et al to letter regarding article, “Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial”. Circulation, 147(14), pp. 1119-1120. (doi: 10.1161/CIRCULATIONAHA.123.064052) (PMID:37011075)
Kondo, T. et al. (2023) Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation, 147(14), pp. 1067-1078. (doi: 10.1161/CIRCULATIONAHA.122.062918) (PMID:36876483)
Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)
Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)
Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)
Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)
Conrad, N., McInnes, I. B. , Mcmurray, J. J.V. and Sattar, N. (2023) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Annals of the Rheumatic Diseases, 82(4), pp. 457-459. (doi: 10.1136/ard-2022-223315) (PMID:36442979)
Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)
Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)
Tardif, J.‐C. et al. (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 10(2), pp. 1066-1076. (doi: 10.1002/ehf2.14268) (PMID:36564955) (PMCID:PMC10053160)
Bhandari, S. et al. (2023) Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. Journal of Nephrology, (doi: 10.1007/s40620-023-01571-6) (PMID:36995528) (PMCID:PMC10061401) (Early Online Publication)
Vaduganathan, M., Claggett, B. L., Jhund, P. , Miao, Z. M., de Boer, R. A., Lam, C. S.P., Desai, A. S., Bengsston, O., McMurray, J. J.V. and Solomon, S. D. (2023) Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 81(10), pp. 1004-1006. (doi: 10.1016/j.jacc.2022.12.026) (PMID:36889870)
Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)
Beernink, J. M. et al. (2023) Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care, 46(3), pp. 602-607. (doi: 10.2337/dc22-1514) (PMID:36662635)
Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)
Platz, E. et al. (2023) Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MI. European Heart Journal: Acute Cardiovascular Care, 12(3), pp. 155-164. (doi: 10.1093/ehjacc/zuad001) (PMID:36649251)
Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)
Wang, X. et al. (2023) Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER. Circulation, 147(8), pp. 624-634. (doi: 10.1161/CIRCULATIONAHA.122.062832) (PMID:36342789) (PMCID:PMC9974767)
Kosiborod, M. N. et al. (2023) Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 81(5), pp. 460-473. (doi: 10.1016/j.jacc.2022.11.006) (PMID:36526515)
Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)
Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)
Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)
Malik, M. E. et al. (2023) Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clinical Research in Cardiology, 112(2), pp. 215-226. (doi: 10.1007/s00392-022-02016-z) (PMID:35396632)
Miller, R. J.H., Chew, D. S., Qin, L., Fine, N. M., Chen, J., McMurray, J. J.V. , Howlett, J. G. and McEwan, P. (2023) Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 25(2), pp. 238-247. (doi: 10.1002/ejhf.2777) (PMID:36644849)
Rohde, L. E. et al. (2023) Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 8(2), pp. 150-158. (doi: 10.1001/jamacardio.2022.4427) (PMID:36477809)
Rawshani, A. et al. (2023) Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes. Scientific Reports, 13, 1192. (doi: 10.1038/s41598-023-27941-5) (PMID:36681691) (PMCID:PMC9867726)
Solomon, S.D., Vaduganathan, M. and McMurray, J.J.V. (2023) Dapagliflozin in heart failure with preserved ejection fraction. New England Journal of Medicine, 388(3), pp. 286-288. (doi: 10.1056/NEJMc2213974) (PMID:36652373)
Conrad, N. and McMurray, J. J.V. (2023) Cardiovascular risk in systemic autoimmune diseases – Authors' reply. Lancet, 401(10370), p. 22. (doi: 10.1016/S0140-6736(22)02426-6) (PMID:36610766) (PMCID:36041475)
Chatur, S., Claggett, B. L., Vardeny, O., Jering, K., Desai, A. S., Pfeffer, M. A., Lefkowitz, M., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2023) Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial. European Journal of Heart Failure, 25(1), pp. 87-94. (doi: 10.1002/ejhf.2703) (PMID:36181769)
Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)
Mc Causland, F. R. et al. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)
Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)
Sattar, N. , McMurray, J. J. V. , McInnes, I. B. , Aroda, V. R. and Lean, M. E. J. (2023) Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes and Endocrinology, 11(1), pp. 58-62. (doi: 10.1016/S2213-8587(22)00317-5) (PMID:36460014)
Schechter, M. et al. (2023) Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD. Annals of Internal Medicine, 176(1), pp. 59-66. (doi: 10.7326/M22-2115) (PMID:36469914)
Selvaraj, S. et al. (2023) Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER. JACC: Heart Failure, 11(1), pp. 76-89. (doi: 10.1016/j.jchf.2022.09.002) (PMID:36599553)
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Vaduganathan, M. and Fonarow, G. C. (2023) Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiology, 8(1), pp. 66-73. (doi: 10.1001/jamacardio.2022.4348) (PMID:36334258)
2022
Singh, A. K. et al. (2022) Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation, 38(8), pp. 1890-1897. (doi: 10.1093/ndt/gfac342) (PMID:36565721) (PMCID:PMC10387380)
Gerstein, H. C. et al. (2022) Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: the ELIXA trial. Diabetes, Obesity and Metabolism, 25(4), pp. 1125-1129. (doi: 10.1111/dom.14954) (PMID:36546588)
Metra, M. et al. (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 43(48), pp. 5006-5016. (doi: 10.1093/eurheartj/ehac293) (PMID:35675469)
Bowman, L. et al. (2022) Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. European Heart Journal, 44(11), pp. 931-934. (doi: 10.1093/eurheartj/ehac633) (PMID:36525339) (PMCID:PMC10011328)
Bowman, L. et al. (2022) Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. Circulation, 147(12), pp. 925-929. (doi: 10.1161/CIRCULATIONAHA.122.063378) (PMID:36524680)
Mehran, R. et al. (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation, 146(23), pp. 1749-1757. (doi: 10.1161/CIRCULATIONAHA.122.060841) (PMID:36321459)
Chandra, A. et al. (2022) Health‐related quality of life outcomes in PARAGON‐HF. European Journal of Heart Failure, 24(12), pp. 2264-2274. (doi: 10.1002/ejhf.2738) (PMID:36394533)
Inzucchi, S. E. et al. (2022) Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 10(12), pp. 869-881. (doi: 10.1016/S2213-8587(22)00308-4) (PMID:36372069)
McEwan, P., Darlington, O., Miller, R., McMurray, J. J.V. , Wheeler, D. C., Heerspink, H. J.L., Briggs, A. , Bergenheim, K. and Garcia Sanchez, J. J. (2022) Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clinical Journal of the American Society of Nephrology, 17(12), pp. 1730-1741. (doi: 10.2215/CJN.03790322) (PMID:36323444)
Myhre, P. L. et al. (2022) Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 10(12), pp. 902-913. (doi: 10.1016/j.jchf.2022.08.007) (PMID:36114137)
Vardeny, O. et al. (2022) Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 28(12), pp. 2504-2511. (doi: 10.1038/s41591-022-02102-9) (PMID:36522606) (PMCID:PMC9800271)
Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)
Vaduganathan, M. et al. (2022) Estimated event-free survival benefits with dapagliflozin in HF with mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(19), pp. 1775-1784. (doi: 10.1016/j.jacc.2022.08.745) (PMID:36041669)
Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)
Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)
Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)
Zhang, L. et al. (2022) Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction. Circulation, 146(13), pp. 1411-1414. (doi: 10.1161/CIRCULATIONAHA.122.061481) (PMID:36029463)
Adamson, C., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'the 50 shades of bilirubin'. Letter regarding the article 'liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF'. European Journal of Heart Failure, 24(11), pp. 2206-2207. (doi: 10.1002/ejhf.2683) (PMID:36097136)
Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)
Ferreira, J. P., Pitt, B., McMurray, J. J.V. , Pocock, S. J., Solomon, S. D., Pfeffer, M. A., Zannad, F. and Rossignol, P. (2022) Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC: Heart Failure, 10(11), pp. 842-850. (doi: 10.1016/j.jchf.2022.06.010) (PMID:36328653)
Jongs, N. et al. (2022) Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. Journal of the American Society of Nephrology, 33(11), pp. 2094-2107. (doi: 10.1681/ASN.2022030306) (PMID:35977807)
Khunti, K. et al. (2022) Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 24(11), pp. 2071-2080. (doi: 10.1111/dom.14805) (PMID:35801339)
Perkovic, V. et al. (2022) The ASCEND-ND trial: study design and participant characteristics. Nephrology Dialysis Transplantation, 37(11), pp. 2157-2170. (doi: 10.1093/ndt/gfab318) (PMID:34865143) (PMCID:PMC9585467)
Smeijer, J. D. et al. (2022) Organic anion transporter gene variants associated with plasma exposure and long-term response to atrasentan in patients with diabetic kidney disease. Clinical Pharmacology and Therapeutics, 112(5), pp. 1098-1107. (doi: 10.1002/cpt.2721) (PMID:35892316)
Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465) (PMCID:PMC9815819)
Tardif, J. C. et al. (2022) Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. European Heart Journal, 43(39), pp. 3947-3956. (doi: 10.1093/eurheartj/ehac374) (PMID:35856777) (PMCID:PMC9565632)
Cunningham, J. W. et al. (2022) Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(14), pp. 1302-1310. (doi: 10.1016/j.jacc.2022.07.021) (PMID:36041912)
Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)
Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)
Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568) (PMCID:PMC9805158)
Bedrouni, W. et al. (2022) Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circulation: Heart Failure, 15(10), pp. 988-990. (doi: 10.1161/CIRCHEARTFAILURE.121.009295) (PMID:35924555)
Berwanger, O. et al. (2022) Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial. European Journal of Heart Failure, 24(10), pp. 1918-1927. (doi: 10.1002/ejhf.2663) (PMID:36054480)
Chatur, S. et al. (2022) Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with HFpEF in the PARAGON‐HF trial. European Journal of Heart Failure, 24(10), pp. 1906-1914. (doi: 10.1002/ejhf.2638) (PMID:35895867)
Claggett, B. L., McCaw, Z. R., Tian, L., McMurray, J. J.V. , Jhund, P. S. , Uno, H., Pfeffer, M. A., Solomon, S. D. and Wei, L.-J. (2022) Quantifying treatment effects in trials with multiple event-time outcomes. NEJM Evidence, 1(10), (doi: 10.1056/EVIDoa2200047)
Dubé, M.‐P. et al. (2022) Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. ESC Heart Failure, 9(5), pp. 2997-3008. (doi: 10.1002/ehf2.14026) (PMID:35736394) (PMCID:PMC9715825)
Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)
McDowell, K., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)
McMurray, J. J. V. and Sattar, N. (2022) Heart failure: now centre-stage in diabetes. Lancet Diabetes and Endocrinology, 10(10), pp. 689-691. (doi: 10.1016/S2213-8587(22)00249-2) (PMID:36057271)
Ostrominski, J. W. et al. (2022) Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure, 24(10), pp. 1892-1901. (doi: 10.1002/ejhf.2652) (PMID:36054231)
Peikert, A. et al. (2022) Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circulation: Heart Failure, 15(10), pp. 934-943. (doi: 10.1161/CIRCHEARTFAILURE.122.010080) (PMID:36029467)
Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)
Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)
Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)
Solomon, S. D. et al. (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), pp. 1089-1098. (doi: 10.1056/NEJMoa2206286) (PMID:36027570)
Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)
Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J.V. and Verbakel, J. Y. (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 400(10354), pp. 733-743. (doi: 10.1016/S0140-6736(22)01349-6) (PMID:36041475)
Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)
Aulin, J. et al. (2022) Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model. American Heart Journal, 251, pp. 13-24. (doi: 10.1016/j.ahj.2022.03.009) (PMID:35569564)
Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)
Gerstein, H. C. et al. (2022) Protein biomarkers and cardiovascular outcomes in people with type 2 diabetes and acute coronary syndrome: the ELIXA biomarker study. Diabetes Care, 45(9), pp. 2152-2155. (doi: 10.2337/dc22-0453) (PMID:35817031)
Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)
Johansson, I. et al. (2022) Factors associated with health‐related quality of life in heart failure in 23,000 patients from 40 countries: results of the G‐CHF Research Program. European Journal of Heart Failure, 24(9), pp. 1478-1490. (doi: 10.1002/ejhf.2535) (PMID:35570198)
Mc Causland, F. R. et al. (2022) Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 24(9), pp. 1591-1598. (doi: 10.1002/ejhf.2421) (PMID:34989105)
Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B., Claggett, B. L., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Zannad, F. and Solomon, S. D. (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. European Journal of Heart Failure, 24(9), pp. 1586-1590. (doi: 10.1002/ejhf.2635) (PMID:35867859)
Wheeler, D. C. et al. (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial. Nephrology Dialysis Transplantation, 37(9), pp. 1647-1656. (doi: 10.1093/ndt/gfab335) (PMID:34850160) (PMCID:PMC9395378)
Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)
Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)
Thomson, P. C. et al. (2022) An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. Kidney International Reports, 7(8), pp. 1793-1801. (doi: 10.1016/j.ekir.2022.05.008) (PMID:35967105) (PMCID:PMC9366296)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)
Smeijer, J. D. et al. (2022) Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure. JACC: Heart Failure, 10(7), pp. 498-507. (doi: 10.1016/j.jchf.2022.03.004) (PMID:35772861)
Thorvaldsen, T., Ferrannini, G., Mellbin, L., Benson, L., Cosentino, F., McMurray, J. J.V. , Dahlström, U., Lund, L. H. and Savarese, G. (2022) Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. Journal of Cardiac Failure, 28(7), pp. 1050-1062. (doi: 10.1016/j.cardfail.2022.04.011) (PMID:35550428)
Waijer, S. W. et al. (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 65(7), pp. 1085-1097. (doi: 10.1007/s00125-022-05694-6) (PMID:35445820) (PMCID:PMC9174107)
Vaduganathan, M., Claggett, B. L., McMurray, J. J.V. and Solomon, S. D. (2022) Health status trajectories before and after hospitalization for heart failure. Circulation, 145(25), pp. 1872-1874. (doi: 10.1161/CIRCULATIONAHA.122.059282) (PMID:35603665)
Wijkman, M. O. et al. (2022) Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 21, 110. (doi: 10.1186/s12933-022-01545-1) (PMID:35717169) (PMCID:PMC9206286)
Lee, K. K. et al. (2022) Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. British Medical Journal, 377, e068424. (doi: 10.1136/bmj-2021-068424) (PMID:35697365) (PMCID:PMC9189738)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)
Curtain, J. P. et al. (2022) Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF. JACC: Heart Failure, 10(6), pp. 415-427. (doi: 10.1016/j.jchf.2022.01.020) (PMID:35654526)
Jackson, A. M., Benson, L., Savarese, G., Hage, C., Jhund, P. S. , Petrie, M. C. , Dahlström, U., McMurray, J. J.V. and Lund, L. H. (2022) Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry. JACC: Heart Failure, 10(6), pp. 380-392. (doi: 10.1016/j.jchf.2022.04.006) (PMID:35654522)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)
McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847) (PMID:35789017) (PMCID:PMC9254667)
Singh, A. K. et al. (2022) Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients. JAMA Internal Medicine, 182(6), pp. 592-602. (doi: 10.1001/jamainternmed.2022.0605) (PMID:35377393) (PMCID:PMC8981070)
Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)
Cikes, M. et al. (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure, 10(5), pp. 336-346. (doi: 10.1016/j.jchf.2022.01.018) (PMID:35483796)
De Caterina, R. et al. (2022) Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 8(3), pp. 227-235. (doi: 10.1093/ehjcvp/pvaa140) (PMID:33367487)
Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)
Peikert, A. et al. (2022) Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF. European Journal of Heart Failure, 24(5), pp. 794-803. (doi: 10.1002/ejhf.2450) (PMID:35119183)
Singh, A. K. et al. (2022) Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation, 37(5), pp. 960-972. (doi: 10.1093/ndt/gfab065) (PMID:33744933)
Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)
Wolsk, E. et al. (2022) Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients with coronary artery disease and type 2 diabetes. Journal of the American Heart Association, 11(8), e021327. (doi: 10.1161/jaha.121.021327) (PMID:35383463) (PMCID:PMC9238457)
Aune, E., McMurray, J. , Lundgren, P., Sattar, N. , Israelsson, J., Nordberg, P., Herlitz, J. and Rawshani, A. (2022) Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. Scientific Reports, 12, 5685. (doi: 10.1038/s41598-022-09510-4) (PMID:35383220) (PMCID:PMC8983650)
Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)
Pabón, M. A. et al. (2022) Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF. European Journal of Heart Failure, 24(4), pp. 672-677. (doi: 10.1002/ejhf.2439) (PMID:35080787)
Vart, P. et al. (2022) Efficacy and safety of dapagliflozin in patients with CKD across major geographic regions. Kidney International Reports, 7(4), pp. 699-707. (doi: 10.1016/j.ekir.2022.01.1060) (PMID:35497805) (PMCID:PMC9039473)
Solomon, S. D. et al. (2022) Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, (doi: 10.1093/eurheartj/ehac144) (PMID:35325102)
Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)
Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)
Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)
Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)
Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)
Solomon, S. D. et al. (2022) Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC: Heart Failure, 10(3), pp. 184-197. (doi: 10.1016/j.jchf.2021.11.006) (PMID:35241246)
Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)
Zahir, D. et al. (2022) Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. European Journal of Heart Failure, 24(3), pp. 539-547. (doi: 10.1002/ejhf.2418) (PMID:34969178)
Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)
Fiuzat, M. et al. (2022) Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week. Journal of the American College of Cardiology, 79(5), pp. 504-510. (doi: 10.1016/j.jacc.2021.11.033) (PMID:35115106)
Weir, R. A.P., Clements, S., Steedman, T., Dargie, H. J. and McMurray, J. J.V. (2022) Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow‐up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial. European Journal of Heart Failure, 24(2), pp. 393-395. (doi: 10.1002/ejhf.2402) (PMID:34907636)
Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)
Chertow, G. M. et al. (2022) Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 24(5), pp. 827-837. (doi: 10.1111/dom.14641) (PMID:34984791)
Pfeffer, M. A. et al. (2022) Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation, 145(1), pp. 87-89. (doi: 10.1161/CIRCULATIONAHA.121.057429) (PMID:34797725)
Felker, G. M. et al. (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. JAMA Cardiology, 7(1), pp. 26-34. (doi: 10.1001/jamacardio.2021.4027) (PMID:34643642) (PMCID:PMC8515258)
Heerspink, H. J.L. et al. (2022) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 101(1), pp. 174-184. (doi: 10.1016/j.kint.2021.09.005) (PMID:34560136)
Lee, M. M.Y. , Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V. and Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1), 102382. (doi: 10.1016/j.dsx.2021.102382) (PMID:35030451)
McMurray, J. J.V. (2022) Can an implanted minipump deliver for diabetes patients? Nature Medicine, 28(1), pp. 27-28. (doi: 10.1038/s41591-021-01628-8) (PMID:34903896)
Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)
2021
Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2313-2324. (doi: 10.1056/NEJMoa2113380) (PMID:34739196)
Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2325-2335. (doi: 10.1056/NEJMoa2113379) (PMID:34739194)
Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)
Codina, P. et al. (2021) Head‐to‐head comparison of contemporary heart failure risk scores. European Journal of Heart Failure, 23(12), pp. 2035-2044. (doi: 10.1002/ejhf.2352) (PMID:34558158)
Desai, A. S. et al. (2021) Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation: Heart Failure, 14(12), e008597. (doi: 10.1161/CIRCHEARTFAILURE.121.008597) (PMID:34807713)
Lumbers, R. T. et al. (2021) The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 8(6), pp. 5531-5541. (doi: 10.1002/ehf2.13517) (PMID:34480422) (PMCID:PMC8712846)
Suzuki, K. et al. (2021) Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial. European Journal of Heart Failure, 23(12), pp. 2085-2090. (doi: 10.1002/ejhf.2262) (PMID:34114720)
Vaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J.V. , Fonarow, G. C. and Solomon, S. D. (2021) Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiology, 6(12), pp. 1415-1423. (doi: 10.1001/jamacardio.2021.3651) (PMID:34524394) (PMCID:PMC8444065)
Waijer, S. W. et al. (2021) The effect of atrasentan on kidney and heart failure outcomes by baseline albuminuria and kidney function: a post hoc analysis of the SONAR randomized trial. Clinical Journal of the American Society of Nephrology, 16(12), pp. 1824-1832. (doi: 10.2215/CJN.07340521) (PMID:34853062)
Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)
Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)
He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)
Heerspink, H. J.L. et al. (2021) Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: a prespecified analysis from the SONAR trial. Journal of the American Society of Nephrology, 32(11), pp. 2900-2911. (doi: 10.1681/ASN.2021030391) (PMID:34551995) (PMCID:PMC8806086)
Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)
Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)
Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)
Sattar, N. et al. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology, 9(10), pp. 653-662. (doi: 10.1016/S2213-8587(21)00203-5) (PMID:34425083)
Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)
Jackson, A. M. et al. (2021) Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 42(36), pp. 3741-3752. (doi: 10.1093/eurheartj/ehab499) (PMID:34392331) (PMCID:PMC8455346)
Selvaraj, S. et al. (2021) Effects of sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction. Journal of the American Heart Association, 10(17), e022069. (doi: 10.1161/JAHA.121.022069) (PMID:33998278) (PMCID:PMC8649234)
Bhatt, A. S., Claggett, B. L., Packer, M., Lefkowitz, M. P., Zile, M. R., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2021) Treatment effects of sacubitril/valsartan compared with valsartan in patients with recent hospitalization. Journal of Cardiac Failure, 27(9), pp. 1027-1030. (doi: 10.1016/j.cardfail.2021.05.020) (PMID:34133969)
Bhatt, A. S. et al. (2021) Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial. European Journal of Heart Failure, 23(9), pp. 1518-1524. (doi: 10.1002/ejhf.2259) (PMID:34101308)
Chertow, G. M. et al. (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. Journal of the American Society of Nephrology, 32(9), pp. 2352-2361. (doi: 10.1681/ASN.2021020167) (PMID:34272327) (PMCID:PMC8729835)
Ferreira, J. P. et al. (2021) Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. European Journal of Heart Failure, 23(9), pp. 1477-1484. (doi: 10.1002/ejhf.2255) (PMID:34050594)
Rørth, R. et al. (2021) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 16(8), e0255364. (doi: 10.1371/journal.pone.0255364) (PMID:34347805) (PMCID:PMC8336831)
Rohde, L. E. et al. (2021) Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. European Journal of Heart Failure, 23(8), pp. 1346-1356. (doi: 10.1002/ejhf.2120) (PMID:33565237)
Shen, L. et al. (2021) Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 110(8), pp. 1334-1349. (doi: 10.1007/s00392-021-01888-x) (PMID:34101002)
Shen, L. et al. (2021) Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 110(8), pp. 1234-1248. (doi: 10.1007/s00392-020-01786-8) (PMID:33301080)
Wamil, M., Coleman, R. L., Adler, A. I., McMurray, J. J.V. and Holman, R. R. (2021) Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care, 44(8), pp. 1877-1884. (doi: 10.2337/dc21-0429) (PMID:34162666)
Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)
Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)
Teerlink, J. R. et al. (2021) Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 78(2), pp. 97-108. (doi: 10.1016/j.jacc.2021.04.065) (PMID:34015475)
Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)
Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)
Simpson, J. et al. (2021) Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), pp. 296-301. (doi: 10.1093/ehjcvp/pvaa071) (PMID:32597982) (PMCID:PMC8302254)
Solomon, S. D. et al. (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure, 23(7), pp. 1217-1225. (doi: 10.1002/ejhf.2249) (PMID:34051124)
Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, 42(24), pp. 2331-2343. (doi: 10.1093/eurheartj/ehab082) (PMID:33791787)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)
Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)
Jering, K. S. et al. (2021) Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics. European Journal of Heart Failure, 23(6), pp. 1040-1048. (doi: 10.1002/ejhf.2191) (PMID:33847047)
Packer, M. and McMurray, J. J.V. (2021) Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 23(6), pp. 882-894. (doi: 10.1002/ejhf.2149) (PMID:33704874) (PMCID:PMC8360176)
Sørensen, T. B. et al. (2021) The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). European Journal of Heart Failure, 23(6), pp. 1052-1056. (doi: 10.1002/ejhf.2181) (PMID:33826209)
Beggs, S. A.S. , Jhund, P. S. and McMurray, J. J.V. (2021) Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 42(20), e5-e7. (doi: 10.1093/eurheartj/ehy609) (PMID:30357375)
Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)
Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)
Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)
Pellicori, P. et al. (2021) Ultrasound imaging of congestion in heart failure – examinations beyond the heart. European Journal of Heart Failure, 23(5), pp. 703-712. (doi: 10.1002/ejhf.2032) (PMID:33118672)
Shen, L. et al. (2021) Incidence and outcomes of pneumonia in patients with heart failure. Journal of the American College of Cardiology, 77(16), pp. 1961-1973. (doi: 10.1016/j.jacc.2021.03.001) (PMID:33888245)
McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)
Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)
Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)
Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)
Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)
Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)
Koomen, J. V. et al. (2021) Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post hoc analysis of the SONAR trial. Diabetes, Obesity and Metabolism, 23(2), pp. 561-568. (doi: 10.1111/dom.14252) (PMID:33184931) (PMCID:PMC7839558)
Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)
Teerlink, J. R. et al. (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine, 384, pp. 105-116. (doi: 10.1056/NEJMoa2025797) (PMID:33185990)
McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)
2020
Felker, G. M., Solomon, S. D., McMurray, J. J.V. , Cleland, J. G.F. , Abbasi, S. A., Malik, F. I., Zhang, H., Globe, G. and Teerlink, J. R. (2020) Effects of omecamtiv mecarbil on symptoms and health-related quality of life in patients with chronic heart failure: results from the COSMIC-HF study. Circulation: Heart Failure, 13(12), e007814. (doi: 10.1161/CIRCHEARTFAILURE.120.007814) (PMID:33176437) (PMCID:PMC7742205)
Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)
Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)
Wamil, M., McMurray, J. J.V. , Scott, C. A.B., Coleman, R. L., Sun, Y., Standl, E., Rydén, L. and Holman, R. R. (2020) Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 170, 108488. (doi: 10.1016/j.diabres.2020.108488) (PMID:33035598)
Yeoh, S. E. et al. (2020) Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Failure, 7(6), pp. 3355-3364. (doi: 10.1002/ehf2.12972) (PMID:33078584) (PMCID:PMC7754973)
Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)
Psotka, M. A. et al. (2020) Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel. Journal of the American College of Cardiology, 76(20), pp. 2368-2378. (doi: 10.1016/j.jacc.2020.09.544) (PMID:33183511)
Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)
Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)
Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)
Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)
McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)
McMurray, J. J.V. (2020) EMPEROR‐Reduced: confirming sodium–glucose co‐transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(11), pp. 1987-1990. (doi: 10.1002/ejhf.2006) (PMID:32946169)
Selvaraj, S. et al. (2020) Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. European Journal of Heart Failure, 22(11), pp. 2093-2101. (doi: 10.1002/ejhf.1984) (PMID:32840930)
Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 22(11), pp. 2160-2171. (doi: 10.1002/ejhf.2015) (PMID:32985088) (PMCID:PMC7756903)
Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)
Heerspink, H. J.L. et al. (2020) Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), pp. 1436-1446. (doi: 10.1056/NEJMoa2024816) (PMID:32970396)
Wheeler, D. C. et al. (2020) The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 35(10), pp. 1700-1711. (doi: 10.1093/ndt/gfaa234) (PMID:32862232) (PMCID:PMC7538235)
Butt, J. H. et al. (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 22(10), pp. 1777-1785. (doi: 10.1002/ejhf.1800) (PMID:32227556)
Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)
Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)
Malachias, M. V.B. et al. (2020) N-terminal pro-B-type natriuretic peptide by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes. Journal of the American Heart Association, 9(19), e017462. (doi: 10.1161/JAHA.120.017462) (PMID:32964800) (PMCID:PMC7792415)
Solomon, S. D. et al. (2020) Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. JACC: Heart Failure, 8(10), pp. 811-818. (doi: 10.1016/j.jchf.2020.04.008) (PMID:32653447)
Mc Causland, F. R. et al. (2020) Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation, 142(13), pp. 1236-1245. (doi: 10.1161/CIRCULATIONAHA.120.047643) (PMID:32845715)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)
Sattar, N. et al. (2020) BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), pp. 1149-1151. (doi: 10.1016/j.dsx.2020.06.060) (PMID:32668401) (PMCID:PMC7326434)
Suzuki, K. et al. (2020) Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(9), pp. 1662-1671. (doi: 10.1002/ejhf.1853) (PMID:32407608)
Vaduganathan, M., McMurray, J. J.V. and Solomon, S. D. (2020) Angiotensin receptor–neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON‐HF. European Journal of Heart Failure, 22(9), pp. 1525-1530. (doi: 10.1002/ejhf.1976) (PMID:32741093)
Berglund, E. et al. (2020) Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 27(12), pp. 1311-1319. (doi: 10.1177/2047487319886959) (PMID:31698965)
Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)
Rossignol, P. et al. (2020) Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 22(8), pp. 1402-1411. (doi: 10.1002/ejhf.1724) (PMID:31919958)
Vaduganathan, M., Claggett, B. L., Jhund, P. , Cunningham, J. W., Ferreira, J. P., Zannad, F., Packer, M., Fonarow, G. C., McMurray, J. and Solomon, S. D. (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, 396(10244), pp. 121-128. (doi: 10.1016/S0140-6736(20)30748-0) (PMID:32446323)
Lam, C. S.P., Voors, A. A., Piotr, P., McMurray, J. J.V. and Solomon, S. D. (2020) Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. European Heart Journal, 41(25), pp. 2353-2355. (doi: 10.1093/eurheartj/ehaa158) (PMID:32227233)
Vaduganathan, M. et al. (2020) A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 41(25), pp. 2356-2362. (doi: 10.1093/eurheartj/ehaa184) (PMID:32221596) (PMCID:PMC7327532)
Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)
Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)
Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)
Shin, S.-H. et al. (2020) Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 22(7), pp. 1133-1143. (doi: 10.1002/ejhf.1790) (PMID:32212368)
Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology 2019: heart failure. Romanian Journal of Cardiology, 30(2), pp. 185-204. (doi: 10.47803/rjc.2020.30.2.185)
Brainin, P. et al. (2020) Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Failure, 7(3), pp. 1201-1209. (doi: 10.1002/ehf2.12640) (PMID:32077268) (PMCID:PMC7261588)
Cunningham, J. W. et al. (2020) Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC: Heart Failure, 8(5), pp. 372-381. (doi: 10.1016/j.jchf.2020.03.002) (PMID:32241619)
Dewan, P. , Jackson, A., Lam, C. S.P., Pfeffer, M. A., Zannad, F., Pitt, B., Solomon, S. D. and McMurray, J. J.V. (2020) Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 22(5), pp. 898-901. (doi: 10.1002/ejhf.1776) (PMID:32115864)
Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)
Jorsal, A., Pryds, K., McMurray, J. J.V. , Wiggers, H., Sommer, A., Nielsen, J. C. and Nielsen, R. R. (2020) Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 109(5), pp. 638-645. (doi: 10.1007/s00392-019-01553-4) (PMID:31559483)
Malik, M. E. et al. (2020) Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. European Journal of Heart Failure, 22(5), pp. 813-820. (doi: 10.1002/ejhf.1819) (PMID:32246806)
Rossello, X., Ferreira, J. P., Pocock, S. J., McMurray, J. J.V. , Solomon, S. D., Lam, C. S.P., Girerd, N., Pitt, B., Rossignol, P. and Zannad, F. (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 22(5), pp. 834-844. (doi: 10.1002/ejhf.1740) (PMID:32077220)
Sattar, N. , McMurray, J. J.V. and Cheng, A. (2020) Cardiorenal risk reduction guidance in diabetes: can we reach consensus? Lancet Diabetes and Endocrinology, 8(5), pp. 357-360. (doi: 10.1016/S2213-8587(20)30062-0) (PMID:32171053)
Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)
Selvaraj, S. et al. (2020) Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. Journal of the American College of Cardiology, 75(14), pp. 1644-1656. (doi: 10.1016/j.jacc.2020.02.009) (PMID:32192799)
Macdougall, I. C. et al. (2020) Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology, 31(4), 2019090972. (doi: 10.1681/ASN.2019090972) (PMID:32253271)
Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)
Tardif, J.-C. et al. (2020) Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal, 222, pp. 157-165. (doi: 10.1016/j.ahj.2020.01.007) (PMID:32087417)
Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC: Heart Failure, 8(4), pp. 329-340. (doi: 10.1016/j.jchf.2019.12.001) (PMID:32035892)
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J.V. , Pfeffer, M. A. and Solomon, S. D. (2020) Renin–Angiotensin–Aldosterone System inhibitors in patients with Covid-19. New England Journal of Medicine, 382(17), pp. 1653-1659. (doi: 10.1056/nejmsr2005760) (PMID:32227760)
Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)
Sharma, A. et al. (2020) Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus. Circulation, 141(10), pp. 843-862. (doi: 10.1161/circulationaha.119.041022) (PMID:31992065)
Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)
Kristensen, S. L. and McMurray, J. J.V. (2020) Diagnosing heart failure with preserved ejection fraction – what's the score? European Journal of Heart Failure, 22(3), pp. 425-427. (doi: 10.1002/ejhf.1764) (PMID:32086989)
Lee, M. M.Y. , Petrie, M. C. , McMurray, J. J.V. and Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. 506-522. (doi: 10.1161/atvbaha.119.311904) (PMID:31996025)
Monzo, L. et al. (2020) Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Journal of Hypertension, 38(3), pp. 420-425. (doi: 10.1097/HJH.0000000000002275) (PMID:31584516)
Shen, L., Jhund, P. and McMurray, J. (2020) Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 22(3), pp. 564-565. (doi: 10.1002/ejhf.1718) (PMID:31919977)
Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)
Rorth, R. et al. (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), e006541. (doi: 10.1161/CIRCHEARTFAILURE.119.006541) (PMID:32065760)
McMurray, J. J.V. et al. (2020) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation, 141(5), pp. 338-351. (doi: 10.1161/CIRCULATIONAHA.119.044491) (PMID:31736337)
Solomon, S. D. et al. (2020) Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation, 141(5), pp. 352-361. (doi: 10.1161/circulationaha.119.044586) (PMID:31736342)
Vaduganathan, M. et al. (2020) Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. Journal of the American College of Cardiology, 75(3), pp. 245-254. (doi: 10.1016/j.jacc.2019.11.003) (PMID:31726194)
Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)
Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)
Shah, S. et al. (2020) Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 11, 163. (doi: 10.1038/s41467-019-13690-5) (PMID:31919418) (PMCID:PMC6952380)
Israr, M. Z. et al. (2020) Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF. European Journal of Heart Failure, 22(8), pp. 1486-1490. (doi: 10.1002/ejhf.1951) (PMID:32666670)
2019
Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)
Shah, A. M. et al. (2019) Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology, 74(23), pp. 2858-2873. (doi: 10.1016/j.jacc.2019.09.063) (PMID:31806129)
Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)
Ferreira, J. P., Rossello, X., Eschalier, R., McMurray, J. J.V. , Pocock, S., Girerd, N., Rossignol, P., Pitt, B. and Zannad, F. (2019) MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. JACC: Heart Failure, 7(12), pp. 1012-1021. (doi: 10.1016/j.jchf.2019.08.017) (PMID:31779922)
Platz, E., Solomon, S. D. and McMurray, J. J.V. (2019) Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 21(12), pp. 1614-1615. (doi: 10.1002/ejhf.1636) (PMID:31702095)
McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)
Ferreira, J. P., Rossignol, P., Dewan, P. , Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J.V. and Zannad, F. (2019) Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 218, pp. 66-74. (doi: 10.1016/j.ahj.2019.08.019) (PMID:31707330)
Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)
Conrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A. C., Millett, E. R.C., Salimi-Khorshidi, G., Cleland, J. G. , McMurray, J. J.V. and Rahimi, K. (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiology, 4(11), pp. 1102-1111. (doi: 10.1001/jamacardio.2019.3593) (PMID:31479100) (PMCID:PMC6724155)
McMurray, J. J.V. et al. (2019) The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 21(11), pp. 1402-1411. (doi: 10.1002/ejhf.1548) (PMID:31309699)
Solomon, S. D. et al. (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine, 381, pp. 1609-1620. (doi: 10.1056/NEJMoa1908655) (PMID:31475794)
Selvaraj, S. et al. (2019) Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. Circulation, 140, pp. 1369-1379. (doi: 10.1161/CIRCULATIONAHA.119.039920) (PMID:31510768)
Coiro, S. et al. (2019) Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.1541) (PMID:31476097)
Lee, M. M.Y. , Sattar, N. , McMurray, J. J.V. and Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21(10), 41. (doi: 10.1007/s11883-019-0800-z)
Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)
Chandra, A. et al. (2019) Health-related quality of life in heart failure with preserved ejection fraction the PARAGON-HF trial. JACC: Heart Failure, 7(10), pp. 862-874. (doi: 10.1016/j.jchf.2019.05.015) (PMID:31302043)
Yap, J. et al. (2019) Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. Journal of the American Heart Association, 8(17), e013114. (doi: 10.1161/jaha.119.013114) (PMID:31431116)
Beggs, S. A.S. , Rørth, R., Gardner, R. S. and McMurray, J. J.V. (2019) Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart, 105(17), pp. 1325-1334. (doi: 10.1136/heartjnl-2018-314381) (PMID:30962190)
Ferreira, J. P. et al. (2019) World Heart Federation Roadmap for heart failure. Global Heart, 14(3), pp. 197-214. (doi: 10.1016/j.gheart.2019.07.004) (PMID:31451235)
Grodin, J. L. et al. (2019) Prognostic implications of changes in amino-terminal pro–B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF. Journal of Cardiac Failure, 25(9), pp. 703-711. (doi: 10.1016/j.cardfail.2019.04.002) (PMID:30953792)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
Tromp, J. et al. (2019) Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care, 42(9), pp. 1792-1799. (doi: 10.2337/dc18-2515) (PMID:31292141)
Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) The importance of randomised vs non-randomised trials - authors' reply. Lancet, 394(10199), p. 635. (doi: 10.1016/S0140-6736(19)31111-0) (PMID:31448734)
McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)
Leong, D. P., McMurray, J. J.V. , Joseph, P. G. and Yusuf, S. (2019) From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5). Journal of the American College of Cardiology, 74(5), pp. 683-698. (doi: 10.1016/j.jacc.2019.04.068) (PMID:31370961)
Tromp, J. et al. (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 74(5), pp. 601-612. (doi: 10.1016/j.jacc.2019.05.052) (PMID:31370950)
Felker, G. M., Borentain, M., Cleland, J. G.F. , DeSouza, M. M., Kessler, P. D., O'Connor, C. M., Seiffert, D., Teerlink, J. R., Voors, A. A. and McMurray, J. J.V. (2019) Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 21(8), pp. 1022-1031. (doi: 10.1002/ejhf.1504) (PMID:31168885)
Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)
Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)
Chin, K. L., Collier, T., Pocock, S., Pitt, B., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Vincent, J., Zannad, F. and Liew, D. (2019) Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 108, pp. 806-814. (doi: 10.1007/s00392-018-1410-4) (PMID:30604047)
Platz, E. et al. (2019) Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 21(7), pp. 844-851. (doi: 10.1002/ejhf.1499)
Robertson, J., Schaufelberger, M., Lindgren, M., Adiels, M., Schiöler, L., Torén, K., McMurray, J. , Sattar, N. , Åberg, M. and Rosengren, A. (2019) Higher body mass index in adolescence predicts cardiomyopathy risk in midlife: long-term follow-up among Swedish men. Circulation, 140, pp. 117-125. (doi: 10.1161/circulationaha.118.039132) (PMID:31132859) (PMCID:PMC6635044)
Stewart, S., Moholdt, T. T., Burrell, L. M., Sliwa, K., Mocumbi, A. O., McMurray, J. J.V. , Keates, A. K. and Hawley, J. A. (2019) Winter peaks in heart failure: an inevitable or preventable consequence of seasonal vulnerability? Cardiac Failure Review, 5(2), pp. 83-85. (doi: 10.15420/cfr.2018.40.2) (PMID:31179017) (PMCID:PMC6546000)
Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)
Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)
Balmforth, C. et al. (2019) Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC: Heart Failure, 7(6), pp. 457-465. (doi: 10.1016/j.jchf.2019.02.015) (PMID:31078482)
Shah, S. J., Voors, A. A., McMurray, J. J.V. , Kitzman, D. W., Viethen, T., Bomfim Wirtz, A., Huang, E., Pap, A. F. and Solomon, S. D. (2019) Effect of neladenoson bialanate on exercise capacity among patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA: Journal of the American Medical Association, 321(21), pp. 2101-2112. (doi: 10.1001/jama.2019.6717) (PMID:31162568) (PMCID:PMC6549300)
Simpson, J., Benson, L., Jhund, P.S. , Dahlström, U., McMurray, J.J.V. and Lund, L.H. (2019) "Real world" eligibility for sacubitril/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 33(3), pp. 315-322. (doi: 10.1007/s10557-019-06873-1) (PMID:30903545) (PMCID:PMC6538576)
Verma, S. and McMurray, J. J.V. (2019) The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58. Circulation, 139(22), pp. 2537-2541. (doi: 10.1161/circulationaha.119.040514) (PMID:30882236)
Stienen, S., Ferreira, J. P., Vincent, J., Busselen, M., Li, B., McMurray, J. J.V. , Pitt, B., Girerd, N., Rossignol, P. and Zannad, F. (2019) Estimated long-term survival with eplerenone. Journal of the American College of Cardiology, 73(18), pp. 2357-2359. (doi: 10.1016/j.jacc.2019.02.043) (PMID:31072582)
Rossello, X., Ariti, C., Pocock, S. J., Ferreira, J. P., Girerd, N., McMurray, J. J.V. , Van Veldhuisen, D. J., Pitt, B. and Zannad, F. (2019) Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology, 108, pp. 477-486. (doi: 10.1007/s00392-018-1378-0) (PMID:30264282)
Conrad, N. et al. (2019) Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients. PLoS Medicine, 16(5), e1002805. (doi: 10.1371/journal.pmed.1002805) (PMID:31112552) (PMCID:PMC6528949)
Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)
Heerspink, H. H.L. et al. (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393(10184), pp. 1937-1947. (doi: 10.1016/S0140-6736(19)30772-X) (PMID:30995972)
McMurray, J. J.V. (2019) Urinalysis: a window to the heart. JACC: Heart Failure, 7(5), pp. 402-403. (doi: 10.1016/j.jchf.2019.04.002)
McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi: 10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)
Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)
Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)
Rossello, X., Ferreira, J. P., McMurray, J. J.V. , Aguilar, D., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P. and Zannad, F. (2019) Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 8(3), pp. 231-241. (doi: 10.1177/2048872618803701) (PMID:30259764)
Dewan, P. et al. (2019) Income inequality and outcomes in heart failure: a global between-country analysis. JACC: Heart Failure, 7(4), pp. 336-346. (doi: 10.1016/j.jchf.2018.11.005) (PMID:30738981)
Welsh, P. , Papacosta, O., Ramsay, S., Whincup, P., McMurray, J. , Wannamethee, G. and Sattar, N. (2019) High sensitivity troponin T and incident heart failure in older men: British Regional Heart Study. Journal of Cardiac Failure, 25(4), pp. 230-237. (doi: 10.1016/j.cardfail.2018.08.002) (PMID:30103019) (PMCID:PMC7083232)
Myhre, P. L. et al. (2019) B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. Journal of the American College of Cardiology, 73(11), pp. 1264-1272. (doi: 10.1016/j.jacc.2019.01.018) (PMID:30846338)
Charytan, D. M. et al. (2019) Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 21(5), pp. 1199-1208. (doi: 10.1111/dom.13642) (PMID:30672083)
Kristensen, S. L. et al. (2019) N-terminal pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status. Circulation: Heart Failure, 12(3), e005766. (doi: 10.1161/circheartfailure.118.005766) (PMID:30871349)
Loader, J. et al. (2019) Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 279, pp. 126-132. (doi: 10.1016/j.ijcard.2018.12.060) (PMID:30638747)
McCausland, F. R. et al. (2019) Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 73(3), pp. 309-315. (doi: 10.1053/j.ajkd.2018.10.006) (PMID:30578152)
Vardeny, O. et al. (2019) Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure, pp. 337-341. (doi: 10.1002/ejhf.1402) (PMID:30741494) (PMCID:PMC6607492)
Zile, M. R. et al. (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. Journal of the American College of Cardiology, 73(7), pp. 795-806. (doi: 10.1016/j.jacc.2018.11.042) (PMID:30784673)
Abraityte, A., Aukrust, P., Kou, L., Anand, I. S., Young, J., McMurray, J. J.V. , van Veldhuisen, D. J., Gullestad, L. and Ueland, T. (2019) T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clinical Research in Cardiology, 108(2), pp. 133-141. (doi: 10.1007/s00392-018-1331-2) (PMID:30051179)
Macdougall, I. C. et al. (2019) Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), pp. 447-458. (doi: 10.1056/NEJMoa1810742) (PMID:30365356)
Macdougall, I. C. et al. (2019) Correction: Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), p. 502. (doi: 10.1056/NEJMx180044) (PMID:30641026)
Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) Real-world studies no substitute for RCTs in establishing efficacy. Lancet, 393(10168), pp. 210-211. (doi: 10.1016/S0140-6736(18)32840-X) (PMID:30663582)
Claggett, B., Pocock, S., Wei, L. J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2019) Response by Claggett et al to letter regarding article, “Comparison of time-to-first event and recurrent-event methods in randomized clinical trials”. Circulation, 139(3), pp. 422-423. (doi: 10.1161/CIRCULATIONAHA.118.038478) (PMID:30640547)
Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)
Lee, M. M. Y. , McMurray, J. J.V. , Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. , Jhund, P. S. and Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105(4), pp. 337-345. (doi: 10.1136/heartjnl-2016-310342) (PMID:30337334)
Rørth, R. et al. (2019) The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 21(1), pp. 40-49. (doi: 10.1002/ejhf.1359) (PMID:30537261) (PMCID:PMC6607514)
Bhatt, D. L. et al. (2019) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, 394(10204), pp. 1169-1180. (doi: 10.1016/S0140-6736(19)31887-2) (PMID:31484629)
Ferreira, J. P. et al. (2019) Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial. European Journal of Heart Failure, 21(3), pp. 345-351. (doi: 10.1002/ejhf.1400) (PMID:30768732)
Schultheiss, H.-P. et al. (2019) Dilated cardiomyopathy. Nature Reviews Disease Primers, 5, 32. (doi: 10.1038/s41572-019-0084-1) (PMID:31073128)
Stienen, S., Ferreira, J. P., Girerd, N., Duarte, K., Lamiral, Z., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2019) Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology, 108(11), pp. 1215-1225. (doi: 10.1007/s00392-019-01453-7) (PMID:30953180)
2018
Tromp, J. et al. (2018) Heart failure with preserved ejection fraction in the young. Circulation, 138(24), pp. 2763-2773. (doi: 10.1161/CIRCULATIONAHA.118.034720) (PMID:30565987)
Beggs, S. A.S. , Gardner, R. S. and McMurray, J. J.V. (2018) Who benefits from a defibrillator—balancing the risk of sudden versus non-sudden death. Current Heart Failure Reports, 15(6), pp. 376-389. (doi: 10.1007/s11897-018-0416-6) (PMID:30413991) (PMCID:PMC6267371)
Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J.V. , O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D. and Rouleau, J. L. (2018) Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 20(12), pp. 1701-1709. (doi: 10.1002/ejhf.1301) (PMID:30204280)
Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 20(12), pp. 1634-1635. (doi: 10.1002/ejhf.1325) (PMID:30328651)
Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Talking to patients with heart failure about end of life. European Journal of Heart Failure, 20(12), pp. 1763-1765. (doi: 10.1002/ejhf.1321) (PMID:30295978) (PMCID:PMC6607510)
Idzerda, N. M.A., Persson, F., Pena, M. J., Brenner, B. M., Brunel, P., Chaturvedi, N., McMurray, J. J. , Parving, H.-H., de Zeeuw, D. and Heerspink, H. J.L. (2018) N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 20(12), pp. 2899-2904. (doi: 10.1111/dom.13465) (PMID:29987919) (PMCID:PMC6282705)
Ramires, F. J.A. et al. (2018) Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al. ESC Heart Failure, 5(6), pp. 1069-1071. (doi: 10.1002/ehf2.12355) (PMID:30298996) (PMCID:PMC6300803)
Srivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. and Fonarow, G. C. (2018) Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiology, 3(12), pp. 1226-1231. (doi: 10.1001/jamacardio.2018.3957) (PMID:30484837) (PMCID:PMC6583093)
Fudim, M. et al. (2018) Relation of volume overload to clinical outcomes in acute heart failure (from ASCEND-HF). American Journal of Cardiology, 122(9), pp. 1506-1512. (doi: 10.1016/j.amjcard.2018.07.023) (PMID:30172362) (PMCID:PMC6924269)
Kristensen, S. L., Rørth, R., Jhund, P. S. , Shen, L., Lee, M. M.Y. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. European Journal of Heart Failure, 20(11), pp. 1549-1556. (doi: 10.1002/ejhf.1201) (PMID:29727039)
Voors, A. A. et al. (2018) Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 20(11), pp. 1601-16010. (doi: 10.1002/ejhf.1295) (PMID:30225882)
Hernandez, A. F. et al. (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), pp. 1519-1529. (doi: 10.1016/S0140-6736(18)32261-X) (PMID:30291013)
Haynes, R. et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial. Circulation, 138(15), pp. 1505-1514. (doi: 10.1161/CIRCULATIONAHA.118.034818) (PMID:30002098)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Petrie, M. C. and McMurray, J. J.V. (2018) Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 39(37), pp. 3417-3438. (doi: 10.1093/eurheartj/ehy407) (PMID:30085087) (PMCID:PMC6166137)
Cosmi, F., Staszewsky, L., McMurray, J. J.V. and Latini, R. (2018) Risk stratification according to insulin type: reply. European Journal of Heart Failure, 20(10), p. 1498. (doi: 10.1002/ejhf.1218) (PMID:29851246)
Januzzi, J. L. et al. (2018) IGFBP7 (insulin-like growth factor–binding protein-7) and neprilysin inhibition in patients with heart failure. Circulation: Heart Failure, 11(10), e005133. (doi: 10.1161/circheartfailure.118.005133) (PMID:30354399)
Campbell, R. T. et al. (2018) Which patients with heart failure should receive specialist palliative care? European Journal of Heart Failure, 20(9), pp. 1338-1347. (doi: 10.1002/ejhf.1240) (PMID:29952090) (PMCID:PMC6607479)
Green, J. B. et al. (2018) Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-rationale, design, and baseline characteristics. American Heart Journal, 203, pp. 30-38. (doi: 10.1016/j.ahj.2018.03.030) (PMID:30015066)
Ueland, T., Gullestad, L., Kou, L., Aukrust, P., Anand, I. S., Broughton, M. N., McMurray, J. J. , van Veldhuisen, D. J., Warren, D. J. and Bolstad, N. (2018) Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Failure, 5(6), pp. 1052-1059. (doi: 10.1002/ehf2.12312) (PMID:30145817) (PMCID:PMC6300802)
Claggett, B., Pocock, S., Wei, L.J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2018) Comparison of time-to-first event and recurrent event methods in randomized clinical trials. Circulation, 138(6), pp. 570-577. (doi: 10.1161/CIRCULATIONAHA.117.033065) (PMID:29588314)
Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)
Ferreira, J. P., Duarte, K., Pitt, B., Dickstein, K., McMurray, J. J.V. , Zannad, F. and Rossignol, P. (2018) Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trials. Journal of Hypertension, 36(8), pp. 1736-1742. (doi: 10.1097/HJH.0000000000001742) (PMID:29683884)
Grodin, J. L. et al. (2018) Circulating cardiac troponin I levels measured by a novel highly sensitive assay in acute decompensated heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 24(8), pp. 512-519. (doi: 10.1016/j.cardfail.2018.06.008) (PMID:30012361)
Heerspink, H. J.L. et al. (2018) Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism, 20(8), pp. 1829-1835. (doi: 10.1111/dom.13315) (PMID:29604160)
Lund, L. H. et al. (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 20(8), pp. 1230-1239. (doi: 10.1002/ejhf.1149) (PMID:29431256)
Abdul-Rahim, A. H. , Shen, L., Rush, C. J., Jhund, P. S. , Lees, K. R. and McMurray, J. J.V. (2018) Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. European Journal of Heart Failure, 20(7), pp. 1139-1145. (doi: 10.1002/ejhf.1160) (PMID:29493058)
Ferreira, J. P., Duarte, K., McMurray, J. J.V. , Pitt, B., van Veldhuisen, D. J., Vincent, J., Ahmad, T., Tromp, J., Rossignol, P. and Zannad, F. (2018) Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. Circulation: Heart Failure, 11(7), e004926. (doi: 10.1161/CIRCHEARTFAILURE.118.004926) (PMID:29997240)
Packer, M., Claggett, B., Lefkowitz, M. P., McMurray, J. J.V. , Rouleau, J. L., Solomon, S. D. and Zile, M. R. (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 6(7), pp. 547-554. (doi: 10.1016/S2213-8587(18)30100-1) (PMID:29661699)
Solomon, S. D. et al. (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure, 11(7), e004962. (doi: 10.1161/CIRCHEARTFAILURE.118.004962) (PMID:29980595)
Vaduganathan, M., Claggett, B., Packer, M., McMurray, J. J.V. , Rouleau, J. L., Zile, M. R., Swedberg, K. and Solomon, S. D. (2018) Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC: Heart Failure, 6(7), pp. 564-569. (doi: 10.1016/j.jchf.2018.02.007) (PMID:29501807)
McMurray, J. J.V. (2018) Only trials tell the truth about treatment effects. Journal of the American College of Cardiology, 71(23), pp. 2640-2642. (doi: 10.1016/j.jacc.2018.04.019) (PMID:29880123)
Rørth, R., Jhund, P. S. , Mogensen, U. M., Kristensen, S. L., Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care, 41(6), pp. 1285-1291. (doi: 10.2337/dc17-2583) (PMID:29626073)
Chanfra, A. et al. (2018) Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 3(6), pp. 498-505. (doi: 10.1001/jamacardio.2018.0398) (PMID:29617523) (PMCID:PMC6128510)
Damman, K. et al. (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure, 6(6), pp. 489-498. (doi: 10.1016/j.jchf.2018.02.004) (PMID:29655829)
Heerspink, H. J.L. et al. (2018) Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 20(6), pp. 1369-1376. (doi: 10.1111/dom.13245) (PMID:29405626)
McMurray, J. J.V. et al. (2018) Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 104(12), pp. 1006-1013. (doi: 10.1136/heartjnl-2016-310661) (PMID:29269379) (PMCID:PMC5992367)
Simpson, J. and McMurray, J. J.V. (2018) Prognostic modeling in heart failure: time for a reboot. JACC: Heart Failure, 6(6), pp. 463-464. (doi: 10.1016/j.jchf.2018.03.020) (PMID:29852930)
Frikha, Z., Ferreira, J. P., Bozec, E., McMurray, J. J.V. , Pitt, B., Dickstein, K., Rossignol, P., Zannad, F. and Girerd, N. (2018) Relation of high serum bilirubin to short-term mortality following a myocardial infarction complicated by left ventricular systolic dysfunction (from the High-Risk Myocardial Infarction Database Initiative). American Journal of Cardiology, 121(9), pp. 1015-1020. (doi: 10.1016/j.amjcard.2018.01.012) (PMID:29631805)
Cosmi, F. et al. (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 20(5), pp. 888-895. (doi: 10.1002/ejhf.1146) (PMID:29488676)
Lupón, J. et al. (2018) Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 20(5), pp. 938-940. (doi: 10.1002/ejhf.949) (PMID:28949101)
O'Meara, E., Prescott, M. F., Claggett, B., Rouleau, J. L., Chiang, L.-M., Solomon, S. D., Packer, M., McMurray, J. J.V. and Zile, M. R. (2018) Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF Trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(5), e004446. (doi: 10.1161/CIRCHEARTFAILURE.117.004446) (PMID:29748349)
Seferović, P. M. et al. (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20(5), pp. 853-872. (doi: 10.1002/ejhf.1170) (PMID:29520964)
Theodorakis, M. J. et al. (2018) Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 199, pp. 170-175. (doi: 10.1016/j.ahj.2017.09.001) (PMID:29754657)
McMurray, J. J.V. (2018) Renin–angiotensin system inhibition—it's been a long but fruitful journey. European Journal of Heart Failure, 20(4), pp. 687-688. (doi: 10.1002/ejhf.1155) (PMID:29405513)
Mogensen, U. M. et al. (2018) Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 20(4), pp. 760-768. (doi: 10.1002/ejhf.1139) (PMID:29431251)
Vardeny, O. et al. (2018) Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(4), e004745. (doi: 10.1161/CIRCHEARTFAILURE.117.004745) (PMID:29643067)
Tromp, J. et al. (2018) Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 15(3), e1002541. (doi: 10.1371/journal.pmed.1002541) (PMID:29584721) (PMCID:PMC5870945)
Bethel, M. A. and McMurray, J. J.V. (2018) Class effect for sodium glucose-cotransporter-2 inhibitors in cardiovascular outcomes: implications for the cardiovascular disease specialist. Circulation, 137(12), pp. 1218-1220. (doi: 10.1161/CIRCULATIONAHA.117.030117) (PMID:29555706)
Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Journal of the American College of Cardiology, 71(9), pp. 1021-1034. (doi: 10.1016/j.jacc.2017.12.048) (PMID:29495982)
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J.V. and Boulton, D. W. (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 20(3), pp. 479-487. (doi: 10.1111/dom.13126) (PMID:29024278)
Jorsal, A., Wiggers, H. and McMurray, J. J.V. (2018) Heart failure: epidemiology, pathophysiology, and management of heart failure in diabetes mellitus. Endocrinology and Metabolism Clinics of North America, 47(1), pp. 117-135. (doi: 10.1016/j.ecl.2017.10.007) (PMID:29407047)
Mogensen, U. M. et al. (2018) Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure, 20(3), pp. 514-522. (doi: 10.1002/ejhf.1056) (PMID:29193563)
Seferovic, J. P., Pfeffer, M. A., Claggett, B., Desai, A. S., de Zeeuw, D., Haffner, S. M., McMurray, J. J.V. , Parving, H.-H., Solomon, S. D. and Chaturvedi, N. (2018) Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia, 61(3), pp. 581-588. (doi: 10.1007/s00125-017-4485-y) (PMID:29098323)
Wolsk, E., Claggett, B., Køber, L., Pocock, S., Yusuf, S., Swedberg, K., McMurray, J. J.V. , Granger, C. B., Pfeffer, M. A. and Solomon, S. D. (2018) Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 20(3), pp. 504-510. (doi: 10.1002/ejhf.1073) (PMID:29193462)
Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation, 137(9), pp. 961-972. (doi: 10.1161/CIRCULATIONAHA.117.033502) (PMID:29483172)
Ferreira, J. P. et al. (2018) Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. Journal of the American College of Cardiology, 71(7), pp. 727-735. (doi: 10.1016/j.jacc.2017.12.011) (PMID:29447733)
Conrad, N. et al. (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, 391(10120), pp. 10-16. (doi: 10.1016/S0140-6736(17)32520-5) (PMID:29174292) (PMCID:PMC5814791)
Cotter, G. et al. (2018) Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? European Journal of Heart Failure, 20(2), pp. 317-322. (doi: 10.1002/ejhf.889) (PMID:28871621)
Ferreira, J. P., Duarte, K., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2018) Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 20(2), pp. 323-331. (doi: 10.1002/ejhf.1131) (PMID:29314455)
Platz, E., Jhund, P. S. , Claggett, B. L., Pfeffer, M. A., Swedberg, K., Granger, C. B., Yusuf, S., Solomon, S. D. and McMurray, J. J. (2018) Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 20(2), pp. 295-303. (doi: 10.1002/ejhf.901) (PMID:28872259)
Rørth, R. et al. (2018) Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure. European Journal of Heart Failure, 20(2), pp. 240-247. (doi: 10.1002/ejhf.1046) (PMID:29148231)
Schwartz, G. G. et al. (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiology, 3(2), pp. 164-168. (doi: 10.1001/jamacardio.2017.3833) (PMID:29071331) (PMCID:PMC5838593)
van der Meer, P. et al. (2018) Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (Reduction of Events by Darbepoetin Alfa in Heart Failure): clinical and prognostic associations. Circulation: Heart Failure, 11(2), e004431. (doi: 10.1161/CIRCHEARTFAILURE.117.004431) (PMID:29367268)
Welsh, P. et al. (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 20(2), pp. 268-277. (doi: 10.1002/ejhf.988) (PMID:28960777) (PMCID:PMC6607475)
Cleland, J. G.F. et al. (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), pp. 26-35. (doi: 10.1093/eurheartj/ehx564) (PMID:29040525)
Masip, J. et al. (2018) Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 39(1), pp. 17-25. (doi: 10.1093/eurheartj/ehx580) (PMID:29186485)
Beggs, S. A.S. , Jhund, P. S. , Jackson, C. E., McMurray, J. J.V. and Gardner, R. S. (2018) Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 104(2), pp. 144-150. (doi: 10.1136/heartjnl-2016-310850) (PMID:28986406)
Kristensen, S. L. et al. (2018) Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. European Journal of Heart Failure, 20(1), pp. 136-147. (doi: 10.1002/ejhf.896) (PMID:28948656)
McMurray, J. J.V. , Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D. and Krum, H. (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC: Heart Failure, 6(1), pp. 8-17. (doi: 10.1016/j.jchf.2017.08.004) (PMID:29032139)
Rørth, R. et al. (2018) Evidence based therapy and its association with workforce detachment following first hospitalization for heart failure. JACC: Heart Failure, 6(1), pp. 41-48. (doi: 10.1016/j.jchf.2017.09.019) (PMID:29226811)
Kraus, W. E., Yates, T., Tuomilehto, J., Sun, J.-L., Thomas, L., McMurray, J. J.V. , Bethel, M. A. and Holman, R. R. (2018) Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. BMJ Open Diabetes Research and Care, 6, e000523. (doi: 10.1136/bmjdrc-2018-000523) (PMID:30073088) (PMCID:PMC6067333)
Macdougall, I. C. et al. (2018) Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. American Journal of Nephrology, 48(4), pp. 260-268. (doi: 10.1159/000493551) (PMID:30304714)
McAllister, D. A. et al. (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation, 138(24), pp. 2774-2785. (doi: 10.1161/CIRCULATIONAHA.118.034986) (PMID:29950404) (PMCID:PMC6287897)
Rørth, R. et al. (2018) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure: a nationwide cohort study. Clinical Epidemiology, 10, pp. 917-930. (doi: 10.2147/CLEP.S164795) (PMID:30123004) (PMCID:PMC6080879)
Seferovic, J. P. et al. (2018) Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. Journal of Diabetes Research, 2018, 1631263. (doi: 10.1155/2018/1631263) (PMID:30648112) (PMCID:PMC6311850)
Verma, S. and McMurray, J. J.V. (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), pp. 2108-2117. (doi: 10.1007/s00125-018-4670-7) (PMID:30132036)
2017
Kristensen, S. L., Jhund, P. S. , Lee, M. M.Y. , Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K. and McMurray, J. J.V. (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovascular Drugs and Therapy, 31(5-6), pp. 545-549. (doi: 10.1007/s10557-017-6754-x) (PMID:28948430)
Senni, M., McMurray, J. J.V. , Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. and Charney, A. (2017) Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 20(3), pp. 491-500. (doi: 10.1002/ejhf.1054) (PMID:29164797)
Shen, L., Jhund, P. S. and McMurray, J. J.V. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(18), pp. 1794-1795. (doi: 10.1056/NEJMc1711901) (PMID:29091558)
Holman, R. R. et al. (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(11), pp. 877-886. (doi: 10.1016/S2213-8587(17)30309-1) (PMID:28917545)
McDonald, M. A. et al. (2017) Mind the gap: current challenges and future state of heart failure care. Canadian Journal of Cardiology, 33(11), pp. 1434-1449. (doi: 10.1016/j.cjca.2017.08.023) (PMID:29111107)
Mogensen, U. M. et al. (2017) Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology, 70(20), pp. 2490-2500. (doi: 10.1016/j.jacc.2017.09.027) (PMID:29145948)
Shen, L. et al. (2017) Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circulation: Heart Failure, 10(11), e004361. (doi: 10.1161/CIRCHEARTFAILURE.117.004361) (PMID:29141857)
Stewart, S., Keates, A. K., Redfern, A. and McMurray, J. J.V. (2017) Seasonal variations in cardiovascular disease. Nature Reviews Cardiology, 14(11), pp. 654-664. (doi: 10.1038/nrcardio.2017.76) (PMID:28518176)
Wong, C. M. et al. (2017) Heart failure in young adults is associated with high mortality: a contemporary population-level analysis. Canadian Journal of Cardiology, 33(11), pp. 1472-1477. (doi: 10.1016/j.cjca.2017.05.009) (PMID:28941947)
Wolsk, E. et al. (2017) Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes mellitus. Circulation, 136(16), pp. 1560-1562. (doi: 10.1161/CIRCULATIONAHA.117.029503) (PMID:29038210)
Charytan, D. M. et al. (2017) ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. American Journal of Kidney Diseases, 70(4), pp. 522-531. (doi: 10.1053/j.ajkd.2017.04.018) (PMID:28599901)
Kristensen, S. L. et al. (2017) Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circulation: Heart Failure, 10(10), e004409. (doi: 10.1161/CIRCHEARTFAILURE.117.004409) (PMID:29018174)
Griffin, E. A. et al. (2017) Cost-effectiveness analysis of natriuretic peptide testing and specialist management in patients with suspected acute heart failure. Value in Health, 20(8), pp. 1025-1033. (doi: 10.1016/j.jval.2017.05.007) (PMID:28964433)
Olivier, A. et al. (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 19(9), pp. 1186-1197. (doi: 10.1002/ejhf.792) (PMID:28303624)
Platz, E., Merz, A. A., Jhund, P. S. , Vazir, A., Campbell, R. and McMurray, J. J. (2017) Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. European Journal of Heart Failure, 19(9), pp. 1154-1163. (doi: 10.1002/ejhf.839) (PMID:28557302)
Verma, S., McMurray, J. J.V. and Cherney, D. Z.I. (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiology, 2(9), pp. 939-940. (doi: 10.1001/jamacardio.2017.1891) (PMID:28636701)
Baigent, C. et al. (2017) Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 92(2), pp. 297-305. (doi: 10.1016/j.kint.2017.04.019) (PMID:28709600)
Lewis, E. F. et al. (2017) Health-related quality of life outcomes in PARADIGM-HF. Circulation: Heart Failure, 10(8), e003430. (doi: 10.1161/CIRCHEARTFAILURE.116.003430) (PMID:28784687)
Shen, L., Jhund, P. S. , Mogensen, U. M., Køber, L., Claggett, B., Rogers, J. K. and McMurray, J. J.V. (2017) A re-examination of the BEST Trial using composite outcomes, including emergency department visits. JACC: Heart Failure, 5(8), pp. 591-599. (doi: 10.1016/j.jchf.2017.04.005) (PMID:28774394)
Shen, L. et al. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(1), pp. 41-51. (doi: 10.1056/NEJMoa1609758) (PMID:28679089)
Price, S. et al. (2017) Expert consensus document: echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nature Reviews Cardiology, 14(7), pp. 427-440. (doi: 10.1038/nrcardio.2017.56) (PMID:28447662)
Solomon, S. D. et al. (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction. JACC: Heart Failure, 5(7), pp. 471-482. (doi: 10.1016/j.jchf.2017.04.013) (PMID:28662936)
MacDonald, T. M. et al. (2017) Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 38(23), pp. 1843-1850. (doi: 10.1093/eurheartj/ehw387) (PMID:27705888) (PMCID:PMC5837371)
Cleland, J. G.F. et al. (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure, 19(6), pp. 739-747. (doi: 10.1002/ejhf.786) (PMID:28296139)
Cowie, M. R. et al. (2017) New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 19(6), pp. 718-727. (doi: 10.1002/ejhf.809) (PMID:28345190)
Currie, G. , Bethel, M. A., Holzhauer, B., Haffner, S. M., Holman, R. R. and McMurray, J. J.V. (2017) Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 19(6), pp. 791-799. (doi: 10.1111/dom.12877) (PMID:28093841)
Guimarães, P. O. et al. (2017) Effect of Apixaban on all-cause death in patients with atrial fibrillation: a meta-analysis based on imputed placebo effect. Cardiovascular Drugs and Therapy, 31(3), pp. 295-301. (doi: 10.1007/s10557-017-6728-z) (PMID:28516318)
Mogensen, U. M. et al. (2017) The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 188, pp. 35-41. (doi: 10.1016/j.ahj.2017.02.034) (PMID:28577679)
Rossignol, P. et al. (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 19(6), pp. 792-799. (doi: 10.1002/ejhf.688) (PMID:27868385)
Wolsk, E. et al. (2017) Role of b-type natriuretic peptide and n-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association, 6(6), e004743. (doi: 10.1161/JAHA.116.004743) (PMID:28554908)
Packer, M. et al. (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine, 376(20), pp. 1956-1964. (doi: 10.1056/NEJMoa1601895) (PMID:28402745)
Packer, M. and McMurray, J. J.V. (2017) Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, 389(10081), pp. 1831-1840. (doi: 10.1016/S0140-6736(16)30969-2) (PMID:27919443)
Bethel, M. A. et al. (2017) Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and its Complications, 31(5), pp. 859-863. (doi: 10.1016/j.jdiacomp.2017.02.012) (PMID:28319004)
Cowper, P. A. et al. (2017) Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. JAMA Cardiology, 2(5), pp. 525-534. (doi: 10.1001/jamacardio.2017.0065) (PMID:28355434)
Ho, C. Y. et al. (2017) Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial. American Heart Journal, 187, pp. 145-155. (doi: 10.1016/j.ahj.2017.02.008) (PMID:28454798) (PMCID:PMC5586211)
Packer, M. et al. (2017) Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure, 19(5), pp. 673-681. (doi: 10.1002/ejhf.698) (PMID:27862700)
Packer, M. et al. (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure : primary results of the ENABLE Trials. JACC: Heart Failure, 5(5), pp. 317-326. (doi: 10.1016/j.jchf.2017.02.021) (PMID:28449795)
Seferovic, J. P. et al. (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 5(5), pp. 333-340. (doi: 10.1016/S2213-8587(17)30087-6) (PMID:28330649) (PMCID:PMC5534167)
Cannon, J. A., Moffitt, P., Perez-Moreno, A. C., Walters, M. R. , Broomfield, N. M., McMurray, J. J.V. and Quinn, T. J. (2017) Cognitive impairment and heart failure: systematic review and meta-analysis. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2017.04.007) (PMID:28433667)
Böhm, M. et al. (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 38(15), pp. 1132-1143. (doi: 10.1093/eurheartj/ehw570) (PMID:28158398)
Nymo, S. H. et al. (2017) Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC: Heart Failure, 5(4), pp. 256-264. (doi: 10.1016/j.jchf.2017.01.008) (PMID:28359413)
Abdul-Rahim, A. H. et al. (2017) Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 38(10), pp. 742-750. (doi: 10.1093/eurheartj/ehw509) (PMID:28426886) (PMCID:PMC5460584)
Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)
Emdin, C. A. et al. (2017) Referral for specialist follow-up and its association with post-discharge mortality among patients with systolic heart failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 119(3), pp. 440-444. (doi: 10.1016/j.amjcard.2016.10.021) (PMID:27884420) (PMCID:PMC5282396)
Beldhuis, I. E., Streng, K. W., Ter Maaten, J. M., Voors, A. A., van der Meer, P., Rossignol, P., McMurray, J. J.V. and Damman, K. (2017) Renin–angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 10(2), e003588. (doi: 10.1161/CIRCHEARTFAILURE.116.003588) (PMID:28209765)
Ferreira, J. P. et al. (2017) Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction. Circulation: Heart Failure, 10(2), e003500. (doi: 10.1161/CIRCHEARTFAILURE.116.003500) (PMID:28159825)
Kitai, T. et al. (2017) Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. European Journal of Heart Failure, 19(2), pp. 241-249. (doi: 10.1002/ejhf.629) (PMID:27634557)
Mueller, C. et al. (2017) European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. European Heart Journal: Acute Cardiovascular Care, 6(1), pp. 81-86. (doi: 10.1177/2048872615593279) (PMID:26124458)
Paton, D. M., Shamy, M., Fedyk, M., Pfeffer, M. A. and McMurray, J. J.V. (2017) Clinical trials involving hypertension [Correspondence]. New England Journal of Medicine, 376(3), pp. 289-290. (doi: 10.1056/NEJMc1615364) (PMID:28099831)
Agewall, S. et al. (2017) 2016 ESC guidelines for the diagnosis and treatment of atrial fibrillation developed in collaboration with the EACTS [Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS]. Revista Española de Cardiología, 70(1), 50.e1-50.e84. (doi: 10.1016/j.recesp.2016.11.014)
Hawkins, N. M., Khosla, A., Virani, S. A., McMurray, J. J.V. and FitzGerald, J. M. (2017) B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 17, 11. (doi: 10.1186/s12890-016-0345-7) (PMID:28073350) (PMCID:PMC5223538)
Cannon, J. A. et al. (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 19(1), pp. 129-137. (doi: 10.1002/ejhf.687) (PMID:27868321) (PMCID:PMC5248626)
Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J.V. , Deschaseaux, C. and Cope, S. (2017) Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure, 10, e003529. (doi: 10.1161/CIRCHEARTFAILURE.116.003529) (PMID:28087688)
Desai, A. S. et al. (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/Valsartan compared with Enalapril: A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiology, 2(1), pp. 79-85. (doi: 10.1001/jamacardio.2016.4733) (PMID:27842179)
Gandhi, P. U. et al. (2017) Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure, 23(1), pp. 20-28. (doi: 10.1016/j.cardfail.2016.06.006) (PMID:27317843)
Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)
Arain, F., Gullestad, L., Nymo, S., Kjekshus, J., Cleland, J. G.F. , Michelsen, A., McMurray, J. J.V. , Wikstrand, J., Aukrust, P. and Ueland, T. (2017) Low YKL-40 in Chronic Heart Failure may predict beneficial effects of statins: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Biomarkers, 22, pp. 261-267. (doi: 10.1080/1354750X.2016.1204003) (PMID:27325138)
Harumi Higuchi dos Santos, M., Sharma, A., Sun, J.‐L., Pieper, K., McMurray, J. J.V. , Holman, R. R. and Lopes, R. D. (2017) International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: insights from the NAVIGATOR Trial. Journal of the American Heart Association, 6(1), e003892. (doi: 10.1161/JAHA.116.003892) (PMID:28087508) (PMCID:PMC5523624)
Mc Causland, F. R. et al. (2017) Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial. American Journal of Nephrology, 46(6), pp. 488-497. (doi: 10.1159/000485326) (PMID:29241199)
Miro, Ò. et al. (2017) European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. European Heart Journal: Acute Cardiovascular Care, 6(4), pp. 311-320. (doi: 10.1177/2048872616633853) (PMID:26900163)
Pitts, R. et al. (2017) Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure. Journal of the American Heart Association, 6(1), e004119. (doi: 10.1161/JAHA.116.004119) (PMID:28073769) (PMCID:PMC5523625)
Ridker, P. M. et al. (2017) Cardiovascular efficacy and safety of Bococizumab in high-risk patients. New England Journal of Medicine, 376(16), pp. 1527-1539. (doi: 10.1056/NEJMoa1701488) (PMID:28304242)
2016
Khder, Y., Shi, V., McMurray, J. J.V. and Lefkowitz, M. P. (2016) Sacubitril/valsartan (LCZ696) in heart failure. In: Handbook of Experimental Pharmacology. Springer. (doi: 10.1007/164_2016_77)
Teerlink, J. R. et al. (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, 388(10062), pp. 2895-2903. (doi: 10.1016/S0140-6736(16)32049-9)
Zile, M. R. et al. (2016) Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology, 68(22), pp. 2425-2436. (doi: 10.1016/j.jacc.2016.09.931) (PMID:27908347)
Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B. and McMurray, J. J.V. (2016) Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure, 18(12), pp. 1508-1517. (doi: 10.1002/ejhf.609) (PMID:27427441)
Mc Causland, F. R. et al. (2016) C-Reactive protein and risk of ESRD: results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 68(6), pp. 873-881. (doi: 10.1053/j.ajkd.2016.07.022) (PMID:27646425) (PMCID:PMC5123931)
Pitts, R. et al. (2016) Treatment with Dalcetrapib modifies the relationship between high-density lipoprotein cholesterol and C-reactive protein. Journal of the American College of Cardiology, 68(22), pp. 2488-2490. (doi: 10.1016/j.jacc.2016.09.932) (PMID:27908356)
Ponikowski, P. et al. (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica]. Revista Española de Cardiología, 69(12), 1167.e1-1167.e85. (doi: 10.1016/j.recesp.2016.10.014)
Ferreira, J. P. et al. (2016) Renal function estimation and Cockroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: the Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 14, 181. (doi: 10.1186/s12916-016-0731-2) (PMID:27829460) (PMCID:PMC5103492)
Pfeffer, M. A. and McMurray, J. J.V. (2016) Lessons in uncertainty and humility — Clinical trials involving hypertension. New England Journal of Medicine, 375(18), pp. 1756-1766. (doi: 10.1056/NEJMra1510067) (PMID:27806228)
Martín-Sánchez, F. J. et al. (2016) Practical approach on frail older patients attended for acute heart failure. International Journal of Cardiology, 222, pp. 62-71. (doi: 10.1016/j.ijcard.2016.07.151) (PMID:27458825)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18(11), pp. 1609-1678. (doi: 10.1093/europace/euw295) (PMID:27567465)
Savarese, G., Giugliano, R. P., Rosano, G. M.C., McMurray, J. , Magnani, G., Filippatos, G., Dellegrottaglie, S., Lund, L. H., Trimarco, B. and Perrone-Filardi, P. (2016) Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC: Heart Failure, 4(11), pp. 881-884. (doi: 10.1016/j.jchf.2016.07.012) (PMID:27614940)
Rørth, R. et al. (2016) Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study. Circulation, 134(14), pp. 999-1009. (doi: 10.1161/CIRCULATIONAHA.116.021859) (PMID:27507406)
Cotter, G. et al. (2016) Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure, 22(10), pp. 815-822. (doi: 10.1016/j.cardfail.2015.12.017) (PMID:26721775)
Solomon, S. D., Claggett, B., McMurray, J. J.V. , Hernandez, A. F. and Fonarow, G. C. (2016) Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. European Journal of Heart Failure, 18(10), pp. 1238-1243. (doi: 10.1002/ejhf.603) (PMID:27364182)
Solomon, S. D., Claggett, B., Packer, M., Desai, A., Zile, M. R., Swedberg, K., Rouleau, J., Shi, V., Lefkowitz, M. and McMurray, J. J.V. (2016) Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC: Heart Failure, 4(10), pp. 816-822. (doi: 10.1016/j.jchf.2016.05.002) (PMID:27395349)
Vardeny, O. et al. (2016) Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 18(10), pp. 1228-1234. (doi: 10.1002/ejhf.580) (PMID:27283779) (PMCID:PMC5095784)
McMurray, J. J.V. (2016) The ICD in heart failure - time for a rethink? New England Journal of Medicine, 375(13), pp. 1283-1284. (doi: 10.1056/NEJMe1609826) (PMID:27571386)
Judge, P.K. et al. (2016) Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfw321) (PMID:27646835)
McMurray, J. J.V. (2016) Site selection and performance in clinical trials. Circulation: Heart Failure, 9(9), e003490. (doi: 10.1161/CIRCHEARTFAILURE.116.003490) (PMID:27623771)
Chin, K. L. et al. (2016) Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. European Journal of Heart Failure, 18(9), pp. 1175-1181. (doi: 10.1002/ejhf.485) (PMID:26833642)
Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J.V. and Solomon, S. D. (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiology, 1(6), pp. 666-672. (doi: 10.1001/jamacardio.2016.1747) (PMID:27438344)
Hawkins, N. M. et al. (2016) Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 18(9), pp. 1162-1171. (doi: 10.1002/ejhf.614) (PMID:27594177)
Jhund, P. S. and McMurray, J. J.V. (2016) The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 102(17), pp. 1342-1347. (doi: 10.1136/heartjnl-2014-306775) (PMID:27207980) (PMCID:PMC5013095)
Okumura, N. et al. (2016) Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. Circulation: Heart Failure, 9(9), e003212. (doi: 10.1161/CIRCHEARTFAILURE.116.003212) (PMID:27618854)
Senni, M. et al. (2016) Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. European Journal of Heart Failure, 18(9), pp. 1193-1202. (doi: 10.1002/ejhf.548) (PMID:27170530) (PMCID:PMC5084812)
McMurray, J. J.V. , Dickstein, K. and Kober, L. V. (2016) The author's reply - Aliskiren, Enalapril, or both in heart failure. New England Journal of Medicine, 375(7), pp. 701-702. (doi: 10.1056/NEJMc1606625) (PMID:27532843)
Hawkins, N. M., Virani, S. A., Sperrin, M., Buchan, I. E., McMurray, J. J.V. and Krahn, A. D. (2016) Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. European Journal of Heart Failure, 18(8), pp. 977-986. (doi: 10.1002/ejhf.458) (PMID:26663507)
Cannon, J. A., Shen, L., Jhund, P. , Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J. V. (2016) Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. European Journal of Heart Failure, 18(8), pp. 1021-1031. (doi: 10.1002/ejhf.547) (PMID:27194023)
Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 18(8), pp. 891-975. (doi: 10.1002/ejhf.592) (PMID:27207191)
Desai, A. S. et al. (2016) Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. Journal of the American College of Cardiology, 68(3), pp. 241-248. (doi: 10.1016/j.jacc.2016.04.047) (PMID:27417000)
McMurray, J. J.V. and Køber, L. V. (2016) End of the road for vagus nerve stimulation? Journal of the American College of Cardiology, 68(2), pp. 159-160. (doi: 10.1016/j.jacc.2016.05.025) (PMID:27386768)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1333-1339. (doi: 10.1007/s00125-016-3956-x) (PMID:27112340) (PMCID:PMC4901113)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J. (2016) Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1573-1574. (doi: 10.1007/s00125-016-3987-3) (PMID:27174369) (PMCID:PMC4969788)
Okumura, N. et al. (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation, 133(23), pp. 2254-2262. (doi: 10.1161/CIRCULATIONAHA.115.020729) (PMID:27143684)
Woodcock, J., Ware, J. H., Miller, P. W., McMurray, J. J.V. , Harrington, D. P. and Drazen, J. M. (2016) Clinical Trials Series. New England Journal of Medicine, 374(22), p. 2167. (doi: 10.1056/NEJMe1601510)
Berry, C. et al. (2016) Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM: An International Journal of Medicine, 109(6), pp. 377-382. (doi: 10.1093/qjmed/hcv087) (PMID:25979270)
Metra, M. et al. (2016) Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology, 117(11), pp. 1771-1778. (doi: 10.1016/j.amjcard.2016.03.002) (PMID:27108685)
Abdul-Rahim, A. H. et al. (2016) Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 1(2), pp. 93-100. (doi: 10.1177/2396987316646025)
Anker, S. D. et al. (2016) Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482-489]. European Journal of Heart Failure, 18(6), p. 727. (doi: 10.1002/ejhf.591) (PMID:27324688)
Desai, A. S., Solomon, S., Claggett, B., McMurray, J. J.V. , Rouleau, J., Swedberg, K., Zile, M., Lefkowitz, M., Shi, V. and Packer, M. (2016) Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circulation: Heart Failure, 9(6), e002735. (doi: 10.1161/CIRCHEARTFAILURE.115.002735) (PMID:27296397)
Lopes, R. D., Pieper, K. S., Stevens, S. R., Solomon, S. D., McMurray, J. J.V. , Pfeffer, M. A., Leimberger, J. D. and Velazquez, E. J. (2016) Predicting outcomes over time in patients with heart failure, left ventricular systolic dysfunction, or both following acute myocardial infarction. Journal of the American Heart Association, 5(6), e003045. (doi: 10.1161/JAHA.115.003045) (PMID:27353607) (PMCID:PMC4937254)
Whellan, D. J., Stebbins, A., Hernandez, A. F., Ezekowitz, J. A., McMurray, J. J.V. , Mather, P. J., Hasselblad, V. and O'Connor, C. M. (2016) Dichotomous relationship between age and 30-day death or rehospitalization in heart failure patients admitted with acute decompensated heart failure: results from the ASCEND-HF trial. Journal of Cardiac Failure, 22(6), pp. 409-416. (doi: 10.1016/j.cardfail.2016.02.011) (PMID:26952241)
McMurray, J. J.V. (2016) Disease management programs in cardiology. Circulation, 133(19), pp. 1836-1837. (doi: 10.1161/circulationaha.116.022480) (PMID:27083508)
Anker, S. D. et al. (2016) Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 18(5), pp. 482-489. (doi: 10.1002/ejhf.516) (PMID:27071916)
Campbell, R. T., Willox, G. P., Jhund, P. S. , Hawkins, N. M., Huang, F., Petrie, M. C. and McMurray, J. J. V. (2016) Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review. Circulation: Heart Failure, 9(5), e002842. (doi: 10.1161/CIRCHEARTFAILURE.115.002842) (PMID:27162229)
McMurray, J. J.V. et al. (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine, 374(16), pp. 1521-1532. (doi: 10.1056/NEJMoa1514859) (PMID:27043774)
Abdul-Rahim, A. H. , MacIsaac, R. L., Jhund, P. S. , Petrie, M. C. , Lees, K. R. and McMurray, J. J.V. (2016) Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 209, pp. 310-316. (doi: 10.1016/j.ijcard.2016.02.074) (PMID:26913372)
Heerspink, H. J.L. et al. (2016) Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes and Endocrinology, 4(4), pp. 309-317. (doi: 10.1016/S2213-8587(15)00469-6) (PMID:26774608)
McMurray, J. J.V. and Køber, L. (2016) Trials and the ‘real world’ - how different are they? European Journal of Heart Failure, 18(4), pp. 411-413. (doi: 10.1002/ejhf.503) (PMID:27019978)
Sabe, M. A. et al. (2016) Coronary artery disease is a predictor of progression to dialysis in patients with chronic kidney disease, type 2 diabetes mellitus, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp therapy (TREAT). Journal of the American Heart Association, 5(4), e002850. (doi: 10.1161/JAHA.115.002850) (PMID:27108247) (PMCID:PMC4859277)
Samsky, M. D. et al. (2016) Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. European Journal of Heart Failure, 18(4), pp. 424-432. (doi: 10.1002/ejhf.440) (PMID:26707029)
Teerlink, J. R. et al. (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. Journal of the American College of Cardiology, 67(12), pp. 1444-1455. (doi: 10.1016/j.jacc.2016.01.031) (PMID:27012405)
Ambrosy, A. P. et al. (2016) The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 18(3), pp. 306-313. (doi: 10.1002/ejhf.420) (PMID:26467269)
Damman, K., Kjekshus, J., Wikstrand, J., Cleland, J. G.F. , Komajda, M., Wedel, H., Waagstein, F. and McMurray, J. J.V. (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 18(3), pp. 328-336. (doi: 10.1002/ejhf.462) (PMID:26693947)
Perez, A. L. et al. (2016) Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 18(3), pp. 290-297. (doi: 10.1002/ejhf.456) (PMID:26663359)
Solomon, S. D. et al. (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circulation: Heart Failure, 9(3), e002744. (doi: 10.1161/CIRCHEARTFAILURE.115.002744) (PMID:26915374)
Heerspink, H.J.L. et al. (2016) Is a reduction in albuminuria associated with renal and cardiovascular protection? A post-hoc analysis of the ALTITUDE trial. Diabetes, Obesity and Metabolism, 18(2), pp. 169-177. (doi: 10.1111/dom.12600) (PMID:26511599)
Vardeny, O. et al. (2016) Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF Trial. JACC: Heart Failure, 4(2), pp. 152-158. (doi: 10.1016/j.jchf.2015.10.012) (PMID:26746371)
Kristensen, S. L. et al. (2016) Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. (doi: 10.1161/CIRCHEARTFAILURE.115.002560) (PMID:26754626) (PMCID:PMC4718182)
McMurray, J. (2016) EMPA-REG – the “diuretic hypothesis”. Journal of Diabetes and its Complications, 30(1), pp. 3-4. (doi: 10.1016/j.jdiacomp.2015.10.012) (PMID:26597600)
Tang, W.H. W. et al. (2016) Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC: Heart Failure, 4(1), pp. 68-77. (doi: 10.1016/j.jchf.2015.07.015) (PMID:26656144)
Theilade, S., Claggett, B., Hansen, T.W., Skali, H., Lewis, E.F., Solomon, S.D., Parving, H.-H., Pfeffer, M., McMurray, J.J. and Rossing, P. (2016) Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 30(1), pp. 46-52. (doi: 10.1038/jhh.2015.22) (PMID:25810068)
Zile, M. R. et al. (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction. Circulation: Heart Failure, 9(1), e002551. (doi: 10.1161/circheartfailure.115.002551) (PMID:26754625)
Emdin, C. A. et al. (2016) Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 103(1), pp. 55-62. (doi: 10.1136/heartjnl-2016-309706) (PMID:27530132)
Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5), e1-e88. (doi: 10.1093/ejcts/ezw313) (PMID:27663299)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37(38), pp. 2893-2962. (doi: 10.1093/eurheartj/ehw210) (PMID:27567408)
Kristensen, S. L. et al. (2016) Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 37(41), pp. 3167-3174. (doi: 10.1093/eurheartj/ehw226) (PMID:27354044) (PMCID:PMC5106574)
Nadruz, W. et al. (2016) Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation, 134(22), pp. 1785-1787. (doi: 10.1161/CIRCULATIONAHA.116.024976) (PMID:27895026)
Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), pp. 2129-2200. (doi: 10.1093/eurheartj/ehw128) (PMID:27206819)
2015
Cannon, J. A., McKean, A. R., Jhund, P. S. and McMurray, J. J.V. (2015) What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open Heart, 2(1), e000283. (doi: 10.1136/openhrt-2015-000283) (PMID:26719808) (PMCID:PMC4692046)
Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(23), pp. 2648-62. (doi: 10.1016/j.jacc.2015.10.023) (PMID:26670066)
Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Making sense of statistics in clinical trial reports: Part 1 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(22), pp. 2536-2549. (doi: 10.1016/j.jacc.2015.10.014) (PMID:26653629)
Claggett, B., Packer, M., McMurray, J. J.V. , Swedberg, K., Rouleau, J., Zile, M. R., Jhund, P., Lefkowitz, M., Shi, V. and Solomon, S. D. (2015) Estimating the long-term treatment benefits of Sacubitril–Valsartan. New England Journal of Medicine, 373(23), pp. 2289-2290. (doi: 10.1056/NEJMc1509753) (PMID:26630151)
Gheorghiade, M. et al. (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction. JAMA: Journal of the American Medical Association, 314(21), pp. 2251-2262. (doi: 10.1001/jama.2015.15734) (PMID:26547357)
McMurray, J. J.J.V. (2015) Improving outcomes in heart failure: a personal perspective. European Heart Journal, 36(48), pp. 3467-3470. (doi: 10.1093/eurheartj/ehv565) (PMID:26578200)
Pfeffer, M. A. et al. (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine, 373(23), pp. 2247-2257. (doi: 10.1056/NEJMoa1509225) (PMID:26630143)
Simpson, J. et al. (2015) Comparing LCZ696 with Enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores. Journal of the American College of Cardiology, 66(19), pp. 2059-2071. (doi: 10.1016/j.jacc.2015.08.878) (PMID:26541915)
McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)
Wang, N. et al. (2015) Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal, (doi: 10.1093/eurheartj/ehv558) (PMID:26530103)
Bello, N. A. et al. (2015) Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 17(11), pp. 1201-1207. (doi: 10.1002/ejhf.412) (PMID:26423928) (PMCID:PMC4703474)
Simpson, J. et al. (2015) Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure, 17(11), pp. 1182-1191. (doi: 10.1002/ejhf.346) (PMID:26358762)
Jhund, P. et al. (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 36(38), pp. 2576-2584. (doi: 10.1093/eurheartj/ehv330) (PMID:26231885) (PMCID:PMC4595742)
Grodin, J. L. et al. (2015) Circulating kidney injury molecule-1 levels in acute heart failure. JACC: Heart Failure, 3(10), pp. 777-785. (doi: 10.1016/j.jchf.2015.06.006) (PMID:26449997)
Krum, H. et al. (2015) The Aliskiren trial to minimize outcomes in patients with heart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure, 17(10), pp. 1075-1083. (doi: 10.1002/ejhf.408) (PMID:26511146)
Jhund, P. et al. (2015) Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 36(36), pp. 2463-2469. (doi: 10.1093/eurheartj/ehv295) (PMID:26188211)
Girerd, N., Collier, T., Pocock, S., Krum, H., McMurray, J. J. , Swedberg, K., Van Veldhuisen, D. J., Vincent, J., Pitt, B. and Zannad, F. (2015) Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 36(34), pp. 2310-2317. (doi: 10.1093/eurheartj/ehv273) (PMID:26093641)
Charytan, D. M. et al. (2015) Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). American Journal of Kidney Diseases, 66(3), pp. 429-440. (doi: 10.1053/j.ajkd.2015.02.324) (PMID:25935581)
Fisher, M., Petrie, M. , Ambery, P., Donaldson, J., McMurray, J. J.V. and Ye, J. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology, 3(9), pp. 697-703. (doi: 10.1016/s2213-8587(15)00233-8) (PMID:26276240)
Kao, D. P., Lewsey, J. D. , Anand, I. S., Massie, B. M., Zile, M. R., Carson, P. E., McKelvie, R. S., Komajda, M., McMurray, J. J.V. and Lindenfeld, J. (2015) Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure, 17(9), pp. 925-935. (doi: 10.1002/ejhf.327) (PMID:26250359)
Platz, E., Jhund, P. S. , Campbell, R. T. and McMurray, J. (2015) Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. European Journal of Heart Failure, 17(9), pp. 906-916. (doi: 10.1002/ejhf.321) (PMID:26230356) (PMCID:PMC4725064)
McMurray, J. J.V. (2015) It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? European Heart Journal, 36(31), pp. 2047-2049. (doi: 10.1093/eurheartj/ehv190) (PMID:25994745)
Desai, A. S. et al. (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 36(30), pp. 1990-1997. (doi: 10.1093/eurheartj/ehv186) (PMID:26022006)
Mebazaa, A. et al. (2015) Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 36(30), pp. 1958-1966. (doi: 10.1093/eurheartj/ehv066) (PMID:25998514)
Askevold, E. T., Gullestad, L., Nymo, S., Kjekshus, J., Yndestad, A., Latini, R., Cleland, J. G.F. , McMurray, J. J.V. , Aukrust, P. and Ueland, T. (2015) Secreted frizzled related protein 3 in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS ONE, 10(8), e0133970. (doi: 10.1371/journal.pone.0133970) (PMID:26288364) (PMCID:PMC4545831)
Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)
Jhund, P. S. , Anand, I. S., Komajda, M., Claggett, B. L., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J.V. (2015) Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. European Journal of Heart Failure, 17(8), pp. 809-817. (doi: 10.1002/ejhf.274) (PMID:25921853)
Khazanie, P. et al. (2015) Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated heart failure outcome models. American Heart Journal, 170(2), pp. 290-297. (doi: 10.1016/j.ahj.2015.04.006) (PMID:26299226)
Lewis, E. F. et al. (2015) Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal, 170(2), 322-329.e4. (doi: 10.1016/j.ahj.2015.05.008) (PMID:26299230)
Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi: 10.1136/bmjopen-2015-007901) (PMID:26275900) (PMCID:PMC4550730)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)
Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi: 10.1111/dme.12762) (PMID:25818859)
Emdin, C. A., Callender, T., Cao, J., McMurray, J. J.V. and Rahimi, K. (2015) Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. American Journal of Cardiology, 116(1), pp. 155-61. (doi: 10.1016/j.amjcard.2015.03.052) (PMID:25937349)
Cannon, J.A. et al. (2015) Clinical outcomes according to QRS duration and morphology in the eplerenone in mild patients: hospitalization and survIval study in heart failure (EMPHASIS-HF). European Journal of Heart Failure, 17(7), pp. 707-716. (doi: 10.1002/ejhf.303) (PMID:26139584)
Green, J. B. et al. (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), pp. 232-242. (doi: 10.1056/NEJMoa1501352) (PMID:26052984)
Harinstein, M. E. et al. (2015) Site selection for heart failure clinical trials in the USA. Heart Failure Reviews, 20(4), pp. 375-383. (doi: 10.1007/s10741-015-9473-z) (PMID:25649127)
Dalzell, J. R., Rocchiccioli, J. P., Weir, R. A.P., Jackson, C. E., Padmanabhan, N., Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) The emerging potential of the apelin-APJ system in heart failure. Journal of Cardiac Failure, 21(6), pp. 489-498. (doi: 10.1016/j.cardfail.2015.03.007) (PMID:25795508)
Kristensen, S. L., Jhund, P. S. , Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F. , Carson, P. E. and McMurray, J. J.V. (2015) Relative importance of history of heart failure hospitalization and N-terminal pro–B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 3(6), pp. 478-486. (doi: 10.1016/j.jchf.2015.01.014) (PMID:26046842)
Mebazaa, A. et al. (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergenc. European Journal of Heart Failure, 17(6), pp. 544-558. (doi: 10.1002/ejhf.289) (PMID:25999021)
Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)
Bentley-Lewis, R. et al. (2015) Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5), 631-638.e7. (doi: 10.1016/j.ahj.2015.02.002) (PMID:25965710)
Abdul-Rahim, A. H. et al. (2015) Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the controlled rosuvastatin in multinational trial heart failure (corona) and the gruppo italiano per lo studio della sopravvivenza nell'insufficienza cardiaca-heart failure (gissi-hf) trials. Circulation, 131(17), pp. 1486-1494. (doi: 10.1161/CIRCULATIONAHA.114.013760) (PMID:25810334)
Ezekowitz, J. A. et al. (2015) Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 1(2), pp. 86-94. (doi: 10.1093/ehjcvp/pvu024) (PMID:27533976)
Feinstein, M. J., Jhund, P. , Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J. and Lloyd-Jones, D. M. (2015) Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 17(4), pp. 434-441. (doi: 10.1002/ejhf.247) (PMID:25684642)
Vazir, A. et al. (2015) Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 36(11), pp. 669-675. (doi: 10.1093/eurheartj/ehu401) (PMID:25368202)
Campbell, R. T. et al. (2015) Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Failure, 2(1), pp. 25-36. (doi: 10.1002/ehf2.12027) (PMID:27347426) (PMCID:PMC4864752)
DeVore, A. D. et al. (2015) Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 17(3), pp. 340-346. (doi: 10.1002/ejhf.235) (PMID:25619549)
Haver, V. G. et al. (2015) Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA). European Journal of Heart Failure, 17(3), pp. 313-9. (doi: 10.1002/ejhf.237) (PMID:25639660)
Katz, M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Thomas, L. and Lopes, R. D. (2015) Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. American Journal of Medicine, 128(3), pp. 297-302. (doi: 10.1016/j.amjmed.2014.08.022) (PMID:25447626)
Metra, M. et al. (2015) Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. Journal of Cardiac Failure, 21(3), pp. 179-88. (doi: 10.1016/j.cardfail.2014.12.012) (PMID:25573829)
Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme. European Journal of Heart Failure, 17(2), pp. 196-204. (doi: 10.1002/ejhf.221)
Hijazi, Z. et al. (2015) Comparison of cardiac troponins i and t measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clinical Chemistry, 61(2), pp. 368-378. (doi: 10.1373/clinchem.2014.226936) (PMID:25451868)
Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)
Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Block, D., Zaugg, C. and Gullestad, L. (2015) Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. Journal of Cardiac Failure, 21(2), pp. 153-9. (doi: 10.1016/j.cardfail.2014.10.016) (PMID:25451704)
Abdul-Rahim, A.H. , Fulton, R.L., Frank, B., McMurray, J.J.V. and Lees, K.R. (2015) Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. European Journal of Neurology, 22(1), pp. 163-169. (doi: 10.1111/ene.12548) (PMID:25370204)
Kristensen, S. L. L. et al. (2015) International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation, 131(1), pp. 43-53. (doi: 10.1161/CIRCULATIONAHA.114.012284)
Packer, M. et al. (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 131(1), pp. 54-61. (doi: 10.1161/circulationaha.114.013748) (PMID:25403646) (PMCID:25403646)
Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi: 10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)
Tang, W.H. W. et al. (2015) Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC: Heart Failure, 3(1), pp. 40-9. (doi: 10.1016/j.jchf.2014.06.014) (PMID:25453534)
Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Wienhues-Thelen, U.-H., Block, D., Zaugg, C. and Gullestad, L. (2015) Predictive value of endostatin in chronic heart failure patients with poor kidney function. Cardiology, 130(1), pp. 17-22. (doi: 10.1159/000368220) (PMID:25428583)
Abdul-Rahim, A. H. et al. (2015) Response to Letter Regarding Article, “Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.”. Circulation, 132(22), e358. (doi: 10.1161/CIRCULATIONAHA.115.018395) (PMID:26621661)
Abualnaja, S., Podder, M., Hernandez, A. F., McMurray, J. J. V. , Starling, R. C., O'Connor, C. M., Califf, R. M., Armstrong, P. W. and Ezekowitz, J. A. (2015) Acute heart failure and atrial fibrillation: insights from the acute study of clinical effectiveness of nesiritide in decompensated heart failure (ASCEND‐HF) trial. Journal of the American Heart Association, 4(8), e002092. (doi: 10.1161/JAHA.115.002092) (PMID:26304935) (PMCID:PMC4599466)
Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina. Circulation: Heart Failure, 8(4), pp. 717-724. (doi: 10.1161/CIRCHEARTFAILURE.114.002024) (PMID:26067854)
Cannon, J. A., McMurray, J. J.V. and Quinn, T. J. (2015) ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure. Alzheimer's Research and Therapy, 7, 22. (doi: 10.1186/s13195-015-0106-5) (PMID:25722749) (PMCID:PMC4342092)
Carson, P. E. et al. (2015) The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC: Heart Failure, 3(6), pp. 429-441. (doi: 10.1016/j.jchf.2014.12.017) (PMID:25982110)
Jackson, C. E. et al. (2015) Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 36(18), pp. 1106-14. (doi: 10.1093/eurheartj/ehu490) (PMID:25616644)
Lam, C. S. P. et al. (2015) Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the valsartan in acute myocardial infarction trial (VALIANT). European Journal of Heart Failure, 17(3), pp. 301-312. (doi: 10.1002/ejhf.238) (PMID:25655011)
Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi: 10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)
McMurray, J. , Zhu, L., McKillop, I. and Chen, H. (2015) Modelling system level health information exchange: an ontological approach. Studies in Health Technology and Informatics, 208, pp. 269-274. (PMID:25676986)
McMurray, J. (2015) Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC: Cardiovascular Imaging, 8(6), pp. 656-665. (doi: 10.1016/j.jcmg.2015.02.014) (PMID:25981507)
McMurray, J. J.V. (2015) Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure, 17(3), pp. 242-7. (doi: 10.1002/ejhf.250) (PMID:25756942)
Roberts, E., Ludman, A. J., Dworzynski, K., Al-Mohammad, A., Cowie, M. R., McMurray, J. J. V. and Mant, J. (2015) The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. British Medical Journal, 350, h910. (doi: 10.1136/bmj.h910) (PMID:25740799) (PMCID:PMC4353288)
Voors, A. A. et al. (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 17(5), pp. 510-517. (doi: 10.1002/ejhf.232) (PMID:25657064)
2014
Badar, A. A. et al. (2014) Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 35(48), pp. 3426-3433. (doi: 10.1093/eurheartj/ehu342)
Damman, K., Tang, W. H. W., Testani, J. M. and McMurray, J. J. V. (2014) Terminology and definition of changes renal function in heart failure. European Heart Journal, 35(48), pp. 3413-3416. (doi: 10.1093/eurheartj/ehu320) (PMID:25157110)
Das, D., Bakal, J. A., Westerhout, C. M., Hernandez, A. F., O'Connor, C. M., Atar, D., McMurray, J. J.V. , Armstrong, P. W. and Ezekowitz, J. A. (2014) The association between meteorological events and acute heart failure: new insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 819-824. (doi: 10.1016/j.ijcard.2014.11.066) (PMID:25465826)
van Diepen, S. et al. (2014) Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 840-846. (doi: 10.1016/j.ijcard.2014.11.007) (PMID:25465830)
McMurray, J. J.V. , Packer, M. and Solomon, S. D. (2014) Neprilysin inhibition for heart failure. New England Journal of Medicine, 371(24), pp. 2336-2337. (doi: 10.1056/NEJMc1412654) (PMID:25494275)
Campbell, R. T., McKean, A. R. and McMurray, J. J.V. (2014) Acute heart failure: have we got it all wrong? European Journal of Heart Failure, 16(12), pp. 1263-1267. (doi: 10.1002/ejhf.197)
Chin, M. P. et al. (2014) Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Journal of Cardiac Failure, 20(12), pp. 953-958. (doi: 10.1016/j.cardfail.2014.10.001) (PMID:25307295)
Cotter, G. et al. (2014) Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure, 16(12), pp. 1362-1371. (doi: 10.1002/ejhf.186) (PMID:25371147)
McMurray, J. J.V. and van Veldhuisen, D. J. (2014) β blockers, atrial fibrillation, and heart failure. Lancet, 384(9961), pp. 2181-2183. (doi: 10.1016/S0140-6736(14)62340-0) (PMID:25625384)
Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi: 10.1111/dom.12320) (PMID:24861892)
Cannon, J. A. and McMurray, J. J.V. (2014) Gut feelings about heart failure. Journal of the American College of Cardiology, 64(18), pp. 1915-1916. (doi: 10.1016/j.jacc.2014.04.088)
Adabag, S., Rector, T. S., Anand, I. S., McMurray, J. J. , Zile, M., Komajda, M., McKelvie, R. S., Massie, B. and Carson, P. E. (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 16(11), pp. 1175-1182. (doi: 10.1002/ejhf.172)
Desai, A. S. et al. (2014) Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure, 7(6), pp. 895-902. (doi: 10.1161/CIRCHEARTFAILURE.114.001567)
Lee, D., Wilson, K., Akehurst, R., Cowie, M.R., Zannad, F., Krum, H., van Veldhuisen, D.J., Vincent, J., Pitt, B. and McMurray, J.J.V. (2014) Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 100(21), pp. 1681-1687. (doi: 10.1136/heartjnl-2014-305673) (PMID:24993605) (PMCID:PMC4215293)
Oluleye, O. W., Rector, T. S., Win, S., McMurray, J. J. V. , Zile, M. R., Komajda, M., McKelvie, R. S., Massie, B., Carson, P. E. and Anand, I. S. (2014) History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulation: Heart Failure, 7(6), pp. 960-966. (doi: 10.1161/CIRCHEARTFAILURE.114.001523)
Patel, P. A. et al. (2014) Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circulation: Heart Failure, 7(6), pp. 918-925. (doi: 10.1161/CIRCHEARTFAILURE.113.000872)
Preiss, D. , McMurray, J. J. and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi: 10.1016/s2213-8587(14)70052-x) (PMID:25439459)
de Barros e Silva, P. G.M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Holman, R., Haffner, S., Thomas, L. and Lopes, R. D. (2014) Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. International Journal of Cardiology, 176(3), pp. 1126-1128. (doi: 10.1016/j.ijcard.2014.07.297) (PMID:25220176)
Wong, C.M. et al. (2014) Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 35(39), pp. 2714-2721. (doi: 10.1093/eurheartj/ehu216)
Dworzynski, K., Roberts, E., Ludman, A., Mant, J. and McMurray, J. (2014) Diagnosing and managing acute heart failure in adults: summary of NICE guidance. British Medical Journal, 349, g5695-g5695. (doi: 10.1136/bmj.g5695) (PMID:25296764)
Shah, A. M. et al. (2014) Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? Journal of the American College of Cardiology, 64(14), pp. 1535-1536. (doi: 10.1016/j.jacc.2014.04.084) (PMID:25277624)
McMurray, J. J.V. , Gerstein, H. C., Holman, R. R. and Pfeffer, M. A. (2014) Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology, 2(10), pp. 843-851. (doi: 10.1016/S2213-8587(14)70031-2)
Rahimi, K., Bennett, D., Conrad, N., Williams, T. M., Basu, J., Dwight, J., Woodward, M., Patel, A., McMurray, J. and MacMahon, S. (2014) Risk prediction in patients with heart failure. JACC: Heart Failure, 2(5), pp. 440-446. (doi: 10.1016/j.jchf.2014.04.008) (PMID:25194291)
Santos, A. B.S. et al. (2014) Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(10), pp. 1096-1103. (doi: 10.1002/ejhf.147) (PMID:25138249)
Damman, K., Perez, A. C., Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Massie, B., Carson, P. E. and McMurray, J. J.V. (2014) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology, 64(11), pp. 1106-1113. (doi: 10.1016/j.jacc.2014.01.087)
Jessup, M., Fox, K. A.A., Komajda, M., McMurray, J. J.V. and Packer, M. (2014) PARADIGM-HF — The experts' discussion. New England Journal of Medicine, 371(11), e15. (doi: 10.1056/NEJMp1410203) (PMID:25184757)
McMurray, J. J.V. et al. (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), pp. 993-1004. (doi: 10.1056/NEJMoa1409077) (PMID:25176015)
van Deursen, V.M. et al. (2014) Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the acute study of clinical effectiveness of nesiritide and decompensated heart failure (ASCEND-HF). Circulation, 130(12), pp. 958-965. (doi: 10.1161/CIRCULATIONAHA.113.003046) (PMID:25074507)
Callender, T. et al. (2014) Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Medicine, 11(8), e1001699. (doi: 10.1371/journal.pmed.1001699) (PMID:25117081) (PMCID:PMC4130667)
Jennings, C. G. et al. (2014) Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 44(1), pp. 25-30. (doi: 10.1016/j.semarthrit.2014.01.004)
Padwal, R. et al. (2014) The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 38(8), pp. 1110-1114. (doi: 10.1038/ijo.2013.203) (PMID:24173404)
Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V. , Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A. and Solomon, S. D. (2014) Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 7(4), pp. 590-595. (doi: 10.1161/CIRCHEARTFAILURE.113.001281)
Böhm, M. et al. (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure, 16(7), pp. 778-787. (doi: 10.1002/ejhf.85)
Campbell, R. T. and McMurray, J. J.V. (2014) Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Failure Clinics, 10(3), pp. 481-501. (doi: 10.1016/j.hfc.2014.04.009)
Holman, R. R. et al. (2014) Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 168(1), 23-29.e2. (doi: 10.1016/j.ahj.2014.03.021)
McMurray, J. J.V. et al. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 16(7), pp. 817-825. (doi: 10.1002/ejhf.115) (PMID:24828035) (PMCID:PMC4312884)
Jhund, P. S. et al. (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. European Journal of Heart Failure, 16(6), pp. 671-677. (doi: 10.1002/ejhf.76)
Rogers, J. K. et al. (2014) Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(3), pp. 289-297. (doi: 10.1016/j.jchf.2013.12.007)
Gori, M. et al. (2014) Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(5), pp. 535-542. (doi: 10.1002/ejhf.67) (PMID:24574260)
Kalogeropoulos, A. P. et al. (2014) High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 20(5), pp. 319-326. (doi: 10.1016/j.cardfail.2014.02.002) (PMID:24530944)
Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved’ [Eur J Heart Fail2014;16:33-40]. European Journal of Heart Failure, 16(5), p. 592. (doi: 10.1002/ejhf.86)
Sliwa, K. et al. (2014) EURObservational research programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure, 16(5), pp. 583-591. (doi: 10.1002/ejhf.68)
Bello, N. A. et al. (2014) Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2(1), e000011. (doi: 10.1136/bmjdrc-2013-000011) (PMID:25452859) (PMCID:PMC4212578)
Butler, J. et al. (2014) Developing therapies for heart failure with preserved ejection fraction. JACC: Heart Failure, 2(2), pp. 97-112. (doi: 10.1016/j.jchf.2013.10.006) (PMID:24720916) (PMCID:PMC4028447)
Huffman, K. M. et al. (2014) Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. Metabolism, 63(4), pp. 554-561. (doi: 10.1016/j.metabol.2014.01.002) (PMID:24559843) (PMCID:PMC4103164)
McMurray, J. J.V. and O'Connor, C. (2014) Lessons from the TOPCAT trial. New England Journal of Medicine, 370(15), pp. 1453-1454. (doi: 10.1056/NEJMe1401231) (PMID:24716685)
Perez-Moreno, A. C. et al. (2014) Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(2), pp. 187-197. (doi: 10.1016/j.jchf.2014.01.001) (PMID:24720928)
Damman, K., Tang, W.H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H. and McMurray, J. J.V. (2014) Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency. Journal of the American College of Cardiology, 63(9), pp. 853-871. (doi: 10.1016/j.jacc.2013.11.031) (PMID:24334210)
Doughty, R. N. et al. (2014) A meta-analysis of echocardiographic measurements of the left heart for the development of normative reference ranges in a large international cohort: the EchoNoRMAL study. European Heart Journal: Cardiovascular Imaging, 15(3), pp. 341-348. (doi: 10.1093/ehjci/jet240) (PMID:24247924)
Moukarbel, G. V., Yu, Z.-F., Dickstein, K., Hou, Y. R., Wittes, J. T., McMurray, J. J.V. , Pitt, B., Zannad, F., Pfeffer, M. A. and Solomon, S. D. (2014) The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure, 16(3), pp. 289-299. (doi: 10.1002/ejhf.11) (PMID:24464979)
Yates, T. et al. (2014) Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet, 383(9922), pp. 1059-1066. (doi: 10.1016/s0140-6736(13)62061-9) (PMID:24361242)
Hijazi, Z. et al. (2014) High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation, 129(6), pp. 625-634. (doi: 10.1161/CIRCULATIONAHA.113.006286) (PMID:24226808)
Kraigher-Krainer, E. et al. (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 63(5), pp. 447-456. (doi: 10.1016/j.jacc.2013.09.052) (PMID:24184245)
Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)
Dalzell, J. R., Seed, A., Berry, C. , Whelan, C. J., Petrie, M. C. , Padmanabhan, N., Clarke, A., Biggerstaff, F., Hillier, C. and McMurray, J. J.V. (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovascular Therapeutics, 32(1), pp. 13-18. (doi: 10.1111/1755-5922.12053) (PMID:24138103)
Perez, A. C., Jhund, P. S. , Stott, D. J. , Gullestad, L., Cleland, J. G.F. , van Veldhuisen, D. J., Wikstrand, J., Kjekshus, J. and McMurray, J. J.V. (2014) Thyroid-stimulating hormone and clinical outcomes. JACC: Heart Failure, 2(1), pp. 35-40. (doi: 10.1016/j.jchf.2013.07.008)
Wikstrand, J., Wedel, H., Castagno, D. and McMurray, J.J.V. (2014) The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. Journal of Internal Medicine, 275(2), pp. 134-143. (doi: 10.1111/joim.12141) (PMID:24118421)
Alexander, J. H. et al. (2014) Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 35(4), pp. 224-232. (doi: 10.1093/eurheartj/eht445) (PMID:24144788)
Damman, K. and McMurray, J. J.V. (2014) Why and when should we worry about worsening renal function? European Journal of Heart Failure, 16(1), pp. 4-5. (doi: 10.1111/ejhf.17) (PMID:24453094)
Gravning, J., Askevold, E.T., Nymo, S.H., Ueland, T., Wikstrand, J., McMurray, J.J.V. , Aukrust, P., Gullestad, L. and Kjekshus, J. (2014) Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation: Heart Failure, 7(1), pp. 96-103. (doi: 10.1161/CIRCHEARTFAILURE.113.000450) (PMID:24284025)
Hijazi, Z. et al. (2014) High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. Journal of the American College of Cardiology, 63(1), pp. 52-61. (doi: 10.1016/j.jacc.2013.07.093) (PMID:24055845)
Jackson, C. E., Myles, R. C. and McMurray, J. J.V. (2014) Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 16(1), p. 113. (doi: 10.1111/ejhf.45) (PMID:24453101)
Nymo, S. H., Hulthe, J., Ueland, T., McMurray, J. , Wikstrand, J., Askevold, E. T., Yndestad, A., Gullestad, L. and Aukrust, P. (2014) Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome: results from CORONA. European Journal of Heart Failure, 16(1), pp. 68-75. (doi: 10.1093/eurjhf/hft125) (PMID:23918775)
Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. European Journal of Heart Failure, 16(1), pp. 33-40. (doi: 10.1002/ejhf.29) (PMID:24453096)
Calvo, G. et al. (2014) Large streamlined trials in cardiovascular disease. European Heart Journal, 35(9), pp. 544-548. (doi: 10.1093/eurheartj/eht535)
Clark, B., DuChane, J., Hou, J., Rubenstein, E., McMurray, J. and Duncan, I. (2014) Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. Journal of Managed Care Pharmacy, 20(2), pp. 141-150. (PMID:24456315)
Eschalier, R. et al. (2014) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function. analyses of the emphasis-hf study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). Rational Pharmacotherapy in Cardiology, 10(1), pp. 106-115. (doi: 10.20996/1819-6446-2014-10-1-106-115)
Gori, M. et al. (2014) Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 35(48), pp. 3442-3451. (doi: 10.1093/eurheartj/ehu254) (PMID:24980489)
Hood, Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R. and McMurray, J. J. (2014) Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews, 2014(4), CD002901. (doi: 10.1002/14651858.CD002901.pub3)
Jhund, P.S. et al. (2014) Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor lcz696. Circulation: Heart Failure, 7(6), pp. 953-959. (doi: 10.1161/CIRCHEARTFAILURE.114.001427)
Kraigher-Krainer, E. et al. (2014) Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456)). Journal of the American College of Cardiology, 64(3), p. 335. (doi: 10.1016/j.jacc.2014.06.011)
MacDonald, T. M. et al. (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 4(7), e005354. (doi: 10.1136/bmjopen-2014-005354)
McMurray, J. et al. (2014) A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 36(7), pp. 434-439. (doi: 10.1093/eurheartj/ehu455) (PMID:25416329) (PMCID:PMC4328198)
Rossignol, P. et al. (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Circulation: Heart Failure, 7(1), pp. 51-58. (doi: 10.1161/CIRCHEARTFAILURE.113.000792) (PMID:24297687)
Santos, A.B.S. et al. (2014) Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 35(1), pp. 42-47. (doi: 10.1093/eurheartj/eht427) (PMID:24164863)
Wallentin, L. et al. (2014) Response to letter regarding article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". Circulation, 129(2), e21-e22. (doi: 10.1161/CIRCULATIONAHA.113.005709)
2013
de Zeeuw, D. et al. (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine, 369(26), pp. 2492-2503. (doi: 10.1056/NEJMoa1306033) (PMID:24206459)
Krum, H., Massie, B., Abraham, W. T., Dickstein, K., Kober, L. and McMurray, J. J.V. (2013) Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. European Journal of Heart Failure, 15(11), pp. 1205-1207. (doi: 10.1093/eurjhf/hft133) (PMID:23989432)
Lambers Heerspink, H.J. et al. (2013) Baseline characteristics in the bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation, 28(11), pp. 2841-2850. (doi: 10.1093/ndt/gft445) (PMID:24169612)
Latini, R. et al. (2013) Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors: a post hoc analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. American Heart Journal, 166(5), 935-940.e1. (doi: 10.1016/j.ahj.2013.08.012) (PMID:24176451)
Wong, C.M. et al. (2013) Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme. Journal of the American College of Cardiology, 62(20), pp. 1845-1854. (doi: 10.1016/j.jacc.2013.05.072)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Journal of the American College of Cardiology, 62(16), pp. 1495-1539. (doi: 10.1016/j.jacc.2013.05.020) (PMID:23741057)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), e147-e239. (doi: 10.1016/j.jacc.2013.05.019) (PMID:23747642)
Dahl, C. P., Aukrust, P., Nymo, S. H., Kjekshus, J., Cleland, J. G.F., McMurray, J. J.V. , Wikstrand, J., Gullestad, L. and Ueland, T. (2013) Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. International Journal of Cardiology, 168(4), pp. 4427-4429. (doi: 10.1016/j.ijcard.2013.05.008) (PMID:23714594)
Eschalier, R. et al. (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survIval study in heart failure). Journal of the American College of Cardiology, 62(17), pp. 1585-1593. (doi: 10.1016/j.jacc.2013.04.086) (PMID:23810881)
Zannad, F. et al. (2013) Clinical outcome endpoints in heart failure trials: a European society of cardiology heart failure association consensus document. European Journal of Heart Failure, 15(10), pp. 1082-1094. (doi: 10.1093/eurjhf/hft095)
Inglis, S.C. et al. (2013) Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology, 168(2), pp. 1094-1101. (doi: 10.1016/j.ijcard.2012.11.033)
Collier, T. J., Pocock, S. J., McMurray, J.J.V. , Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2013) The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal, 34(36), pp. 2823-2829. (doi: 10.1093/eurheartj/eht247) (PMID:23864130)
Ball, J., Carrington, M.J., McMurray, J.J.V. and Stewart, S. (2013) Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. International Journal of Cardiology, 167(5), pp. 1807-1824. (doi: 10.1016/j.ijcard.2012.12.093)
McMurray, J.J.V. et al. (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 15(9), pp. 1062-1073. (doi: 10.1093/eurjhf/hft052)
Mentz, R. J. et al. (2013) The past, present and future of renin–angiotensin aldosterone system inhibition. International Journal of Cardiology, 167(5), pp. 1677-1687. (doi: 10.1016/j.ijcard.2012.10.007) (PMID:23121914) (PMCID:PMC4145865)
Seferović, P. M. et al. (2013) Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 15(9), pp. 947-959. (doi: 10.1093/eurjhf/hft092) (PMID:23787723)
McMurray, J. J.V. and Jhund, P. S. (2013) Cardiovascular risks with azithromycin. New England Journal of Medicine, 369(6), pp. 579-580. (doi: 10.1056/NEJMc1306999)
Swedberg, K., McMurray, J. J.V. and Young, J. B. (2013) Darbepoetin alfa in systolic heart failure. New England Journal of Medicine, 369(5), pp. 487-489. (doi: 10.1056/NEJMc1306321) (PMID:23902504)
Bourge, R. C. et al. (2013) Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. American Journal of Medicine, 126(8), pp. 701-708. (doi: 10.1016/j.amjmed.2013.02.001) (PMID:23490060) (PMCID:PMC3926199)
Lopes, R. D. et al. (2013) Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal, 166(2), 208-216.e28. (doi: 10.1016/j.ahj.2013.05.005) (PMID:23895802)
Mahaffey, K. W. et al. (2013) Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal, 166(2), 240-249.e1. (doi: 10.1016/j.ahj.2013.05.004) (PMID:23895806)
Bethel, M. A. et al. (2013) A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. American Journal of Cardiology, 112(2), pp. 231-237. (doi: 10.1016/j.amjcard.2013.03.019) (PMID:23608615)
Eapen, Z.J. et al. (2013) Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: findings from ASCEND-HF. Circulation: Heart Failure, 6(4), pp. 727-732. (doi: 10.1161/circheartfailure.112.000265) (PMID:23770519)
Krum, H., Shi, H., Pitt, B., McMurray, J. , Swedberg, K., van Veldhuisen, D.J., Vincent, J., Pocock, S. and Zannad, F. (2013) Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circulation: Heart Failure, 6(4), pp. 711-718. (doi: 10.1161/circheartfailure.112.000173) (PMID:23625945)
Ueland, T. et al. (2013) CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. European Journal of Heart Failure, 15(7), pp. 747-755. (doi: 10.1093/eurjhf/hft031) (PMID:23487539)
Weir, R. A.P. et al. (2013) Response to letter regarding article, "Galectin-3 and cardiac function in survivors of acute myocardial infarction". Circulation: Heart Failure, 6(4), e58. (doi: 10.1161/CIRCHEARTFAILURE.113.000382)
Verheugt, F.W.A. et al. (2013) Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. European Heart Journal, 34(22), pp. 1621-1629. (doi: 10.1093/eurheartj/eht013)
Hijazi, Z. et al. (2013) N-terminal Pro–B-Type natriuretic peptide for risk assessment in patients with atrial fibrillation. Journal of the American College of Cardiology, 61(22), pp. 2274-2284. (doi: 10.1016/j.jacc.2012.11.082)
Wallentin, L. et al. (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation, 127(22), pp. 2166-2176. (doi: 10.1161/circulationaha.112.142158) (PMID:23640971)
Weir, R. A.P. et al. (2013) Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation: Heart Failure, 6(3), pp. 492-498. (doi: 10.1161/CIRCHEARTFAILURE.112.000146) (PMID:23505301)
Al Suhaim, S.A., Lewsey, J.L. , Jhund, P.S. and McMurray, J.J.V. (2013) 129 prescribing multiple classes of evidence based pharmacotherapy in the community is associated with lower mortality. Heart, 99(Sup 2), A77. (doi: 10.1136/heartjnl-2013-304019.129)
Gheorghiade, M. et al. (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 15(5), pp. 551-559. (doi: 10.1093/eurjhf/hft010) (PMID:23355060) (PMCID:PMC3707428)
Pocock, S.J. et al. (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal, 34(19), pp. 1404-1413. (doi: 10.1093/eurheartj/ehs337)
Campbell, R. T. and McMurray, J. J.V. (2013) Reply: Diagnosis of Heart Failure With Preserved Ejection Fraction: Still a Challenge, Journal of the American College of Cardiology, Volume 61, Issue 16, 23 April 2013, Pages 1748-1749. Journal of the American College of Cardiology, 61(16), p. 1749. (doi: 10.1016/j.jacc.2013.01.012)
de Zeeuw, D. et al. (2013) Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). American Journal of Nephrology, 37(3), pp. 212-222. (doi: 10.1159/000346948) (PMID:23467003)
Perez, A.C., Jhund, P. , Preiss, D. , Kjekshus, J. and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi: 10.1016/j.jacc.2012.12.004)
McMurray, J.J.V. et al. (2013) Corrigendum to: ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012’ [Eur J Heart Fail 2012;14: 803-869]. European Journal of Heart Failure, 15(3), pp. 361-362. (doi: 10.1093/eurjhf/hft016)
McMurray, J.J.V. et al. (2013) Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). European Journal of Heart Failure, 15(3), pp. 334-341. (doi: 10.1093/eurjhf/hfs204)
Swedberg, K. et al. (2013) Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 368(13), pp. 1210-1219. (doi: 10.1056/NEJMoa1214865)
Rienstra, M., Damman, K., Mulder, B. A., Van Gelder, I. C., McMurray, J. J.V. and Van Veldhuisen, D. J. (2013) Beta-blockers and outcome in heart failure and atrial fibrillation. JACC: Heart Failure, 1(1), pp. 21-28. (doi: 10.1016/j.jchf.2012.09.002)
Skali, H. et al. (2013) Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm. American Journal of Kidney Diseases, 61(2), pp. 238-246. (doi: 10.1053/j.ajkd.2012.08.043)
Askevold, E. T. et al. (2013) Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation: Heart Failure, 6(1), pp. 91-98. (doi: 10.1161/circheartfailure.112.972653) (PMID:23230311)
van Veldhuisen, D.J. and McMurray, J.J.V. (2013) Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? European Journal of Heart Failure, 15(1), pp. 5-8. (doi: 10.1093/eurjhf/hfs194)
Inglis, S.C., Lewsey, J.D. , Lowe, G.D.O., Jhund, P. , Gillies, M., Stewart, S., Capewell, S., MacIntyre, K. and McMurray, J.J.V. (2013) Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. International Journal of Cardiology, 167(5), pp. 2149-2155. (doi: 10.1016/j.ijcard.2012.05.099)
Jackson, C.E. et al. (2013) Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 15(11), pp. 1253-1261. (doi: 10.1093/eurjhf/hft085)
Jackson, C.E. et al. (2013) Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. European Journal of Heart Failure, 14(6), pp. 676-677. (doi: 10.1093/eurjhf/hfs050)
Jankowska, E.A. et al. (2013) Iron status in patients with chronic heart failure. European Heart Journal, 34(11), pp. 827-834. (doi: 10.1093/eurheartj/ehs377)
MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2013) Letter by MacDonald et al regarding article, "catheter ablation of atrial fibrillation". Circulation, 127(4), e433-e433. (doi: 10.1161/CIRCULATIONAHA.112.137604)
McMurray, J.J.V. et al. (2013) Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation: Heart Failure, 6(3), pp. 451-460. (doi: 10.1161/CIRCHEARTFAILURE.112.000143)
Parving, H.H., Brenner, B.M. and McMurray, J.J. (2013) Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Annals of Internal Medicine, 158(6), JC7. (doi: 10.7326/0003-4819-158-6-201303190-02007)
Pfeffer, M. A., Brenner, B. M. and McMurray, J. J.V. (2013) The author's reply - Aliskirenin Type 2 diabetes and cardiorenal end points. New England Journal of Medicine, 368(11), pp. 1064-1066. (doi: 10.1056/NEJMc1300257)
Poppe, K.K. et al. (2013) Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. European Journal of Heart Failure, 15(11), pp. 1220-1227. (doi: 10.1093/eurjhf/hft101)
Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi: 10.1161/STROKEAHA.113.001177)
Shen, L. et al. (2013) Role of diuretics, blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. British Medical Journal, 2013(347), f6745. (doi: 10.1136/bmj.f6745) (PMID:24322398) (PMCID:PMC3898638)
Wong, Y. W. et al. (2013) Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the nateglinide and valsartan in Impaired Glucose Tolerance Outcomes Research study. Circulation: Heart Failure, 6(2), pp. 203-210. (doi: 10.1161/circheartfailure.112.000086) (PMID:23388113)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), e240-e327. (doi: 10.1161/CIR.0b013e31829e8776) (PMID:23741058)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), pp. 1810-1852. (doi: 10.1161/CIR.0b013e31829e8807) (PMID:23741057)
Yancy, C.W. and McMurray, J.J.V. (2013) ECG — still the best for selecting patients for CRT. New England Journal of Medicine, 369, pp. 1463-1464. (doi: 10.1056/NEJMe1310406)
2012
Campbell, R.T., Jhund, P.S. , Castagno, D., Hawkins, N.M., Petrie, M.C. and McMurray, J.J.V. (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? Journal of the American College of Cardiology, 60(23), pp. 2349-2356. (doi: 10.1016/j.jacc.2012.04.064)
Parving, H.-H. et al. (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), pp. 2204-2213. (doi: 10.1056/NEJMoa1208799) (PMID:23121378)
Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S.H., Hulthe, J., Muntendam, P., McMurray, J.J.V. , Wikstrand, J. and Aukrust, P. (2012) The predictive value of galectin-3 for mortality and cardiovascular events in the controlled rosuvastatin multinational trial in heart failure (CORONA). American Heart Journal, 164(6), pp. 878-883. (doi: 10.1016/j.ahj.2012.08.021)
Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi: 10.1136/bmjopen-2012-001925)
Schwartz, G.G. et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine, 367(22), pp. 2089-2099. (doi: 10.1056/NEJMoa1206797)
McMurray, J., J. et al. (2012) Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012'[Eur Heart J 2012;33:1787-1847, doi:10.1093/eurheartj/ehs104. European Heart Journal, 34(2), p. 158. (doi: 10.1093/eurheartj/ehs370)
Felker, G.M. et al. (2012) Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Failure, 14(11), pp. 1257-1264. (doi: 10.1093/eurjhf/hfs110)
Lopes, R.D. et al. (2012) Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, 380(9855), pp. 1749-1758. (doi: 10.1016/S0140-6736(12)60986-6)
Pettit, S.J., Jhund, P.S. , Hawkins, N.M., Gardner, R.S., Haj-Yahia, S., McMurray, J.J.V. and Petrie, M.C. (2012) How small is too small? A systematic review of center volume and outcome after cardiac transplantation. Circulation: Cardiovascular Quality and Outcomes, 5(6), pp. 783-790. (doi: 10.1161/CIRCOUTCOMES.112.966630)
McMurray, J.J.V. , Haffner, S.M., Califf, R.M. and Holman, R.R. (2012) Prediabetes and the risk of diabetes. Lancet, 380(9849), pp. 1225-1226. (doi: 10.1016/S0140-6736(12)61706-1)
McMurray, J.J. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 = Akut ve Kronik Kalp Yetersizligi Tani ve Tedavisine Yönelik 2012 ESC Kilavuzu. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 40(1), pp. 77-137. (PMID:27305718)
Weir, R. A.P., Miller, A. M., Petrie, C. J., Clements, S., Steedman, T., Dargie, H. J., Squire, I. B., Ng, L. L., McInnes, I. B. and McMurray, J. J.V. (2012) Interleukin-21 – a biomarker of importance in predicting myocardial function following acute infarction? Cytokine, 60(1), pp. 220-225. (doi: 10.1016/j.cyto.2012.06.002) (PMID:22748465)
McMurray, J.J.V. , Califf, R.M., Bethel, A.M., Haffner, S.M. and Holman, R.R. (2012) Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. Journal of Clinical Hypertension, 14(10), p. 731. (doi: 10.1111/j.1751-7176.2012.00687.x)
McMurray, J. J.V. et al. (2012) Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012 = ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Revista Española de Cardiología, 65(10), 938.e1-938.e59. (doi: 10.1016/j.recesp.2012.08.003)
Seed, A., Kuc, R.E., Maguire, J.J., Hillier, C., Johnston, F., Essers, H., de Voogd, H.J., McMurray, J.J.V. and Davenport, A.P. (2012) The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sciences, 91(13-14), pp. 743-748. (doi: 10.1016/j.lfs.2012.03.022)
Solomon, S.D. et al. (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 380(9851), pp. 1387-1395. (doi: 10.1016/S0140-6736(12)61227-6)
McMurray, J.J.V. et al. (2012) Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements, 2(4), 279-335-279-335. (doi: 10.1038/kisup.2012.37)
McMurray, J. J.V. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 14(8), pp. 803-869. (doi: 10.1093/eurjhf/hfs105)
Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi: 10.1001/jama.2012.8439)
Lip, G. Y.H. et al. (2012) Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 14(7), pp. 681-695. (doi: 10.1093/eurjhf/hfs073) (PMID:22611046)
McMurray, J.J.V. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology: developed in collaboration with the heart failure association (HFA) of the ESC. European Heart Journal, 33(14), pp. 1787-1847. (doi: 10.1093/eurheartj/ehs104) (PMID:22611136)
Castagno, D., Skali, H., Takeuchi, M., Swedberg, K., Yusuf, S., Granger, C. B., Michelson, E. L., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. Journal of the American College of Cardiology, 59(20), pp. 1785-1795. (doi: 10.1016/j.jacc.2011.12.044) (PMID:22575317)
Perk, J. et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 33(13), pp. 1635-1701. (doi: 10.1093/eurheartj/ehs092) (PMID:22555213)
Welsh, P. and McMurray, J.J. (2012) B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia, 55(5), pp. 1240-1243. (doi: 10.1007/s00125-012-2515-3)
Castagno, D., Petrie, M.C. , Claggett, B. and McMurray, J. (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal, 33(9), pp. 1137-1141. (doi: 10.1093/eurheartj/ehs004)
Castagno, D., Baird-Gunning, J., Jhund, P. , Zoccai, G. B., MacDonald, M. R., Petrie, M. , Gaita, F. and McMurray, J. (2012) Reply to the letter by Dr Erqou regarding "Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients". American Heart Journal, 163(5), e37. (doi: 10.1016/j.ahj.2012.02.022)
Martínez-Sellés, M. et al. (2012) Gender and survival in patients with heart failure: interactions with diabetes and aetiology: results from the MAGGIC individual patient meta-analysis. European Journal of Heart Failure, 14(5), pp. 473-479. (doi: 10.1093/eurjhf/hfs026) (PMID:22402958)
Meris, A. et al. (2012) Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. Journal of the American Society of Echocardiography, 25(5), pp. 535-542. (doi: 10.1016/j.echo.2012.01.006) (PMID:22305962) (PMCID:PMC3501447)
Nymo, S.H. et al. (2012) The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. Journal of Internal Medicine, 271(5), pp. 436-443. (doi: 10.1111/j.1365-2796.2011.02503.x) (PMID:22211640)
Swedberg, K., Zannad, F., McMurray, J. J.V. , Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study. Journal of the American College of Cardiology, 59(18), pp. 1598-1603. (doi: 10.1016/j.jacc.2011.11.063) (PMID:22538330)
Ezekowitz, J.A., Hernandez, A.F., O'Connor, C.M., Starling, R.C., Proulx, G., Weiss, M.H., Bakal, J.A., Califf, R.M., McMurray, J.J.V. and Armstrong, P.W. (2012) Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. Journal of the American College of Cardiology, 59(16), pp. 1441-1448. (doi: 10.1016/j.jacc.2011.11.061)
MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2012) Catheter ablation for atrial fibrillation. New England Journal of Medicine, 366(11), p. 1060.
Broch, K. et al. (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 14(3), pp. 268-277. (doi: 10.1093/eurjhf/hfs006) (PMID:22302661)
Lowrie, R., Mair, F.S. , Greenlaw, N. , Forsyth, P., Jhund, P.S. , McConnachie, A. , Rae, B. and McMurray, J.J.V. (2012) Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. European Heart Journal, 33(3), pp. 314-324. (doi: 10.1093/eurheartj/ehr433)
McMurray, J.J.V. (2012) Heart failure in 2011: heart failure therapy — technology to the fore. Nature Reviews Cardiology, 9(2), pp. 73-74. (doi: 10.1038/nrcardio.2011.212)
Anker, S.D. and McMurray, J.J.V. (2012) Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? European Heart Journal, 33(22), pp. 2764-2765. (doi: 10.1093/eurheartj/ehs277)
Gullestad, L. et al. (2012) Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 33(18), pp. 2290-2296. (doi: 10.1093/eurheartj/ehs077) (PMID:22513778)
Hawkins, N.M., Jhund, P.S. , McMurray, J.J.M. and Capewell, S. (2012) Heart failure and socioeconomic status: accumulating evidence of inequality. European Journal of Heart Failure, 14(2), pp. 138-146. (doi: 10.1093/eurjhf/hfr168)
Jackson, C.E., Myles, R.C. , Cobbe, S.M., Petrie, M.C. and McMurray, J.J.V. (2012) Microvolt T-wave alternans testing has no role at present in guiding therapy for patients at high risk of ventricular arrhythmias. Journal of the American College of Cardiology, 59(9), p. 856. (doi: 10.1016/j.jacc.2011.10.897)
Jackson, C.E. et al. (2012) Microvolt T-wave alternans (MTWA) testing in 'real world' heart failure (HF): a study of prevalence and incremental prognostic value. Heart, 2012(98), A12. (doi: 10.1136/heartjnl-2012-301877b.17)
Jackson, C.E. et al. (2012) Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 14(6), p. 678. (doi: 10.1093/eurjhf/hfs077)
Jackson, C.E. et al. (2012) Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. European Journal of Heart Failure, 14(4), pp. 377-386. (doi: 10.1093/eurjhf/hfs010)
Lam, C. S. P. et al. (2012) Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation: Heart Failure, 5(5), pp. 571-578. (doi: 10.1161/CIRCHEARTFAILURE.112.970061)
McMurray, J.J.V. (2012) Heart failure in 2011: heart failure therapy—technology to the fore. Nature Reviews Cardiology, 9(2), pp. 73-74. (doi: 10.1038/nrcardio.2011.212)
McMurray, J.J.V. , Abraham, W.T., Dickstein, K., Kober, L., Massie, B.M. and Krum, H. (2012) Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. European Journal of Heart Failure, 14(4), pp. 341-343. (doi: 10.1093/eurjhf/hfs033)
McMurray, J.J.V. et al. (2012) Wytyczne ESC dotycza̧ce rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca na 2012 rok. Kardiologia Polska, 70(S2), pp. 101-175.
McMurray, J. J.V. and Pfeffer, M. A. (2012) Heart failure: management and prognosis. In: Goldman, L. and Schafer, A. I. (eds.) Goldman's Cecil Medicine. Elsevier Saunders: Philadelphia, Pa, pp. 303-318. ISBN 9781437716047 (doi: 10.1016/B978-1-4377-1604-7.00059-2)
Parving, H.-H. et al. (2012) Baseline characteristics in the Aliskiren Trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). Journal of the Renin-Angiotensin-Aldosterone System, 13(3), pp. 387-393. (doi: 10.1177/1470320311434818)
Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi: 10.1093/eurjhf/hfs067)
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J. and McMurray, J.J.V. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine, 9(9), e1001310. (doi: 10.1371/journal.pmed.1001310) (PMID:23028261) (PMCID:PMC3445446)
Rector, T.S., Carson, P.E., Anand, I.S., McMurray, J.J. , Zile, M.R., McKelvie, R.S., Komajda, M., Kuskowski, M. and Massie, B.M. (2012) Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota living with heart failure questionnaire in the Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial. Circulation: Heart Failure, 5(2), pp. 217-225. (doi: 10.1161/CIRCHEARTFAILURE.111.964221)
Rogers, J.K., McMurray, J.J.V. , Pocock, S.J., Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation, 126(19), pp. 2317-2323. (doi: 10.1161/CIRCULATIONAHA.112.110536)
Shah, A.M. et al. (2012) Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. European Journal of Heart Failure, 14(2), pp. 185-192. (doi: 10.1093/eurjhf/hfr125)
Zannad, F., Gattis Stough, W., McMurray, J.J.V. , Remme, W.J., Pitt, B., Borer, J.S., Geller, N.L. and Pocock, S.J. (2012) When to stop a clinical trial early for benefit: lessons learned and future approaches. Circulation: Heart Failure, 5(2), pp. 294-302. (doi: 10.1161/circheartfailure.111.965707)
Zannad, F. et al. (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 33(22), pp. 2782-2795. (doi: 10.1093/eurheartj/ehs257)
Zannad, F. et al. (2012) Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? European Heart Journal, 33(9), pp. 1049-1057. (doi: 10.1093/eurheartj/ehr437) (PMID:22422830)
Zile, M.R., Baicu, C.F., Gottdiener, J.S., Hetzel, S.J., McMurray, J.J. , Komajda, M., McKelvie, R., Massie, B.M. and Carson, P.E. (2012) Response to letters regarding article, "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction". Circulation, 126(5), e64-e65. (doi: 10.1161/CIRCULATIONAHA.112.110809)
2011
Zile, M.R., Gottdiener, J.S., Hetzel, S.J., McMurray, J.J.V. , Komajda, M., McKelvie, R., Baicu, C.F., Massie, B.M. and Carson, P.E. (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation, 124(23), pp. 2491-2501. (doi: 10.1161/CIRCULATIONAHA.110.011031)
Ariti, C. A., Cleland, J. G.F. , Pocock, S. J., Pfeffer, M. A., Swedberg, K., Granger, C. B., McMurray, J. J.V. , Michelson, E. L., Östergren, J. and Yusuf, S. (2011) Days alive and out of hospital and the patient journey in patients with heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 162(5), pp. 900-906. (doi: 10.1016/j.ahj.2011.08.003) (PMID:22093207)
Desai, A.S. et al. (2011) Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKd. American Journal of Kidney Diseases, 58(5), pp. 717-728. (doi: 10.1053/j.ajkd.2011.05.020)
Anand, I. S. et al. (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation: Heart Failure, 4(5), pp. 569-577. (doi: 10.1161/CIRCHEARTFAILURE.111.962654) (PMID:21715583)
Granger, C.B. et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), pp. 981-992. (doi: 10.1056/NEJMoa1107039)
Tendera, M. et al. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 32(22), pp. 2851-2906. (doi: 10.1093/eurheartj/ehr211) (PMID:21873417)
Cleland, J. G.F. et al. (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, 378(9792), pp. 676-683. (doi: 10.1016/S0140-6736(11)61126-4) (PMID:21856481)
Sidik, N. P., Solomon, S. D., Latini, R., Maggioni, A. P., Wright, M., Gimpelewicz, C. R., Pitt, B. and McMurray, J. J. V. (2011) Effect of aliskiren in patients with heart failure according to background dose of ace inhibitor: a retrospective analysis of the aliskiren observation of heart failure treatment (ALOFT) trial. Cardiovascular Drugs and Therapy, 25(4), pp. 315-321. (doi: 10.1007/s10557-011-6319-3)
McMurray, J. and Ponikowski, P. (2011) Heart failure: not enough pump iron? Journal of the American College of Cardiology, 58(5), pp. 481-482. (doi: 10.1016/j.jacc.2011.02.066)
O'Connor, C.M. et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. New England Journal of Medicine, 365(1), pp. 32-43. (doi: 10.1056/NEJMoa1100171)
Verma, A., Pfeffer, M.A., Skali, H., Rouleau, J., Maggioni, A., McMurray, J.J.V. , Califf, R.M., Velazquez, E.J. and Solomon, S.D. (2011) Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. American Heart Journal, 161(6), pp. 1156-1162. (doi: 10.1016/j.ahj.2011.03.024)
Hawkins, N.M., Petrie, M.C. , MacDonald, M.R., Jhund, P.S. , Fabbri, L.M., Wikstrand, J. and McMurray, J.J.V. (2011) Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists. Journal of the American College of Cardiology, 57(21), pp. 2127-2138. (doi: 10.1016/j.jacc.2011.02.020)
MacDonald, M.R. et al. (2011) Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD) study. Diabetes Care, 34(6), pp. 1394-1396. (doi: 10.2337/dc10-2398)
McMurray, J. J.V. (2011) Low Coenzyme Q(10) Levels and the Outcome of Statin Treatment in Heart Failure Reply. Journal of the American College of Cardiology, 57(14), p. 1569. (doi: 10.1016/j.jacc.2010.12.018)
Piepoli, M. F. et al. (2011) Exercise training in heart failure: from theory to practice: a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Heart Failure, 13(4), pp. 347-357. (doi: 10.1093/eurjhf/hfr017) (PMID:21436360)
Teo, K.K. et al. (2011) Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. The ARB Trialists Collaboration. Journal of Hypertension, 29(4), pp. 623-635. (doi: 10.1097/HJH.0b013e328344a7de)
Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi: 10.1186/1471-2377-11-38)
Gheorghiade, M., Pang, P.S., O'Connor, C.M., Prasad, K., McMurray, J. , Teerlink, J.R., Fiuzat, M., Sabbah, H. and Komajda, M. (2011) Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 161(2), pp. 224-232. (doi: 10.1016/j.ahj.2010.10.023)
Horowitz, J. D., Rosenson, R. S., McMurray, J. J.V. , Marx, N. and Remme, W. J. (2011) Clinical Trials Update AHA Congress 2010. Cardiovascular Drugs and Therapy, 25(1), pp. 69-76. (doi: 10.1007/s10557-011-6285-9) (PMID:21340529)
Lewis, E.F. et al. (2011) Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of the American Society of Nephrology, 6(4), pp. 845-855. (doi: 10.2215/CJN.06450710)
Castagno, D., Baird-Gunning, J., Jhund, P.S. , Biondi-Zoccai, G., MacDonald, M.R., Petrie, M.C. , Gaita, F. and McMurray, J.J.V. (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 162(5), 938-948.e2. (doi: 10.1016/j.ahj.2011.07.030)
Dickstein, K., Vardas, P.E., Auricchio, A., Daubert, J.-C., Linde, C., McMurray, J. , Ponikowski, P., Priori, S.G. and Sutton, R. (2011) Focused Update Recommendation European Society of Cardiology instrumentation for use in heart failure therapy, 2010 | Cielená aktualizácia Odporúčaní Európskej kardiologickej spoločnosti pre využitie prístrojovej terapie pri srdcovom zlyhávaní 2010. Cardiology Letters, 20(3), pp. 246-253.
Gallanagh, S. et al. (2011) Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). Cardiovascular Drugs and Therapy, 25(1), pp. 77-85. (doi: 10.1007/s10557-011-6284-x)
Hawkins, N. M., Petrie, M. C. and McMurray, J. J.V. (2011) Selecting patients for cardiac resynchronization therapy: Electrical or mechanical dyssynchrony? In: Cardiac Resynchronization Therapy in Heart Failure. Wolters Kluwer Health. ISBN 9780781798440
Jackson, C.E. et al. (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure, 13(7), pp. 746-754. (doi: 10.1093/eurjhf/hfr031)
Jankowska, E.A. et al. (2011) Erratum: Iron deficiency: an ominous sign in patients with systolic chronic heart failure [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. European Heart Journal, 32(9), p. 1054. (doi: 10.1093/eurheartj/ehr115)
Krum, H. et al. (2011) Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation: Heart Failure, 4(5), pp. 561-568. (doi: 10.1161/CIRCHEARTFAILURE.110.960716)
Lowrie, R. et al. (2011) The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. European Journal of Heart Failure, 13(8), pp. 917-924. (doi: 10.1093/eurjhf/hfr083)
MacDonald, M. R. et al. (2011) Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart, 97(9), pp. 740-747. (doi: 10.1136/hrt.2010.207340)
McMurray, J.J.V. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure, 13(9), pp. 929-936. (doi: 10.1093/eurjhf/hfr093)
McMurray, J.J.V. (2011) Heart failure: Acute ischemic events in HF—should we include sudden death? Nature Reviews Cardiology, 8(4), pp. 192-193. (doi: 10.1038/nrcardio.2011.22)
McMurray, J.J.V. and Smith, G.L. (2011) Calcium handling in the failing heart and SUMO — weighing the eviden. New England Journal of Medicine, (doi: 10.1056/NEJMcibr1110758)
McMurray, J.J.V. et al. (2011) Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal, 162(4), 748-755.e3. (doi: 10.1016/j.ahj.2011.07.016)
Milo-Cotter, O. et al. (2011) Neurohormonal activation in acute heart failure: results from VERITAs. Cardiology, 119(2), pp. 96-105. (doi: 10.1159/000330409)
Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Smith, B.A., Wright, M., Prescott, M.F. and McMurray, J.J.V. (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 13(7), pp. 755-764. (doi: 10.1093/eurjhf/hfr034)
Pouleur, A.-C. et al. (2011) Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both". Circulation, 123(18), e586. (doi: 10.1161/CIRCULATIONAHA.111.021600)
Preiss, D. , Sattar, N. and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi: 10.1016/j.ahj.2010.10.019)
Shah, A.M. et al. (2011) Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal, 162(4), pp. 685-691. (doi: 10.1016/j.ahj.2011.07.015)
Skali, H. et al. (2011) Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with aranesp therapy (TREAT) experience. Circulation, 124(25), pp. 2903-2908. (doi: 10.1161/CIRCULATIONAHA.111.030411)
Solomon, S.D. et al. (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 32(10), pp. 1227-1234. (doi: 10.1093/eurheartj/ehq522) (PMID:21317148)
Thune, J. J. et al. (2011) Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarctio. European Journal of Heart Failure, 13(2), pp. 148-153. (doi: 10.1093/eurjhf/hfq194)
Weir, R.A.P., Clements, S., Steedman, T., Dargie, H.J., McMurray, J.J.V. , Squire, I.B. and Ng, L.L. (2011) Plasma TIMP-4 Predicts Left Ventricular Remodeling After Acute Myocardial Infarction. Journal of Cardiac Failure, 17(6), pp. 465-471. (doi: 10.1016/j.cardfail.2011.02.002)
Weir, R.A.P., Tsorlalis, I.K., Steedman, T., Dargie, H.J., Fraser, R., McMurray, J.J.V. and Connell, J.M.C. (2011) Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. European Journal of Heart Failure, 13(12), pp. 1305-1313. (doi: 10.1093/eurjhf/hfr129)
Ye, S. et al. (2011) Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction: Implications for Prevention. Circulation, 123(23), pp. 2674-2680. (doi: 10.1161/CIRCULATIONAHA.110.990655)
Zannad, F., McMurray, J.J.V. and Swedberg, K. (2011) The authors reply. New England Journal of Medicine, 364(14), pp. 1372-1375. (doi: 10.1056/NEJMc1101504)
2010
Lainscak, M. et al. (2010) Self-care management of heart failure practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 13(2), pp. 115-126. (doi: 10.1093/eurjhf/hfq219)
Dickstein, K. et al. (2010) Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 12(4), p. 416. (doi: 10.1093/eurjhf/hfq025)
Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)
Zile, M. R. et al. (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (i-preserve) trial. Circulation, 121(12), pp. 1393-1405. (doi: 10.1161/circulationaha.109.909614) (PMID:20231531)
Preiss, D. , Sattar, N. and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi: 10.1001/jama.2010.137)
McMurray, J.J. (2010) Systolic heart failure. New England Journal of Medicine, 362(3), pp. 228-238. (doi: 10.1056/NEJMcp0909392)
Weir, R.A.P., Miller, A.M., Murphy, G., Clements, S., Steedman, T., Connell, J., McInnes, I. , Dargie, H. and McMurray, J.J. (2010) Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Journal of the American College of Cardiology, 55(3), pp. 243-250. (doi: 10.1016/j.jacc.2009.08.047) (PMID:20117403)
Hawkins, N.M., Jhund, P.S., Simpson, C.R., Petrie, M.C., MacDonald, M.R., Dunn, F.G., MacIntyre, K. and McMurray, J.J.V. (2010) Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 12(1), pp. 17-24. (doi: 10.1093/eurjhf/hfp160)
Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi: 10.1093/eurjhf/hfp172)
Piccini, J.P., Zhang, M., Pieper, K., Solomon, S.D., Al-Khatib, S.M., Van de Werf, F., Pfeffer, M.A., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2010) Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal, 31(2), pp. 211-221. (doi: 10.1093/eurheartj/ehp425)
Castagno, D. et al. (2010) Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure, 12(6), pp. 607-616. (doi: 10.1093/eurjhf/hfq038)
Chang, S. M. et al. (2010) Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 12(7), pp. 738-745. (doi: 10.1093/eurjhf/hfq065)
Cleland, J.G.F., McMurray, J.J.V. and Kjekshus, J. (2010) Statins and Heart Failure - Reply. Journal of the American College of Cardiology, 55(15), p. 1646. (doi: 10.1016/j.jacc.2010.01.018)
Desai, A., Lewis, E., Solomon, S., McMurray, J. J. V. and Pfeffer, M. (2010) Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. European Journal of Heart Failure, 12(9), pp. 936-942. (doi: 10.1093/eurjhf/hfq094)
Dickstein, K. et al. (2010) Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [Eur Heart J 2008;29:2388-2442]. European Heart Journal, 31(5), p. 624. (doi: 10.1093/eurheartj/ehq027)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy * Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Journal of Heart Failure, 12(11), pp. 1143-1153. (doi: 10.1093/eurjhf/hfq192)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy * Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace, 12(11), pp. 1526-1536. (doi: 10.1093/europace/euq392)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Heart Journal, 31(21), pp. 2677-2687. (doi: 10.1093/eurheartj/ehq337)
Felker, G. M. et al. (2010) Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward. Circulation: Heart Failure, 3(2), pp. 314-325. (doi: 10.1161/CIRCHEARTFAILURE.109.893222)
Gheorghiade, M. et al. (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 12(5), pp. 423-433. (doi: 10.1093/eurjhf/hfq045)
Hawkins, N. M. et al. (2010) Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 12(6), pp. 557-565. (doi: 10.1093/eurjhf/hfq040)
Hogg, K. J. and McMurray, J. J. V. (2010) HEART FAILURE Hospital-at-home care for CHF-verdict, 'not proven'. Nature Reviews Cardiology, 7(2), pp. 63-64. (doi: 10.1038/nrcardio.2009.225)
Hogg, K.J. and McMurray, J.J.V. (2010) Evaluating dyspnoea in acute heart failure: progress at last! European Heart Journal, 31(7), pp. 771-772. (doi: 10.1093/eurheartj/ehq015)
Holman, R. R. et al. (2010) Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), pp. 1463-1476. (doi: 10.1056/NEJMoa1001122)
Hung, C.L. et al. (2010) Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. Journal of the American College of Cardiology, 56(22), pp. 1812-1822. (doi: 10.1016/j.jacc.2010.06.044)
Inglis, S. C. et al. (2010) Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). European Journal of Heart Failure, 12(7), pp. 698-705. (doi: 10.1093/eurjhf/hfq070)
Jankowska, E. A. et al. (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 31(15), pp. 1872-1880. (doi: 10.1093/eurheartj/ehq158)
Komajda, M., Carson, P. E., Hetzel, S., McKelvie, R., McMurray, J. , Ptaszynska, A., Zile, M. R., DeMets, D. and Massie, B. M. (2010) Factors Associated with Outcome in Heart Failure with Preserved Ejection Fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation: Heart Failure, 4(1), pp. 27-35. (doi: 10.1161/CIRCHEARTFAILURE.109.932996)
Komajda, M., McMurray, J. J. V. , Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P. and Home, P. D. (2010) Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal, 31(7), pp. 824-831. (doi: 10.1093/eurheartj/ehp604)
Krum, H. et al. (2010) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to minimize outcomes in patients with heart failure (ATMOSPHERE)study. European Journal of Heart Failure, 13(1), pp. 107-114. (doi: 10.1093/eurjhf/hfq212)
Krum, H., McMurray, J. J. V. , Horton, E., Gerlock, T., Holzhauer, B., Zuurman, L., Haffner, S. M., Bethel, M. A., Holman, R. R. and Califf, R. M. (2010) Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. Cardiovascular Therapeutics, 28(2), pp. 124-132. (doi: 10.1111/j.1755-5922.2010.00146.x)
Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi: 10.1136/jnnp.2009.195131)
Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi: 10.1186/1741-7015-8-23)
Lopes, R. D. et al. (2010) Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 159(3), pp. 331-339. (doi: 10.1016/j.ahj.2009.07.035)
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D. , Bhagra, S., Jhund, P. S. , Petrie, M. C., McMurray, J. J. V. , Petrie, J.R. and McAlister, F. A. (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care, 33(6), pp. 1213-1218. (doi: 10.2337/dc09-2227)
McKelvie, R.S., Komajda, M., McMurray, J. , Zile, M., Ptaszynska, A., Donovan, M., Carson, P. and Massie, B.M. (2010) Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 16(2), pp. 128-134. (doi: 10.1016/j.cardfail.2009.09.007)
McMurray, J. J. et al. (2010) Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), pp. 1477-1490. (doi: 10.1056/NEJMoa1001121)
McMurray, J. J. V. and Swedberg, K. (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure-lessons learnt from a decade of trials. European Journal of Heart Failure, 12(2), pp. 99-103. (doi: 10.1093/eurjhf/hfp197)
McMurray, J.J.V. , Dunselman, P., Wedel, H., Cleland, J.G.F., Lindberg, M., Hjalmarson, Å., Kjekshus, J., Waagstein, F., Apetrei, E. and Barrios, V. (2010) Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart FailureA Pre-Specified Substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). Journal of the American College of Cardiology, 56(15), pp. 1196-1204. (doi: 10.1016/j.jacc.2010.02.075)
McMurray, J. J.V. et al. (2010) Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial’ [Eur J Heart Fail2009;11:795-801]. European Journal of Heart Failure, 12(7), p. 765. (doi: 10.1093/eurjhf/hfq067)
Nilsson, K. R. et al. (2010) Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart, 96(11), pp. 838-842. (doi: 10.1136/hrt.2009.180182)
Park, J.H. , Balmain, S., Berry, C. , Morton, J.J. and McMurray, J.J.V. (2010) Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart, 96(7), pp. 533-538. (doi: 10.1136/hrt.2009.175257) (PMID:20350990)
Pouleur, A.-C. et al. (2010) Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation, 122(6), pp. 597-602. (doi: 10.1161/CIRCULATIONAHA.110.940619)
Rocchiccioli, J. P. and McMurray, J. J.V. (2010) Epidemiology and prevention of heart failure and management of asymptomatic left ventricular systolic dysfunction. In: Yusuf, S., Cairns, J. A., Camm, A. J., Fallen, E. L. and Gersh, B. J. (eds.) Evidence-Based Cardiology. Wiley-Blackwell: Chichester, pp. 735-755. ISBN 9781405159258
Rocchiccioli, J.P., McMurray, J.J.V. and Dominiczak, A.F. (2010) Biomarkers in heart failure: a clinical review. Heart Failure Reviews, 15(4), pp. 251-273. (doi: 10.1007/s10741-008-9123-9)
Shah, A. M. et al. (2010) The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. European Journal of Heart Failure, 12(11), pp. 1229-1237. (doi: 10.1093/eurjhf/hfq179)
Shamshad, F., Kenchaiah, S., Finn, P.V., Soler-Soler, J., McMurray, J.J.V. , Velazquez, E.J., Maggioni, A. P., Califf, R.M., Swedberg, K. and Kober, L. (2010) Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal, 160(1), pp. 145-151. (doi: 10.1016/j.ahj.2010.02.037)
Sliwa, K. et al. (2010) Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy A Proof-of-Concept Pilot Study. Circulation, 121(13), pp. 1465-1473. (doi: 10.1161/CIRCULATIONAHA.109.901496)
Sliwa, K. et al. (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121(13), pp. 1465-1473. (doi: 10.1161/circulationaha.109.901496) (PMID:20308616)
Sliwa, K. et al. (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 12(8), pp. 767-778. (doi: 10.1093/eurjhf/hfq120)
Solomon, S.D. et al. (2010) Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 363(12), pp. 1146-1155. (doi: 10.1056/NEJMoa1005109)
Weir, R. A. P., Murphy, C. A., Petrie, C. J., Martin, T. N., Balmain, S., Clements, S., Steedman, T., Wagner, G. S., Dargie, H. J. and McMurray, J. J. V. (2010) Microvascular Obstruction Remains a Portent of Adverse Remodeling in Optimally Treated Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. Circulation: Cardiovascular Imaging, 3(4), pp. 360-367. (doi: 10.1161/CIRCIMAGING.109.897439)
Weir, R.A.P., Murphy, C.A., Petrie, C.J., Martin, T.N., Clements, S., Steedman, T., Wagner, G.S., McMurray, J.J.V. and Dargie, H.J. (2010) Monocyte chemoattractant protein-1: A dichotomous role in cardiac remodeling following acute myocardial infarction in man? Cytokine, 50(2), pp. 158-162. (doi: 10.1016/j.cyto.2010.02.020)
Zannad, F., McMurray, J.J.V. , Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 12(6), pp. 617-622. (doi: 10.1093/eurjhf/hfq049)
Zannad, F., McMurray, J.J.V. , Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J. and Pitt, B. (2010) Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine, 364(1), pp. 11-21. (doi: 10.1056/NEJMoa1009492)
Zile, M. R. et al. (2010) Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial. Circulation, 121(12), pp. 1393-1405. (doi: 10.1161/CIRCULATIONAHA.109.909614)
2009
Freel, E.M., Tsorlalis, I.K., Lewsey, J.D., Latini, R., Maggioni, A.P., Solomon, S., Pitt, B., Connell, J.M.C. and McMurray, J.J.V. (2009) Aldosterone status associates with insulin resistance in patients with heart failure-data from the ALOFT study. Heart, 95(23), pp. 1920-1924. (doi: 10.1136/hrt.2009.173344)
Schwartz, G.G. et al. (2009) Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 158(6), pp. 896-901. (doi: 10.1016/j.ahj.2009.09.017)
Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi: 10.1161/CIRCOUTCOMES.108.825968)
Parving, H.-H., Brenner, B. M., McMurray, J. J.V. , de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N. and Pfeffer, M. A. (2009) Dual renin-angiotensin system blockade and kidney disease. Journal of the American College of Cardiology, 54(3), pp. 278-279. (doi: 10.1016/j.jacc.2009.02.074)
Berry, C. , Pieper, K., White, H., Solomon, S., Van de Werf, F., Velazquez, E., Maggioni, A., Califf, R., Pfeffer, M. and McMurray, J. (2009) Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal, 30(12), pp. 1450-1456. (doi: 10.1093/eurheartj/ehp102)
Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi: 10.2337/dc08-1709) (PMID:19196892)
Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi: 10.1161/STROKEAHA.108.542787)
Dickstein, K. et al. (2009) Linee guida ESC per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico 2008 = Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Giornale Italiano di Cardiologia, 10(3), pp. 141-198.
Jhund, P.S. , MacIntyre, K., Simpson, C.R., Lewsey, J.D., Stewart, S., Redpath, A., Chalmers, J.W.T., Capewell, S. and McMurray, J.J.V. (2009) Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation, 119(4), pp. 515-523. (doi: 10.1161/CIRCULATIONAHA.108.812172)
Abrahamsson, P., Dobson, J., Granger, C.B., McMurray, J.J.V. , Michelson, E.L., Pfeffer, M., Pocock, S., Solomon, S.D., Yusuf, S. and Swedberg, K. (2009) Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. European Heart Journal, 30(3), pp. 338-345. (doi: 10.1093/eurheartj/ehn503)
Hawkins, N. M., Petrie, M. C. , Jhund, P. S. , Chalmers, G. W., Dunn, F. G. and McMurray, J. J.V. (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 11(2), pp. 130-139. (doi: 10.1093/eurjhf/hfn013)
Dickstein, K. et al. (2009) Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 11(1), p. 110. (doi: 10.1093/eurjhf/hfn030)
Allen, L. A., Felker, G. M., Pocock, S., McMurray, J. J.V. , Pfeffer, M. A., Swedberg, K., Wang, D., Yusuf, S., Michelson, E. L. and Granger, C. B. (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 11(2), pp. 170-177. (doi: 10.1093/eurjhf/hfn031)
Califf, R., Lokhnygina, Y., Velazquez, E., McMurray, J. , Leimberger, J., Lewis, E., Diaz, R., Murin, J. and Pfeffer, M. (2009) Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). American Journal of Cardiology, 104(2), pp. 151-157. (doi: 10.1016/j.amjcard.2009.03.020)
Cleland, J. et al. (2009) Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Journal of the American College of Cardiology, 54(20), pp. 1850-1859. (doi: 10.1016/j.jacc.2009.06.041)
Dickstein, K. and McMurray, J. J.V. (2009) Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma? Reply. European Heart Journal, 30(10), pp. 1287-1288. (doi: 10.1093/eurheartj/ehp147)
Gheorghiade, M. et al. (2009) Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 157(6), pp. 957-970. (doi: 10.1016/j.ahj.2009.04.010)
Granger, B. B., Ekman, I., Granger, C. B., Ostergren, J., Olofsson, B., Michelson, E., McMurray, J. J.V. , Yusuf, S., Pfeffer, M. A. and Swedberg, K. (2009) Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure, 11(11), pp. 1092-1098. (doi: 10.1093/eurjhf/hfp142)
Hawkins, N. M., Huang, Z., Pieper, K. S., Solomon, S. D., Kober, L., Velazquez, E. J., Swedberg, K., Pfeffer, M. A., McMurray, J. J.V. and Maggioni, A. P. (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure, 11(3), pp. 292-298. (doi: 10.1093/eurjhf/hfp001)
Hawkins, N.M., MacDonald, M.R., Petrie, M.C., Chalmers, G., Carter, R., Dunn, F.G. and McMurray, J.J. (2009) Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure, 11(7), pp. 684-690. (doi: 10.1093/eurjhf/hfp066)
Hawkins, N., Petrie, M. , Burgess, M. and McMurray, J. (2009) Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. Journal of the American College of Cardiology, 53(21), pp. 1944-1959. (doi: 10.1016/j.jacc.2008.11.062)
Hawkins, N., Petrie, M., Jhund, P. , Chalmers, G., Dunn, F. and McMurray, J. (2009) Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 11(6), pp. 632-633.
Hernandez, A. et al. (2009) Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal, 157(2), pp. 271-277. (doi: 10.1016/j.ahj.2008.07.031)
Heymans, S. et al. (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 11(2), pp. 119-129. (doi: 10.1093/eurjhf/hfn043)
Home, P., Pocock, S., Beck-Nielsen, H., Curtis, P., Gomis, R., Hanefeld, M., Jones, N., Komajda, M. and McMurray, J. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373(9681), pp. 2125-2135. (doi: 10.1016/S0140-6736(09)60953-3)
Hood, W.B., Dans, A., Guyatt, G.H., Jaeschke, R. and McMurray, J.J.V. (2009) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews(2), CD002901. (doi: 10.1002/14651858.CD002901.pub2)
Jaarsma, T. et al. (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 11(5), pp. 433-443. (doi: 10.1093/eurjhf/hfp041)
Jackson, C. et al. (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet, 374(9689), pp. 543-550. (doi: 10.1016/S0140-6736(09)61378-7)
Jackson, C.E., Dalzell, J.R., Bezlyak, V., Tsorlalis, I.K., Myles, R.C., Spooner, R., Ford, I., Petrie, M.C., Cobbe, S. and McMurray, J.J. (2009) Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. European Journal of Heart Failure, 11(12), pp. 1152-1154. (doi: 10.1093/eurjhf/hfp157)
MacDonald, M.R., Petrie, M.C., Fisher, M. and McMurray, J.J.V. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 6(2), pp. 126-132. (doi: 10.1007/s11897-009-0019-3)
McMurray, J.J. et al. (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation, 120(22), 2188-2U51. (doi: 10.1161/CIRCULATIONAHA.109.849117)
McMurray, J.J.V. , Granger, C.B., Ostergren, J., Yusuf, S., Pfeffer, M.A. and Swedberg, K. (2009) Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 54(3), p. 278. (doi: 10.1016/j.jacc.2009.02.073)
McMurray, J. et al. (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure, 11(8), pp. 795-801.
McMurray, J. , Jhund, P. , MacIntyre, K. and Stewart, S. (2009) Heart failure in the UK. Heart, 95(2), p. 156.
Meris, A. et al. (2009) Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. European Heart Journal, 30(1), pp. 56-65. (doi: 10.1093/eurheartj/ehn499)
Moukarbel, G., Signorovitch, J., Pfeffer, M., McMurray, J. , White, H., Maggioni, A., Velazquez, E., Califf, R., Scheiman, J. and Solomon, S. (2009) Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal, 30(18), pp. 2226-2232.
Parving, H. et al. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation, 24(5), pp. 1663-1671.
Pfeffer, M.A. et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine, 361(21), pp. 2019-2032. (doi: 10.1056/NEJMoa0907845)
Pfeffer, M.A. et al. (2009) Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 54(1), pp. 59-69. (doi: 10.1053/j.ajkd.2009.04.008)
Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.
Sochalski, J., Jaarsma, T., Krumholz, H., Laramee, A., McMurray, J. , Naylor, M., Rich, M., Riegel, B. and Stewart, S. (2009) What Works In Chronic Care Management: The Case Of Heart Failure. Health Affairs, 28(1), pp. 179-189. (doi: 10.1377/hlthaff.28.1.179)
Somaratne, J., Berry, C. , McMurray, J. , Poppe, K., Doughty, R. and Whalley, G. (2009) The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. European Journal of Heart Failure, 11(9), pp. 855-862. (doi: 10.1093/eurjhf/hfp103)
Stanton, T., Hawkins, N. M., Hogg, K. J., Goodfield, N. E.R., Petrie, M. C. and McMurray, J. J.V. (2009) Three-dimensional echocardiography for optimization of cardiac resynchronization therapy: reply. European Heart Journal, 30(4), pp. 505-506. (doi: 10.1093/eurheartj/ehp002)
Wedel, H. et al. (2009) Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure, 11(3), pp. 281-291. (doi: 10.1093/eurjhf/hfn046)
Weir, R. A.P., Chong, K. S., Dalzell, J. R., Petrie, C. J., Murphy, C. A., Steedman, T., Mark, P.B. , McDonagh, T. A., Dargie, H. J. and McMurray, J. J.V. (2009) Plasma apelin concentration is depressed following acute myocardial infarction in man. European Journal of Heart Failure, 11(6), pp. 551-558. (doi: 10.1093/eurjhf/hfp043)
Weir, R.A.P., Mark, P.B. , Petrie, C.J., Clements, S., Steedman, T., Ford, I. , Ng, L.L., Squire, I.B., Wagner, G.S. and McMurray, J.J.V. (2009) Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect? American Heart Journal, 157(6), pp. 1088-1096. (doi: 10.1016/j.ahj.2009.04.001)
Weir, R., Martin, T., Petrie, C., Murphy, A., Clements, S., Steedman, T., Wagner, G., McMurray, J. and Dargie, H. (2009) Cardiac and Extracardiac Abnormalities Detected by Cardiac Magnetic Resonance in a Post-Myocardial Infarction Cohort. Cardiology, 113(1), pp. 1-8. (doi: 10.1159/000161233)
2008
Dickstein, K. et al. (2008) Corrigendum to 'ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008' * [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 29(24), p. 3069. (doi: 10.1093/eurheartj/ehn528)
Carson, P. et al. (2008) Health related quality of life in I-PRESERVE trial. Journal of Cardiac Failure, 14(6), S73. (doi: 10.1016/j.cardfail.2008.06.200)
Wynn, G. J., Rammohan, H. S., Stephens, B., Hawkins, N. M., McMurray, J. J.V. and Rodrigues, E. (2008) How many patients with heart failure are suitable for combination ACE inhibitor and candesartan therapy? Journal of Cardiac Failure, 14(6), S114. (doi: 10.1016/j.cardfail.2008.06.397)
, (2008) The editorialst replies [Anesthesia awareness and the bispectral index]. New England Journal of Medicine, 359(4), pp. 427-431. (doi: 10.1056/NEJMc086136)
Anavekar, N.S. et al. (2008) Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO study). American Journal of Cardiology, 101(5), pp. 607-612. (doi: 10.1016/j.amjcard.2007.09.115)
Anavekar, N.S., Solomon, S.D., McMurray, J.J. , Maggioni, A., Rouleau, J.L., Califf, R., White, H., Kober, L., Velazquez, E. and Pfeffer, M.A. (2008) Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. American Journal of Cardiology, 101(7), pp. 925-929. (doi: 10.1016/j.amjcard.2007.11.037)
Anderson, R.E. et al. (2008) High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 155(4), pp. 706-711. (doi: 10.1016/j.ahj.2007.11.016)
Berry, C., Brett, M., Stevenson, K., McMurray, J.J. and Norrie, J. (2008) Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart, 94(3), pp. 296-304. (doi: 10.1136/hrt.2006.110999)
Bethel, M., Holman, R., Haffner, S., Califf, R., Huntsman-Labed, A., Hua, T. and McMurray, J. (2008) Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal, 156(4), pp. 633-640. (doi: 10.1016/j.ahj.2008.05.018)
Califf, R., Boolell, M., Haffner, S., Bethel, M., McMurray, J. , Duggal, A. and Holman, R. (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 156(4), pp. 623-632. (doi: 10.1016/j.ahj.2008.05.017)
Carrington, M., Murphy, N.F., Strange, G., Peacock, A., McMurray, J.J. and Stewart, S. (2008) Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 124(2), pp. 183-187. (doi: 10.1016/j.ijcard.2006.12.045)
Clark, A.M., Reid, M.E., Morrison, C.E., Capewell, S., Murdoch, D.L. and McMurray, J.J. (2008) The complex nature of informal care in home-based heart failure management. Journal of Advanced Nursing, 61(4), pp. 373-383. (doi: 10.1111/j.1365-2648.2007.04527.x)
Cleland, J. et al. (2008) The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure (10/8/08). Journal of Cardiac Failure, 14(9), pp. 797-798.
Cohen-Solal, A., McMurray, J. , Swedberg, K., Pfeffer, M., Puu, M., Solomon, S., Michelson, E., Yusuf, S. and Granger, C. (2008) Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity programme. European Heart Journal, 29(24), pp. 3022-3028. (doi: 10.1093/eurheartj/ehn476)
Dickstein, K. et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure, 10(10), pp. 933-989. (doi: 10.1016/j.ejheart.2008.08.005)
Dickstein, K. et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 29(19), pp. 2388-2442. (doi: 10.1093/eurheartj/ehn309)
Dickstein, K. et al. (2008) ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008 = [Guía de práctica clínica de la sociedad europea de cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008)]. Revista Espanola de Cardiología (English Edition), 61(12), p. 1329. (doi: 10.1016/S1885-5857(09)60059-1)
Gerstein, H. C., Swedberg, K., Carlsson, J., McMurray, J. J. V. , Michelson, E. L., Olofsson, B., Pfeffer, M. A. and Yusuf, S. (2008) The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Archives of Internal Medicine, 168(15), pp. 1699-1704. (doi: 10.1001/archinte.168.15.1699)
Jhund, P. and McMurray, J. J.V. (2008) Heart failure after acute myocardial infarction: a lost bBattle in the war on heart failure? Circulation, 118(20), pp. 2019-2021. (doi: 10.1161/circulationaha.108.813493)
Kjekshus, J., McMurray, J.J. and Wikstrand, J. (2008) The authors reply. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine, 358(12), p. 1301. (doi: 10.1056/NEJMc073536)
Kober, L., Torp-Pedersen, C., McMurray, J.J. , Gotzsche, O., Levy, S., Crijns, H., Amlie, J., Carlsen, J. and Dronedarone Study, G. (2008) Increased mortality after dronedarone therapy for severe heart failure. New England Journal of Medicine, 358(25), pp. 2678-2687. (doi: 10.1056/NEJMoa0800456)
Lewis, E.F. et al. (2008) Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal, 29(6), pp. 748-756. (doi: 10.1093/eurheartj/ehn062)
MacDonald, M.R., Hawkins, N.M., Balmain, S., Dalzell, J., McMurray, J.J. and Petrie, M.C. (2008) Transthoracic echocardiography: a survey of current practice in the UK. QJM: An International Journal of Medicine, 101(5), pp. 345-349.
MacDonald, M.R. et al. (2008) Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circulation: Heart Failure, 1(4), pp. 234-241. (doi: 10.1161/CIRCHEARTFAILURE.108.794008)
MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Petrie, J.R. , Fisher, M., McKelvie, R., Aguilar, D., Krum, H. and McMurray, J.J.V. (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal, 29(10), pp. 1224-1240. (doi: 10.1093/eurheartj/ehn156)
MacDonald, M.R. et al. (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 29(11), pp. 1377-1385. (doi: 10.1093/eurheartj/ehn153)
Massie, B. et al. (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 359(23), pp. 2456-2467. (doi: 10.1056/NEJMoa0805450)
McMurray, J.J. (2008) ACE inhibitors in cardiovascular disease - Unbeatable? New England Journal of Medicine, 358(15), pp. 1615-1616. (doi: 10.1056/NEJMe0801925)
McMurray, J.J.V., Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Keefe, D.L., Ford, J., Verma, A. and Lewsey, J. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure, 1(1), pp. 17-24. (doi: 10.1161/CIRCHEARTFAILURE.107.740704)
McMurray, J. , Carson, P., Komajda, M., McKelvie, R., Zile, M., Ptaszynska, A., Staiger, C., Donovan, J. and Massie, B. (2008) Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure, 10(2), pp. 149-156. (doi: 10.1016/j.ejheart.2007.12.010)
Meredith, P. et al. (2008) Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 52(24), pp. 2000-2007. (doi: 10.1016/j.jacc.2008.09.011)
Murphy, C.L. and McMurray, J.j. (2008) Approaches to the treatment of anaemia in patients with chronic heart failure. Heart Failure Reviews, 13(4), pp. 431-438. (doi: 10.1007/s10741-008-9085-y)
Pocock, S. J. et al. (2008) Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29(21), pp. 2641-2650. (doi: 10.1093/eurheartj/ehn420)
Prisant, L.M., Thomas, K.L., Lewis, E.F., Huang, Z., Francis, G.S., Weaver, W.D., Pfeffer, M.A., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2008) Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Journal of the American College of Cardiology, 51(19), pp. 1865-1871. (doi: 10.1016/j.jacc.2007.12.050)
Radauceanu, A. et al. (2008) Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. Journal of Cardiac Failure, 14(6), pp. 467-474. (doi: 10.1016/j.cardfail.2008.02.014)
Remme, W. J. et al. (2008) Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal, 29(14), pp. 1739-1752. (doi: 10.1093/eurheartj/ehn196)
Rocchiccioli, J. P. and McMurray, J. J.V. (2008) Heart failure—optimal pharmacological therapy. In: Beattie, J. and Goodlin, S. (eds.) Supportive Care in Heart Failure. Series: Supportive care series. Oxford University Press: Oxford ; New York, pp. 49-74. ISBN 9780198570288 (doi: 10.1093/acprof:oso/9780198570288.003.0004)
Rocchiccioli, J.P. and McMurray, J. (2008) Medical management of advanced heart failure. Progress in Palliative Care, 16(5-6), pp. 229-240. (doi: 10.1179/096992608X346233)
Solomon, S.D., Pfeffer, M.A., Pocock, S., Marro, J., McMurray, J.J.V. , Granger, C.B., Yusuf, S., Swedberg, K., Young, J.B. and Michelson, E. (2008) Response to letter regarding article, "Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure". Circulation, 118(1), e8. (doi: 10.1161/circulationaha.107.759662)
Stanton, T., Hawkins, N.M., Hogg, K.J., Goodfield, N.E.R., Petrie, M.C. and McMurray, J.J.V. (2008) How should we optimize cardiac resynchronization therapy? European Heart Journal, 29(20), pp. 2458-2472. (doi: 10.1093/eurheartj/ehn380)
Stewart, S., Wilkinson, D., Hansen, C., Vaghela, V., Mvungi, R., McMurray, J. and Sliwa, K. (2008) Predominance of Heart Failure in the Heart of Soweto Study Cohort Emerging Challenges for Urban African Communities. Circulation, 118(23), pp. 2360-2367. (doi: 10.1161/CIRCULATIONAHA.108.786244) (PMID:19029467)
Tardif, J.C. et al. (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 371(9626), pp. 1761-1768. (doi: 10.1016/S0140-6736(08)60763-1)
Taylor, G.L., Murphy, N.F., Berry, C. , Christie, J., Finlayson, A., MacIntyre, K., Morrison, C. and McMurray, J.J. (2008) Long-term outcome of low-risk patients attending a rapid-assessment chest pain clinic. Heart, 94(5), pp. 628-632. (doi: 10.1136/hrt.2007.125344)
Thomas, K.L., Al Khatib, S.M., Lokhnygina, Y., Solomon, S.D., Kober, L., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2008) Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal, 155, pp. 87-93. (doi: 10.1016/j.ahj.2007.09.010)
Thune, J.J. et al. (2008) Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension, 51, pp. 48-54. (doi: 10.1161/HYPERTENSIONAHA.107.093682)
Thune, J.J. et al. (2008) Response to the J-point revisited. Hypertension, 51(5), E35-E35. (doi: 10.1161/HYPERTENSIONAHA.108.109975)
Torp-Pedersen, C., Kober, L., Carlsen, J.E., Akkan, D., Bruun, N.E., Dacoronias, D., Dickstein, K., Haghfelt, T., Ohlin, H. and McMurray, J.J. (2008) A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure, 10, pp. 89-95. (doi: 10.1016/j.ejheart.2007.10.012)
Verma, A. et al. (2008) Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial InfarctionThe VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC: Cardiovascular Imaging, 1(5), pp. 582-591. (doi: 10.1016/j.jcmg.2008.05.012)
Weir, R.A.P. et al. (2008) Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. European Journal of Heart Failure, 10(2), pp. 157-163. (doi: 10.1016/j.ejheart.2007.12.006)
2007
Recio-Mayoral, A., Kaski, J.C., McMurray, J.J. , Horowitz, J., van Veldhuisen, D.J. and Remme, W.J. (2007) Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovascular Drugs and Therapy, 21(6), pp. 459-465. (doi: 10.1007/s10557-007-6069-4) (PMID:17992567)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N. , Vallance, P., Hillis, W. S. and McMurray, J. (2007) Corrigendum to “Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker” [European Journal of Heart Failure 9/4 (2007) 429-434]. European Journal of Heart Failure, 9(10), p. 1074. (doi: 10.1016/j.ejheart.2007.08.003)
Kenchaiah, S. et al. (2007) Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation, 116(6), pp. 627-636. (doi: 10.1161/circulationaha.106.679779) (PMID:17638930)
O'Meara, E. et al. (2007) Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation, 115(24), pp. 3111-3120. (doi: 10.1161/CIRCULATIONAHA.106.673442) (PMID:17562950)
Murphy, C.L., Fitzsimons, E.J., Jardine, A.J. , Sattar, N. and McMurray, J.J.V. (2007) 103 routine assessment of iron status in all patients with heart failure may identify those at risk of developing anaemia. European Journal of Heart Failure, 6(1), p. 24. (doi: 10.1016/s1567-4215(07)60065-4)
McMurray, J.J.V. et al. (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS Randomized controlled trials. JAMA: Journal of the American Medical Association, 298(17), pp. 2009-2019. (doi: 10.1001/jama.298.17.2009)
Petrie, M. C. and McMurray, J. J.V. (2007) Dysglycemia and heart failure hospitalization: what is the link? Circulation, 115(11), pp. 1334-1335. (doi: 10.1161/circulationaha.106.685214) (PMID:17372185)
Fisher, M. and McMurray, J. J. eds. (2007) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd. ISBN 9780470862049 (doi: 10.1002/9780470723807)
Amigoni, M. et al. (2007) Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal, 28, pp. 326-333. (doi: 10.1093/eurheartj/ehl464)
Balmain, S., Padmanabhan, N., Ferrell, W., Morton, J. and McMurray, J. (2007) Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. European Journal of Heart Failure, 9, pp. 865-871. (doi: 10.1016/j.ejheart.2007.06.003)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N. , Vallance, P., Hillis, W. and McMurray, J. (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. European Journal of Heart Failure, 9, pp. 429-434. (doi: 10.1016/j.ejheart.2006.10.005)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N., Vallance, P., Hillis, W. and McMurray, J. (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker (vol 9, pg 429, 2007). European Journal of Heart Failure, 9, p. 1074.
Berry, C. , Fisher, M. and McMurray, J. J. (2007) Coronary heart disease and diabetes. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 37-67. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch3)
Berry, C. , Fisher, M. and McMurray, J. J. (2007) Diabetes and acute coronary syndromes. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 69-92. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch4)
Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J. , McMorn, S., Roberts, J., Zambanini, A. and Wilding, J. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. Journal of the American College of Cardiology, 49, pp. 1696-1704. (doi: 10.1016/j.jacc.2006.10.077)
Desai, A. et al. (2007) Incidence and predictors of hyperkalemia in patients with heart failure. Journal of the American College of Cardiology, 50, pp. 1959-1966. (doi: 10.1016/j.jacc.2007.07.067)
Dickstein, K., Drexler, H., Mcmurray, J. and Bohm, M. (2007) Abstracts of the Heart Failure Congress 2007 - Hamburg, Germany, 9-12 June, 2007 - Welcome address. European Journal of Heart Failure, 6, IX-IX.
Felker, G. et al. (2007) Red cell distribution width as a novel prognostic marker in heart failure - Data from the CHARM program and the Duke Databank. Journal of the American College of Cardiology, 50, pp. 40-47. (doi: 10.1016/j.jacc.2007.02.067)
Granger, C. and McMurray, J. (2007) Efficacy and safety in clinical trials - Reply. Journal of the American College of Cardiology, 49(6), p. 729. (doi: 10.1016/j.jacc.2006.11.016)
Hawkins, N. et al. (2007) Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart, 93, pp. 59-64. (doi: 10.1136/hrt.2005.083949)
Hawkins, N. et al. (2007) Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. European Journal of Heart Failure, 9, pp. 510-517. (doi: 10.1016/j.ejheart.2006.11.006)
Home, P., Pocock, S., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N., Komajda, M., McMurray, J. and Grp, R. (2007) Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis. New England Journal of Medicine, 357, pp. 28-38. (doi: 10.1056/NEJMoa073394)
Kjekshus, J. et al. (2007) Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine, 357, pp. 2248-2261. (doi: 10.1056/NEJMoa0706201)
Lewis, E. et al. (2007) Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 9(1), pp. 83-91. (doi: 10.1016/j.ejheart.2006.10.012) (PMID:17188020)
MacDonald, M. R., Petrie, M. C. , Hawkins, N. M. and McMurray, J. J. (2007) Diabetes, left ventricular systolic dysfunction and chronic heart failure. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 93-134. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch5)
McEntegart, M., Awede, B., Petrie, M. , Sattar, N., Dunn, F., MacFarlane, N. and McMurray, J. (2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European Heart Journal, 28, pp. 829-835. (doi: 10.1093/eurheartj/ehm033)
Metra, M. et al. (2007) Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 9, pp. 684-694. (doi: 10.1016/j.ejheart.2007.04.003)
Murphy, A. and McMurray, J. (2007) Heart failure: are we neglecting the silent majority? European Heart Journal, 28(9), pp. 1047-1048.
Murphy, N., Simpson, C., Jhund, P. , Stewart, S., Kirkpatrick, M., Chalmers, J., MacIntyre, K. and McMurray, J. (2007) A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 93, pp. 606-612. (doi: 10.1136/hrt.2006.107573)
Myles, R., Jackson, C., Tsorlalis, I., Petrie, M. , McMurray, J. and Cobbe, S. (2007) Is microvolt T-wave alternans the answer to risk stratification in heart failure? Circulation, 116, pp. 2984-2991. (doi: 10.1161/CIRCULATIONAHA.107.699918) (PMID:18086940)
Peacock, A., Murphy, N., McMurray, J. , Caballero, L. and Stewart, S. (2007) An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal, 30, pp. 104-109. (doi: 10.1183/09031936.00092306)
Pfeffer, M. et al. (2007) An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine, 356(9), pp. 959-961.
Sampson, U., Pfeffer, M., McMurray, J. , Lokhnygina, Y., White, H., Solomon, S. and Valsartan Acute, M. (2007) Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. European Heart Journal, 28, pp. 685-691. (doi: 10.1093/eurheartj/ehl197)
Seed, A., Gardner, R., Mcmurray, J. , Hillier, C., Murdoch, D., MacFadyen, R., Bobillier, A., Mann, J. and McDonagh, T. (2007) Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. European Journal of Heart Failure, 9(11), pp. 1120-1127. (doi: 10.1016/j.ejheart.2007.09.002) (PMID:17945530)
Solomon, S.D. et al. (2007) Response to letter regarding article, "Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas". Circulation, 115(12), e349. (doi: 10.1161/circulationaha.106.675553)
Solomon, S. et al. (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation, 116, pp. 1482-1487. (doi: 10.1161/CIRCULATIONAHA.107.696906)
Stephenson, K. et al. (2007) Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm, 4, pp. 308-313. (doi: 10.1016/j.hrthm.2006.11.021)
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2007) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK (vol 90, pg 282, 2004). Heart, 93(11), p. 1472. (doi: 10.1136/hrt.2002.008748corr1)
Vahanian, A. et al. (2007) Guía de práctica clínica sobre el tratamiento de las valvulopatías = [Guide of clinical practice on the treatment of the valvulopatías]. Revista Espanola de Cardiología, 60(6), e1-e50. (doi: 10.1157/13107119) (PMID:17580051)
van Veldhuisen, D. and McMurray, J. (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. European Journal of Heart Failure, 9(2), pp. 110-112. (doi: 10.1016/j.ejheart.2007.01.004)
van Veldhuisen, D., McMurray, J. and Comm, R. (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial (vol 9, pg 110, 2007). European Journal of Heart Failure, 9(3), p. 323.
Verma, A., Anavekar, N., Meris, A., Thune, J., Arnold, J., Ghali, J., Velazquez, E., McMurray, J. , Pfeffer, M. and Solomon, S. (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction - The VALIANT Echo study. Journal of the American College of Cardiology, 50, pp. 1238-1245. (doi: 10.1016/j.jacc.2007.06.018) (PMID:17888840)
2006
Hawkins, N. M., Petrie, M. C. , MacDonald, M. R., Hogg, K. J. and McMurray, J. J.V. (2006) QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence? European Heart Journal, 27(24), pp. 3074-3075. (doi: 10.1093/eurheartj/ehl386) (PMID:17121753)
Murphy, N.F., Stewart, S., Hart, C. , MacIntyre, K., Hole, D.J. and McMurray, J.J.V. (2006) A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew–Paisley study. Heart, 92(12), pp. 1739-1746. (doi: 10.1136/hrt.2006.090118)
MacDonald, M. R., Hawkins, N. M., McMurray, J. J.V. , Dargie, H. J. and Petrie, M. C. (2006) Is CHARM-added candesartan tolerated in 'real-life” patients with advanced chronic heart failure? Journal of Cardiac Failure, 12(6), S126. (doi: 10.1016/j.cardfail.2006.06.434)
Massie, B., Carson, P., Komajda, M., McKelvie, R., McMurray, J. , Zile, M., Frangin, G. and Ptaszynska, A. (2006) The baseline characteristics of patients enrolled in the irbesartan in heart failure with preserved systolic function trial are similar to those in the community but differ from charm-preserved. Journal of Cardiac Failure, 12(6), S77. (doi: 10.1016/j.cardfail.2006.06.262)
Verma, A., Anavekar, N.S., Meris, A., Thune, J.J., Arnold, J.M.O., Ghali, J.K., Velazquez, E.J., McMurray, J.J.V. , Pfeffer, M.A. and Solomon, S.D. (2006) Renal function and cardiac structure and function following MI: the VALIANT echo study. Journal of Cardiac Failure, 12(6), S26. (doi: 10.1016/j.cardfail.2006.06.093)
Young, J.B. et al. (2006) Reduction of events with darbepoetin alfa in heart failure (RED-HF)™ trial. Journal of Cardiac Failure, 12(6), S77. (doi: 10.1016/j.cardfail.2006.06.264)
Yerra, L., Anavekar, N., Skali, H., Zelenkofske, S., Velazquez, E., McMurray, J. , Pfeffer, M. and Solomon, S. (2006) Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm, 3(3), pp. 313-316. (doi: 10.1016/j.hrthm.2005.11.024) (PMID:16500304)
Murphy, N.F., MacIntyre, K., Stewart, S., Hart, C., Hole, D. and McMurray, J. (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew–Paisley study). European Heart Journal, 27(1), pp. 96-106. (doi: 10.1093/eurheartj/ehi506)
Berry, C. , Norrie, J., Hogg, K., Brett, M., Stevenson, K. and McMurray, J. (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. American Heart Journal, 151(6), pp. 1313-1321.
Capewell, S., Unal, B., Critchley, J. and McMurray, J. (2006) Over 20 000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart, 92(4), pp. 521-523.
Capewell, S., Murphy, N.F., MacIntyre, K., Frame, S., Stewart, S., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A. and McMurray, J.J.V. (2006) Short-term and long-term outcomes in 133 429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart, 92(11), pp. 1563-1570. (doi: 10.1136/hrt.2005.085399)
Ducharme, A. et al. (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 151(5), pp. 985-991.
Granger, C. and McMurray, J. (2006) Using measures of disease progression to determine therapeutic effect - A sirens' song. Journal of the American College of Cardiology, 48(3), pp. 434-437.
Hawkins, N., Petrie, M., MacDonald, M., Hogg, K. and McMurray, J. (2006) QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence? European Heart Journal, 27(24), pp. 3074-3075.
Hawkins, N., Petrie, M., MacDonald, M., Hogg, K. and McMurray, J. (2006) Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony? European Heart Journal, 27(11), pp. 1270-1281.
Hillege, H. et al. (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation, 113, pp. 671-678. (doi: 10.1161/CIRCULATIONAHA.105.580506)
Hogg, K. and McMurray, J. (2006) The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Failure Reviews, 11, pp. 141-146. (doi: 10.1007/s10741-006-9488-6)
Hogg, K. and McMurray, J. (2006) The treatment of heart failure with preserved ejection fraction ('diastolic heart failure'). Heart Failure Reviews, 11(2), pp. 141-146.
Janardhanan, R. et al. (2006) Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. American Heart Journal, 152, pp. 183-189. (doi: 10.1016/j.ahj.2005.11.013)
Jhund, P. and McMurray, J. J.V. (2006) Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? - Choosing between the scylla of observational studies and the charybdis of subgroup analysis. Circulation, 113(22), pp. 2566-2568. (doi: 10.1161/CIRCULATIONAHA.106.629212)
Kauf, T. et al. (2006) The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. American Heart Journal, 151, pp. 206-212. (doi: 10.1016/j.ahj.2005.02.028)
Kober, L. et al. (2006) Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. European Journal of Heart Failure, 8, pp. 591-598. (doi: 10.1016/j.ejheart.2005.11.007)
MacIntyre, K., Murphy, N., Chalmers, J., Capewell, S., Frame, S., Finlayson, A., Pell, J., Redpath, A. and McMurray, J. (2006) Hospital burden of suspected acute coronary syndromes: recent trends. Heart, 92(5), pp. 691-692.
McMurray, J. et al. (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction - An analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology, 47, pp. 726-733. (doi: 10.1016/j.jacc.2005.09.055)
Mcmurray, J. and Swedberg, K. (2006) Treatment of chronic heart failure: a comparison between the major guidelines. European Heart Journal, 27(15), pp. 1773-1777.
McMurray, J. (2006) Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. European Heart Journal, 27(19), pp. 2257-2259.
McMurray, J. et al. (2006) Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 27(12), pp. 1447-1458.
McMurray, J. , Califf, R. and Pfeffer, M. (2006) Of statistical significance: 'Trends' toward significance and optimism bias - Reply. Journal of the American College of Cardiology, 48(7), p. 1471.
McMurray, J. et al. (2006) Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM)-Added trial. American Heart Journal, 151, pp. 985-991. (doi: 10.1016/j.ahj.2006.02.028)
McMurray, J. J.V. (2006) Beta-blockers and heart failure in older people: reply. European Heart Journal, 27(7), pp. 888-889. (doi: 10.1093/eurheartj/ehi786)
McMurray, J. J.V. (2006) Drug safety in cardiovascular disease: A call to ACTION. Cardiovascular Drugs and Therapy, 20(1), pp. 9-10. (doi: 10.1007/s10557-006-6690-7) (PMID:16552471)
McMurray, J. J.V. (2006) Editorial. Drugs in Context, 2(4), p. 139.
Murphy, N.F., Simpson, C.R., MacIntyre, K., McAlister, F.A., Chalmers, J. and McMurray, J.J.V. (2006) Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart, 92(8), pp. 1047-1054. (doi: 10.1136/hrt.2005.069419)
Murphy, N., MacIntyre, K., Stewart, S., Hart, C., Hole, D. and McMurray, J. (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew-Paisley study). European Heart Journal, 27, pp. 96-106. (doi: 10.1093/eurheartj/ehi506)
Murphy, N., Stewart, S., Hart, C., MacIntyre, K., Hole, D. and McMurray, J. (2006) A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew Paisley study. Heart, 92, pp. 1739-1746. (doi: 10.1136/hrt.2006.090118)
O'Meara, E. et al. (2006) Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure - Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation, 113, pp. 986-994. (doi: 10.1161/CIRCULATIONAHA.105.582577)
Olsson, L., Swedberg, K., Ducharme, A., Granger, C., Michelson, E., McMurray, J. , Puu, M., Yusuf, S., Pfeffer, M. and Investigators, C. (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction - Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program. Journal of the American College of Cardiology, 47, pp. 1997-2004. (doi: 10.1016/j.jacc.2006.01.060)
Pitt, B., Ferrari, R., Gheorghiade, M., van Veldhuisen, D.J., Krum, H., McMurray, J. and Lopez-Sendon, J. (2006) Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology, 29(10), pp. 434-438. (doi: 10.1002/clc.4960291004) (PMID:17063946)
Pocock, S. et al. (2006) Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal, 27, pp. 65-75. (doi: 10.1093/eurheartj/ehi555)
Reed, S. et al. (2006) Geographic variation in the treatment of acute myocardial infarction in the VALsartan in acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 152, pp. 500-508. (doi: 10.1016/j.ahj.2006.02.032)
Reid, M., Clark, A., Murdoch, D., Morrison, C., Capewell, S. and McMurray, J. (2006) Patients strategies for managing medication for chronic heart failure. International Journal of Cardiology, 109, pp. 66-73. (doi: 10.1016/j.ijcard.2005.05.051)
Solomon, S. D. et al. (2006) Effect of Celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114(10), pp. 1028-1035. (doi: 10.1161/CIRCULATIONAHA.106.636746) (PMID:16943394)
Stewart, S., Murphy, N., McMurray, J. , Jhund, P. , Hart, C. and Hole, D. (2006) Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. European Journal of Heart Failure, 8, pp. 856-863. (doi: 10.1016/j.ejheart.2006.02.008)
Stewart, S., Wilkinson, D., Becker, A., Askew, D., Ntyintyane, L., McMurray, J. and Sliwa, K. (2006) Mapping the emergence of heart disease in a black, urban population in Africa: The Heart of Soweto Study. International Journal of Cardiology, 108, pp. 101-108. (doi: 10.1016/j.ijcard.2006.01.001)
Stewart, S. and McMurray, J. J.V. (2006) Chilling findings: The need for winter vigilance in heart failure. Journal of Cardiac Failure, 12(2), pp. 120-121. (doi: 10.1016/j.cardfail.2005.12.004) (PMID:16520259)
Tardif, J.C., Pfeffer, M.A., McMurray, J.J.V. , Klug, E., Scott, R., Smith, D.H.G., Smith, J.A. and Small, R.D. (2006) Th-P16:264 impact of a major randomized clinical trial on LDL cholesterol levels in the aggressive reduction of inflammation stops events (ARISE) trial. Atherosclerosis Supplements, 7(3), p. 551. (doi: 10.1016/s1567-5688(06)82222-1)
Valeur, N., Nielsen, O., McMurray, J. , Torp-Pedersen, C., Kober, L. and Grp, T. (2006) Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. European Journal of Heart Failure, 8, pp. 577-584. (doi: 10.1016/j.ejheart.2005.11.017)
Walker, A., McMurray, J. , Stewart, S., Berger, W., McMahon, A., Dargie, H., Fox, K., Hillis, S., Henderson, N. and Ford, I. (2006) Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart, 92, pp. 619-624. (doi: 10.1136/hrt.2003.026385) (PMID:16614274) (PMCID:PMC1860935)
Weir, R.A.P., McMurray, J.J.V. , Taylor, J. and Brady, A.J.B. (2006) Heart failure in older patients. British Journal of Cardiology, 13(4), pp. 257-266.
Weir, R. and McMurray, J. (2006) Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Current Heart Failure Reports, 3(4), pp. 175-180. (doi: 10.1007/s11897-006-0019-5)
Weir, R., McMurray, J. , Granger, C., Puu, M., Ostergren, J., Yusuf, S., Swedberg, K. and Pfeffer, M. (2006) Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial. European Heart Journal, 27(Suppl.),
Weir, R., McMurray, J. and Velazquez, E. (2006) Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: Prevalence, clinical characteristics, and prognostic importance. American Journal of Cardiology, 97, 13F-25F. (doi: 10.1016/j.amjcard.2006.03.005)
2005
Clark, A.M., McMurray, J.J.V. , Morrison, C.E., Murdoch, D.L., Capewell, S. and Reid, M.E. (2005) A qualitative study of the contribution of pharmacists to heart failure management in Scotland. Pharmacy World and Science, 27(6), pp. 453-458. (doi: 10.1007/s11096-005-1637-9)
Demers, C. et al. (2005) Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA: Journal of the American Medical Association, 294(14), pp. 1794-1798. (doi: 10.1001/jama.294.14.1794)
Anavekar, N., McMurray, J. and Pfeffer, M. (2005) Chronic renal disease and cardiovascular risk - Reply. New England Journal of Medicine, 352(2), p. 200.
Berry, C. , Hogg, K., Norrie, J., Stevenson, K., Brett, M. and McMurray, J. (2005) Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart, 91, pp. 907-913. (doi: 10.1136/hrt.2004.041996)
Berry, C. , Norrie, J. and McMurray, J. (2005) Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. Cardiovascular Drugs and Therapy, 19, pp. 149-151. (doi: 10.1007/s10557-005-3405-4)
Blue, L. and McMurray, J. (2005) How much responsibility should heart failure nurses take? European Journal of Heart Failure, 7, pp. 351-361. (doi: 10.1016/j.ejheart.2005.01.005)
Boehm, M., Hjalmarson, A., Kjekshus, J., Laufs, U., McMurray, J. and van Veldhuisen, D.J. (2005) Heart failure and statins - Why do we need a clinical trial? Zeitschrift für Kardiologie, 94(4), pp. 223-230. (doi: 10.1007/s00392-005-0210-9)
Carson, P., Massie, B., McKelvie, R., McMurray, J. , Komajda, M., Zile, M., Ptaszynska, A., Frangin, G. and Investigators, I. (2005) The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design. Journal of Cardiac Failure, 11, pp. 576-585. (doi: 10.1016/j.cardfail.2005.06.432)
Clark, A., McMurray, J., Morrison, C., Murdoch, D., Capewell, S. and Reid, M. (2005) A qualitative study of the contribution of pharmacists to heart failure management in Scotland. Pharmacy World and Science, 27, pp. 453-458. (doi: 10.1007/s11096-005-1637-9)
Cowie, M., Mcmurray, J. , Cleland, J., McDonagh, T. and Pearson, M. (2005) Question and answer session. Heart, 91, p. 31.
Dargie, H. et al. (2005) Determinants of coronary events in patients with stable angina: Results from the Impact of Nicorandil in Angina Study. American Heart Journal, 150, (doi: 10.1016/j.ahj.2005.03.040)
Granger, B., Swedberg, K., Ekman, I., Granger, C., Olofsson, B., McMurray, J. , Yusuf, S., Michelson, E., Pfeffer, M. and Investigators, C. (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet, 366, pp. 2005-2011. (doi: 10.1016/S0140-6736(05)67760-4)
Hogg, K. and Mcmurray, J. (2005) Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases, 47(6), pp. 357-366.
Kjekshus, J., Dunselman, P., Blideskog, M., Eskilson, C., Hjalmarson, A., McMurray, J. , Waagstein, F., Wedel, H., Wessman, P. and Wikstrand, J. (2005) A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. European Journal of Heart Failure, 7(6), pp. 1059-1069. (doi: 10.1016/j.ejheart.2005.09.005)
MacIntrye, I., Jhund, P. and McMurray, J. (2005) Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovascular Drugs and Therapy, 19, pp. 261-265. (doi: 10.1007/s10557-005-3309-3)
Mcmurray, J. (2005) Baseline left ventricular wall thickness after myocardial infarction predicts death or heart failure: Findings from the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U588.
Mcmurray, J. (2005) Extent of coronary artery disease and cardiovascular outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: Findings from the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U568.
Mcmurray, J. (2005) Possible beneficial interaction between statins and combination anglotensin receptor blocker (ARB) and ACE inhibitor treatment in patients with myocardial infarction: A post hoc analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U545.
Mcmurray, J. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 26(3), pp. 215-225. (doi: 10.1093/eurheartj/ehi115)
McMurray, J. et al. (2005) Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. European Journal of Heart Failure, 7, pp. 710-721. (doi: 10.1016/j.ejheart.2005.07.002)
McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. and Ford, I. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction - Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, pp. 525-530.
McMurray, J. (2005) Optimising the use of angiotensin receptor blockers in the management of chronic heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 6, S2-S5.
McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, N. and Ford, I. (2005) Antiarrythmic effect of carvedilol after acute myocardial infarction. Journal of the American College of Cardiology, 45(4), pp. 525-530. (doi: 10.1016/j.jacc.2004.09.076)
McMurray, J. (2005) Angiotensin receptor blockers and myocardial infarction - Analysis of evidence is incomplete and inaccurate. British Medical Journal, 330(7502), p. 1269.
McMurray, J. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International, 68(4), pp. 1419-1426.
McMurray, J. (2005) Making sense of SENIORS. European Heart Journal, 26(3), pp. 203-206.
McMurray, J. (2005) Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy? Nature Clinical Practice Cardiovascular Medicine, 2(3), pp. 128-129.
McMurray, J. (2005) The role of angiotensin II receptor blockers in the management of heart failure. European Heart Journal Supplements, 7, J10-J14. (doi: 10.1093/eurheartj/sui057)
McMurray, J. and Pfeffer, M. (2005) Heart failure. Lancet, 365, pp. 1877-1889.
Miller, P., Drummond, M., Langkilde, L., McMurray, J. and Ogren, M. (2005) Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. European Heart Journal Supplements, 7(C), C41-C54.
Mix, T. et al. (2005) Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 149, pp. 408-413. (doi: 10.7016/j.ahj.2004.09.047)
Murphy, N., MacIntyre, K., Stewart, S., Capewell, S. and McMurray, J. (2005) Reduced between-hospital variation in short term survival after acute myocardial infarction: the result of improved cardiac care? Heart, 91, pp. 726-730. (doi: 10.1136/hrt.2004.042929)
O'Meara, E. et al. (2005) Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 7(4), pp. 650-656.
O'Meara, E. and McMurray, J. (2005) Myocardial metabolic manipulation: a new therapeutic approach in heart failure? Heart, 91(2), pp. 131-132.
Packer, M. et al. (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: Results of a pilot study. Journal of Cardiac Failure, 11, pp. 12-20. (doi: 10.1016/j.cardfail.2004.05.006)
Pfeffer, M., Solomon, S., Singh, A., Ivanovich, P. and McMurray, J. (2005) Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med, 6 Supp, S35-S41.
Reed, S. et al. (2005) Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal, 150, pp. 323-329. (doi: 10.1016/j.ahj.2004.08.037)
Remme, W. et al. (2005) Public awareness of heart failure in Europe: first results from SHAPE. European Heart Journal, 26, pp. 2413-2421. (doi: 10.1093/eurheartj/ehi447)
Solomon, S. et al. (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation, 112, pp. 3738-3744. (doi: 10.1161/CIRCULATIONAHA.105.561423)
Solomon, S. et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 352, pp. 1071-1080.
Solomon, S. et al. (2005) Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation, 111(25), pp. 3411-3419.
Solomon, S., Wittes, J., McMurray, J. and Co, A. (2005) Cardiovascular risk associated with celecoxib - The authors reply. New England Journal of Medicine, 352(25), p. 2649.
Solomon, S. et al. (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. New England Journal of Medicine, 352, pp. 2581-2588.
Stewart, S., McAlister, F. and McMurray, J. (2005) Heart failure management programs reduce readmissions and prolong survival. Arch Intern Med, 165(11), p. 1311.
Stewart, S., McMurray, J. , Hebborn, A., Coats, A., Packer, M. and Grp, C. (2005) Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. International Journal of Cardiology, 100, pp. 143-149. (doi: 10.1016/j.ijcard.2004.12.003)
Szummer, K. et al. (2005) Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal, 26, pp. 2114-2119. (doi: 10.1093/eurheartj/ehi352)
Teerlink, J. et al. (2005) Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 150, pp. 46-53. (doi: 10.1016/j.ahj.2005.04.035)
Voors, A., Petrie, C., Petrie, M. , Charlesworth, A., Hillege, H., Zijlstra, F., McMurray, J. and van Veldhuisen, D. (2005) Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. European Heart Journal, 26, pp. 1759-1764. (doi: 10.1093/eurheartj/ehi270)
Weir, R. and McMurray, J. (2005) Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart, 91, pp. 17-20. (doi: 10.1136/hrt.2005.062042)
White, H. et al. (2005) Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction - Results from the Valsartan in Acute Myocardial Infarc. Circulation, 112, pp. 3391-3399. (doi: 10.1161/CIRCULATIONHA.105.551143)
Yusuf, S. et al. (2005) Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation, 112, pp. 48-53. (doi: 10.1161/CIRCULATIONAHA.104.528166)
2004
Murphy, N.F., Stewart, S., MacIntyre, K., Capewell, S. and McMurray, J.J.V. (2004) Seasonal variation in morbidity and mortality related to atrial fibrillation. International Journal of Cardiology, 97(2), pp. 283-288. (doi: 10.1016/j.ijcard.2004.03.041)
Kober, L., Maggioni, A.P., McMurray, J.J. , Velazquez, E.J., Zelenkofske, S., Zannad, F., Van de Werf, F. and Swedberg, K. (2004) Increased risk of both mortality and morbidity with prior as well as current atrial fibrillation after MI: results of VALIANT. Journal of Cardiac Failure, 10(4), S100. (doi: 10.1016/j.cardfail.2004.06.305)
Lewis, E.F. et al. (2004) Heart failure post-myocardial infarction in the new millennium: how often does it occur, can we predict it, and what are the consequences? Journal of Cardiac Failure, 10(4), S101. (doi: 10.1016/j.cardfail.2004.06.309)
Maggioni, A.P., McMurray, J.J.V. , Rouleau, J.L., Velazquez, E.J., Califf, R.M., White, H., Opolski, G. and Pfeffer, M.A. (2004) Who is at risk of early hypotension and renal dysfunction with an inhibitor of the renin angiotensin system after myocardial infarction? data from VALIANT. Journal of Cardiac Failure, 10(4), S89-S90. (doi: 10.1016/j.cardfail.2004.06.262)
Tang, W.H.W., Velazquez, E.J., Kilaru, R., Maroo, A., White, H., Kober, L., Rouleau, J.L., McMurray, J.J.V. , Califf, R.M. and Francis, G.S. (2004) Patterns and outcomes of revascularization in patients with heart failure and/or left ventricular systolic dysfunction following acute myocardial infarction: observations from the VALIANT registry. Journal of Cardiac Failure, 10(4), S104. (doi: 10.1016/j.cardfail.2004.06.321)
Zelenkofske, S., McMurray, J.J.V. , Califf, R.M., Rouleau, J.L., Pfeffer, M.A., Ertl, G., Harsanyi, A. and Solomon, S.D. (2004) Do sudden cardiac death rates warrant earlier treatment following myocardial infarction? experience from the VALIANT Trial. Journal of Cardiac Failure, 10(4), S71. (doi: 10.1016/j.cardfail.2004.06.196)
McMurray, J. J.V. and O'Meara, E. (2004) Treatment of heart failure with spironolactone — trial and tribulations. New England Journal of Medicine, 351(6), pp. 526-528. (doi: 10.1056/NEJMp048144) (PMID:15295043)
Riegel, B., Naylor, M., Stewart, S., McMurray, J.J.V. and Rich, M.W. (2004) Interventions to prevent readmission for congestive heart failure. JAMA: Journal of the American Medical Association, 291(23), p. 2816. (doi: 10.1001/jama.291.23.2816-a)
McAlister, F.A., Murphy, N.F., Simpson, C.R., Stewart, S., MacIntyre, K., Kirkpatrick, M., Chalmers, J., Redpath, A., Capewell, S. and McMurray, J.J.V. (2004) Influence of socioeconomic deprivation on the primary care burden and treatment of patients with a diagnosis of heart failure in general practice in Scotland: population based study. British Medical Journal, 328(7448), pp. 1110-1113. (doi: 10.1136/bmj.38043.414074.EE)
Berry, C., Hogg, K., Stevenson, K., Norrie, J. and McMurray, J. (2004) Relationship between plasma C-reactive protein concentration on admission and long-term outcome in unselected hospitalized heart failure patients. Journal of the American College of Cardiology, 43(5), A229. (doi: 10.1016/s0735-1097(04)90976-x)
Berry, C. and McMurray, J. (2004) 1069-116 Prevalence and importance of renal dysfunction in hospitalized heart failure patients. Journal of the American College of Cardiology, 43(Sup 1), A181. (doi: 10.1016/s0735-1097(04)90770-x)
McMurray, J. J. et al. (2004) 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). Journal of the American College of Cardiology, 43(5), A197. (doi: 10.1016/s0735-1097(04)90836-4)
McMurray, J. J. , Östergren, J., Olofsson, B., Granger, C. B., Michelson, E., Young, J. B., Dunlap, M., Yusuf, S., Swedberg, K. and Pfeffer, M. A. (2004) 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM). Journal of the American College of Cardiology, 43(5), A206. (doi: 10.1016/s0735-1097(04)90878-9)
Hogg, K. J., Rooney, E., Lundmark, E., Christie, J., Newman, E., Kay, D. and McMurray, J. J.V. (2004) What proportion of patients with heart failure and preserved left ventricular systolic function has an elevated plasma concentration of B-type natriuretic peptide? Journal of the American College of Cardiology, 43(5), A241-A242. (doi: 10.1016/s0735-1097(04)91028-5)
Aguilar, D. et al. (2004) Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction - The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 110, pp. 1572-1578. (doi: 10.1161/01.CIR.0000142047.28024.F2)
Anand, I., McMurray, J. , Cohn, J., Konstam, M., Notter, T., Quitzau, K., Ruschitzka, F., Luscher, T. and Investigators, E. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin(A) Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, 364, pp. 347-354.
Anand, I., McMurray, J. , Whitmore, J., Warren, M., Pham, A., McCamish, M. and Burton, P. (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation, 110, pp. 149-154. (doi: 10.1161/01.CIR.0000134279.79571.73)
Anavekar, N. et al. (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine, 351, pp. 1285-1295.
Bunton, D., Petrie, M. , Hillier, C., Johnston, F. and McMurray, J. (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacology and Therapeutics, 103, pp. 179-201. (doi: 10.1016/j.pharmthera.2004.07.002)
Dargie, H. et al. (2004) Impact of nicorandil in angina: subgroup analyses. Heart, 90, pp. 1427-1430. (doi: 10.1136/hrt.2003.026310)
Hogg, K. and McMurray, J. (2004) Treatment of heart failure with preserved systolic function: a review of the evidence. European Heart Journal Supplements, 6(H), H61-H66.
Hogg, K., Swedberg, K. and McMurray, J. (2004) Heart failure with preserved left ventricular Systolic function - Epidemiology clinical characteristics and prognosis. Journal of the American College of Cardiology, 43, pp. 317-327. (doi: 10.1016/j.jacc.2003.09.046)
Hood, W., Dans, A., Guyatt, G., Jaeschke, R. and McMurray, J. (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: A systematic review and meta-analysis. Journal of Cardiac Failure, 10, pp. 155-164. (doi: 10.1016/j.cardfail.2003.12.005)
Jhund, P. , Dawson, N., Davie, A., Norrie, J., O'Kane, K. and McMurray, J. (2004) 17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenopausal women. Cardiovascular Drugs and Therapy, 18, pp. 31-36.
Lopez-Sendon, J. et al. (2004) Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal, 25(15), pp. 1341-1362.
Lopez-Sendon, J. et al. (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease - The task force on ACE-inhibitors of the European Society of Cardiolgy. European Heart Journal, 25(16), pp. 1454-1470.
Lopez-Sendon, J. et al. (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Revista Espanola de Cardiologia, 57(12), pp. 1213-1232.
Mann, D. et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL). Circulation, 109(13), pp. 1594-1602.
McAlister, F., Stewart, S., Ferrua, S. and Mcmurray, J. (2004) Multidisciplinary strategies for the management of heart failure patients at high risk for admission - A systematic review of randomized trials. Journal of the American College of Cardiology, 44(4), pp. 810-819.
McMurray, J.J. (2004) Angiotensin inhibition in heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 5, S17-S22.
McMurray, J.J. (2004) The optimal management of heart failure - Introduction. Journal of the Renin-Angiotensin-Aldosterone System, 5, S1-S1.
McMurray, J. and O'Meara, E. (2004) Treatment of heart failure with spironolactone - Trial and tribulations. New England Journal of Medicine, 351(6), pp. 526-528.
McMurray, J. and Pfeffer, M. (2004) The year in heart failure. Journal of the American College of Cardiology, 44(12), pp. 2398-2405.
McMurray, J. (2004) What are the clinical consequences of anemia in patients with chronic heart failure? Journal of Cardiac Failure, 10, S10-S12. (doi: 10.1016/j.cardfail.2004.01.001)
McMurray, J., Pfeffer, M., Swedberg, K. and Dzau, V. (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation, 110, pp. 3281-3288. (doi: 10.1161/01.CIR.0000147274.83071.68)
Meredith, P.A., Murray, L.S. and McMurray, J.J. (2004) A putative placebo comparison of the SCOPE and LIFE trials. Journal of the Renin-Angiotensin-Aldosterone System, 5, pp. 59-63.
Murphy, N., McMurray, J. and MacIntyre, K. (2004) Discharge rates for suspected acute coronary syndromes - Clinical assessment tools need improving - Reply. British Medical Journal, 329(7458), p. 173.
Murphy, N., MacIntyre, K., Capewell, S., Stewart, S., Pell, J., Chalmers, P., Redpath, A., Frame, S., Boyd, J. and McMurray, J. (2004) Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis. British Medical Journal, 328, pp. 1413-1414.
Murphy, N., Simpson, C., McAlister, F., Stewart, S., MacIntyre, K., Kirkpatrick, M., Chalmers, J., Redpath, A., Capewell, S. and McMurray, J. (2004) National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart, 90, pp. 1129-1136. (doi: 10.1136/hrt.2003.029553)
O'Meara, E., Murphy, C. and McMurray, J. (2004) Anemia and heart failure. Current Heart Failure Reports, 1(4), pp. 176-182.
O'Meara, E., Solomon, S., McMurray, J. , Pfeffer, M., Yusuf, S., Michelson, E., Granger, C., Olofsson, B., Young, J. and Swedberg, K. (2004) Effect of candesartan on New York Heart Association functional class - Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 25, pp. 1920-1926. (doi: 10.1016/j.ehj.2004.07.025)
Petrie, M. , Hogg, K., Caruana, L. and McMurray, J. (2004) Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart, 90, pp. 511-517. (doi: 10.1136/hrt.2003.011403)
Pfeffer, M., McMurray, J. and Califf, R. (2004) Valsartan, captopril, or both in myocardial infarction - Reply. New England Journal of Medicine, 350(9), pp. 944-945.
Remme, W. et al. (2004) Increasing awareness and perception of heart failure in Europe and improving care - Rationale and design of the SHAPE study. Cardiovascular Drugs and Therapy, 18(2), pp. 153-159.
Solomon, S. et al. (2004) Effect of candesartan on cause-specific mortality in heart failure patients - The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation, 110, pp. 2180-2183. (doi: 10.1161/01.CIR.0000144474.65922.AA)
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2004) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart, 90, pp. 286-292. (doi: 10.1136/hrt.2002.008748)
Swedberg, K. and McMurray, J. (2004) Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT? European Heart Journal, 25(5), pp. 357-358.
Velazquez, E.J., Califf, R.M., White, H., Zelenkofske, S., Francis, G.S., Lewis, E.F., Pfeffer, M.A. and McMurray, J. (2004) Is the combination of valsartan and captopril better than captopril alone in patients with heart failure and left ventricular systolic dysfunction after myocardial infarction? results of VALIANT. Journal of Cardiac Failure, 10(4), S76. (doi: 10.1016/j.cardfail.2004.06.213)
Velazquez, E.J., Moreira, M., Rouleau, J.L., Swedberg, K., Kvasnicka, J., Marin-Neto, J.A., Manes, C., Pfeffer, M.A. and McMurray, J. (2004) Does the gender gap still persist after myocardial infarction? Treatments and outcomes in VALIANT. Journal of Cardiac Failure, 10(4), S114. (doi: 10.1016/j.cardfail.2004.06.357)
Velazquez, E. et al. (2004) An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal, 25, pp. 1911-1919. (doi: 10.1016/j.ehj.2004.08.006)
Young, J. et al. (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction - Results of the CHARM low-left ventricular ejection fraction trials. Circulation, 110, pp. 2618-2626. (doi: 10.1161/01.CIR.0000146819.43235.A9)
2003
Ostergren, J. and McMurray, J. J.V. (2003) Angiotensin receptor blockers in heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 4(3), pp. 171-175. (PMID:14608522)
McMurray, J. , Östergren, J., Pfeffer, M., Swedberg, K., Granger, C., Yusuf, S., Held, P., Michelson, E. and Olofsson, B. (2003) Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 5(3), pp. 261-270. (doi: 10.1016/s1388-9842(03)00052-7) (PMID:12798823)
Gurr, E. et al. (2003) The European register for specialists in clinical chemistry and laboratory medicine: guide to the register version 2-2003 and procedure for re-registration. Clinical Chemistry and Laboratory Medicine, 41(2), (doi: 10.1515/cclm.2003.038)
Dunselman, P., Hjalmarson, A., Kjekshus, J., McMurray, J. , Waagstein, F. and Executive Comm, C. (2003) The statin wars. Lancet, 362(9398), p. 1854.
Fisher, C., Al Benna, S., Kirk, A., Morton, J. and McMurray, J. (2003) Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin. Heart, 89(7), pp. 789-790.
Fisher, C., Berry, C. , Blue, L., Morton, J. and McMurray, J. (2003) N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart, 89, pp. 879-881.
Granger, C., McMurray, J. , Yusuf, S., Held, P., Michelson, E., Olofsson, B., Ostergren, J., Pfeffer, M., Swedberg, K. and CHARM Investigators Comm, (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 362, pp. 772-776.
Mcmurray, J. (2003) Effects of newly diagnosed and previously known diabetes mellitus on 1-year outcomes of acute myocardial infarction: The VALIANT Trial. Circulation, 108(17 Sup), IV-745.
Mcmurray, J. (2003) Influence of renal function on one-year cardiovascular outcomes in the VALIANT trial. Circulation, 108(17 Sup), IV-485.
Mcmurray, J. (2003) One-year mortality, stroke, and myocardial infarction rates remain high in the elderly despite beta-blockade plus angiotensin-converting-enzyme inhibition, angiotensin receptor blockade, or both: The VALIANT Trial. Circulation, 108(17 Sup), IV-695.
Mcmurray, J. (2003) Relationship between left ventricular structure and function and plasma neurohormones in patients with heart failure: Results from the EARTH Trial. Circulation, 108(17 Sup), IV-519.
Mcmurray, J. (2003) SHAPE: A Pan-European general public heart failure awareness and perception survey. Circulation, 108(17 Sup), IV-693.
McMurray, J. et al. (2003) Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program. European Journal of Heart Failure, 5, pp. 261-270. (doi: 10.1016/S1388-9842(03)00052-7)
McMurray, J. and Hillier, C. (2003) The rise and fall of myotrophin in heart failure. Journal of the American College of Cardiology, 42(4), pp. 726-727.
McMurray, J. , Pfeffer, M., Swedberg, K., Granger, C. and Yusuf, S. (2003) The CHARM programme - Reply. Lancet, 362(9396), pp. 1678-1679.
McMurray, J. , Ostergren, J., Swedberg, K., Granger, C., Held, P., Michelson, E., Olofsson, B., Yusuf, S., Pfeffer, M. and Comm, C. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362, pp. 767-771.
McMurray, J. and Stewart, S. (2003) The burden of heart failure. European Heart Journal Supplements, 5, pp. 3-13.
Petrie, M. and McMurray, J. (2003) It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. European Journal of Heart Failure, 5(2), pp. 117-119.
Pfeffer, M. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349, pp. 1893-1906.
Pfeffer, M., Swedberg, K., Granger, C., Held, P., McMurray, J. , Michelson, E., Olofsson, B., Ostergren, J., Yusuf, S. and Comm, C. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362, pp. 759-766.
Senior, R., Galasko, G., McMurray, J. and Mayet, J. (2003) Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Heart, 89, pp. 24-28.
Stewart, S., MacIntyre, K., Capewell, S. and McMurray, J. (2003) Heart failure and the aging population: an increasing burden in the 21st century? Heart, 89, pp. 49-53.
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2003) The current cost of angina pectoris to the National Health Service in the UK. Heart, 89, pp. 848-853.
Velazquez, E. et al. (2003) VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 5, pp. 537-544.
Yusuf, S., Pfeffer, M., Swedberg, K., Granger, C., Held, P., McMurray, J. , Michelson, E., Olofsson, B., Ostergren, J. and Comm, C. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 362, pp. 777-781. (doi: 10.1016/s0140-6736(03)14285-7)
2002
McMurray, J. (2002) Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 106(20), 147e. (doi: 10.1161/01.cir.0000037125.61227.68) (PMID:12427668)
McMurray, J.J.V. (2002) Heart failure in 10 years time: Focus on pharmacological treatment. Heart, 88(Suppl2), ii40-ii46. (doi: 10.1136/heart.88.suppl_2.ii40) (PMID:12213800) (PMCID:PMC1876267)
Stewart, S., Hart, C. L. , Hole, D. J. and McMurray, J. J.V. (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. American Journal of Medicine, 113(5), pp. 359-364. (doi: 10.1016/S0002-9343(02)01236-6)
Stewart, S., MacIntyre, K., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J.P. , Capewell, S. and McMurray, J.J.V. (2002) Trends in case-fatality in 22 968 patients admitted for the first time with atrial fibrillation in Scotland, 1986–1995. International Journal of Cardiology, 82(3), pp. 229-236. (doi: 10.1016/s0167-5273(01)00626-x) (PMID:11911910)
Berry, C. and Mcmurray, J. (2002) CHF: a GP guide to management. Practitioner, 246(1639), 669-72, 675.
Berry, C. and McMurray, J. (2002) Editorial comment - Amlodipine for all undergoing PCI? The evidence is unconvincing. International Journal of Cardiology, 84(1), pp. 30-32.
Berry, C., Davie, A., Mcmurray, J. and Schmitz, G. (2002) Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease. HMG-COA Reductase Inhibitors, pp. 135-147.
Byrne, J., Murdoch, D., Morrison, C. and McMurray, J. (2002) An audit of activity and outcome from a daily and a weekly "one stop" rapid assessment chest pain clinic. Postgraduate Medical Journal, 78, pp. 43-46.
Byrne, J., Murdoch, D., Morrison, C. and McMurray, J. (2002) An audit of activity and outcome from a daily and a weekly 'one stop' rapid assessment chest pain clinic. Postgraduate Medical Journal, 78(915), pp. 43-46.
Davie, A. and McMurray, J. (2002) Cost-effectiveness of invasive strategy in unstable coronary disease - what are we waiting for? European Heart Journal, 23(1), pp. 1-3.
Davie, A. and McMurray, J. (2002) Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. British Journal of Clinical Pharmacology, 53, pp. 37-42.
De Vito, G., Galloway, S., Nimmo, M., Maas, P. and McMurray, J. (2002) Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans. Clinical Physiology and Functional Imaging, 22, pp. 32-38.
Fisher, C., MacLean, M., Morecroft, I., Seed, A., Johnston, F., Hillier, C. and McMurray, J. (2002) Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation, 106, pp. 292-295. (doi: 10.1161/01.CIR.0000025630.05387.45)
Fisher, C. and McMurray, J. (2002) Current management of heart failure. Practitioner, 246(1635), pp. 438-443.
Krum, H. and McMurray, J. (2002) Statins and chronic heart failure: Do we need a large-scale outcome trial? Journal of the American College of Cardiology, 39, pp. 1567-1573.
McMurray, J. and Pfeffer, M. (2002) New therapeutic options in congestive heart failure - Part II. Circulation, 105, pp. 2223-2228. (doi: 10.1161/01.CIR.0000014771.38666.22)
McMurray, J. and Pfeffer, M. (2002) New therapeutic options in congestive heart failure: Part I. Circulation, 105, pp. 2099-2106. (doi: 10.1161/01.CIR.0000014763.63528.9D)
McMurray, J. , Struthers, A. and Mcmurray, J. (2002) The role of the specialist nurse - Question and answer session. Heart, 88, p. 35.
McMurray, J. and Pfeffer, M. A. (2002) New therapeutic options in congestive heart failure: part II. Circulation, 105(18), pp. 2223-2228. (doi: 10.1161/01.cir.0000014771.38666.22) (PMID:11994259)
Packer, M., Califf, R., Konstam, M., Krum, H., McMurray, J. , Rouleau, J., Swedberg, K. and Grp, O. (2002) Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation, 106, pp. 920-926. (doi: 10.1161/01.CIR.0000029801.86489.50)
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J. , Rouleau, J.-L. and Swedberg, K. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation, 106(8), pp. 920-926. (doi: 10.1161/01.cir.0000029801.86489.50) (PMID:12186794)
Pell, J. P. , MacIntyre, K., Walsh, D. , Capewell, S., McMurray, J.J. , Chalmers, J.W., Boyd, J.H., Finlayson, A.R., Stewart, S. and Redpath, A.D. (2002) Time trends in survival and readmission following coronary artery bypass grafting in Scotland, 1981-96: retrospective observational study. British Medical Journal, 324, pp. 201-202. (doi: 10.1136/bmj.324.7331.201)
Petrie, M., Caruana, L., Berry, C. and McMurray, J. (2002) 'Diastolic heart failure' or heart failure caused by subtle left ventricular systolic dysfunction? Heart, 87(1), pp. 29-31.
Petrie, M. , Caruana, L., Berry, C. and McMurray, J. (2002) "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart, 87, pp. 29-31.
Pfeffer, M. and McMurray, J. (2002) Myocardial infarct - No one size fits all. Circulation, 105(22), pp. 2577-2579.
Seed, A., Hillier, C., Berry, C., Johnston, F., Brown, A., Petrie, M. and McMurray, J. (2002) Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition. Clinical Science, 103(1), 13P.
Seed, A., Hillier, C., Berry, C., Johnston, F., Petrie, M. and McMurray, J. (2002) Evidence that a novel orally active NEP/ECE inhibitor blocks the vasoconstrictor response to big endothelin in human resistance arteries. Clinical Science, 103(1), 14P.
Stewart, S., Blue, L., Walker, A., Morrison, C. and McMurray, J. (2002) An economic analysis of specialist heart failure nurse management in the UK - Can we afford not to implement it? European Heart Journal, 23, pp. 1369-1378. (doi: 10.1053/euhj.2001.3114)
Stewart, S., Demers, C., Murdoch, D., McIntyre, K., MacLeod, M., Kendrick, S., Capewell, S. and McMurray, J. (2002) Substantial between-hospital variation in outcome following first emergency admission for heart failure. European Heart Journal, 23, pp. 650-657. (doi: 10.1053/euhj.2001.2890)
Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S. and McMurray, J. (2002) The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure, 4, pp. 361-371.
Stewart, S., MacIntyre, K., Chalmers, J., Boyd, J., Finlayson, A., Redpath, A., Pell, J., Capewell, S. and McMurray, J. (2002) Trends in case-fatality in 22,968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. International Journal of Cardiology, 82, pp. 229-236.
Stewart, S., McIntyre, K., Capewell, S. and McMurray, J. (2002) Heart failure in a cold climate - Seasonal variation in heart failure-related morbidity and mortality. Journal of the American College of Cardiology, 39, pp. 760-766.
Stewart, S. and McMurray, J. (2002) Palliative care for heart failure - Time to move beyond treating and curing to improving the end of life. British Medical Journal, 325(7370), pp. 915-916.
2001
Berry, C. and McMurray, J. (2001) Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. American Journal of Medicine, 111(7), p. 587. (doi: 10.1016/S0002-9343(01)00927-5)
Stewart, S., Hart, C.L. , Hole, D.J. and McMurray, J.J.V. (2001) Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart, 86(5), pp. 516-521. (doi: 10.1136/heart.86.5.516)
Capewell, S., MacIntyre, K., Stewart, S., Chalmers, J. W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J. P. and McMurray, J. J.V. (2001) Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986–95: a retrospective cohort study. Lancet, 358(9289), pp. 1213-1217. (doi: 10.1016/s0140-6736(01)06343-7) (PMID:11675057)
Hood, W.B., Dans, A., Guyatt, G.H., Jaeschke, R. and McMurray, J. (2001) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Nursing Times, 97(34), p. 40. (PMID:11957658)
Stewart, S. and McMurray, J.J.V. (2001) Older and more complicated heart failure patients: an increasing challenge to the health care system! Coronary Health Care, 5(3), pp. 121-125. (doi: 10.1054/chec.2001.0115)
McMurray, J. J.V. (2001) Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? Journal of the Renin-Angiotensin-Aldosterone System, 2(2), pp. 89-92. (doi: 10.3317/jraas.2001.017) (PMID:11881104)
Hood, W.B., Dans, A.L., Guyatt, G.H., Jaeschke, R. and McMurray, J.J.V. (2001) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews, CD002901. (doi: 10.1002/14651858.CD002901) (PMID:11279775)
Jhund, P. S. , Davie, A. P. and McMurray, J. J.V. (2001) Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. Journal of the American College of Cardiology, 37(5), pp. 1234-1238. (doi: 10.1016/S0735-1097(01)01169-X) (PMID:11300428)
Jhund, P. S. , Dawson, N., Davie, A. P., Sattar, N. , Norrie, J., O’Kane, K. P.J. and McMurray, J. J.V. (2001) Attenuation of endothelin-1 induced vasoconstriction by 17β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 37(5), pp. 1367-1373. (doi: 10.1016/s0735-1097(01)01168-8) (PMID:11300448)
Coats, P., Johnston, F., MacDonald, J., McMurray, J. J.V. and Hillier, C. (2001) Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation, 103(12), pp. 1702-1708. (doi: 10.1161/01.CIR.103.12.1702) (PMID:11274000)
Bacquet, P. et al. (2001) Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). European Heart Journal, 22, pp. 1021-1031.
Berry, C. , Anderson, N., Kirk, A., Dominiczak, A. and McMurray, J. (2001) Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart, 86(2), pp. 217-220. (doi: 10.1136/heart.86.2.217)
Berry, C., Brosnan, M., Alexander, M., Hamilton, C., McMurray, J. and Dominiczak, A.F. (2001) Mechanisms of oxidative free radical generation in human arteries. Clinical Science, 101(2), 7P.
Berry, C. and McMurray, J. (2001) Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart, 85(4), E8.
Berry, C. and McMurray, J. (2001) Undertreatment of heart failure has high cost to patients. British Medical Journal, 322(7288), pp. 731-732.
Berry, C. , Murdoch, D. R. and McMurray, J. J.V. (2001) Economics of chronic heart failure. European Journal of Heart Failure, 3(3), pp. 283-291. (doi: 10.1016/S1388-9842(01)00123-4) (PMID:11377998)
Berry, C. , Norrie, J. and McMurray, J. J.V. (2001) Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. American Journal of Cardiology, 87(5), pp. 606-607. (doi: 10.1016/S0002-9149(00)01439-9) (PMID:11230847)
Berry, C. , Stewart, S., Payne, E. M., McArthur, J. D. and McMurray, J. J.V. (2001) Electrical cardioversion for atrial fibrillation: outcomes in 'real-life' clinical practice. International Journal of Cardiology, 81, pp. 29-35. (doi: 10.1016/S0167-5273(01)00522-8) (PMID:11690662)
Blue, L. et al. (2001) Randomised controlled trial of specialist nurse intervention in heart failure. British Medical Journal, 323, pp. 715-718. (doi: 10.1136/bmj.323.7315.715)
Capewell, S., MacIntyre, K., Stewart, S., Chalmers, J., Boyd, J., Finlayson, A., Redpath, A., Pell, J. and McMurray, J. (2001) Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet, 358, pp. 1213-1217.
Caruana, L., Petrie, M. C. , McMurray, J. j. and MacFarlane, N. G. (2001) Altered diaphragm position and function in patients with chronic heart failure. European Journal of Heart Failure, 3(2), pp. 183-187. (doi: 10.1016/S1388-9842(00)00133-1) (PMID:11246055)
Coats, P., Johnston, F., MacDonald, J., McMurray, J. and Hillier, C. (2001) Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries. Cardiovascular Research, 49, pp. 828-837.
Coats, P., Johnston, F., MacDonald, J., McMurray, J. and Hillier, C. (2001) Endothelium-derived hyperpolarizing factor - Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation, 103, pp. 1702-1708.
Davie, A.P., Rumley, A., Lowe, G.D.O. and McMurray, J.J.V. (2001) Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure. Thrombosis and Haemostasis, 86(6), pp. 1585-1586. (PMID:11776334)
Fisher, C., Johnston, F., Hillier, C. and McMurray, J. (2001) Relaxin, a newly described cardiac hormone, is a more potent vasodilator than atrial natriuretic factor in human resistance arteries. Circulation, 104(17 Sup), II.
Hillier, C., Berry, C. , Petrie, M. C. , O'Dwyer, P. J., Hamilton, C., Brown, A. and McMurray, J. (2001) Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103, pp. 1378-1381. (doi: 10.1161/01.CIR.103.10.1378) (PMID:11245639)
Hillier, C., Petrie, M. , Love, M. P., Johnston, F., MacLean, M. R. and McMurray, J. J.V. (2001) Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clinical Science, 101, pp. 45-51. (doi: 10.1042/cs1010045) (PMID:11410113)
Love, M.P. and McMurray, J.J.V. (2001) Endothelin receptor antagonists and cardiovascular diseases of aging. Drugs and Aging, 18(6), pp. 425-440. (PMID:11419917)
Luscher, T.F., Ruschitzka, F., Anand, I., Konstam, M.A., McMurray, J. , Notter, T. and Cohn, J.N. (2001) EARTH: EndothelinA receptor antagonist trial in heart failure. Rationale and design. Heartdrug, 1(6), pp. 294-298. (doi: 10.1159/000048978)
MacIntyre, K., Stewart, S., Capewell, S., Chalmers, J., Pell, J., Boyd, J., Finlayson, A., Redpath, A., Gilmour, H. and McMurray, J. (2001) Gender and survival: A population-based study of 201,114 men and women following a first acute myocardial infarction. Journal of the American College of Cardiology, 38, pp. 729-735.
MacIntyre, K., Stewart, S. and McMurray, J. (2001) Is prognosis improving in heart failure? Cardiology Review, 18(7), pp. 29-35.
MacIntyre, K., Stewart, S., Chalmers, J., Pell, J., Finlays, A., Boyd, J., Redpath, A., McMurray, J. and Capewell, S. (2001) Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. British Medical Journal, 322, pp. 1152-1153. (doi: 10.1136/bmj.322.7295.1152)
McDonagh, T., Cunningham, A., Morrison, C., McMurray, J. , Ford, I. , Morton, J. and Dargie, H. (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart, 86, pp. 21-26.
McDonald, J., Petrie, M., Padmanabhan, N., Hillier, C., Connell, J. and McMurray, J. (2001) Non-ace mediated angiotensin II production. Clinical Science, 100(2), 8P.
McDonald, J., Padmanabhan, N., Petrie, M., Hillier, C., Connell, J. and McMurray, J. (2001) Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(D)(11)-Ala(12)] angiotensin I in human dorsal hand veins - In vivo demonstration of non-ACE production of angiotensin II in humans. Circulation, 104, pp. 1805-1808.
McDonald, J. E., Padmanabhan, N., Petrie, M. C. , Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Vasoconstrictor Effect of the Angiotensin-Converting Enzyme-Resistant, Chymase-Specific Substrate [Pro11D-Ala12] Angiotensin I in Human Dorsal Hand Veins: In Vivo Demonstration of Non-ACE Production of Angiotensin II in Humans. Circulation, 104(15), pp. 1805-1808. (doi: 10.1161/hc4001.097220) (PMID:11591618)
Mcmurray, J. (2001) Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: Evidence from the CAPRICORN study. Circulation, 104(17 Sup), II.
Mcmurray, J. (2001) An economic analysis of specialist heart failure nurse management in the UK: Can we afford not to implement it? Circulation, 104(17 Sup), II.
Mcmurray, J. (2001) Endothelium-derived hyperpolarizing factor in human pressurised small subcutaneous resistance arteries may be a product of phospholipase A2 and cytochrome P450 metabolism. British Journal of Pharmacology, 133(Procee), 67P.
Mcmurray, J. (2001) The incidence and natural history of heart failure during 20-year follow-up of 15,406 men and women: The Renfrew/Paisley Study. Circulation, 104(17 Sup), II.
Mcmurray, J. , Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, R., Maggioni, A., Pina, I., Soler-Soler, J. and Swedberg, K. (2001) Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure, 3(4), pp. 495-502.
McMurray, J. (2001) Reduced costs with bisoprolol treatment for heart failure: An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). European Heart Journal, 22(12), pp. 1021-1031.
McMurray, J. (2001) What is suspected heart failure with preserved left ventricular systolic function? Reply. British Medical Journal, 322(7280), p. 239.
McMurray, J. J.V. (2001) Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart, 86(1), pp. 97-103. (doi: 10.1136/heart.86.1.97) (PMID:11410575) (PMCID:PMC1729819)
Morris, S., McMurray, J. , Spiers, A. and Jardine, A. (2001) Impaired endothelial function in isolated human uremic resistance arteries. Kidney International, 60, pp. 1077-1082.
Murdoch, D. R., McDonagh, T. A., Farmer, R., Morton, J. J., McMurray, J. J.V. and Dargie, H. j. (2001) ADEPT: Addition of the AT(1) receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. American Heart Journal, 141, pp. 800-807. (doi: 10.1067/mhj.2001.114802) (PMID:11320369)
Petrie, M.C. , Hillier, C., Johnston, F. and McMurray, J.J.V. (2001) Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. Hypertension, 38, pp. 412-416. (doi: 10.1161/01.HYP.38.3.412) (PMID:11566914)
Petrie, M.C. , McDonald, J.E., Hillier, C., Morton, J.J. and McMurray, J.J.V. (2001) Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. British Journal of Clinical Pharmacology, 52(2), pp. 165-168. (doi: 10.1046/j.0306-5251.2001.01428.x) (PMID:11488773)
Petrie, M. and McMurray, J. J.V. (2001) Changes in notions about heart failure. Lancet, 358(9280), pp. 432-434. (doi: 10.1016/S0140-6736(01)05664-1) (PMID:11513900)
Petrie, M. C. , Padmanabhan, N., McDonald, J. E., Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. Journal of the American College of Cardiology, 37(4), pp. 1056-1061. (doi: 10.1016/S0735-1097(01)01111-1) (PMID:11263608)
Petrie, M. , Berry, C., Stewart, S. and McMurray, J. (2001) Failing ageing hearts. European Heart Journal, 22, pp. 1978-1990. (doi: 10.1053/euhj.2000.2558)
Seed, A., Love, M. P. and McMurray, J. J.V. (2001) Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Reviews, 6(4), pp. 317-323. (doi: 10.1023/A:1011408425878) (PMID:11447306)
Seed, A. and McMurray, J. (2001) Acute endothelin A receptor blockade in heart failure. Circulation, 103(18), E94-E94. (doi: 10.1161/01.CIR.103.18.e94) (PMCID:11342484)
Stewart, S., Blue, L., Capewell, S., Horowitz, J.D. and McMurray, J.J. (2001) Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. European Journal of Heart Failure, 3(2), pp. 249-255. (doi: 10.1016/S1388-9842(00)00144-6)
Stewart, S., MacIntyre, K., Hole, D.J., Capewell, S. and McMurray, J.J.V. (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure. European Journal of Heart Failure, 3(3), pp. 315-322. (doi: 10.1016/S1388-9842(00)00141-0)
Stewart, S., MacIntyre, K., MacLeod, M.M.C., Bailey, A.E.M., Capewell, S. and McMurray, J.J.V. (2001) Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. European Heart Journal, 22(8), pp. 693-701. (doi: 10.1053/euhj.2000.2511)
Stewart, S., MacIntyre, K., MacLeod, M.M.C., Bailey, A.E.M., Capewell, S. and McMurray, J.J.V. (2001) Trends in hospitalization for heart failure in Scotland, 1990-1996 - An epidemic that has reached its peak? European Heart Journal, 22(3), pp. 209-217. (doi: 10.1053/euhj.2000.2291)
2000
Pfeffer, M. A. et al. (2000) Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. American Heart Journal, 140(5), pp. 727-750. (doi: 10.1067/mhj.2000.108832) (PMID:11054617)
Shah, M. R. et al. (2000) Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. American Journal of Medicine, 109(6), pp. 489-492. (doi: 10.1016/s0002-9343(00)00529-5) (PMID:11042239)
McMurray, J. (2000) AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment. Heart, 84(90001), 42i-45. (doi: 10.1136/heart.84.suppl_1.i42) (PMID:10956322) (PMCID:PMC1766530)
Jhund, P. S. , McMurray, J. J.V. and Davie, A. P. (2000) The acute vascular effects of frusemide in heart failure. British Journal of Clinical Pharmacology, 50(1), pp. 9-13. (doi: 10.1046/j.1365-2125.2000.00219.x)
McMurray, J. (2000) Why we need new strategies in CHF management. Journal of the Renin-Angiotensin-Aldosterone System, 1(1), pp. 12-16. (doi: 10.3317/jraas.2000.027) (PMID:11967787)
McMurray, J. (2000) Digoxin and heart failure. Lancet, 355(9197), p. 69. (doi: 10.1016/s0140-6736(05)72013-4) (PMID:10615915)
Berry, C., Brosnan, M.J., Alexander, Y.M., Hamilton, C.A., Dominiczak, A.F. and McMurray, J.J.V. (2000) Angiotensin II increases superoxide production in human arteries. Heart, 83(S1), p. 6.
Capewell, S., Livingston, B.M., MacIntyre, K., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J.P., Evans, C.J. and McMurray, J.J.V. (2000) Trends in case-fatality in 117718 patients admitted with acute myocardial infarction in Scotland. European Heart Journal, 21(22), pp. 1833-1840. (doi: 10.1053/euhj.2000.2318)
Capewell, S. and McMurray, J. (2000) "Chest pain---please admit": is there an alternative?. A rapid cardiological assessment service may prevent unnecessary admissions. British Medical Journal, 320(7240), pp. 951-952. (doi: 10.1136/bmj.320.7240.951) (PMID:10753127) (PMCID:PMC1117892)
Caruana, L., Petrie, M.C. , Davie, A.P. and McMurray, J. (2000) Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. British Medical Journal, 321, pp. 215-218. (doi: 10.1136/bmj.321.7255.215)
Dudley, N., Berry, C. and McMurray, J. (2000) Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data. British Medical Journal, 321(7261), p. 638. (doi: 10.1136/bmj.321.7261.638) (PMID:11023330) (PMCID:PMC1118517)
Evans, C., Chalmers, J., Capewell, S., Redpath, A., Finlayson, A., Boyd, J., Pell, J. , McMurray, J. , MacIntyre, K. and Graham, L. (2000) "I don't like Mondays"--day of the week of coronary heart disease deaths in Scotland: study of routinely collected data. British Medical Journal, 320(7229), pp. 218-219. (doi: 10.1136/bmj.320.7229.218) (PMID:10642230) (PMCID:PMC32257)
Galloway, S. D.R., De Vito, G., McClure, S., Nimmo, M. A. and McMurray, J. J.V. (2000) Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans. Clinical Science, 99(3), pp. 223-230. (doi: 10.1042/cs19990329) (PMID:11787475)
Love, M. P., Haynes, W. G., Webb, D. J. and McMurray, J. J.V. (2000) Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 98(1), pp. 65-70. (doi: 10.1042/cs19990174) (PMID:10600660)
McMurray, J. (2000) Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems. European Heart Journal, 21(15), pp. 1214-1215. (doi: 10.1053/euhj.2000.2257) (PMID:10924310)
McMurray, J. (2000) Heart failure: we need more trials in typical patients. European Heart Journal, 21(9), pp. 699-700. (doi: 10.1053/euhj.1999.1974) (PMID:10739720)
McMurray, J. J. and Stewart, S. (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart, 83(5), pp. 596-602. (doi: 10.1136/heart.83.5.596) (PMID:10768918) (PMCID:PMC1760825)
Morris, S. T.W., McMurray, J. J.V. , Rodger, R. S. C., Farmer, R. and Jardine, A. G. (2000) Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney International, 57(3), pp. 1100-1106. (doi: 10.1046/j.1523-1755.2000.00937.x) (PMID:10720962)
Petrie, M. C. , Hillier, C., Morton, J. and McMurray, J. J.V. (2000) Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. Journal of Hypertension, 18(1), pp. 61-64. (doi: 10.1097/00004872-200018010-00009) (PMID:10678544)
1999
Berry, C. and McMurray, J.J.V. (1999) Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. International Journal of Cardiology, 71(3), pp. 263-264. (doi: 10.1016/s0167-5273(99)00170-9)
Berry, C. and McMurray, J. (1999) A review of quality-of-life evaluations in patients with congestive heart failure. PharmacoEconomics, 16(3), pp. 247-271. (doi: 10.2165/00019053-199916030-00003) (PMID:10558038)
Darnley, G. M., Gray, A. C., McClure, S. J., Neary, P., Petrie, M. , McMurray, J. J.V. and MacFarlane, N. G. (1999) Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. European Journal of Heart Failure, 1(3), pp. 297-300. (doi: 10.1016/s1388-9842(99)00027-6) (PMID:10935679)
McMurray, J. (1999) Transmyocardial laser re vascularisation. Lancet, 353(9165), p. 1704. (doi: 10.1016/s0140-6736(99)00087-2) (PMID:10335808)
Petrie, M. C. , Dawson, N. F., Murdoch, D. R., Davie, A. P. and McMurray, J. J.V. (1999) Failure of women's hearts. Circulation, 99(17), pp. 2334-2341. (doi: 10.1161/01.CIR.99.17.2334) (PMID:10226101)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. , Dargie, H. J. and Morton, J. J. (1999) EndothelinB receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology, 33(4), pp. 932-938. (doi: 10.1016/s0735-1097(98)00663-9) (PMID:10091818)
Northridge, D. B., Currie, P. F., Newby, D. E., McMurray, J. J.V. , Ford, M., Boon, N. A. and Dargie, H. J. (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. European Journal of Heart Failure, 1(1), pp. 67-72. (doi: 10.1016/s1388-9842(98)00003-8) (PMID:10937982)
Petrie, M. C. , McClure, S. J., Love, M. P. and McMurray, J. J.V. (1999) Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1(1), pp. 25-29. (doi: 10.1016/s1388-9842(98)00013-0) (PMID:10937975)
Morris, S.T.W., McMurray, J.J.V. , Rodger, R.S.C., Briggs, J.D. and Jardine, A.G. (1999) Impaired vascular responsiveness to nitric oxide in renal transplant recipients. Transplantation Proceedings, 31(1-2), pp. 304-305. (doi: 10.1016/s0041-1345(98)01637-6) (PMID:10083118)
Hillier, C., Cowburn, P.J., Morton, J.J., Dargie, H.J., Cleland, J.G.F., McMurray, J.J.V. and McGrath, J.C. (1999) Structural and functional assessment of small arteries in patients with chronic heart failure. Clinical Science, 97(6), pp. 671-679. (doi: 10.1042/cs19990166) (PMID:10585894)
1998
McMurray, J.J. , Petrie, M.C. , Murdoch, D.R. and Davie, A.P. (1998) Clinical epidemiology of heart failure: public and private health burden. European Heart Journal, 19 Sup, P9-16. (PMID:9886707)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. and Dargie, H. J. (1998) Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet, 352(9123), pp. 201-202. (doi: 10.1016/s0140-6736(05)77807-7) (PMID:9683214)
Davie, A.P., Caesar, D., Caruana, L., Clegg, G., Spiller, J., Capewell, S., Starkey, I.R., Shaw, T.R. and McMurray, J.J.V. (1998) Outcome from a rapid-assessment chest pain clinic. QJM: An International Journal of Medicine, 91(5), pp. 339-343. (doi: 10.1093/qjmed/91.5.339) (PMID:9709467)
Grant, S., McMurray, J. , Aitchison, T., McDonagh, T., Christie, J., Davie, A. and Dargie, H.J. (1998) The reproducibility of symptoms during a submaximal exercise test in chronic heart failure. British Journal of Clinical Pharmacology, 45(3), pp. 287-290. (doi: 10.1046/j.1365-2125.1998.00682.x) (PMID:9517373)
McDonagh, T.A., Morrison, C.E., McMurray, J.J. and Dargie, H.J. (1998) Left-ventricular dysfunction. Lancet, 351(9099), pp. 371-372. (doi: 10.1016/s0140-6736(05)78299-4)
McDonagh, T., Robb, S.D., Murdoch, D.R., Morton, J.J., Ford, I. , Morrison, C.E., Tunstall-Pedoe, H., McMurray, J. and Dargie, H. (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet, 351(9095), pp. 9-13. (doi: 10.1016/S0140-6736(97)03034-1)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. and Dargie, H. J. (1998) Pulmonary and systemic responses to exogenous endothelin-1 in patients with left ventricular dysfunction. Journal of Cardiovascular Pharmacology, 31(Sup 1), S290-S293. (doi: 10.1097/00005344-199800001-00081) (PMID:9595462)
McMurray, J. , Davie, A.P. and McClure, S.J. (1998) Assessment of heart failure with plasma natriuretic peptides. Lancet, 351(9100), p. 444. (doi: 10.1016/s0140-6736(05)78386-0) (PMID:9482327)
1997
Caro, J., Klittoch, W., McGuire, A., Ford, I. , Norrie, J., Pettitt, D., McMurray, J. and Shepherd, J. (1997) The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. British Medical Journal, 315, pp. 1577-1582. (doi: 10.1136/bmj.315.7122.1577)
Clark, A.L., Galloway, S., MacFarlane, N., Henderson, E., Aitchison, T. and McMurray, J.J.V. (1997) Catecholamines contribute to exertional dyspnoea and to the ventilatory response to exercise in normal humans. European Heart Journal, 18(11), pp. 1829-33. (doi: 10.1093/oxfordjournals.eurheartj.a015179) (PMID:9402459)
McDonagh, T.A., Morrison, C.E., Lawrence, A., Ford, I. , Tunstall-Pedoe, H., McMurray, J.J.V. and Dargie, H.J. (1997) Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet, 350(9081), pp. 829-833. (doi: 10.1016/S0140-6736(97)03033-X)
Garner, M., Reglinski, J., Smith, W. E., McMurray, J. , Abdullah, I. and Wilson, R. (1997) A 1 H spin echo and 51 V NMR study of the interaction of vanadate with intact erythrocytes. Journal of Biological Inorganic Chemistry, 2(2), pp. 235-241. (doi: 10.1007/s007750050129)
McMurray, J. and Murdoch, D. (1997) Calcium-antagonist controversy: the long and short of it? Lancet, 349(9052), pp. 585-586. (doi: 10.1016/s0140-6736(05)61561-9) (PMID:9057725)
McMurray, J. and Davie, A.P. (1997) Digoxin for patients with heart failure in sinus rhythm. Lancet, 350(9076), p. 519. (doi: 10.1016/s0140-6736(05)63111-x) (PMID:9274604)
1996
Murdoch, D. R., Byrne, J., McDonagh, T., Morton, J. J. and McMurray, J. J.V. (1996) Measurement of brain natriuretic peptide. Lancet, 348(9041), p. 1589. (doi: 10.1016/s0140-6736(05)66206-x) (PMID:8950904)
Davie, A. and McMurray, J. (1996) Open-access echocardiography. Lancet, 348(9038), p. 1387. (doi: 10.1016/s0140-6736(05)65456-6) (PMID:8918303)
Love, M. P. and McMurray, J. J.V. (1996) Endothelin in chronic heart failure: current position and future prospects. Cardiovascular Research, 31(5), pp. 665-674. (doi: 10.1016/s0008-6363(96)00055-7) (PMID:8763394)
Laycock, S.K., Kane, K.A., McMurray, J. and Parratt, J.R. (1996) Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. Journal of Cardiovascular Pharmacology, 27(5), pp. 667-672. (doi: 10.1097/00005344-199605000-00008) (PMID:8859936)
Dargie, H.J., McMurray, J.J.V. and McDonagh, T. (1996) Heart failure - implications of the true size of the problem. Journal of Internal Medicine, 239(4), pp. 309-315. (doi: 10.1046/j.1365-2796.1996.461800000.x) (PMID:8774385)
1995
Laycock, S. K., McMurray, J. , Kane, K. A. and Parratt, J. R. (1995) Effects of chronic norepinephrine administration on cardiac function in rats. Journal of Cardiovascular Pharmacology, 26(4), pp. 584-589. (doi: 10.1097/00005344-199510000-00012) (PMID:8569219)
1994
Russell, J., Ness, J., Chopra, M., McMurray, J. and Smith, W.E. (1994) The assessment of the HO· scavenging action of therapeutic agents. Journal of Pharmaceutical and Biomedical Analysis, 12(7), pp. 863-866. (doi: 10.1016/0731-7085(94)e0022-s) (PMID:7981313)
1993
Laycock, S. K., McMurray, J. , Kane, K. A. and Parratt, J. R. (1993) Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. Free Radical Biology and Medicine, 15(3), pp. 249-255. (doi: 10.1016/0891-5849(93)90071-2) (PMID:8406124)
1992
McMurray, J. and McInnes, G. T. (1992) The J-curve hypothesis. Lancet, 339(8792), pp. 561-562. (doi: 10.1016/0140-6736(92)90390-o) (PMID:1346917)
Chopra, M., Beswick, H., Clapperton, M., Dargie, H.J., Smith, W.E. and McMurray, J. (1992) Antioxidant effects of Angiotensin-Converting Enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. Journal of Cardiovascular Pharmacology, 19(3), pp. 330-340. (doi: 10.1097/00005344-199203000-00005)
McMurray, J. , Dargie, H., Hall, A., Tan, L., Gray, D., Ball, S., Cruickshank, J.M., Roy-Chaudhury, P., Khan, I. and Catto, G.D. (1992) ACE inhibitors for myocardial infarction and unstable angina. Lancet, 340(8834-8), pp. 1547-1549. (doi: 10.1016/0140-6736(92)92803-n) (PMID:1361633)
1991
MacFarlane, N., McMurray, J. , O'Dowd, J. J., Dargie, H. J. and Miller, D. J. (1991) Synergism of histidyl dipeptides as antioxidants. Journal of Molecular and Cellular Cardiology, 23(11), pp. 1205-1207. (doi: 10.1016/0022-2828(91)90077-Y) (PMID:1803015)
McMurray, J. , Lang, C.C., MacLean, D., Struthers, A.D. and McDevitt, D.G. (1991) Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. International Journal of Cardiology, 31(3), pp. 295-303. (doi: 10.1016/0167-5273(91)90380-8) (PMID:1679047)
McMurray, J. , MacLenachan, J. and Dargie, H. J. (1991) Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. Journal of Hypertension, 9(5), pp. 393-397. (doi: 10.1097/00004872-199105000-00002)
McMurray, J. , McLenachan, J. and Dargie, H. J. (1991) Angiotensin converting enzyme inhibitors [reply]. Journal of Hypertension, 9(11), pp. 1075-1076. (doi: 10.1097/00004872-199111000-00016)
1990
McMurray, J. J. , Lang, C. C., MacLean, D., McDevitt, D. G. and Struthers, A. D. (1990) Neuroendocrine changes post myocardial infarction: effects of xamoterol. American Heart Journal, 120(1), pp. 56-62. (doi: 10.1016/0002-8703(90)90160-y) (PMID:1972861)
McMurray, J. , McLay, J., Chopra, M., Bridges, A. and Belch, J.J.F. (1990) Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 65(18), pp. 1261-1262. (doi: 10.1016/0002-9149(90)90985-a) (PMID:2337039)
McMurray, J. , Chopra, M., Stewart, J., Blaney, S., Ewen Smith, W. E. and Dargie, H. J. (1990) Does free radical generation occur in unstable angina? Journal of Molecular and Cellular Cardiology, 22(S3), S120. (doi: 10.1016/0022-2828(90)91883-9)
Ray, S., McMurray, J. , Dargie, H. J. and Morton, J. (1990) Dissociation of endothelin and atrial natriuretic factor after acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 22(Sup 3), S34. (doi: 10.1016/0022-2828(90)91629-l)
Reglinski, J., Chopra, M., McMurray, J. , Dargie, H. J. and Smith, W. E. (1990) Demonstration of oxidative stress across cell membranes in chronic heart failure using 1H spin echo NMR spectroscopy of intact erythrocytes. Journal of Molecular and Cellular Cardiology, 22(Sup 3), S99. (doi: 10.1016/0022-2828(90)91820-w)
Chopra, M., McMurray, J. , Dargie, H.J. and Smith, W.E. (1990) Antioxidant potential of -SH containing angiotensin converting enzyme (ACE) inhibitors. Free Radical Biology and Medicine, 9(Sup 1), p. 151. (doi: 10.1016/0891-5849(90)90714-t)
Chopra, M., Reglinski, J., McMurray, J. and Smith, W.E. (1990) Evidence of oxidative stress across membranes in chronic heart failure using 1H spin echo NMR spectroscopy. Free Radical Biology and Medicine, 9(Sup 1), p. 89. (doi: 10.1016/0891-5849(90)90488-5)
1989
McMurray, J. , McFarlane, L., Coutie, W., Balfour, D. and Struthers, A. (1989) Atrial natriuretic factor attenuates prostaglandin E2-stimulated plasma renin activity in humans. Journal of Cardiovascular Pharmacology, 14(2), pp. 326-330. (doi: 10.1097/00005344-198908000-00021) (PMID:2476609)
McMurray, J. J. and Dargie, H. J. (1989) Neurohumoral aspects of heart failure. Current Opinion in Cardiology, 4(3), pp. 355-359. (doi: 10.1097/00001573-198906000-00004)
1988
McMurray, J. , Forsling, M. L. and Struthers, A. D. (1988) Arginine vasopressin dissociates the diuresis and natriuresis due to atrial natriuretic factor in man. European Journal of Clinical Investigation, 18(6), pp. 627-632. (doi: 10.1111/j.1365-2362.1988.tb01278.x) (PMID:2975995)
McMurray, J. , Coutie, W.J.R., McFarlane, L. and Struthers, A.D. (1988) Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man. European Journal of Clinical Pharmacology, 35(4), pp. 409-412. (doi: 10.1007/BF00561373)
McMurray, J. and Struthers, A.D. (1988) Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. European Journal of Clinical Pharmacology, 35(4), pp. 333-338. (doi: 10.1007/BF00561360) (PMID:2973989)
McMurray, J. and Struthers, A.D. (1988) Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man. Clinical Science, 74(4), pp. 419-425. (doi: 10.1042/cs0740419)
McMurray, J. J. and Struthers, A. D. (1988) Captopril in patients with ileus. Lancet, 331(8583), p. 471. (doi: 10.1016/S0140-6736(88)91260-3)
McMurray, J. , Seidelin, P.H. and Struthers, A.D. (1988) Intrarenal sites of action of atrial natriuretic factor in man. British Journal of Clinical Pharmacology, 25(5), 630P.
McMurray, J. and Struthers, A.D. (1988) The place of ACE inhibitors in the current treatment of chronic heart failure. Postgraduate Medical Journal, 64(755), pp. 653-655. (doi: 10.1136/pgmj.64.755.653)
McMurray, J. and Struthers, A.D. (1988) Significance of atrial natriuretic factor in chronic heart failure. British Journal of Hospital Medicine, 40(1), pp. 55-57.
McMurray, J. , Seidelin, P. H., Howey, J. E.A., Balfour, D. J. and Struthers, A. D. (1988) The effect of atrial natriuretic factor on urinary albumin and β2-microglobulin excretion in man. Journal of Hypertension, 6(10), pp. 783-786.
McMurray, J. J. , Seidelin, P. H., Balfour, D. J.K. and Struthers, A. D. (1988) Physiological increases in circulating noradrenaline are antinatriuretic in man. Journal of Hypertension, 6(9), pp. 757-761. (PMID:3183378)
1987
Lawson, A., McMurray, J. and Northridge, D.B. (1987) Association between liberalization of Scotland's liquor licensing laws and admissions for self poisoning. British Medical Journal (Clinical Research Ed.), 294(6568), pp. 371-372. (PMID:3101883) (PMCID:PMC1245373)
McMurray, J. and Matthews, D.M. (1987) Consequences of fluid loss in patients treated with ACE inhibitors. Postgraduate Medical Journal, 63(739), pp. 385-387. (doi: 10.1136/pgmj.63.739.385) (PMID:2823245) (PMCID:PMC2428483)
McMurray, J. and Struthers, A.D. (1987) The role of neuroendocrine abnormalities in the enhanced sodium and water retention of chronic heart failure. Pharmacology and Toxicology, 61(4), pp. 209-214. (doi: 10.1111/j.1600-0773.1987.tb01805.x) (PMID:3324091)
McMurray, J.J. , Fraser, D.M. and Brogan, O. (1987) Fatal Streptococcus pyogenes pneumonia. Journal of the Royal Society of Medicine, 80(8), pp. 525-526. (doi: 10.1177/014107688708000821) (PMID:3309306)
McMurray, J.J. , Northridge, D.B., Abernathy, V.A. and Lawson, A.A.H. (1987) Trends in analgesic self-poisoning in West-Fife, 1971-1985. QJM: An International Journal of Medicine, 65(246), pp. 835-843. (PMID:3449888)
McMurray, J.J. , Seidelin, P.H. and Fraser, D.M. (1987) Hyperglycaemic non-ketotic focal epilepsy. Practical Diabetes, 4(2), pp. 78-79. (doi: 10.1002/pdi.1960040210)
McMurray, J.J. and Struthers, A.D. (1987) Renal effects of angiotensin II, atrial natriuretic peptide and their interaction in man. Journal of Hypertension, 5(S5), S59-S62. (PMID:2965232)
Northridge, D.B., McMurray, J. , Colledge, N.R. and Fraser, D.M. (1987) Hypertensive hypertrophic cardiomyopathy of the elderly. British Journal of Hospital Medicine, 38(6), p. 567. (PMID:3435805)
1986
McMurray, J. and Fraser, D.M. (1986) Captopril, enalapril, and blood glucose. Lancet, 327(8488), p. 1035. (doi: 10.1016/S0140-6736(86)91304-8) (PMID:2871313)
McMurray, J. , Bloomfield, P. and Miller, H.C. (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. British Medical Journal (Clinical Research Ed.), 292(6515), pp. 239-240. (doi: 10.1136/bmj.292.6515.239-a) (PMID:3081088)
McMurray, J. , Bloomfield, P. and Miller, H.C. (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. British Medical Journal (Clinical Research Ed.), 293(6538), pp. 51-52. (doi: 10.1136/bmj.293.6538.51-d) (PMID:3089403)
McMurray, J. and Fraser, D. M. (1986) Pneumonia. Postgraduate Medical Journal, 62(731), p. 895. (doi: 10.1136/pgmj.62.731.895) (PMCID:PMC2422815)
McMurray, J. and Matthews, D. M. (1986) Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. Heart, 56(5), p. 490. (doi: 10.1136/hrt.56.5.490-a) (PMCID:PMC1236903)
Northridge, D.B., McMurray, J. and Lawson, A.A.H. (1986) Association between liberalization of Scotland's liquor licensing laws and admissions for self poisoning in West Fife. British Medical Journal, 293(6560), pp. 1466-1468. (doi: 10.1136/bmj.293.6560.1466) (PMID:3099914) (PMCID:PMC1342238)
1985
McMurray, J. and Matthews, D. M. (1985) Effect of diarrhoea on a patient taking captopril. Lancet, 325(8428), p. 581. (doi: 10.1016/S0140-6736(85)91240-1) (PMID:2857931)
Articles
Osmanska, J., Petrie, M. C. , Docherty, K. F. , Lee, M. M.Y. , McMurray, J. J.V. and Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083) (Accepted for Publication)
Lu, H. et al. (2024) Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the PARADIGM‐HF and PARAGON‐HF trials. European Journal of Heart Failure, (doi: 10.1002/ejhf.3487) (PMID:39439294) (Early Online Publication)
Docherty, K. F. et al. (2024) Wearable accelerometer-derived measures of physical activity in heart failure: insights from the DETERMINE trials. Journal of Cardiac Failure, (Accepted for Publication)
Chatur, S. et al. (2024) Sacubitril/valsartan in patients with heart failure and deterioration in eGFR to <30 mL/min/1.73 m2. JACC: Heart Failure, 12(10), pp. 1692-1703. (doi: 10.1016/j.jchf.2024.03.014) (PMID:38842957)
Docherty, K. F. et al. (2024) Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials. Circulation: Heart Failure, 17(10), e012349. (doi: 10.1161/CIRCHEARTFAILURE.124.012349) (PMID:39212948) (PMCID:PMC11472896)
Wang, X. et al. (2024) Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE‐MI echocardiographic substudy. European Journal of Heart Failure, (doi: 10.1002/ejhf.3472) (PMID:39315586) (Early Online Publication)
Jhund, P. S. et al. (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet, 404(10458), pp. 1119-1131. (doi: 10.1016/S0140-6736(24)01733-1) (PMID:39232490)
Pabon, M. A. et al. (2024) In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3410) (PMID:39300780) (Early Online Publication)
Lu, H. et al. (2024) Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3414) (PMID:39217577) (Early Online Publication)
Abdin, A. et al. (2024) Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: an analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, 26(9), pp. 1952-1963. (doi: 10.1002/ejhf.3350) (PMID:39016033)
Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)
Butt, J. H. et al. (2024) Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. Circulation, (doi: 10.1161/circulationaha.124.071110) (PMID:39217458) (Accepted for Publication)
Mc Causland, F. R. et al. (2024) Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI. European Journal of Heart Failure, 26(9), pp. 1984-1992. (doi: 10.1002/ejhf.3386) (PMID:39056455)
Matsumoto, S. et al. (2024) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.3383) (PMID:39215677) (Early Online Publication)
Yang, M. et al. (2024) Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment. European Journal of Heart Failure, (doi: 10.1002/ejhf.3417) (PMID:39169481) (Early Online Publication)
Butt, J. H. et al. (2024) Anthropometric measures and long‐term mortality in non‐ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox. European Journal of Heart Failure, (doi: 10.1002/ejhf.3424) (PMID:39155576) (Early Online Publication)
Cleland, J. et al. (2024) The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Journal of the American College of Cardiology, (Accepted for Publication)
Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)
Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)
Kondo, T. et al. (2024) Low natriuretic peptide levels and outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 12(8), pp. 1442-1455. (doi: 10.1016/j.jchf.2024.04.027) (PMID:38904646)
Lam, C. S.P. et al. (2024) Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial. European Journal of Heart Failure, 26(8), pp. 1727-1735. (doi: 10.1002/ejhf.3294) (PMID:38783712)
Lassen, M. C.H. et al. (2024) Cardiovascular‐kidney‐metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON‐HF. European Journal of Heart Failure, 26(8), pp. 1762-1774. (doi: 10.1002/ejhf.3304) (PMID:38932589)
Matsumoto, S. et al. (2024) Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. Journal of Cardiology, 84(2), pp. 133-140. (doi: 10.1016/j.jjcc.2023.11.005) (PMID:38000538)
O'Hara, D. V., Lam, C. S.P., McMurray, J. J.V. , Yi, T. W., Hocking, S., Dawson, J., Raichand, S., Januszewski, A. S. and Jardine, M. J. (2024) Applications of SGLT2 inhibitors beyond glycaemic control. Nature Reviews Nephrology, 20(8), pp. 513-529. (doi: 10.1038/s41581-024-00836-y) (PMID:38671190)
Yang, M. et al. (2024) Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 26(8), pp. 1788-1803. (doi: 10.1002/ejhf.3352) (PMID:38923118)
Zahir Anjum, D. et al. (2024) Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study. European Journal of Heart Failure, 26(8), pp. 1717-1726. (doi: 10.1002/ejhf.3249) (PMID:38700461)
Espersen, C. et al. (2024) Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, 132036. (doi: 10.1016/j.ijcard.2024.132036) (PMID:38599465)
Ostrominski, J. W. et al. (2024) Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction a trial-level analysis. Journal of the American College of Cardiology, 84(2), pp. 223-228. (doi: 10.1016/j.jacc.2024.05.005) (PMID:38744407)
Yang, M. et al. (2024) Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, 26(7), pp. 1524-1538. (doi: 10.1002/ejhf.3263) (PMID:38700986)
Conrad, N. et al. (2024) Temporal trends and patterns in cardiovascular disease incidence: a population-based study in 22 million individuals. British Medical Journal, 385, e078523. (doi: 10.1136/bmj-2023-078523) (PMID:38925788) (PMCID:PMC11203392)
Shen, L. et al. (2024) Revisiting race and the benefit of RAS blockade in heart failure. A meta-analysis of randomized clinical trials. JAMA: Journal of the American Medical Association, 331(24), 2094. (doi: 10.1001/jama.2024.6774) (PMID:38809561)
Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)
Friday, J. M. et al. (2024) Loop diuretic utilisation with or without heart failure: impact on prognosis. European Heart Journal, (doi: 10.1093/eurheartj/ehae345) (PMID:38845446) (Early Online Publication)
Chatur, S. et al. (2024) Effects of sacubitril/valsartan across the spectrum of renal impairment in patients with heart failure. Journal of the American College of Cardiology, 83(22), pp. 2148-2159. (doi: 10.1016/j.jacc.2024.03.392) (PMID:38588927)
Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)
Pabón, M. A. et al. (2024) Sex differences in heart failure with improved ejection fraction. JACC: Heart Failure, 12(6), pp. 1119-1122. (doi: 10.1016/j.jchf.2024.03.011) (PMID:38661586)
Solomon, S. D. et al. (2024) Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial. European Journal of Heart Failure, 26(6), pp. 1334-1346. (doi: 10.1002/ejhf.3266) (PMID:38733212)
Vaduganathan, M. et al. (2024) Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial. European Journal of Heart Failure, 26(6), pp. 1324-1333. (doi: 10.1002/ejhf.3253) (PMID:38742248)
Kondo, T. et al. (2024) Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83(20), pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385) (PMID:38537918)
Davis, J. A., Booth, D., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2024) Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data. European Journal of Heart Failure, 26(3), pp. 664-673. (doi: 10.1002/ejhf.3197) (PMID:38509642)
Lassen, M. C. H. et al. (2024) Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: a pre‐specified analysis of the DELIVER trial. European Journal of Heart Failure, 26(7), pp. 1539-1548. (doi: 10.1002/ejhf.3269) (PMID:38745498)
Foà, A. et al. (2024) Sacubitril/Valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 83(18), pp. 1731-1739. (doi: 10.1016/j.jacc.2024.02.035) (PMID:38537919)
McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)
Gilbert, M. P., Skelly, J., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J.V. , Del Prato, S. and Pratley, R. E. (2024) Effect of albiglutide on cardiovascular outcomes in older adults: a post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 26(5), pp. 1714-1722. (doi: 10.1111/dom.15479) (PMID:38317618)
Kondo, T. et al. (2024) A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nature Medicine, 30(5), pp. 1432-1439. (doi: 10.1038/s41591-024-02941-8) (PMID:38710952) (PMCID:PMC11108780)
Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
Heerspink, H. J.L. et al. (2024) Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria. American Heart Journal, 270, pp. 125-135. (doi: 10.1016/j.ahj.2024.02.006) (PMID:38367893)
Minamisawa, M. et al. (2024) Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: the PARAGON‐HF study. European Journal of Heart Failure, 26(4), pp. 871-881. (doi: 10.1002/ejhf.3167) (PMID:38369856)
Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, 30(4), pp. 618-623. (doi: 10.1016/j.cardfail.2023.11.020) (PMID:38122924)
Peikert, A. et al. (2024) Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER Trial. JACC: Heart Failure, 12(4), pp. 631-644. (doi: 10.1016/j.jchf.2023.09.007) (PMID:37767674)
Peikert, A. et al. (2024) Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, 26(4), pp. 912-924. (doi: 10.1002/ejhf.3184) (PMID:38487939)
Knigge, P. et al. (2024) Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016. Journal of the American Heart Association, 13(6), e032539. (doi: 10.1161/JAHA.123.032539) (PMID:38471834) (PMCID:PMC11009989)
Bhatt, A. S. et al. (2024) Cost effectiveness of dapagliflozin for heart failure across the spectrum of ejection fraction: an economic evaluation based on pooled, individual participant data from the DELIVER and DAPA-HF trials. Journal of the American Heart Association, 13(5), e032279. (doi: 10.1161/JAHA.123.032279) (PMID:38390793) (PMCID:PMC10944049)
Mann, D. L. et al. (2024) Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI. Journal of the American College of Cardiology, 83(9), pp. 904-914. (doi: 10.1016/j.jacc.2024.01.002) (PMID:38418004)
Adamo, M. et al. (2024) Tricuspid regurgitation and clinical outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 12(3), pp. 552-563. (doi: 10.1016/j.jchf.2023.11.018) (PMID:38300212)
Dimond, M. G. et al. (2024) Left ventricular ejection fraction and the future of heart failure phenotyping. JACC: Heart Failure, 12(3), pp. 451-460. (doi: 10.1016/j.jchf.2023.11.005) (PMID:38099892)
Butt, J. H. et al. (2024) Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER. Journal of Cardiac Failure, 30(3), pp. 436-448. (doi: 10.1016/j.cardfail.2023.08.027) (PMID:38104937)
Ferguson, L. D. , Molenberghs, G., Verbeke, G., Rahimi, K., Rao, S., McInnes, I. B. , McMurray, J. J.V. , Sattar, N. and Conrad, N. (2024) Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatology, 6(3), e156-e167. (doi: 10.1016/S2665-9913(23)00338-7)
Wang, X. et al. (2024) Effects of dapagliflozin in patients in Asia: a post hoc subgroup analysis from the DELIVER trial. JACC: Asia, 4(2), pp. 108-118. (doi: 10.1016/j.jacasi.2023.10.005) (PMID:38371292) (PMCID:PMC10866733)
Brum, W. S., Docherty, K. F. , Ashton, N. J., Zetterberg, H., Hansson, O., McMurray, J. J. V. and Blennow, K. (2024) Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81(2), pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719) (PMID:38109077) (PMCID:PMC10728797)
Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)
Owen, R. et al. (2024) Sex differences in the clinical presentation and natural history of dilated cardiomyopathy. JACC: Heart Failure, 12(2), pp. 352-363. (doi: 10.1016/j.jchf.2023.10.009) (PMID:38032570) (PMCID:PMC10857810)
Vart, P. et al. (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 79(2), glad181. (doi: 10.1093/gerona/glad181) (PMID:37527836) (PMCID:PMC10809037)
Vardeny, O. et al. (2024) Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiology, 9(3), pp. 283-289. (doi: 10.1001/jamacardio.2023.5318) (PMID:38265835) (PMCID:PMC10809142)
Omerovic, E. et al. (2024) Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation. Trials, 25, 80. (doi: 10.1186/s13063-024-07935-y) (PMID:38263138) (PMCID:PMC10807265)
Petrie, M. C. et al. (2024) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, 149(4), pp. 335-38. (doi: 10.1161/CIRCULATIONAHA.123.066163) (PMID:38252738)
Docherty, K. F. et al. (2024) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, 30(1), pp. 26-35. (doi: 10.1016/j.cardfail.2023.08.020) (PMID:37683911)
Lala, A. et al. (2024) Standardized definitions for evaluation of acute decompensated heart failure therapies: HF-ARC expert panel paper. JACC: Heart Failure, 12(1), pp. 1-15. (doi: 10.1016/j.jchf.2023.09.030) (PMID:38069997)
Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)
McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)
Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)
Pellicori, P. et al. (2024) Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS‐986231). European Journal of Heart Failure, 26(1), pp. 142-151. (doi: 10.1002/ejhf.3077) (PMID:37990754)
Schou, M. et al. (2024) Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial. European Journal of Heart Failure, 26(1), pp. 130-139. (doi: 10.1002/ejhf.3079) (PMID:37933184)
Jackson, A. M. et al. (2023) A 20-year population study of peripartum cardiomyopathy. European Heart Journal, 44(48), pp. 5128-5141. (doi: 10.1093/eurheartj/ehad626) (PMID:37804234) (PMCID:PMC10733720)
Ostrominski, J. W. et al. (2023) Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial. Circulation, 148(24), pp. 1945-1957. (doi: 10.1161/CIRCULATIONAHA.123.065254) (PMID:37830208)
McMurray, J. J.V. et al. (2023) Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, (doi: 10.1161/CIRCULATIONAHA.123.065061) (PMID:38059368) (Early Online Publication)
Bhatt, A. S. et al. (2023) Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal of Heart Failure, 25(12), pp. 2177-2188. (doi: 10.1002/ejhf.3043) (PMID:37771274)
Fletcher, R. A. et al. (2023) Effect of SGLT2 inhibitors on discontinuation of renin–angiotensin system blockade: A joint analysis of the CREDENCE and DAPA-CKD trials. Journal of the American Society of Nephrology, 34(12), pp. 1965-1975. (doi: 10.1681/ASN.0000000000000248) (PMID:37876229)
Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)
Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)
Pabon, M. et al. (2023) Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial. JACC: Heart Failure, 11(12), pp. 1729-1738. (doi: 10.1016/j.jchf.2023.07.029) (PMID:37831045)
Vardeny, O. et al. (2023) Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 29(12), p. 3269. (doi: 10.1038/s41591-023-02302-x) (PMID:36932245)
Zahir Anjum, D. et al. (2023) Initiation of medical therapy for heart failure patients according to kidney function: a Danish nationwide study. Clinical Epidemiology, 15, pp. 855-866. (doi: 10.2147/clep.s412787) (PMID:37489222) (PMCID:PMC10363354)
Chatur, S. et al. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793)
Mc Causland, F. R. et al. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176)
Chatur, S. et al. (2023) Dapagliflozin in patients with heart failure and deterioration in renal function. Journal of the American College of Cardiology, 82(19), pp. 1854-1863. (doi: 10.1016/j.jacc.2023.08.026) (PMID:37634707)
Leong, D. P. et al. (2023) Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries. European Heart Journal, 44(42), pp. 4435-4444. (doi: 10.1093/eurheartj/ehad595) (PMID:37639487) (PMCID:PMC10635666)
Ostrominski, J. W. et al. (2023) Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 11(11), pp. 1491-1503. (doi: 10.1016/j.jchf.2023.05.015) (PMID:37226448)
Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Heart Journal, 44(41), pp. 4310-4320. (doi: 10.1093/eurheartj/ehad476) (PMID:37632756)
Bhatt, A. S. et al. (2023) Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiology, 8(11), pp. 1041-1048. (doi: 10.1001/jamacardio.2023.3216) (PMID:37755814)
Burger, P. M. et al. (2023) Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. European Journal of Heart Failure, 25(11), pp. 1962-1975. (doi: 10.1002/ejhf.3028) (PMID:37691140)
Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)
Heerspink, H. J. L. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309)
Kondo, T. et al. (2023) Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials. NEJM Evidence, 2(11), (doi: 10.1056/EVIDoa2300042)
Ostrominski, J. W. et al. (2023) Duration of heart failure with preserved ejection fraction and outcomes with sacubitril/valsartan: insights from the PARAGON-HF trial. Journal of Cardiac Failure, 29(11), pp. 1494-1503. (doi: 10.1016/j.cardfail.2023.05.003) (PMID:37220823)
Vissing, C. R. et al. (2023) Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial. JAMA Cardiology, 8(11), pp. 1083-1088. (doi: 10.1001/jamacardio.2023.2808) (PMID:37672268)
McDonagh, T. A. et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 44(37), pp. 3627-3639. (doi: 10.1093/eurheartj/ehad195) (PMID:37622666)
Rohde, L. E. and McMurray, J. J.V. (2023) REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed. European Heart Journal, 44(37), pp. 3652-3654. (doi: 10.1093/eurheartj/ehad488) (PMID:37525996)
Bozkurt, B., Desai, A. S., Ahmad, T., Deswal, A., Heidenreich, P. A., Ibrahim, N. E., McMurray, J. , Pinney, S. P., Vaduganathan, M. and Walsh, M. N. (2023) As we embark on a second year. JACC: Heart Failure, 11(10), pp. 1466-1469. (doi: 10.1016/j.jchf.2023.09.001) (PMID:37793737)
Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)
Lam, C. S.P., Docherty, K. F. , Ho, J. E., McMurray, J. J.V. , Myhre, P. L. and Omland, T. (2023) Recent successes in heart failure treatment. Nature Medicine, 29(10), pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2) (PMID:37814060)
Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)
Peikert, A. et al. (2023) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC: Heart Failure, 11(10), pp. 1380-1393. (doi: 10.1016/j.jchf.2023.05.014) (PMID:37294244)
Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 25(10), pp. 1831-1839. (doi: 10.1002/ejhf.2944) (PMID:37369637) (PMCID:PMC10947165)
Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398)
Wang, X. et al. (2023) Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE‐MI. Journal of the American Heart Association, 12(17), e028942. (doi: 10.1161/JAHA.122.028942) (PMID:37609931) (PMCID:PMC10547323)
Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)
Bhatt, A. S. et al. (2023) Operational challenges and mitigation measures during the COVID-19 pandemic – lessons from DELIVER. American Heart Journal, 263, pp. 133-140. (doi: 10.1016/j.ahj.2023.05.013) (PMID:37220822) (PMCID:PMC10200275)
Pabon, M. et al. (2023) Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, 25(9), pp. 1663-1670. (doi: 10.1002/ejhf.3001) (PMID:37632711)
Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, 25(9), pp. 1606-1618. (doi: 10.1002/ejhf.2962) (PMID:37401511)
Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)
Chatur, S. et al. (2023) Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal, 44(31), pp. 2930-2943. (doi: 10.1093/eurheartj/ehad283) (PMID:37220093)
Ioannou, A. et al. (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 44(31), pp. 2893-2907. (doi: 10.1093/eurheartj/ehad347) (PMID:37216684) (PMCID:PMC10424879)
Vaduganathan, M. et al. (2023) Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal, 44(31), pp. 2982-2993. (doi: 10.1093/eurheartj/ehad344) (PMID:37210743) (PMCID:PMC10424880)
Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)
Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)
Inciardi, R. M. et al. (2023) Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 82(6), pp. 489-499. (doi: 10.1016/j.jacc.2023.05.010) (PMID:37225045)
Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422)
Foroutan, F. et al. (2023) Global comparison of readmission rates for patients with heart failure. Journal of the American College of Cardiology, 82(5), pp. 430-444. (doi: 10.1016/j.jacc.2023.05.040) (PMID:37495280)
Barat, A. et al. (2023) Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM-associated genes: a subgroup analysis of the PARADIGM-HF trial. European Journal of Heart Failure, 25(8), pp. 1256-1266. (doi: 10.1002/ejhf.2886) (PMID:37191081)
Booth, D., Davis, J. A., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2023) The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health‐economic analysis of the DELIVER trial. European Journal of Heart Failure, 25(8), pp. 1386-1395. (doi: 10.1002/ejhf.2940) (PMID:37344985)
Butt, J. H. et al. (2023) Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial. European Journal of Heart Failure, 25(8), pp. 1228-1242. (doi: 10.1002/ejhf.2851) (PMID:37042062)
Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Journal of Cardio-Thoracic Surgery, 64(2), ezad286. (doi: 10.1093/ejcts/ezad286) (PMID:37632766)
Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, 25(8), pp. 1364-1371. (doi: 10.1002/ejhf.2912) (PMID:37210608)
Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)
Heidenreich, P. A. and McMurray, J. J.V. (2023) Should beta-blockers be used in heart failure if the LVEF is not reduced? JACC: Heart Failure, 11(8), pp. 901-902. (doi: 10.1016/j.jchf.2023.05.023) (PMID:37452802)
Jankowska, E. A. et al. (2023) Optimizing outcomes in heart failure: 2022 and beyond. ESC Heart Failure, 10(4), pp. 2159-2169. (doi: 10.1002/ehf2.14363) (PMID:37060168) (PMCID:PMC10375115)
McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)
Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial. European Journal of Heart Failure, 25(8), pp. 1444-1449. (doi: 10.1002/ejhf.2952) (PMID:37370197)
Myhre, P. L. et al. (2023) Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan. European Journal of Heart Failure, 25(8), pp. 1396-1405. (doi: 10.1002/ejhf.2957) (PMID:37401523)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
Peikert, A. et al. (2023) Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(7), pp. 684-690. (doi: 10.1001/jamacardio.2023.1342) (PMID:37208998) (PMCID:PMC10200027)
Bhatt, A. S. et al. (2023) Effect of dapagliflozin on health status and quality-of-life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF & DELIVER trials. European Journal of Heart Failure, 25(7), pp. 981-988. (doi: 10.1002/ejhf.2909) (PMID:37211977)
Chatur, S. et al. (2023) Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. European Journal of Heart Failure, 25(7), pp. 1170-1175. (doi: 10.1002/ejhf.2915) (PMID:37212168)
Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)
Desai, A. S., Deswal, A., McMurray, J. J.V. , Pinney, S. P. and Vaduganathan, M. (2023) Optimizing background therapy for heart failure in clinical trials. JACC: Heart Failure, 11(7), pp. 806-809. (doi: 10.1016/j.jchf.2023.05.012) (PMID:37407155)
Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)
Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25(7), pp. 999-1009. (doi: 10.1002/ejhf.2864) (PMID:37062865)
Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)
Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)
Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2023) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, 12(12), e026844. (doi: 10.1161/JAHA.122.026844) (PMID:37301739) (PMCID:PMC10356033)
Sattar, N. et al. (2023) Years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation, 147(25), pp. 1872-1886. (doi: 10.1161/CIRCULATIONAHA.122.063374) (PMID:37154040)
Desai, A. S., Lam, C. S.P., McMurray, J. J.V. and Redfield, M. M. (2023) How to manage heart failure with preserved ejection fraction: Practical guidance for clinicians. JACC: Heart Failure, 11(6), pp. 619-636. (doi: 10.1016/j.jchf.2023.03.011) (PMID:37140514)
Conrad, N. et al. (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, 401(10391), pp. 1878-1890. (doi: 10.1016/S0140-6736(23)00457-9) (PMID:37156255)
McMurray, J. J.V. and Metra, M. (2023) Transcatheter repair of secondary mitral regurgitation. New England Journal of Medicine, 388(22), pp. 2097-2098. (doi: 10.1056/NEJMe2302924) (PMID:37256981)
Biering-Sørensen, T. et al. (2023) The effect of sacubitril/valsartan on left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). Journal of Cardiac Failure, 29(6), pp. 968-973. (doi: 10.1016/j.cardfail.2023.03.019) (PMID:37031887)
Curtain, J. P., Lee, M. M.Y. , McMurray, J. J.V. , Gardner, R. S., Petrie, M. C. and Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109(11), pp. 823-831. (doi: 10.1136/heartjnl-2022-321885) (PMID:36522146) (PMCID:PMC10314022)
Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)
Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)
Clephas, P.R.D., Radhoe, S.P., Boersma, E., Gregson, J., Jhund, P.S. , Abraham, W.T., McMurray, J.J.V. , de Boer, R.A. and Brugts, J.J. (2023) Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. European Heart Journal, (doi: 10.1093/eurheartj/ehad346) (PMID:37210750) (Early Online Publication)
Rasmussen, M. et al. (2023) Global variations in heart failure etiology, management, and outcomes. JAMA: Journal of the American Medical Association, 329(19), pp. 1650-1661. (doi: 10.1001/jama.2023.5942) (PMID:37191704) (PMCID:PMC10189564)
Chertow, G. M. et al. (2023) Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. Journal of the American Heart Association, 12(9), e028739. (doi: 10.1161/JAHA.122.028739) (PMID:37119064) (PMCID:PMC10227210)
Jering, K. S. et al. (2023) Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circulation: Heart Failure, (doi: 10.1161/CIRCHEARTFAILURE.122.010259) (PMID:37125529) (Early Online Publication)
Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)
Lanfear, D. E. et al. (2023) Omecamtiv mecarbil in Black patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF. JACC: Heart Failure, 11(5), pp. 569-579. (doi: 10.1016/j.jchf.2022.11.021) (PMID:36881396)
McEwan, P. et al. (2023) Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrology Dialysis Transplantation, 38(5), pp. 1260-1270. (doi: 10.1093/ndt/gfac280) (PMID:36301617) (PMCID:PMC10157747)
Chatur, S. et al. (2023) Variation in renal function following transition to sacubitril/valsartan in patients with heart failure. Journal of the American College of Cardiology, 81(15), pp. 1443-1455. (doi: 10.1016/j.jacc.2023.02.009) (PMID:36812948)
Biering-Sørensen, T. et al. (2023) Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction. European Heart Journal: Cardiovascular Imaging, (doi: 10.1093/ehjci/jead062) (PMID:37039073) (Early Online Publication)
Lee, M. M. Y. and McMurray, J. J. V. (2023) Lack of benefit of renin-angiotensin system inhibitors in COVID-19. JAMA: Journal of the American Medical Association, 329(14), pp. 1155-1156. (doi: 10.1001/jama.2023.4405) (PMID:37039803)
Butt, J. H., Solomon, S. D. and McMurray, J. J.V. (2023) Response by Butt et al to letter regarding article, “Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial”. Circulation, 147(14), pp. 1119-1120. (doi: 10.1161/CIRCULATIONAHA.123.064052) (PMID:37011075)
Kondo, T. et al. (2023) Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation, 147(14), pp. 1067-1078. (doi: 10.1161/CIRCULATIONAHA.122.062918) (PMID:36876483)
Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)
Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)
Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)
Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)
Conrad, N., McInnes, I. B. , Mcmurray, J. J.V. and Sattar, N. (2023) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Annals of the Rheumatic Diseases, 82(4), pp. 457-459. (doi: 10.1136/ard-2022-223315) (PMID:36442979)
Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)
Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)
Tardif, J.‐C. et al. (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 10(2), pp. 1066-1076. (doi: 10.1002/ehf2.14268) (PMID:36564955) (PMCID:PMC10053160)
Bhandari, S. et al. (2023) Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. Journal of Nephrology, (doi: 10.1007/s40620-023-01571-6) (PMID:36995528) (PMCID:PMC10061401) (Early Online Publication)
Vaduganathan, M., Claggett, B. L., Jhund, P. , Miao, Z. M., de Boer, R. A., Lam, C. S.P., Desai, A. S., Bengsston, O., McMurray, J. J.V. and Solomon, S. D. (2023) Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 81(10), pp. 1004-1006. (doi: 10.1016/j.jacc.2022.12.026) (PMID:36889870)
Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)
Beernink, J. M. et al. (2023) Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care, 46(3), pp. 602-607. (doi: 10.2337/dc22-1514) (PMID:36662635)
Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)
Platz, E. et al. (2023) Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MI. European Heart Journal: Acute Cardiovascular Care, 12(3), pp. 155-164. (doi: 10.1093/ehjacc/zuad001) (PMID:36649251)
Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)
Wang, X. et al. (2023) Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER. Circulation, 147(8), pp. 624-634. (doi: 10.1161/CIRCULATIONAHA.122.062832) (PMID:36342789) (PMCID:PMC9974767)
Kosiborod, M. N. et al. (2023) Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 81(5), pp. 460-473. (doi: 10.1016/j.jacc.2022.11.006) (PMID:36526515)
Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)
Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)
Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)
Malik, M. E. et al. (2023) Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clinical Research in Cardiology, 112(2), pp. 215-226. (doi: 10.1007/s00392-022-02016-z) (PMID:35396632)
Miller, R. J.H., Chew, D. S., Qin, L., Fine, N. M., Chen, J., McMurray, J. J.V. , Howlett, J. G. and McEwan, P. (2023) Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 25(2), pp. 238-247. (doi: 10.1002/ejhf.2777) (PMID:36644849)
Rohde, L. E. et al. (2023) Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 8(2), pp. 150-158. (doi: 10.1001/jamacardio.2022.4427) (PMID:36477809)
Rawshani, A. et al. (2023) Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes. Scientific Reports, 13, 1192. (doi: 10.1038/s41598-023-27941-5) (PMID:36681691) (PMCID:PMC9867726)
Solomon, S.D., Vaduganathan, M. and McMurray, J.J.V. (2023) Dapagliflozin in heart failure with preserved ejection fraction. New England Journal of Medicine, 388(3), pp. 286-288. (doi: 10.1056/NEJMc2213974) (PMID:36652373)
Conrad, N. and McMurray, J. J.V. (2023) Cardiovascular risk in systemic autoimmune diseases – Authors' reply. Lancet, 401(10370), p. 22. (doi: 10.1016/S0140-6736(22)02426-6) (PMID:36610766) (PMCID:36041475)
Chatur, S., Claggett, B. L., Vardeny, O., Jering, K., Desai, A. S., Pfeffer, M. A., Lefkowitz, M., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2023) Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial. European Journal of Heart Failure, 25(1), pp. 87-94. (doi: 10.1002/ejhf.2703) (PMID:36181769)
Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)
Mc Causland, F. R. et al. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)
Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)
Sattar, N. , McMurray, J. J. V. , McInnes, I. B. , Aroda, V. R. and Lean, M. E. J. (2023) Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes and Endocrinology, 11(1), pp. 58-62. (doi: 10.1016/S2213-8587(22)00317-5) (PMID:36460014)
Schechter, M. et al. (2023) Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD. Annals of Internal Medicine, 176(1), pp. 59-66. (doi: 10.7326/M22-2115) (PMID:36469914)
Selvaraj, S. et al. (2023) Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER. JACC: Heart Failure, 11(1), pp. 76-89. (doi: 10.1016/j.jchf.2022.09.002) (PMID:36599553)
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Vaduganathan, M. and Fonarow, G. C. (2023) Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiology, 8(1), pp. 66-73. (doi: 10.1001/jamacardio.2022.4348) (PMID:36334258)
Singh, A. K. et al. (2022) Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation, 38(8), pp. 1890-1897. (doi: 10.1093/ndt/gfac342) (PMID:36565721) (PMCID:PMC10387380)
Gerstein, H. C. et al. (2022) Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: the ELIXA trial. Diabetes, Obesity and Metabolism, 25(4), pp. 1125-1129. (doi: 10.1111/dom.14954) (PMID:36546588)
Metra, M. et al. (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 43(48), pp. 5006-5016. (doi: 10.1093/eurheartj/ehac293) (PMID:35675469)
Bowman, L. et al. (2022) Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. European Heart Journal, 44(11), pp. 931-934. (doi: 10.1093/eurheartj/ehac633) (PMID:36525339) (PMCID:PMC10011328)
Bowman, L. et al. (2022) Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. Circulation, 147(12), pp. 925-929. (doi: 10.1161/CIRCULATIONAHA.122.063378) (PMID:36524680)
Mehran, R. et al. (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation, 146(23), pp. 1749-1757. (doi: 10.1161/CIRCULATIONAHA.122.060841) (PMID:36321459)
Chandra, A. et al. (2022) Health‐related quality of life outcomes in PARAGON‐HF. European Journal of Heart Failure, 24(12), pp. 2264-2274. (doi: 10.1002/ejhf.2738) (PMID:36394533)
Inzucchi, S. E. et al. (2022) Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 10(12), pp. 869-881. (doi: 10.1016/S2213-8587(22)00308-4) (PMID:36372069)
McEwan, P., Darlington, O., Miller, R., McMurray, J. J.V. , Wheeler, D. C., Heerspink, H. J.L., Briggs, A. , Bergenheim, K. and Garcia Sanchez, J. J. (2022) Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clinical Journal of the American Society of Nephrology, 17(12), pp. 1730-1741. (doi: 10.2215/CJN.03790322) (PMID:36323444)
Myhre, P. L. et al. (2022) Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 10(12), pp. 902-913. (doi: 10.1016/j.jchf.2022.08.007) (PMID:36114137)
Vardeny, O. et al. (2022) Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 28(12), pp. 2504-2511. (doi: 10.1038/s41591-022-02102-9) (PMID:36522606) (PMCID:PMC9800271)
Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)
Vaduganathan, M. et al. (2022) Estimated event-free survival benefits with dapagliflozin in HF with mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(19), pp. 1775-1784. (doi: 10.1016/j.jacc.2022.08.745) (PMID:36041669)
Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)
Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)
Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)
Zhang, L. et al. (2022) Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction. Circulation, 146(13), pp. 1411-1414. (doi: 10.1161/CIRCULATIONAHA.122.061481) (PMID:36029463)
Adamson, C., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'the 50 shades of bilirubin'. Letter regarding the article 'liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF'. European Journal of Heart Failure, 24(11), pp. 2206-2207. (doi: 10.1002/ejhf.2683) (PMID:36097136)
Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)
Ferreira, J. P., Pitt, B., McMurray, J. J.V. , Pocock, S. J., Solomon, S. D., Pfeffer, M. A., Zannad, F. and Rossignol, P. (2022) Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC: Heart Failure, 10(11), pp. 842-850. (doi: 10.1016/j.jchf.2022.06.010) (PMID:36328653)
Jongs, N. et al. (2022) Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. Journal of the American Society of Nephrology, 33(11), pp. 2094-2107. (doi: 10.1681/ASN.2022030306) (PMID:35977807)
Khunti, K. et al. (2022) Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 24(11), pp. 2071-2080. (doi: 10.1111/dom.14805) (PMID:35801339)
Perkovic, V. et al. (2022) The ASCEND-ND trial: study design and participant characteristics. Nephrology Dialysis Transplantation, 37(11), pp. 2157-2170. (doi: 10.1093/ndt/gfab318) (PMID:34865143) (PMCID:PMC9585467)
Smeijer, J. D. et al. (2022) Organic anion transporter gene variants associated with plasma exposure and long-term response to atrasentan in patients with diabetic kidney disease. Clinical Pharmacology and Therapeutics, 112(5), pp. 1098-1107. (doi: 10.1002/cpt.2721) (PMID:35892316)
Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465) (PMCID:PMC9815819)
Tardif, J. C. et al. (2022) Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. European Heart Journal, 43(39), pp. 3947-3956. (doi: 10.1093/eurheartj/ehac374) (PMID:35856777) (PMCID:PMC9565632)
Cunningham, J. W. et al. (2022) Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(14), pp. 1302-1310. (doi: 10.1016/j.jacc.2022.07.021) (PMID:36041912)
Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)
Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)
Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568) (PMCID:PMC9805158)
Bedrouni, W. et al. (2022) Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circulation: Heart Failure, 15(10), pp. 988-990. (doi: 10.1161/CIRCHEARTFAILURE.121.009295) (PMID:35924555)
Berwanger, O. et al. (2022) Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial. European Journal of Heart Failure, 24(10), pp. 1918-1927. (doi: 10.1002/ejhf.2663) (PMID:36054480)
Chatur, S. et al. (2022) Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with HFpEF in the PARAGON‐HF trial. European Journal of Heart Failure, 24(10), pp. 1906-1914. (doi: 10.1002/ejhf.2638) (PMID:35895867)
Claggett, B. L., McCaw, Z. R., Tian, L., McMurray, J. J.V. , Jhund, P. S. , Uno, H., Pfeffer, M. A., Solomon, S. D. and Wei, L.-J. (2022) Quantifying treatment effects in trials with multiple event-time outcomes. NEJM Evidence, 1(10), (doi: 10.1056/EVIDoa2200047)
Dubé, M.‐P. et al. (2022) Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. ESC Heart Failure, 9(5), pp. 2997-3008. (doi: 10.1002/ehf2.14026) (PMID:35736394) (PMCID:PMC9715825)
Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)
McDowell, K., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)
McMurray, J. J. V. and Sattar, N. (2022) Heart failure: now centre-stage in diabetes. Lancet Diabetes and Endocrinology, 10(10), pp. 689-691. (doi: 10.1016/S2213-8587(22)00249-2) (PMID:36057271)
Ostrominski, J. W. et al. (2022) Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure, 24(10), pp. 1892-1901. (doi: 10.1002/ejhf.2652) (PMID:36054231)
Peikert, A. et al. (2022) Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circulation: Heart Failure, 15(10), pp. 934-943. (doi: 10.1161/CIRCHEARTFAILURE.122.010080) (PMID:36029467)
Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)
Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)
Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)
Solomon, S. D. et al. (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), pp. 1089-1098. (doi: 10.1056/NEJMoa2206286) (PMID:36027570)
Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)
Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J.V. and Verbakel, J. Y. (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 400(10354), pp. 733-743. (doi: 10.1016/S0140-6736(22)01349-6) (PMID:36041475)
Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)
Aulin, J. et al. (2022) Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model. American Heart Journal, 251, pp. 13-24. (doi: 10.1016/j.ahj.2022.03.009) (PMID:35569564)
Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)
Gerstein, H. C. et al. (2022) Protein biomarkers and cardiovascular outcomes in people with type 2 diabetes and acute coronary syndrome: the ELIXA biomarker study. Diabetes Care, 45(9), pp. 2152-2155. (doi: 10.2337/dc22-0453) (PMID:35817031)
Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)
Johansson, I. et al. (2022) Factors associated with health‐related quality of life in heart failure in 23,000 patients from 40 countries: results of the G‐CHF Research Program. European Journal of Heart Failure, 24(9), pp. 1478-1490. (doi: 10.1002/ejhf.2535) (PMID:35570198)
Mc Causland, F. R. et al. (2022) Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 24(9), pp. 1591-1598. (doi: 10.1002/ejhf.2421) (PMID:34989105)
Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B., Claggett, B. L., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Zannad, F. and Solomon, S. D. (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. European Journal of Heart Failure, 24(9), pp. 1586-1590. (doi: 10.1002/ejhf.2635) (PMID:35867859)
Wheeler, D. C. et al. (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial. Nephrology Dialysis Transplantation, 37(9), pp. 1647-1656. (doi: 10.1093/ndt/gfab335) (PMID:34850160) (PMCID:PMC9395378)
Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)
Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)
Thomson, P. C. et al. (2022) An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. Kidney International Reports, 7(8), pp. 1793-1801. (doi: 10.1016/j.ekir.2022.05.008) (PMID:35967105) (PMCID:PMC9366296)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)
Smeijer, J. D. et al. (2022) Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure. JACC: Heart Failure, 10(7), pp. 498-507. (doi: 10.1016/j.jchf.2022.03.004) (PMID:35772861)
Thorvaldsen, T., Ferrannini, G., Mellbin, L., Benson, L., Cosentino, F., McMurray, J. J.V. , Dahlström, U., Lund, L. H. and Savarese, G. (2022) Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. Journal of Cardiac Failure, 28(7), pp. 1050-1062. (doi: 10.1016/j.cardfail.2022.04.011) (PMID:35550428)
Waijer, S. W. et al. (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 65(7), pp. 1085-1097. (doi: 10.1007/s00125-022-05694-6) (PMID:35445820) (PMCID:PMC9174107)
Vaduganathan, M., Claggett, B. L., McMurray, J. J.V. and Solomon, S. D. (2022) Health status trajectories before and after hospitalization for heart failure. Circulation, 145(25), pp. 1872-1874. (doi: 10.1161/CIRCULATIONAHA.122.059282) (PMID:35603665)
Wijkman, M. O. et al. (2022) Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 21, 110. (doi: 10.1186/s12933-022-01545-1) (PMID:35717169) (PMCID:PMC9206286)
Lee, K. K. et al. (2022) Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. British Medical Journal, 377, e068424. (doi: 10.1136/bmj-2021-068424) (PMID:35697365) (PMCID:PMC9189738)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)
Curtain, J. P. et al. (2022) Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF. JACC: Heart Failure, 10(6), pp. 415-427. (doi: 10.1016/j.jchf.2022.01.020) (PMID:35654526)
Jackson, A. M., Benson, L., Savarese, G., Hage, C., Jhund, P. S. , Petrie, M. C. , Dahlström, U., McMurray, J. J.V. and Lund, L. H. (2022) Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry. JACC: Heart Failure, 10(6), pp. 380-392. (doi: 10.1016/j.jchf.2022.04.006) (PMID:35654522)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)
McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847) (PMID:35789017) (PMCID:PMC9254667)
Singh, A. K. et al. (2022) Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients. JAMA Internal Medicine, 182(6), pp. 592-602. (doi: 10.1001/jamainternmed.2022.0605) (PMID:35377393) (PMCID:PMC8981070)
Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)
Cikes, M. et al. (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure, 10(5), pp. 336-346. (doi: 10.1016/j.jchf.2022.01.018) (PMID:35483796)
De Caterina, R. et al. (2022) Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 8(3), pp. 227-235. (doi: 10.1093/ehjcvp/pvaa140) (PMID:33367487)
Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)
Peikert, A. et al. (2022) Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF. European Journal of Heart Failure, 24(5), pp. 794-803. (doi: 10.1002/ejhf.2450) (PMID:35119183)
Singh, A. K. et al. (2022) Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation, 37(5), pp. 960-972. (doi: 10.1093/ndt/gfab065) (PMID:33744933)
Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)
Wolsk, E. et al. (2022) Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients with coronary artery disease and type 2 diabetes. Journal of the American Heart Association, 11(8), e021327. (doi: 10.1161/jaha.121.021327) (PMID:35383463) (PMCID:PMC9238457)
Aune, E., McMurray, J. , Lundgren, P., Sattar, N. , Israelsson, J., Nordberg, P., Herlitz, J. and Rawshani, A. (2022) Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. Scientific Reports, 12, 5685. (doi: 10.1038/s41598-022-09510-4) (PMID:35383220) (PMCID:PMC8983650)
Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)
Pabón, M. A. et al. (2022) Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF. European Journal of Heart Failure, 24(4), pp. 672-677. (doi: 10.1002/ejhf.2439) (PMID:35080787)
Vart, P. et al. (2022) Efficacy and safety of dapagliflozin in patients with CKD across major geographic regions. Kidney International Reports, 7(4), pp. 699-707. (doi: 10.1016/j.ekir.2022.01.1060) (PMID:35497805) (PMCID:PMC9039473)
Solomon, S. D. et al. (2022) Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, (doi: 10.1093/eurheartj/ehac144) (PMID:35325102)
Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)
Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)
Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)
Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)
Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)
Solomon, S. D. et al. (2022) Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC: Heart Failure, 10(3), pp. 184-197. (doi: 10.1016/j.jchf.2021.11.006) (PMID:35241246)
Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)
Zahir, D. et al. (2022) Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. European Journal of Heart Failure, 24(3), pp. 539-547. (doi: 10.1002/ejhf.2418) (PMID:34969178)
Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)
Fiuzat, M. et al. (2022) Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week. Journal of the American College of Cardiology, 79(5), pp. 504-510. (doi: 10.1016/j.jacc.2021.11.033) (PMID:35115106)
Weir, R. A.P., Clements, S., Steedman, T., Dargie, H. J. and McMurray, J. J.V. (2022) Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow‐up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial. European Journal of Heart Failure, 24(2), pp. 393-395. (doi: 10.1002/ejhf.2402) (PMID:34907636)
Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)
Chertow, G. M. et al. (2022) Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 24(5), pp. 827-837. (doi: 10.1111/dom.14641) (PMID:34984791)
Pfeffer, M. A. et al. (2022) Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation, 145(1), pp. 87-89. (doi: 10.1161/CIRCULATIONAHA.121.057429) (PMID:34797725)
Felker, G. M. et al. (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. JAMA Cardiology, 7(1), pp. 26-34. (doi: 10.1001/jamacardio.2021.4027) (PMID:34643642) (PMCID:PMC8515258)
Heerspink, H. J.L. et al. (2022) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 101(1), pp. 174-184. (doi: 10.1016/j.kint.2021.09.005) (PMID:34560136)
Lee, M. M.Y. , Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V. and Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1), 102382. (doi: 10.1016/j.dsx.2021.102382) (PMID:35030451)
McMurray, J. J.V. (2022) Can an implanted minipump deliver for diabetes patients? Nature Medicine, 28(1), pp. 27-28. (doi: 10.1038/s41591-021-01628-8) (PMID:34903896)
Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)
Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2313-2324. (doi: 10.1056/NEJMoa2113380) (PMID:34739196)
Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2325-2335. (doi: 10.1056/NEJMoa2113379) (PMID:34739194)
Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)
Codina, P. et al. (2021) Head‐to‐head comparison of contemporary heart failure risk scores. European Journal of Heart Failure, 23(12), pp. 2035-2044. (doi: 10.1002/ejhf.2352) (PMID:34558158)
Desai, A. S. et al. (2021) Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation: Heart Failure, 14(12), e008597. (doi: 10.1161/CIRCHEARTFAILURE.121.008597) (PMID:34807713)
Lumbers, R. T. et al. (2021) The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 8(6), pp. 5531-5541. (doi: 10.1002/ehf2.13517) (PMID:34480422) (PMCID:PMC8712846)
Suzuki, K. et al. (2021) Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial. European Journal of Heart Failure, 23(12), pp. 2085-2090. (doi: 10.1002/ejhf.2262) (PMID:34114720)
Vaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J.V. , Fonarow, G. C. and Solomon, S. D. (2021) Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiology, 6(12), pp. 1415-1423. (doi: 10.1001/jamacardio.2021.3651) (PMID:34524394) (PMCID:PMC8444065)
Waijer, S. W. et al. (2021) The effect of atrasentan on kidney and heart failure outcomes by baseline albuminuria and kidney function: a post hoc analysis of the SONAR randomized trial. Clinical Journal of the American Society of Nephrology, 16(12), pp. 1824-1832. (doi: 10.2215/CJN.07340521) (PMID:34853062)
Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)
Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)
He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)
Heerspink, H. J.L. et al. (2021) Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: a prespecified analysis from the SONAR trial. Journal of the American Society of Nephrology, 32(11), pp. 2900-2911. (doi: 10.1681/ASN.2021030391) (PMID:34551995) (PMCID:PMC8806086)
Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)
Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)
Sattar, N. et al. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology, 9(10), pp. 653-662. (doi: 10.1016/S2213-8587(21)00203-5) (PMID:34425083)
Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)
Jackson, A. M. et al. (2021) Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 42(36), pp. 3741-3752. (doi: 10.1093/eurheartj/ehab499) (PMID:34392331) (PMCID:PMC8455346)
Selvaraj, S. et al. (2021) Effects of sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction. Journal of the American Heart Association, 10(17), e022069. (doi: 10.1161/JAHA.121.022069) (PMID:33998278) (PMCID:PMC8649234)
Bhatt, A. S., Claggett, B. L., Packer, M., Lefkowitz, M. P., Zile, M. R., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2021) Treatment effects of sacubitril/valsartan compared with valsartan in patients with recent hospitalization. Journal of Cardiac Failure, 27(9), pp. 1027-1030. (doi: 10.1016/j.cardfail.2021.05.020) (PMID:34133969)
Bhatt, A. S. et al. (2021) Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial. European Journal of Heart Failure, 23(9), pp. 1518-1524. (doi: 10.1002/ejhf.2259) (PMID:34101308)
Chertow, G. M. et al. (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. Journal of the American Society of Nephrology, 32(9), pp. 2352-2361. (doi: 10.1681/ASN.2021020167) (PMID:34272327) (PMCID:PMC8729835)
Ferreira, J. P. et al. (2021) Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. European Journal of Heart Failure, 23(9), pp. 1477-1484. (doi: 10.1002/ejhf.2255) (PMID:34050594)
Rørth, R. et al. (2021) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 16(8), e0255364. (doi: 10.1371/journal.pone.0255364) (PMID:34347805) (PMCID:PMC8336831)
Rohde, L. E. et al. (2021) Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. European Journal of Heart Failure, 23(8), pp. 1346-1356. (doi: 10.1002/ejhf.2120) (PMID:33565237)
Shen, L. et al. (2021) Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 110(8), pp. 1334-1349. (doi: 10.1007/s00392-021-01888-x) (PMID:34101002)
Shen, L. et al. (2021) Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 110(8), pp. 1234-1248. (doi: 10.1007/s00392-020-01786-8) (PMID:33301080)
Wamil, M., Coleman, R. L., Adler, A. I., McMurray, J. J.V. and Holman, R. R. (2021) Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care, 44(8), pp. 1877-1884. (doi: 10.2337/dc21-0429) (PMID:34162666)
Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)
Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)
Teerlink, J. R. et al. (2021) Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 78(2), pp. 97-108. (doi: 10.1016/j.jacc.2021.04.065) (PMID:34015475)
Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)
Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)
Simpson, J. et al. (2021) Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), pp. 296-301. (doi: 10.1093/ehjcvp/pvaa071) (PMID:32597982) (PMCID:PMC8302254)
Solomon, S. D. et al. (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure, 23(7), pp. 1217-1225. (doi: 10.1002/ejhf.2249) (PMID:34051124)
Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, 42(24), pp. 2331-2343. (doi: 10.1093/eurheartj/ehab082) (PMID:33791787)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)
Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)
Jering, K. S. et al. (2021) Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics. European Journal of Heart Failure, 23(6), pp. 1040-1048. (doi: 10.1002/ejhf.2191) (PMID:33847047)
Packer, M. and McMurray, J. J.V. (2021) Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 23(6), pp. 882-894. (doi: 10.1002/ejhf.2149) (PMID:33704874) (PMCID:PMC8360176)
Sørensen, T. B. et al. (2021) The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). European Journal of Heart Failure, 23(6), pp. 1052-1056. (doi: 10.1002/ejhf.2181) (PMID:33826209)
Beggs, S. A.S. , Jhund, P. S. and McMurray, J. J.V. (2021) Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 42(20), e5-e7. (doi: 10.1093/eurheartj/ehy609) (PMID:30357375)
Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)
Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)
Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)
Pellicori, P. et al. (2021) Ultrasound imaging of congestion in heart failure – examinations beyond the heart. European Journal of Heart Failure, 23(5), pp. 703-712. (doi: 10.1002/ejhf.2032) (PMID:33118672)
Shen, L. et al. (2021) Incidence and outcomes of pneumonia in patients with heart failure. Journal of the American College of Cardiology, 77(16), pp. 1961-1973. (doi: 10.1016/j.jacc.2021.03.001) (PMID:33888245)
McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)
Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)
Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)
Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)
Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)
Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)
Koomen, J. V. et al. (2021) Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post hoc analysis of the SONAR trial. Diabetes, Obesity and Metabolism, 23(2), pp. 561-568. (doi: 10.1111/dom.14252) (PMID:33184931) (PMCID:PMC7839558)
Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)
Teerlink, J. R. et al. (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine, 384, pp. 105-116. (doi: 10.1056/NEJMoa2025797) (PMID:33185990)
McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)
Felker, G. M., Solomon, S. D., McMurray, J. J.V. , Cleland, J. G.F. , Abbasi, S. A., Malik, F. I., Zhang, H., Globe, G. and Teerlink, J. R. (2020) Effects of omecamtiv mecarbil on symptoms and health-related quality of life in patients with chronic heart failure: results from the COSMIC-HF study. Circulation: Heart Failure, 13(12), e007814. (doi: 10.1161/CIRCHEARTFAILURE.120.007814) (PMID:33176437) (PMCID:PMC7742205)
Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)
Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)
Wamil, M., McMurray, J. J.V. , Scott, C. A.B., Coleman, R. L., Sun, Y., Standl, E., Rydén, L. and Holman, R. R. (2020) Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 170, 108488. (doi: 10.1016/j.diabres.2020.108488) (PMID:33035598)
Yeoh, S. E. et al. (2020) Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Failure, 7(6), pp. 3355-3364. (doi: 10.1002/ehf2.12972) (PMID:33078584) (PMCID:PMC7754973)
Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)
Psotka, M. A. et al. (2020) Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel. Journal of the American College of Cardiology, 76(20), pp. 2368-2378. (doi: 10.1016/j.jacc.2020.09.544) (PMID:33183511)
Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)
Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)
Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)
Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)
McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)
McMurray, J. J.V. (2020) EMPEROR‐Reduced: confirming sodium–glucose co‐transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(11), pp. 1987-1990. (doi: 10.1002/ejhf.2006) (PMID:32946169)
Selvaraj, S. et al. (2020) Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. European Journal of Heart Failure, 22(11), pp. 2093-2101. (doi: 10.1002/ejhf.1984) (PMID:32840930)
Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 22(11), pp. 2160-2171. (doi: 10.1002/ejhf.2015) (PMID:32985088) (PMCID:PMC7756903)
Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)
Heerspink, H. J.L. et al. (2020) Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), pp. 1436-1446. (doi: 10.1056/NEJMoa2024816) (PMID:32970396)
Wheeler, D. C. et al. (2020) The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 35(10), pp. 1700-1711. (doi: 10.1093/ndt/gfaa234) (PMID:32862232) (PMCID:PMC7538235)
Butt, J. H. et al. (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 22(10), pp. 1777-1785. (doi: 10.1002/ejhf.1800) (PMID:32227556)
Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)
Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)
Malachias, M. V.B. et al. (2020) N-terminal pro-B-type natriuretic peptide by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes. Journal of the American Heart Association, 9(19), e017462. (doi: 10.1161/JAHA.120.017462) (PMID:32964800) (PMCID:PMC7792415)
Solomon, S. D. et al. (2020) Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. JACC: Heart Failure, 8(10), pp. 811-818. (doi: 10.1016/j.jchf.2020.04.008) (PMID:32653447)
Mc Causland, F. R. et al. (2020) Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation, 142(13), pp. 1236-1245. (doi: 10.1161/CIRCULATIONAHA.120.047643) (PMID:32845715)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)
Sattar, N. et al. (2020) BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), pp. 1149-1151. (doi: 10.1016/j.dsx.2020.06.060) (PMID:32668401) (PMCID:PMC7326434)
Suzuki, K. et al. (2020) Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(9), pp. 1662-1671. (doi: 10.1002/ejhf.1853) (PMID:32407608)
Vaduganathan, M., McMurray, J. J.V. and Solomon, S. D. (2020) Angiotensin receptor–neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON‐HF. European Journal of Heart Failure, 22(9), pp. 1525-1530. (doi: 10.1002/ejhf.1976) (PMID:32741093)
Berglund, E. et al. (2020) Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 27(12), pp. 1311-1319. (doi: 10.1177/2047487319886959) (PMID:31698965)
Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)
Rossignol, P. et al. (2020) Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 22(8), pp. 1402-1411. (doi: 10.1002/ejhf.1724) (PMID:31919958)
Vaduganathan, M., Claggett, B. L., Jhund, P. , Cunningham, J. W., Ferreira, J. P., Zannad, F., Packer, M., Fonarow, G. C., McMurray, J. and Solomon, S. D. (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, 396(10244), pp. 121-128. (doi: 10.1016/S0140-6736(20)30748-0) (PMID:32446323)
Lam, C. S.P., Voors, A. A., Piotr, P., McMurray, J. J.V. and Solomon, S. D. (2020) Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. European Heart Journal, 41(25), pp. 2353-2355. (doi: 10.1093/eurheartj/ehaa158) (PMID:32227233)
Vaduganathan, M. et al. (2020) A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 41(25), pp. 2356-2362. (doi: 10.1093/eurheartj/ehaa184) (PMID:32221596) (PMCID:PMC7327532)
Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)
Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)
Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)
Shin, S.-H. et al. (2020) Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 22(7), pp. 1133-1143. (doi: 10.1002/ejhf.1790) (PMID:32212368)
Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology 2019: heart failure. Romanian Journal of Cardiology, 30(2), pp. 185-204. (doi: 10.47803/rjc.2020.30.2.185)
Brainin, P. et al. (2020) Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Failure, 7(3), pp. 1201-1209. (doi: 10.1002/ehf2.12640) (PMID:32077268) (PMCID:PMC7261588)
Cunningham, J. W. et al. (2020) Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC: Heart Failure, 8(5), pp. 372-381. (doi: 10.1016/j.jchf.2020.03.002) (PMID:32241619)
Dewan, P. , Jackson, A., Lam, C. S.P., Pfeffer, M. A., Zannad, F., Pitt, B., Solomon, S. D. and McMurray, J. J.V. (2020) Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 22(5), pp. 898-901. (doi: 10.1002/ejhf.1776) (PMID:32115864)
Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)
Jorsal, A., Pryds, K., McMurray, J. J.V. , Wiggers, H., Sommer, A., Nielsen, J. C. and Nielsen, R. R. (2020) Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 109(5), pp. 638-645. (doi: 10.1007/s00392-019-01553-4) (PMID:31559483)
Malik, M. E. et al. (2020) Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. European Journal of Heart Failure, 22(5), pp. 813-820. (doi: 10.1002/ejhf.1819) (PMID:32246806)
Rossello, X., Ferreira, J. P., Pocock, S. J., McMurray, J. J.V. , Solomon, S. D., Lam, C. S.P., Girerd, N., Pitt, B., Rossignol, P. and Zannad, F. (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 22(5), pp. 834-844. (doi: 10.1002/ejhf.1740) (PMID:32077220)
Sattar, N. , McMurray, J. J.V. and Cheng, A. (2020) Cardiorenal risk reduction guidance in diabetes: can we reach consensus? Lancet Diabetes and Endocrinology, 8(5), pp. 357-360. (doi: 10.1016/S2213-8587(20)30062-0) (PMID:32171053)
Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)
Selvaraj, S. et al. (2020) Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. Journal of the American College of Cardiology, 75(14), pp. 1644-1656. (doi: 10.1016/j.jacc.2020.02.009) (PMID:32192799)
Macdougall, I. C. et al. (2020) Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology, 31(4), 2019090972. (doi: 10.1681/ASN.2019090972) (PMID:32253271)
Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)
Tardif, J.-C. et al. (2020) Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal, 222, pp. 157-165. (doi: 10.1016/j.ahj.2020.01.007) (PMID:32087417)
Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC: Heart Failure, 8(4), pp. 329-340. (doi: 10.1016/j.jchf.2019.12.001) (PMID:32035892)
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J.V. , Pfeffer, M. A. and Solomon, S. D. (2020) Renin–Angiotensin–Aldosterone System inhibitors in patients with Covid-19. New England Journal of Medicine, 382(17), pp. 1653-1659. (doi: 10.1056/nejmsr2005760) (PMID:32227760)
Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)
Sharma, A. et al. (2020) Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus. Circulation, 141(10), pp. 843-862. (doi: 10.1161/circulationaha.119.041022) (PMID:31992065)
Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)
Kristensen, S. L. and McMurray, J. J.V. (2020) Diagnosing heart failure with preserved ejection fraction – what's the score? European Journal of Heart Failure, 22(3), pp. 425-427. (doi: 10.1002/ejhf.1764) (PMID:32086989)
Lee, M. M.Y. , Petrie, M. C. , McMurray, J. J.V. and Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. 506-522. (doi: 10.1161/atvbaha.119.311904) (PMID:31996025)
Monzo, L. et al. (2020) Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Journal of Hypertension, 38(3), pp. 420-425. (doi: 10.1097/HJH.0000000000002275) (PMID:31584516)
Shen, L., Jhund, P. and McMurray, J. (2020) Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 22(3), pp. 564-565. (doi: 10.1002/ejhf.1718) (PMID:31919977)
Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)
Rorth, R. et al. (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), e006541. (doi: 10.1161/CIRCHEARTFAILURE.119.006541) (PMID:32065760)
McMurray, J. J.V. et al. (2020) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation, 141(5), pp. 338-351. (doi: 10.1161/CIRCULATIONAHA.119.044491) (PMID:31736337)
Solomon, S. D. et al. (2020) Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation, 141(5), pp. 352-361. (doi: 10.1161/circulationaha.119.044586) (PMID:31736342)
Vaduganathan, M. et al. (2020) Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. Journal of the American College of Cardiology, 75(3), pp. 245-254. (doi: 10.1016/j.jacc.2019.11.003) (PMID:31726194)
Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)
Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)
Shah, S. et al. (2020) Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 11, 163. (doi: 10.1038/s41467-019-13690-5) (PMID:31919418) (PMCID:PMC6952380)
Israr, M. Z. et al. (2020) Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF. European Journal of Heart Failure, 22(8), pp. 1486-1490. (doi: 10.1002/ejhf.1951) (PMID:32666670)
Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)
Shah, A. M. et al. (2019) Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology, 74(23), pp. 2858-2873. (doi: 10.1016/j.jacc.2019.09.063) (PMID:31806129)
Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)
Ferreira, J. P., Rossello, X., Eschalier, R., McMurray, J. J.V. , Pocock, S., Girerd, N., Rossignol, P., Pitt, B. and Zannad, F. (2019) MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. JACC: Heart Failure, 7(12), pp. 1012-1021. (doi: 10.1016/j.jchf.2019.08.017) (PMID:31779922)
Platz, E., Solomon, S. D. and McMurray, J. J.V. (2019) Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 21(12), pp. 1614-1615. (doi: 10.1002/ejhf.1636) (PMID:31702095)
McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)
Ferreira, J. P., Rossignol, P., Dewan, P. , Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J.V. and Zannad, F. (2019) Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 218, pp. 66-74. (doi: 10.1016/j.ahj.2019.08.019) (PMID:31707330)
Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)
Conrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A. C., Millett, E. R.C., Salimi-Khorshidi, G., Cleland, J. G. , McMurray, J. J.V. and Rahimi, K. (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiology, 4(11), pp. 1102-1111. (doi: 10.1001/jamacardio.2019.3593) (PMID:31479100) (PMCID:PMC6724155)
McMurray, J. J.V. et al. (2019) The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 21(11), pp. 1402-1411. (doi: 10.1002/ejhf.1548) (PMID:31309699)
Solomon, S. D. et al. (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine, 381, pp. 1609-1620. (doi: 10.1056/NEJMoa1908655) (PMID:31475794)
Selvaraj, S. et al. (2019) Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. Circulation, 140, pp. 1369-1379. (doi: 10.1161/CIRCULATIONAHA.119.039920) (PMID:31510768)
Coiro, S. et al. (2019) Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.1541) (PMID:31476097)
Lee, M. M.Y. , Sattar, N. , McMurray, J. J.V. and Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21(10), 41. (doi: 10.1007/s11883-019-0800-z)
Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)
Chandra, A. et al. (2019) Health-related quality of life in heart failure with preserved ejection fraction the PARAGON-HF trial. JACC: Heart Failure, 7(10), pp. 862-874. (doi: 10.1016/j.jchf.2019.05.015) (PMID:31302043)
Yap, J. et al. (2019) Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. Journal of the American Heart Association, 8(17), e013114. (doi: 10.1161/jaha.119.013114) (PMID:31431116)
Beggs, S. A.S. , Rørth, R., Gardner, R. S. and McMurray, J. J.V. (2019) Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart, 105(17), pp. 1325-1334. (doi: 10.1136/heartjnl-2018-314381) (PMID:30962190)
Ferreira, J. P. et al. (2019) World Heart Federation Roadmap for heart failure. Global Heart, 14(3), pp. 197-214. (doi: 10.1016/j.gheart.2019.07.004) (PMID:31451235)
Grodin, J. L. et al. (2019) Prognostic implications of changes in amino-terminal pro–B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF. Journal of Cardiac Failure, 25(9), pp. 703-711. (doi: 10.1016/j.cardfail.2019.04.002) (PMID:30953792)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
Tromp, J. et al. (2019) Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care, 42(9), pp. 1792-1799. (doi: 10.2337/dc18-2515) (PMID:31292141)
Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) The importance of randomised vs non-randomised trials - authors' reply. Lancet, 394(10199), p. 635. (doi: 10.1016/S0140-6736(19)31111-0) (PMID:31448734)
McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)
Leong, D. P., McMurray, J. J.V. , Joseph, P. G. and Yusuf, S. (2019) From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5). Journal of the American College of Cardiology, 74(5), pp. 683-698. (doi: 10.1016/j.jacc.2019.04.068) (PMID:31370961)
Tromp, J. et al. (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 74(5), pp. 601-612. (doi: 10.1016/j.jacc.2019.05.052) (PMID:31370950)
Felker, G. M., Borentain, M., Cleland, J. G.F. , DeSouza, M. M., Kessler, P. D., O'Connor, C. M., Seiffert, D., Teerlink, J. R., Voors, A. A. and McMurray, J. J.V. (2019) Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 21(8), pp. 1022-1031. (doi: 10.1002/ejhf.1504) (PMID:31168885)
Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)
Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)
Chin, K. L., Collier, T., Pocock, S., Pitt, B., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Vincent, J., Zannad, F. and Liew, D. (2019) Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 108, pp. 806-814. (doi: 10.1007/s00392-018-1410-4) (PMID:30604047)
Platz, E. et al. (2019) Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 21(7), pp. 844-851. (doi: 10.1002/ejhf.1499)
Robertson, J., Schaufelberger, M., Lindgren, M., Adiels, M., Schiöler, L., Torén, K., McMurray, J. , Sattar, N. , Åberg, M. and Rosengren, A. (2019) Higher body mass index in adolescence predicts cardiomyopathy risk in midlife: long-term follow-up among Swedish men. Circulation, 140, pp. 117-125. (doi: 10.1161/circulationaha.118.039132) (PMID:31132859) (PMCID:PMC6635044)
Stewart, S., Moholdt, T. T., Burrell, L. M., Sliwa, K., Mocumbi, A. O., McMurray, J. J.V. , Keates, A. K. and Hawley, J. A. (2019) Winter peaks in heart failure: an inevitable or preventable consequence of seasonal vulnerability? Cardiac Failure Review, 5(2), pp. 83-85. (doi: 10.15420/cfr.2018.40.2) (PMID:31179017) (PMCID:PMC6546000)
Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)
Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)
Balmforth, C. et al. (2019) Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC: Heart Failure, 7(6), pp. 457-465. (doi: 10.1016/j.jchf.2019.02.015) (PMID:31078482)
Shah, S. J., Voors, A. A., McMurray, J. J.V. , Kitzman, D. W., Viethen, T., Bomfim Wirtz, A., Huang, E., Pap, A. F. and Solomon, S. D. (2019) Effect of neladenoson bialanate on exercise capacity among patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA: Journal of the American Medical Association, 321(21), pp. 2101-2112. (doi: 10.1001/jama.2019.6717) (PMID:31162568) (PMCID:PMC6549300)
Simpson, J., Benson, L., Jhund, P.S. , Dahlström, U., McMurray, J.J.V. and Lund, L.H. (2019) "Real world" eligibility for sacubitril/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 33(3), pp. 315-322. (doi: 10.1007/s10557-019-06873-1) (PMID:30903545) (PMCID:PMC6538576)
Verma, S. and McMurray, J. J.V. (2019) The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58. Circulation, 139(22), pp. 2537-2541. (doi: 10.1161/circulationaha.119.040514) (PMID:30882236)
Stienen, S., Ferreira, J. P., Vincent, J., Busselen, M., Li, B., McMurray, J. J.V. , Pitt, B., Girerd, N., Rossignol, P. and Zannad, F. (2019) Estimated long-term survival with eplerenone. Journal of the American College of Cardiology, 73(18), pp. 2357-2359. (doi: 10.1016/j.jacc.2019.02.043) (PMID:31072582)
Rossello, X., Ariti, C., Pocock, S. J., Ferreira, J. P., Girerd, N., McMurray, J. J.V. , Van Veldhuisen, D. J., Pitt, B. and Zannad, F. (2019) Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology, 108, pp. 477-486. (doi: 10.1007/s00392-018-1378-0) (PMID:30264282)
Conrad, N. et al. (2019) Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients. PLoS Medicine, 16(5), e1002805. (doi: 10.1371/journal.pmed.1002805) (PMID:31112552) (PMCID:PMC6528949)
Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)
Heerspink, H. H.L. et al. (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393(10184), pp. 1937-1947. (doi: 10.1016/S0140-6736(19)30772-X) (PMID:30995972)
McMurray, J. J.V. (2019) Urinalysis: a window to the heart. JACC: Heart Failure, 7(5), pp. 402-403. (doi: 10.1016/j.jchf.2019.04.002)
McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi: 10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)
Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)
Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)
Rossello, X., Ferreira, J. P., McMurray, J. J.V. , Aguilar, D., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P. and Zannad, F. (2019) Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 8(3), pp. 231-241. (doi: 10.1177/2048872618803701) (PMID:30259764)
Dewan, P. et al. (2019) Income inequality and outcomes in heart failure: a global between-country analysis. JACC: Heart Failure, 7(4), pp. 336-346. (doi: 10.1016/j.jchf.2018.11.005) (PMID:30738981)
Welsh, P. , Papacosta, O., Ramsay, S., Whincup, P., McMurray, J. , Wannamethee, G. and Sattar, N. (2019) High sensitivity troponin T and incident heart failure in older men: British Regional Heart Study. Journal of Cardiac Failure, 25(4), pp. 230-237. (doi: 10.1016/j.cardfail.2018.08.002) (PMID:30103019) (PMCID:PMC7083232)
Myhre, P. L. et al. (2019) B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. Journal of the American College of Cardiology, 73(11), pp. 1264-1272. (doi: 10.1016/j.jacc.2019.01.018) (PMID:30846338)
Charytan, D. M. et al. (2019) Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 21(5), pp. 1199-1208. (doi: 10.1111/dom.13642) (PMID:30672083)
Kristensen, S. L. et al. (2019) N-terminal pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status. Circulation: Heart Failure, 12(3), e005766. (doi: 10.1161/circheartfailure.118.005766) (PMID:30871349)
Loader, J. et al. (2019) Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 279, pp. 126-132. (doi: 10.1016/j.ijcard.2018.12.060) (PMID:30638747)
McCausland, F. R. et al. (2019) Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 73(3), pp. 309-315. (doi: 10.1053/j.ajkd.2018.10.006) (PMID:30578152)
Vardeny, O. et al. (2019) Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure, pp. 337-341. (doi: 10.1002/ejhf.1402) (PMID:30741494) (PMCID:PMC6607492)
Zile, M. R. et al. (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. Journal of the American College of Cardiology, 73(7), pp. 795-806. (doi: 10.1016/j.jacc.2018.11.042) (PMID:30784673)
Abraityte, A., Aukrust, P., Kou, L., Anand, I. S., Young, J., McMurray, J. J.V. , van Veldhuisen, D. J., Gullestad, L. and Ueland, T. (2019) T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clinical Research in Cardiology, 108(2), pp. 133-141. (doi: 10.1007/s00392-018-1331-2) (PMID:30051179)
Macdougall, I. C. et al. (2019) Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), pp. 447-458. (doi: 10.1056/NEJMoa1810742) (PMID:30365356)
Macdougall, I. C. et al. (2019) Correction: Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), p. 502. (doi: 10.1056/NEJMx180044) (PMID:30641026)
Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) Real-world studies no substitute for RCTs in establishing efficacy. Lancet, 393(10168), pp. 210-211. (doi: 10.1016/S0140-6736(18)32840-X) (PMID:30663582)
Claggett, B., Pocock, S., Wei, L. J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2019) Response by Claggett et al to letter regarding article, “Comparison of time-to-first event and recurrent-event methods in randomized clinical trials”. Circulation, 139(3), pp. 422-423. (doi: 10.1161/CIRCULATIONAHA.118.038478) (PMID:30640547)
Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)
Lee, M. M. Y. , McMurray, J. J.V. , Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. , Jhund, P. S. and Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105(4), pp. 337-345. (doi: 10.1136/heartjnl-2016-310342) (PMID:30337334)
Rørth, R. et al. (2019) The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 21(1), pp. 40-49. (doi: 10.1002/ejhf.1359) (PMID:30537261) (PMCID:PMC6607514)
Bhatt, D. L. et al. (2019) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, 394(10204), pp. 1169-1180. (doi: 10.1016/S0140-6736(19)31887-2) (PMID:31484629)
Ferreira, J. P. et al. (2019) Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial. European Journal of Heart Failure, 21(3), pp. 345-351. (doi: 10.1002/ejhf.1400) (PMID:30768732)
Schultheiss, H.-P. et al. (2019) Dilated cardiomyopathy. Nature Reviews Disease Primers, 5, 32. (doi: 10.1038/s41572-019-0084-1) (PMID:31073128)
Stienen, S., Ferreira, J. P., Girerd, N., Duarte, K., Lamiral, Z., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2019) Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology, 108(11), pp. 1215-1225. (doi: 10.1007/s00392-019-01453-7) (PMID:30953180)
Tromp, J. et al. (2018) Heart failure with preserved ejection fraction in the young. Circulation, 138(24), pp. 2763-2773. (doi: 10.1161/CIRCULATIONAHA.118.034720) (PMID:30565987)
Beggs, S. A.S. , Gardner, R. S. and McMurray, J. J.V. (2018) Who benefits from a defibrillator—balancing the risk of sudden versus non-sudden death. Current Heart Failure Reports, 15(6), pp. 376-389. (doi: 10.1007/s11897-018-0416-6) (PMID:30413991) (PMCID:PMC6267371)
Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J.V. , O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D. and Rouleau, J. L. (2018) Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 20(12), pp. 1701-1709. (doi: 10.1002/ejhf.1301) (PMID:30204280)
Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 20(12), pp. 1634-1635. (doi: 10.1002/ejhf.1325) (PMID:30328651)
Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Talking to patients with heart failure about end of life. European Journal of Heart Failure, 20(12), pp. 1763-1765. (doi: 10.1002/ejhf.1321) (PMID:30295978) (PMCID:PMC6607510)
Idzerda, N. M.A., Persson, F., Pena, M. J., Brenner, B. M., Brunel, P., Chaturvedi, N., McMurray, J. J. , Parving, H.-H., de Zeeuw, D. and Heerspink, H. J.L. (2018) N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 20(12), pp. 2899-2904. (doi: 10.1111/dom.13465) (PMID:29987919) (PMCID:PMC6282705)
Ramires, F. J.A. et al. (2018) Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al. ESC Heart Failure, 5(6), pp. 1069-1071. (doi: 10.1002/ehf2.12355) (PMID:30298996) (PMCID:PMC6300803)
Srivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. and Fonarow, G. C. (2018) Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiology, 3(12), pp. 1226-1231. (doi: 10.1001/jamacardio.2018.3957) (PMID:30484837) (PMCID:PMC6583093)
Fudim, M. et al. (2018) Relation of volume overload to clinical outcomes in acute heart failure (from ASCEND-HF). American Journal of Cardiology, 122(9), pp. 1506-1512. (doi: 10.1016/j.amjcard.2018.07.023) (PMID:30172362) (PMCID:PMC6924269)
Kristensen, S. L., Rørth, R., Jhund, P. S. , Shen, L., Lee, M. M.Y. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. European Journal of Heart Failure, 20(11), pp. 1549-1556. (doi: 10.1002/ejhf.1201) (PMID:29727039)
Voors, A. A. et al. (2018) Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 20(11), pp. 1601-16010. (doi: 10.1002/ejhf.1295) (PMID:30225882)
Hernandez, A. F. et al. (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), pp. 1519-1529. (doi: 10.1016/S0140-6736(18)32261-X) (PMID:30291013)
Haynes, R. et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial. Circulation, 138(15), pp. 1505-1514. (doi: 10.1161/CIRCULATIONAHA.118.034818) (PMID:30002098)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Petrie, M. C. and McMurray, J. J.V. (2018) Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 39(37), pp. 3417-3438. (doi: 10.1093/eurheartj/ehy407) (PMID:30085087) (PMCID:PMC6166137)
Cosmi, F., Staszewsky, L., McMurray, J. J.V. and Latini, R. (2018) Risk stratification according to insulin type: reply. European Journal of Heart Failure, 20(10), p. 1498. (doi: 10.1002/ejhf.1218) (PMID:29851246)
Januzzi, J. L. et al. (2018) IGFBP7 (insulin-like growth factor–binding protein-7) and neprilysin inhibition in patients with heart failure. Circulation: Heart Failure, 11(10), e005133. (doi: 10.1161/circheartfailure.118.005133) (PMID:30354399)
Campbell, R. T. et al. (2018) Which patients with heart failure should receive specialist palliative care? European Journal of Heart Failure, 20(9), pp. 1338-1347. (doi: 10.1002/ejhf.1240) (PMID:29952090) (PMCID:PMC6607479)
Green, J. B. et al. (2018) Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-rationale, design, and baseline characteristics. American Heart Journal, 203, pp. 30-38. (doi: 10.1016/j.ahj.2018.03.030) (PMID:30015066)
Ueland, T., Gullestad, L., Kou, L., Aukrust, P., Anand, I. S., Broughton, M. N., McMurray, J. J. , van Veldhuisen, D. J., Warren, D. J. and Bolstad, N. (2018) Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Failure, 5(6), pp. 1052-1059. (doi: 10.1002/ehf2.12312) (PMID:30145817) (PMCID:PMC6300802)
Claggett, B., Pocock, S., Wei, L.J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2018) Comparison of time-to-first event and recurrent event methods in randomized clinical trials. Circulation, 138(6), pp. 570-577. (doi: 10.1161/CIRCULATIONAHA.117.033065) (PMID:29588314)
Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)
Ferreira, J. P., Duarte, K., Pitt, B., Dickstein, K., McMurray, J. J.V. , Zannad, F. and Rossignol, P. (2018) Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trials. Journal of Hypertension, 36(8), pp. 1736-1742. (doi: 10.1097/HJH.0000000000001742) (PMID:29683884)
Grodin, J. L. et al. (2018) Circulating cardiac troponin I levels measured by a novel highly sensitive assay in acute decompensated heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 24(8), pp. 512-519. (doi: 10.1016/j.cardfail.2018.06.008) (PMID:30012361)
Heerspink, H. J.L. et al. (2018) Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism, 20(8), pp. 1829-1835. (doi: 10.1111/dom.13315) (PMID:29604160)
Lund, L. H. et al. (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 20(8), pp. 1230-1239. (doi: 10.1002/ejhf.1149) (PMID:29431256)
Abdul-Rahim, A. H. , Shen, L., Rush, C. J., Jhund, P. S. , Lees, K. R. and McMurray, J. J.V. (2018) Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. European Journal of Heart Failure, 20(7), pp. 1139-1145. (doi: 10.1002/ejhf.1160) (PMID:29493058)
Ferreira, J. P., Duarte, K., McMurray, J. J.V. , Pitt, B., van Veldhuisen, D. J., Vincent, J., Ahmad, T., Tromp, J., Rossignol, P. and Zannad, F. (2018) Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. Circulation: Heart Failure, 11(7), e004926. (doi: 10.1161/CIRCHEARTFAILURE.118.004926) (PMID:29997240)
Packer, M., Claggett, B., Lefkowitz, M. P., McMurray, J. J.V. , Rouleau, J. L., Solomon, S. D. and Zile, M. R. (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 6(7), pp. 547-554. (doi: 10.1016/S2213-8587(18)30100-1) (PMID:29661699)
Solomon, S. D. et al. (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure, 11(7), e004962. (doi: 10.1161/CIRCHEARTFAILURE.118.004962) (PMID:29980595)
Vaduganathan, M., Claggett, B., Packer, M., McMurray, J. J.V. , Rouleau, J. L., Zile, M. R., Swedberg, K. and Solomon, S. D. (2018) Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC: Heart Failure, 6(7), pp. 564-569. (doi: 10.1016/j.jchf.2018.02.007) (PMID:29501807)
McMurray, J. J.V. (2018) Only trials tell the truth about treatment effects. Journal of the American College of Cardiology, 71(23), pp. 2640-2642. (doi: 10.1016/j.jacc.2018.04.019) (PMID:29880123)
Rørth, R., Jhund, P. S. , Mogensen, U. M., Kristensen, S. L., Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care, 41(6), pp. 1285-1291. (doi: 10.2337/dc17-2583) (PMID:29626073)
Chanfra, A. et al. (2018) Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 3(6), pp. 498-505. (doi: 10.1001/jamacardio.2018.0398) (PMID:29617523) (PMCID:PMC6128510)
Damman, K. et al. (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure, 6(6), pp. 489-498. (doi: 10.1016/j.jchf.2018.02.004) (PMID:29655829)
Heerspink, H. J.L. et al. (2018) Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 20(6), pp. 1369-1376. (doi: 10.1111/dom.13245) (PMID:29405626)
McMurray, J. J.V. et al. (2018) Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 104(12), pp. 1006-1013. (doi: 10.1136/heartjnl-2016-310661) (PMID:29269379) (PMCID:PMC5992367)
Simpson, J. and McMurray, J. J.V. (2018) Prognostic modeling in heart failure: time for a reboot. JACC: Heart Failure, 6(6), pp. 463-464. (doi: 10.1016/j.jchf.2018.03.020) (PMID:29852930)
Frikha, Z., Ferreira, J. P., Bozec, E., McMurray, J. J.V. , Pitt, B., Dickstein, K., Rossignol, P., Zannad, F. and Girerd, N. (2018) Relation of high serum bilirubin to short-term mortality following a myocardial infarction complicated by left ventricular systolic dysfunction (from the High-Risk Myocardial Infarction Database Initiative). American Journal of Cardiology, 121(9), pp. 1015-1020. (doi: 10.1016/j.amjcard.2018.01.012) (PMID:29631805)
Cosmi, F. et al. (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 20(5), pp. 888-895. (doi: 10.1002/ejhf.1146) (PMID:29488676)
Lupón, J. et al. (2018) Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 20(5), pp. 938-940. (doi: 10.1002/ejhf.949) (PMID:28949101)
O'Meara, E., Prescott, M. F., Claggett, B., Rouleau, J. L., Chiang, L.-M., Solomon, S. D., Packer, M., McMurray, J. J.V. and Zile, M. R. (2018) Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF Trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(5), e004446. (doi: 10.1161/CIRCHEARTFAILURE.117.004446) (PMID:29748349)
Seferović, P. M. et al. (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20(5), pp. 853-872. (doi: 10.1002/ejhf.1170) (PMID:29520964)
Theodorakis, M. J. et al. (2018) Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 199, pp. 170-175. (doi: 10.1016/j.ahj.2017.09.001) (PMID:29754657)
McMurray, J. J.V. (2018) Renin–angiotensin system inhibition—it's been a long but fruitful journey. European Journal of Heart Failure, 20(4), pp. 687-688. (doi: 10.1002/ejhf.1155) (PMID:29405513)
Mogensen, U. M. et al. (2018) Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 20(4), pp. 760-768. (doi: 10.1002/ejhf.1139) (PMID:29431251)
Vardeny, O. et al. (2018) Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(4), e004745. (doi: 10.1161/CIRCHEARTFAILURE.117.004745) (PMID:29643067)
Tromp, J. et al. (2018) Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 15(3), e1002541. (doi: 10.1371/journal.pmed.1002541) (PMID:29584721) (PMCID:PMC5870945)
Bethel, M. A. and McMurray, J. J.V. (2018) Class effect for sodium glucose-cotransporter-2 inhibitors in cardiovascular outcomes: implications for the cardiovascular disease specialist. Circulation, 137(12), pp. 1218-1220. (doi: 10.1161/CIRCULATIONAHA.117.030117) (PMID:29555706)
Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Journal of the American College of Cardiology, 71(9), pp. 1021-1034. (doi: 10.1016/j.jacc.2017.12.048) (PMID:29495982)
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J.V. and Boulton, D. W. (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 20(3), pp. 479-487. (doi: 10.1111/dom.13126) (PMID:29024278)
Jorsal, A., Wiggers, H. and McMurray, J. J.V. (2018) Heart failure: epidemiology, pathophysiology, and management of heart failure in diabetes mellitus. Endocrinology and Metabolism Clinics of North America, 47(1), pp. 117-135. (doi: 10.1016/j.ecl.2017.10.007) (PMID:29407047)
Mogensen, U. M. et al. (2018) Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure, 20(3), pp. 514-522. (doi: 10.1002/ejhf.1056) (PMID:29193563)
Seferovic, J. P., Pfeffer, M. A., Claggett, B., Desai, A. S., de Zeeuw, D., Haffner, S. M., McMurray, J. J.V. , Parving, H.-H., Solomon, S. D. and Chaturvedi, N. (2018) Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia, 61(3), pp. 581-588. (doi: 10.1007/s00125-017-4485-y) (PMID:29098323)
Wolsk, E., Claggett, B., Køber, L., Pocock, S., Yusuf, S., Swedberg, K., McMurray, J. J.V. , Granger, C. B., Pfeffer, M. A. and Solomon, S. D. (2018) Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 20(3), pp. 504-510. (doi: 10.1002/ejhf.1073) (PMID:29193462)
Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation, 137(9), pp. 961-972. (doi: 10.1161/CIRCULATIONAHA.117.033502) (PMID:29483172)
Ferreira, J. P. et al. (2018) Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. Journal of the American College of Cardiology, 71(7), pp. 727-735. (doi: 10.1016/j.jacc.2017.12.011) (PMID:29447733)
Conrad, N. et al. (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, 391(10120), pp. 10-16. (doi: 10.1016/S0140-6736(17)32520-5) (PMID:29174292) (PMCID:PMC5814791)
Cotter, G. et al. (2018) Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? European Journal of Heart Failure, 20(2), pp. 317-322. (doi: 10.1002/ejhf.889) (PMID:28871621)
Ferreira, J. P., Duarte, K., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2018) Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 20(2), pp. 323-331. (doi: 10.1002/ejhf.1131) (PMID:29314455)
Platz, E., Jhund, P. S. , Claggett, B. L., Pfeffer, M. A., Swedberg, K., Granger, C. B., Yusuf, S., Solomon, S. D. and McMurray, J. J. (2018) Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 20(2), pp. 295-303. (doi: 10.1002/ejhf.901) (PMID:28872259)
Rørth, R. et al. (2018) Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure. European Journal of Heart Failure, 20(2), pp. 240-247. (doi: 10.1002/ejhf.1046) (PMID:29148231)
Schwartz, G. G. et al. (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiology, 3(2), pp. 164-168. (doi: 10.1001/jamacardio.2017.3833) (PMID:29071331) (PMCID:PMC5838593)
van der Meer, P. et al. (2018) Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (Reduction of Events by Darbepoetin Alfa in Heart Failure): clinical and prognostic associations. Circulation: Heart Failure, 11(2), e004431. (doi: 10.1161/CIRCHEARTFAILURE.117.004431) (PMID:29367268)
Welsh, P. et al. (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 20(2), pp. 268-277. (doi: 10.1002/ejhf.988) (PMID:28960777) (PMCID:PMC6607475)
Cleland, J. G.F. et al. (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), pp. 26-35. (doi: 10.1093/eurheartj/ehx564) (PMID:29040525)
Masip, J. et al. (2018) Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 39(1), pp. 17-25. (doi: 10.1093/eurheartj/ehx580) (PMID:29186485)
Beggs, S. A.S. , Jhund, P. S. , Jackson, C. E., McMurray, J. J.V. and Gardner, R. S. (2018) Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 104(2), pp. 144-150. (doi: 10.1136/heartjnl-2016-310850) (PMID:28986406)
Kristensen, S. L. et al. (2018) Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. European Journal of Heart Failure, 20(1), pp. 136-147. (doi: 10.1002/ejhf.896) (PMID:28948656)
McMurray, J. J.V. , Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D. and Krum, H. (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC: Heart Failure, 6(1), pp. 8-17. (doi: 10.1016/j.jchf.2017.08.004) (PMID:29032139)
Rørth, R. et al. (2018) Evidence based therapy and its association with workforce detachment following first hospitalization for heart failure. JACC: Heart Failure, 6(1), pp. 41-48. (doi: 10.1016/j.jchf.2017.09.019) (PMID:29226811)
Kraus, W. E., Yates, T., Tuomilehto, J., Sun, J.-L., Thomas, L., McMurray, J. J.V. , Bethel, M. A. and Holman, R. R. (2018) Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. BMJ Open Diabetes Research and Care, 6, e000523. (doi: 10.1136/bmjdrc-2018-000523) (PMID:30073088) (PMCID:PMC6067333)
Macdougall, I. C. et al. (2018) Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. American Journal of Nephrology, 48(4), pp. 260-268. (doi: 10.1159/000493551) (PMID:30304714)
McAllister, D. A. et al. (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation, 138(24), pp. 2774-2785. (doi: 10.1161/CIRCULATIONAHA.118.034986) (PMID:29950404) (PMCID:PMC6287897)
Rørth, R. et al. (2018) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure: a nationwide cohort study. Clinical Epidemiology, 10, pp. 917-930. (doi: 10.2147/CLEP.S164795) (PMID:30123004) (PMCID:PMC6080879)
Seferovic, J. P. et al. (2018) Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. Journal of Diabetes Research, 2018, 1631263. (doi: 10.1155/2018/1631263) (PMID:30648112) (PMCID:PMC6311850)
Verma, S. and McMurray, J. J.V. (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), pp. 2108-2117. (doi: 10.1007/s00125-018-4670-7) (PMID:30132036)
Kristensen, S. L., Jhund, P. S. , Lee, M. M.Y. , Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K. and McMurray, J. J.V. (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovascular Drugs and Therapy, 31(5-6), pp. 545-549. (doi: 10.1007/s10557-017-6754-x) (PMID:28948430)
Senni, M., McMurray, J. J.V. , Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. and Charney, A. (2017) Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 20(3), pp. 491-500. (doi: 10.1002/ejhf.1054) (PMID:29164797)
Shen, L., Jhund, P. S. and McMurray, J. J.V. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(18), pp. 1794-1795. (doi: 10.1056/NEJMc1711901) (PMID:29091558)
Holman, R. R. et al. (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(11), pp. 877-886. (doi: 10.1016/S2213-8587(17)30309-1) (PMID:28917545)
McDonald, M. A. et al. (2017) Mind the gap: current challenges and future state of heart failure care. Canadian Journal of Cardiology, 33(11), pp. 1434-1449. (doi: 10.1016/j.cjca.2017.08.023) (PMID:29111107)
Mogensen, U. M. et al. (2017) Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology, 70(20), pp. 2490-2500. (doi: 10.1016/j.jacc.2017.09.027) (PMID:29145948)
Shen, L. et al. (2017) Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circulation: Heart Failure, 10(11), e004361. (doi: 10.1161/CIRCHEARTFAILURE.117.004361) (PMID:29141857)
Stewart, S., Keates, A. K., Redfern, A. and McMurray, J. J.V. (2017) Seasonal variations in cardiovascular disease. Nature Reviews Cardiology, 14(11), pp. 654-664. (doi: 10.1038/nrcardio.2017.76) (PMID:28518176)
Wong, C. M. et al. (2017) Heart failure in young adults is associated with high mortality: a contemporary population-level analysis. Canadian Journal of Cardiology, 33(11), pp. 1472-1477. (doi: 10.1016/j.cjca.2017.05.009) (PMID:28941947)
Wolsk, E. et al. (2017) Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes mellitus. Circulation, 136(16), pp. 1560-1562. (doi: 10.1161/CIRCULATIONAHA.117.029503) (PMID:29038210)
Charytan, D. M. et al. (2017) ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. American Journal of Kidney Diseases, 70(4), pp. 522-531. (doi: 10.1053/j.ajkd.2017.04.018) (PMID:28599901)
Kristensen, S. L. et al. (2017) Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circulation: Heart Failure, 10(10), e004409. (doi: 10.1161/CIRCHEARTFAILURE.117.004409) (PMID:29018174)
Griffin, E. A. et al. (2017) Cost-effectiveness analysis of natriuretic peptide testing and specialist management in patients with suspected acute heart failure. Value in Health, 20(8), pp. 1025-1033. (doi: 10.1016/j.jval.2017.05.007) (PMID:28964433)
Olivier, A. et al. (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 19(9), pp. 1186-1197. (doi: 10.1002/ejhf.792) (PMID:28303624)
Platz, E., Merz, A. A., Jhund, P. S. , Vazir, A., Campbell, R. and McMurray, J. J. (2017) Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. European Journal of Heart Failure, 19(9), pp. 1154-1163. (doi: 10.1002/ejhf.839) (PMID:28557302)
Verma, S., McMurray, J. J.V. and Cherney, D. Z.I. (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiology, 2(9), pp. 939-940. (doi: 10.1001/jamacardio.2017.1891) (PMID:28636701)
Baigent, C. et al. (2017) Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 92(2), pp. 297-305. (doi: 10.1016/j.kint.2017.04.019) (PMID:28709600)
Lewis, E. F. et al. (2017) Health-related quality of life outcomes in PARADIGM-HF. Circulation: Heart Failure, 10(8), e003430. (doi: 10.1161/CIRCHEARTFAILURE.116.003430) (PMID:28784687)
Shen, L., Jhund, P. S. , Mogensen, U. M., Køber, L., Claggett, B., Rogers, J. K. and McMurray, J. J.V. (2017) A re-examination of the BEST Trial using composite outcomes, including emergency department visits. JACC: Heart Failure, 5(8), pp. 591-599. (doi: 10.1016/j.jchf.2017.04.005) (PMID:28774394)
Shen, L. et al. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(1), pp. 41-51. (doi: 10.1056/NEJMoa1609758) (PMID:28679089)
Price, S. et al. (2017) Expert consensus document: echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nature Reviews Cardiology, 14(7), pp. 427-440. (doi: 10.1038/nrcardio.2017.56) (PMID:28447662)
Solomon, S. D. et al. (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction. JACC: Heart Failure, 5(7), pp. 471-482. (doi: 10.1016/j.jchf.2017.04.013) (PMID:28662936)
MacDonald, T. M. et al. (2017) Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 38(23), pp. 1843-1850. (doi: 10.1093/eurheartj/ehw387) (PMID:27705888) (PMCID:PMC5837371)
Cleland, J. G.F. et al. (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure, 19(6), pp. 739-747. (doi: 10.1002/ejhf.786) (PMID:28296139)
Cowie, M. R. et al. (2017) New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 19(6), pp. 718-727. (doi: 10.1002/ejhf.809) (PMID:28345190)
Currie, G. , Bethel, M. A., Holzhauer, B., Haffner, S. M., Holman, R. R. and McMurray, J. J.V. (2017) Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 19(6), pp. 791-799. (doi: 10.1111/dom.12877) (PMID:28093841)
Guimarães, P. O. et al. (2017) Effect of Apixaban on all-cause death in patients with atrial fibrillation: a meta-analysis based on imputed placebo effect. Cardiovascular Drugs and Therapy, 31(3), pp. 295-301. (doi: 10.1007/s10557-017-6728-z) (PMID:28516318)
Mogensen, U. M. et al. (2017) The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 188, pp. 35-41. (doi: 10.1016/j.ahj.2017.02.034) (PMID:28577679)
Rossignol, P. et al. (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 19(6), pp. 792-799. (doi: 10.1002/ejhf.688) (PMID:27868385)
Wolsk, E. et al. (2017) Role of b-type natriuretic peptide and n-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association, 6(6), e004743. (doi: 10.1161/JAHA.116.004743) (PMID:28554908)
Packer, M. et al. (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine, 376(20), pp. 1956-1964. (doi: 10.1056/NEJMoa1601895) (PMID:28402745)
Packer, M. and McMurray, J. J.V. (2017) Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, 389(10081), pp. 1831-1840. (doi: 10.1016/S0140-6736(16)30969-2) (PMID:27919443)
Bethel, M. A. et al. (2017) Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and its Complications, 31(5), pp. 859-863. (doi: 10.1016/j.jdiacomp.2017.02.012) (PMID:28319004)
Cowper, P. A. et al. (2017) Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. JAMA Cardiology, 2(5), pp. 525-534. (doi: 10.1001/jamacardio.2017.0065) (PMID:28355434)
Ho, C. Y. et al. (2017) Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial. American Heart Journal, 187, pp. 145-155. (doi: 10.1016/j.ahj.2017.02.008) (PMID:28454798) (PMCID:PMC5586211)
Packer, M. et al. (2017) Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure, 19(5), pp. 673-681. (doi: 10.1002/ejhf.698) (PMID:27862700)
Packer, M. et al. (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure : primary results of the ENABLE Trials. JACC: Heart Failure, 5(5), pp. 317-326. (doi: 10.1016/j.jchf.2017.02.021) (PMID:28449795)
Seferovic, J. P. et al. (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 5(5), pp. 333-340. (doi: 10.1016/S2213-8587(17)30087-6) (PMID:28330649) (PMCID:PMC5534167)
Cannon, J. A., Moffitt, P., Perez-Moreno, A. C., Walters, M. R. , Broomfield, N. M., McMurray, J. J.V. and Quinn, T. J. (2017) Cognitive impairment and heart failure: systematic review and meta-analysis. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2017.04.007) (PMID:28433667)
Böhm, M. et al. (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 38(15), pp. 1132-1143. (doi: 10.1093/eurheartj/ehw570) (PMID:28158398)
Nymo, S. H. et al. (2017) Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC: Heart Failure, 5(4), pp. 256-264. (doi: 10.1016/j.jchf.2017.01.008) (PMID:28359413)
Abdul-Rahim, A. H. et al. (2017) Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 38(10), pp. 742-750. (doi: 10.1093/eurheartj/ehw509) (PMID:28426886) (PMCID:PMC5460584)
Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)
Emdin, C. A. et al. (2017) Referral for specialist follow-up and its association with post-discharge mortality among patients with systolic heart failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 119(3), pp. 440-444. (doi: 10.1016/j.amjcard.2016.10.021) (PMID:27884420) (PMCID:PMC5282396)
Beldhuis, I. E., Streng, K. W., Ter Maaten, J. M., Voors, A. A., van der Meer, P., Rossignol, P., McMurray, J. J.V. and Damman, K. (2017) Renin–angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 10(2), e003588. (doi: 10.1161/CIRCHEARTFAILURE.116.003588) (PMID:28209765)
Ferreira, J. P. et al. (2017) Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction. Circulation: Heart Failure, 10(2), e003500. (doi: 10.1161/CIRCHEARTFAILURE.116.003500) (PMID:28159825)
Kitai, T. et al. (2017) Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. European Journal of Heart Failure, 19(2), pp. 241-249. (doi: 10.1002/ejhf.629) (PMID:27634557)
Mueller, C. et al. (2017) European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. European Heart Journal: Acute Cardiovascular Care, 6(1), pp. 81-86. (doi: 10.1177/2048872615593279) (PMID:26124458)
Paton, D. M., Shamy, M., Fedyk, M., Pfeffer, M. A. and McMurray, J. J.V. (2017) Clinical trials involving hypertension [Correspondence]. New England Journal of Medicine, 376(3), pp. 289-290. (doi: 10.1056/NEJMc1615364) (PMID:28099831)
Agewall, S. et al. (2017) 2016 ESC guidelines for the diagnosis and treatment of atrial fibrillation developed in collaboration with the EACTS [Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS]. Revista Española de Cardiología, 70(1), 50.e1-50.e84. (doi: 10.1016/j.recesp.2016.11.014)
Hawkins, N. M., Khosla, A., Virani, S. A., McMurray, J. J.V. and FitzGerald, J. M. (2017) B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 17, 11. (doi: 10.1186/s12890-016-0345-7) (PMID:28073350) (PMCID:PMC5223538)
Cannon, J. A. et al. (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 19(1), pp. 129-137. (doi: 10.1002/ejhf.687) (PMID:27868321) (PMCID:PMC5248626)
Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J.V. , Deschaseaux, C. and Cope, S. (2017) Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure, 10, e003529. (doi: 10.1161/CIRCHEARTFAILURE.116.003529) (PMID:28087688)
Desai, A. S. et al. (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/Valsartan compared with Enalapril: A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiology, 2(1), pp. 79-85. (doi: 10.1001/jamacardio.2016.4733) (PMID:27842179)
Gandhi, P. U. et al. (2017) Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure, 23(1), pp. 20-28. (doi: 10.1016/j.cardfail.2016.06.006) (PMID:27317843)
Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)
Arain, F., Gullestad, L., Nymo, S., Kjekshus, J., Cleland, J. G.F. , Michelsen, A., McMurray, J. J.V. , Wikstrand, J., Aukrust, P. and Ueland, T. (2017) Low YKL-40 in Chronic Heart Failure may predict beneficial effects of statins: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Biomarkers, 22, pp. 261-267. (doi: 10.1080/1354750X.2016.1204003) (PMID:27325138)
Harumi Higuchi dos Santos, M., Sharma, A., Sun, J.‐L., Pieper, K., McMurray, J. J.V. , Holman, R. R. and Lopes, R. D. (2017) International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: insights from the NAVIGATOR Trial. Journal of the American Heart Association, 6(1), e003892. (doi: 10.1161/JAHA.116.003892) (PMID:28087508) (PMCID:PMC5523624)
Mc Causland, F. R. et al. (2017) Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial. American Journal of Nephrology, 46(6), pp. 488-497. (doi: 10.1159/000485326) (PMID:29241199)
Miro, Ò. et al. (2017) European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. European Heart Journal: Acute Cardiovascular Care, 6(4), pp. 311-320. (doi: 10.1177/2048872616633853) (PMID:26900163)
Pitts, R. et al. (2017) Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure. Journal of the American Heart Association, 6(1), e004119. (doi: 10.1161/JAHA.116.004119) (PMID:28073769) (PMCID:PMC5523625)
Ridker, P. M. et al. (2017) Cardiovascular efficacy and safety of Bococizumab in high-risk patients. New England Journal of Medicine, 376(16), pp. 1527-1539. (doi: 10.1056/NEJMoa1701488) (PMID:28304242)
Teerlink, J. R. et al. (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, 388(10062), pp. 2895-2903. (doi: 10.1016/S0140-6736(16)32049-9)
Zile, M. R. et al. (2016) Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology, 68(22), pp. 2425-2436. (doi: 10.1016/j.jacc.2016.09.931) (PMID:27908347)
Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B. and McMurray, J. J.V. (2016) Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure, 18(12), pp. 1508-1517. (doi: 10.1002/ejhf.609) (PMID:27427441)
Mc Causland, F. R. et al. (2016) C-Reactive protein and risk of ESRD: results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 68(6), pp. 873-881. (doi: 10.1053/j.ajkd.2016.07.022) (PMID:27646425) (PMCID:PMC5123931)
Pitts, R. et al. (2016) Treatment with Dalcetrapib modifies the relationship between high-density lipoprotein cholesterol and C-reactive protein. Journal of the American College of Cardiology, 68(22), pp. 2488-2490. (doi: 10.1016/j.jacc.2016.09.932) (PMID:27908356)
Ponikowski, P. et al. (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica]. Revista Española de Cardiología, 69(12), 1167.e1-1167.e85. (doi: 10.1016/j.recesp.2016.10.014)
Ferreira, J. P. et al. (2016) Renal function estimation and Cockroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: the Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 14, 181. (doi: 10.1186/s12916-016-0731-2) (PMID:27829460) (PMCID:PMC5103492)
Pfeffer, M. A. and McMurray, J. J.V. (2016) Lessons in uncertainty and humility — Clinical trials involving hypertension. New England Journal of Medicine, 375(18), pp. 1756-1766. (doi: 10.1056/NEJMra1510067) (PMID:27806228)
Martín-Sánchez, F. J. et al. (2016) Practical approach on frail older patients attended for acute heart failure. International Journal of Cardiology, 222, pp. 62-71. (doi: 10.1016/j.ijcard.2016.07.151) (PMID:27458825)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18(11), pp. 1609-1678. (doi: 10.1093/europace/euw295) (PMID:27567465)
Savarese, G., Giugliano, R. P., Rosano, G. M.C., McMurray, J. , Magnani, G., Filippatos, G., Dellegrottaglie, S., Lund, L. H., Trimarco, B. and Perrone-Filardi, P. (2016) Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC: Heart Failure, 4(11), pp. 881-884. (doi: 10.1016/j.jchf.2016.07.012) (PMID:27614940)
Rørth, R. et al. (2016) Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study. Circulation, 134(14), pp. 999-1009. (doi: 10.1161/CIRCULATIONAHA.116.021859) (PMID:27507406)
Cotter, G. et al. (2016) Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure, 22(10), pp. 815-822. (doi: 10.1016/j.cardfail.2015.12.017) (PMID:26721775)
Solomon, S. D., Claggett, B., McMurray, J. J.V. , Hernandez, A. F. and Fonarow, G. C. (2016) Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. European Journal of Heart Failure, 18(10), pp. 1238-1243. (doi: 10.1002/ejhf.603) (PMID:27364182)
Solomon, S. D., Claggett, B., Packer, M., Desai, A., Zile, M. R., Swedberg, K., Rouleau, J., Shi, V., Lefkowitz, M. and McMurray, J. J.V. (2016) Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC: Heart Failure, 4(10), pp. 816-822. (doi: 10.1016/j.jchf.2016.05.002) (PMID:27395349)
Vardeny, O. et al. (2016) Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 18(10), pp. 1228-1234. (doi: 10.1002/ejhf.580) (PMID:27283779) (PMCID:PMC5095784)
McMurray, J. J.V. (2016) The ICD in heart failure - time for a rethink? New England Journal of Medicine, 375(13), pp. 1283-1284. (doi: 10.1056/NEJMe1609826) (PMID:27571386)
Judge, P.K. et al. (2016) Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfw321) (PMID:27646835)
McMurray, J. J.V. (2016) Site selection and performance in clinical trials. Circulation: Heart Failure, 9(9), e003490. (doi: 10.1161/CIRCHEARTFAILURE.116.003490) (PMID:27623771)
Chin, K. L. et al. (2016) Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. European Journal of Heart Failure, 18(9), pp. 1175-1181. (doi: 10.1002/ejhf.485) (PMID:26833642)
Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J.V. and Solomon, S. D. (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiology, 1(6), pp. 666-672. (doi: 10.1001/jamacardio.2016.1747) (PMID:27438344)
Hawkins, N. M. et al. (2016) Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 18(9), pp. 1162-1171. (doi: 10.1002/ejhf.614) (PMID:27594177)
Jhund, P. S. and McMurray, J. J.V. (2016) The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 102(17), pp. 1342-1347. (doi: 10.1136/heartjnl-2014-306775) (PMID:27207980) (PMCID:PMC5013095)
Okumura, N. et al. (2016) Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. Circulation: Heart Failure, 9(9), e003212. (doi: 10.1161/CIRCHEARTFAILURE.116.003212) (PMID:27618854)
Senni, M. et al. (2016) Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. European Journal of Heart Failure, 18(9), pp. 1193-1202. (doi: 10.1002/ejhf.548) (PMID:27170530) (PMCID:PMC5084812)
McMurray, J. J.V. , Dickstein, K. and Kober, L. V. (2016) The author's reply - Aliskiren, Enalapril, or both in heart failure. New England Journal of Medicine, 375(7), pp. 701-702. (doi: 10.1056/NEJMc1606625) (PMID:27532843)
Hawkins, N. M., Virani, S. A., Sperrin, M., Buchan, I. E., McMurray, J. J.V. and Krahn, A. D. (2016) Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. European Journal of Heart Failure, 18(8), pp. 977-986. (doi: 10.1002/ejhf.458) (PMID:26663507)
Cannon, J. A., Shen, L., Jhund, P. , Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J. V. (2016) Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. European Journal of Heart Failure, 18(8), pp. 1021-1031. (doi: 10.1002/ejhf.547) (PMID:27194023)
Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 18(8), pp. 891-975. (doi: 10.1002/ejhf.592) (PMID:27207191)
Desai, A. S. et al. (2016) Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. Journal of the American College of Cardiology, 68(3), pp. 241-248. (doi: 10.1016/j.jacc.2016.04.047) (PMID:27417000)
McMurray, J. J.V. and Køber, L. V. (2016) End of the road for vagus nerve stimulation? Journal of the American College of Cardiology, 68(2), pp. 159-160. (doi: 10.1016/j.jacc.2016.05.025) (PMID:27386768)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1333-1339. (doi: 10.1007/s00125-016-3956-x) (PMID:27112340) (PMCID:PMC4901113)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J. (2016) Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1573-1574. (doi: 10.1007/s00125-016-3987-3) (PMID:27174369) (PMCID:PMC4969788)
Okumura, N. et al. (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation, 133(23), pp. 2254-2262. (doi: 10.1161/CIRCULATIONAHA.115.020729) (PMID:27143684)
Woodcock, J., Ware, J. H., Miller, P. W., McMurray, J. J.V. , Harrington, D. P. and Drazen, J. M. (2016) Clinical Trials Series. New England Journal of Medicine, 374(22), p. 2167. (doi: 10.1056/NEJMe1601510)
Berry, C. et al. (2016) Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM: An International Journal of Medicine, 109(6), pp. 377-382. (doi: 10.1093/qjmed/hcv087) (PMID:25979270)
Metra, M. et al. (2016) Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology, 117(11), pp. 1771-1778. (doi: 10.1016/j.amjcard.2016.03.002) (PMID:27108685)
Abdul-Rahim, A. H. et al. (2016) Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 1(2), pp. 93-100. (doi: 10.1177/2396987316646025)
Anker, S. D. et al. (2016) Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482-489]. European Journal of Heart Failure, 18(6), p. 727. (doi: 10.1002/ejhf.591) (PMID:27324688)
Desai, A. S., Solomon, S., Claggett, B., McMurray, J. J.V. , Rouleau, J., Swedberg, K., Zile, M., Lefkowitz, M., Shi, V. and Packer, M. (2016) Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circulation: Heart Failure, 9(6), e002735. (doi: 10.1161/CIRCHEARTFAILURE.115.002735) (PMID:27296397)
Lopes, R. D., Pieper, K. S., Stevens, S. R., Solomon, S. D., McMurray, J. J.V. , Pfeffer, M. A., Leimberger, J. D. and Velazquez, E. J. (2016) Predicting outcomes over time in patients with heart failure, left ventricular systolic dysfunction, or both following acute myocardial infarction. Journal of the American Heart Association, 5(6), e003045. (doi: 10.1161/JAHA.115.003045) (PMID:27353607) (PMCID:PMC4937254)
Whellan, D. J., Stebbins, A., Hernandez, A. F., Ezekowitz, J. A., McMurray, J. J.V. , Mather, P. J., Hasselblad, V. and O'Connor, C. M. (2016) Dichotomous relationship between age and 30-day death or rehospitalization in heart failure patients admitted with acute decompensated heart failure: results from the ASCEND-HF trial. Journal of Cardiac Failure, 22(6), pp. 409-416. (doi: 10.1016/j.cardfail.2016.02.011) (PMID:26952241)
McMurray, J. J.V. (2016) Disease management programs in cardiology. Circulation, 133(19), pp. 1836-1837. (doi: 10.1161/circulationaha.116.022480) (PMID:27083508)
Anker, S. D. et al. (2016) Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 18(5), pp. 482-489. (doi: 10.1002/ejhf.516) (PMID:27071916)
Campbell, R. T., Willox, G. P., Jhund, P. S. , Hawkins, N. M., Huang, F., Petrie, M. C. and McMurray, J. J. V. (2016) Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review. Circulation: Heart Failure, 9(5), e002842. (doi: 10.1161/CIRCHEARTFAILURE.115.002842) (PMID:27162229)
McMurray, J. J.V. et al. (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine, 374(16), pp. 1521-1532. (doi: 10.1056/NEJMoa1514859) (PMID:27043774)
Abdul-Rahim, A. H. , MacIsaac, R. L., Jhund, P. S. , Petrie, M. C. , Lees, K. R. and McMurray, J. J.V. (2016) Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 209, pp. 310-316. (doi: 10.1016/j.ijcard.2016.02.074) (PMID:26913372)
Heerspink, H. J.L. et al. (2016) Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes and Endocrinology, 4(4), pp. 309-317. (doi: 10.1016/S2213-8587(15)00469-6) (PMID:26774608)
McMurray, J. J.V. and Køber, L. (2016) Trials and the ‘real world’ - how different are they? European Journal of Heart Failure, 18(4), pp. 411-413. (doi: 10.1002/ejhf.503) (PMID:27019978)
Sabe, M. A. et al. (2016) Coronary artery disease is a predictor of progression to dialysis in patients with chronic kidney disease, type 2 diabetes mellitus, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp therapy (TREAT). Journal of the American Heart Association, 5(4), e002850. (doi: 10.1161/JAHA.115.002850) (PMID:27108247) (PMCID:PMC4859277)
Samsky, M. D. et al. (2016) Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. European Journal of Heart Failure, 18(4), pp. 424-432. (doi: 10.1002/ejhf.440) (PMID:26707029)
Teerlink, J. R. et al. (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. Journal of the American College of Cardiology, 67(12), pp. 1444-1455. (doi: 10.1016/j.jacc.2016.01.031) (PMID:27012405)
Ambrosy, A. P. et al. (2016) The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 18(3), pp. 306-313. (doi: 10.1002/ejhf.420) (PMID:26467269)
Damman, K., Kjekshus, J., Wikstrand, J., Cleland, J. G.F. , Komajda, M., Wedel, H., Waagstein, F. and McMurray, J. J.V. (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 18(3), pp. 328-336. (doi: 10.1002/ejhf.462) (PMID:26693947)
Perez, A. L. et al. (2016) Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 18(3), pp. 290-297. (doi: 10.1002/ejhf.456) (PMID:26663359)
Solomon, S. D. et al. (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circulation: Heart Failure, 9(3), e002744. (doi: 10.1161/CIRCHEARTFAILURE.115.002744) (PMID:26915374)
Heerspink, H.J.L. et al. (2016) Is a reduction in albuminuria associated with renal and cardiovascular protection? A post-hoc analysis of the ALTITUDE trial. Diabetes, Obesity and Metabolism, 18(2), pp. 169-177. (doi: 10.1111/dom.12600) (PMID:26511599)
Vardeny, O. et al. (2016) Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF Trial. JACC: Heart Failure, 4(2), pp. 152-158. (doi: 10.1016/j.jchf.2015.10.012) (PMID:26746371)
Kristensen, S. L. et al. (2016) Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. (doi: 10.1161/CIRCHEARTFAILURE.115.002560) (PMID:26754626) (PMCID:PMC4718182)
McMurray, J. (2016) EMPA-REG – the “diuretic hypothesis”. Journal of Diabetes and its Complications, 30(1), pp. 3-4. (doi: 10.1016/j.jdiacomp.2015.10.012) (PMID:26597600)
Tang, W.H. W. et al. (2016) Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC: Heart Failure, 4(1), pp. 68-77. (doi: 10.1016/j.jchf.2015.07.015) (PMID:26656144)
Theilade, S., Claggett, B., Hansen, T.W., Skali, H., Lewis, E.F., Solomon, S.D., Parving, H.-H., Pfeffer, M., McMurray, J.J. and Rossing, P. (2016) Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 30(1), pp. 46-52. (doi: 10.1038/jhh.2015.22) (PMID:25810068)
Zile, M. R. et al. (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction. Circulation: Heart Failure, 9(1), e002551. (doi: 10.1161/circheartfailure.115.002551) (PMID:26754625)
Emdin, C. A. et al. (2016) Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 103(1), pp. 55-62. (doi: 10.1136/heartjnl-2016-309706) (PMID:27530132)
Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5), e1-e88. (doi: 10.1093/ejcts/ezw313) (PMID:27663299)
Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37(38), pp. 2893-2962. (doi: 10.1093/eurheartj/ehw210) (PMID:27567408)
Kristensen, S. L. et al. (2016) Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 37(41), pp. 3167-3174. (doi: 10.1093/eurheartj/ehw226) (PMID:27354044) (PMCID:PMC5106574)
Nadruz, W. et al. (2016) Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation, 134(22), pp. 1785-1787. (doi: 10.1161/CIRCULATIONAHA.116.024976) (PMID:27895026)
Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), pp. 2129-2200. (doi: 10.1093/eurheartj/ehw128) (PMID:27206819)
Cannon, J. A., McKean, A. R., Jhund, P. S. and McMurray, J. J.V. (2015) What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open Heart, 2(1), e000283. (doi: 10.1136/openhrt-2015-000283) (PMID:26719808) (PMCID:PMC4692046)
Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(23), pp. 2648-62. (doi: 10.1016/j.jacc.2015.10.023) (PMID:26670066)
Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Making sense of statistics in clinical trial reports: Part 1 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(22), pp. 2536-2549. (doi: 10.1016/j.jacc.2015.10.014) (PMID:26653629)
Claggett, B., Packer, M., McMurray, J. J.V. , Swedberg, K., Rouleau, J., Zile, M. R., Jhund, P., Lefkowitz, M., Shi, V. and Solomon, S. D. (2015) Estimating the long-term treatment benefits of Sacubitril–Valsartan. New England Journal of Medicine, 373(23), pp. 2289-2290. (doi: 10.1056/NEJMc1509753) (PMID:26630151)
Gheorghiade, M. et al. (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction. JAMA: Journal of the American Medical Association, 314(21), pp. 2251-2262. (doi: 10.1001/jama.2015.15734) (PMID:26547357)
McMurray, J. J.J.V. (2015) Improving outcomes in heart failure: a personal perspective. European Heart Journal, 36(48), pp. 3467-3470. (doi: 10.1093/eurheartj/ehv565) (PMID:26578200)
Pfeffer, M. A. et al. (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine, 373(23), pp. 2247-2257. (doi: 10.1056/NEJMoa1509225) (PMID:26630143)
Simpson, J. et al. (2015) Comparing LCZ696 with Enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores. Journal of the American College of Cardiology, 66(19), pp. 2059-2071. (doi: 10.1016/j.jacc.2015.08.878) (PMID:26541915)
McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)
Wang, N. et al. (2015) Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal, (doi: 10.1093/eurheartj/ehv558) (PMID:26530103)
Bello, N. A. et al. (2015) Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 17(11), pp. 1201-1207. (doi: 10.1002/ejhf.412) (PMID:26423928) (PMCID:PMC4703474)
Simpson, J. et al. (2015) Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure, 17(11), pp. 1182-1191. (doi: 10.1002/ejhf.346) (PMID:26358762)
Jhund, P. et al. (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 36(38), pp. 2576-2584. (doi: 10.1093/eurheartj/ehv330) (PMID:26231885) (PMCID:PMC4595742)
Grodin, J. L. et al. (2015) Circulating kidney injury molecule-1 levels in acute heart failure. JACC: Heart Failure, 3(10), pp. 777-785. (doi: 10.1016/j.jchf.2015.06.006) (PMID:26449997)
Krum, H. et al. (2015) The Aliskiren trial to minimize outcomes in patients with heart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure, 17(10), pp. 1075-1083. (doi: 10.1002/ejhf.408) (PMID:26511146)
Jhund, P. et al. (2015) Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 36(36), pp. 2463-2469. (doi: 10.1093/eurheartj/ehv295) (PMID:26188211)
Girerd, N., Collier, T., Pocock, S., Krum, H., McMurray, J. J. , Swedberg, K., Van Veldhuisen, D. J., Vincent, J., Pitt, B. and Zannad, F. (2015) Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 36(34), pp. 2310-2317. (doi: 10.1093/eurheartj/ehv273) (PMID:26093641)
Charytan, D. M. et al. (2015) Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). American Journal of Kidney Diseases, 66(3), pp. 429-440. (doi: 10.1053/j.ajkd.2015.02.324) (PMID:25935581)
Fisher, M., Petrie, M. , Ambery, P., Donaldson, J., McMurray, J. J.V. and Ye, J. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology, 3(9), pp. 697-703. (doi: 10.1016/s2213-8587(15)00233-8) (PMID:26276240)
Kao, D. P., Lewsey, J. D. , Anand, I. S., Massie, B. M., Zile, M. R., Carson, P. E., McKelvie, R. S., Komajda, M., McMurray, J. J.V. and Lindenfeld, J. (2015) Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure, 17(9), pp. 925-935. (doi: 10.1002/ejhf.327) (PMID:26250359)
Platz, E., Jhund, P. S. , Campbell, R. T. and McMurray, J. (2015) Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. European Journal of Heart Failure, 17(9), pp. 906-916. (doi: 10.1002/ejhf.321) (PMID:26230356) (PMCID:PMC4725064)
McMurray, J. J.V. (2015) It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? European Heart Journal, 36(31), pp. 2047-2049. (doi: 10.1093/eurheartj/ehv190) (PMID:25994745)
Desai, A. S. et al. (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 36(30), pp. 1990-1997. (doi: 10.1093/eurheartj/ehv186) (PMID:26022006)
Mebazaa, A. et al. (2015) Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 36(30), pp. 1958-1966. (doi: 10.1093/eurheartj/ehv066) (PMID:25998514)
Askevold, E. T., Gullestad, L., Nymo, S., Kjekshus, J., Yndestad, A., Latini, R., Cleland, J. G.F. , McMurray, J. J.V. , Aukrust, P. and Ueland, T. (2015) Secreted frizzled related protein 3 in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS ONE, 10(8), e0133970. (doi: 10.1371/journal.pone.0133970) (PMID:26288364) (PMCID:PMC4545831)
Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)
Jhund, P. S. , Anand, I. S., Komajda, M., Claggett, B. L., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J.V. (2015) Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. European Journal of Heart Failure, 17(8), pp. 809-817. (doi: 10.1002/ejhf.274) (PMID:25921853)
Khazanie, P. et al. (2015) Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated heart failure outcome models. American Heart Journal, 170(2), pp. 290-297. (doi: 10.1016/j.ahj.2015.04.006) (PMID:26299226)
Lewis, E. F. et al. (2015) Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal, 170(2), 322-329.e4. (doi: 10.1016/j.ahj.2015.05.008) (PMID:26299230)
Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi: 10.1136/bmjopen-2015-007901) (PMID:26275900) (PMCID:PMC4550730)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)
Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi: 10.1111/dme.12762) (PMID:25818859)
Emdin, C. A., Callender, T., Cao, J., McMurray, J. J.V. and Rahimi, K. (2015) Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. American Journal of Cardiology, 116(1), pp. 155-61. (doi: 10.1016/j.amjcard.2015.03.052) (PMID:25937349)
Cannon, J.A. et al. (2015) Clinical outcomes according to QRS duration and morphology in the eplerenone in mild patients: hospitalization and survIval study in heart failure (EMPHASIS-HF). European Journal of Heart Failure, 17(7), pp. 707-716. (doi: 10.1002/ejhf.303) (PMID:26139584)
Green, J. B. et al. (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), pp. 232-242. (doi: 10.1056/NEJMoa1501352) (PMID:26052984)
Harinstein, M. E. et al. (2015) Site selection for heart failure clinical trials in the USA. Heart Failure Reviews, 20(4), pp. 375-383. (doi: 10.1007/s10741-015-9473-z) (PMID:25649127)
Dalzell, J. R., Rocchiccioli, J. P., Weir, R. A.P., Jackson, C. E., Padmanabhan, N., Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) The emerging potential of the apelin-APJ system in heart failure. Journal of Cardiac Failure, 21(6), pp. 489-498. (doi: 10.1016/j.cardfail.2015.03.007) (PMID:25795508)
Kristensen, S. L., Jhund, P. S. , Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F. , Carson, P. E. and McMurray, J. J.V. (2015) Relative importance of history of heart failure hospitalization and N-terminal pro–B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 3(6), pp. 478-486. (doi: 10.1016/j.jchf.2015.01.014) (PMID:26046842)
Mebazaa, A. et al. (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergenc. European Journal of Heart Failure, 17(6), pp. 544-558. (doi: 10.1002/ejhf.289) (PMID:25999021)
Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)
Bentley-Lewis, R. et al. (2015) Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5), 631-638.e7. (doi: 10.1016/j.ahj.2015.02.002) (PMID:25965710)
Abdul-Rahim, A. H. et al. (2015) Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the controlled rosuvastatin in multinational trial heart failure (corona) and the gruppo italiano per lo studio della sopravvivenza nell'insufficienza cardiaca-heart failure (gissi-hf) trials. Circulation, 131(17), pp. 1486-1494. (doi: 10.1161/CIRCULATIONAHA.114.013760) (PMID:25810334)
Ezekowitz, J. A. et al. (2015) Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 1(2), pp. 86-94. (doi: 10.1093/ehjcvp/pvu024) (PMID:27533976)
Feinstein, M. J., Jhund, P. , Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J. and Lloyd-Jones, D. M. (2015) Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 17(4), pp. 434-441. (doi: 10.1002/ejhf.247) (PMID:25684642)
Vazir, A. et al. (2015) Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 36(11), pp. 669-675. (doi: 10.1093/eurheartj/ehu401) (PMID:25368202)
Campbell, R. T. et al. (2015) Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Failure, 2(1), pp. 25-36. (doi: 10.1002/ehf2.12027) (PMID:27347426) (PMCID:PMC4864752)
DeVore, A. D. et al. (2015) Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 17(3), pp. 340-346. (doi: 10.1002/ejhf.235) (PMID:25619549)
Haver, V. G. et al. (2015) Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA). European Journal of Heart Failure, 17(3), pp. 313-9. (doi: 10.1002/ejhf.237) (PMID:25639660)
Katz, M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Thomas, L. and Lopes, R. D. (2015) Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. American Journal of Medicine, 128(3), pp. 297-302. (doi: 10.1016/j.amjmed.2014.08.022) (PMID:25447626)
Metra, M. et al. (2015) Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. Journal of Cardiac Failure, 21(3), pp. 179-88. (doi: 10.1016/j.cardfail.2014.12.012) (PMID:25573829)
Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme. European Journal of Heart Failure, 17(2), pp. 196-204. (doi: 10.1002/ejhf.221)
Hijazi, Z. et al. (2015) Comparison of cardiac troponins i and t measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clinical Chemistry, 61(2), pp. 368-378. (doi: 10.1373/clinchem.2014.226936) (PMID:25451868)
Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)
Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Block, D., Zaugg, C. and Gullestad, L. (2015) Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. Journal of Cardiac Failure, 21(2), pp. 153-9. (doi: 10.1016/j.cardfail.2014.10.016) (PMID:25451704)
Abdul-Rahim, A.H. , Fulton, R.L., Frank, B., McMurray, J.J.V. and Lees, K.R. (2015) Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. European Journal of Neurology, 22(1), pp. 163-169. (doi: 10.1111/ene.12548) (PMID:25370204)
Kristensen, S. L. L. et al. (2015) International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation, 131(1), pp. 43-53. (doi: 10.1161/CIRCULATIONAHA.114.012284)
Packer, M. et al. (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 131(1), pp. 54-61. (doi: 10.1161/circulationaha.114.013748) (PMID:25403646) (PMCID:25403646)
Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi: 10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)
Tang, W.H. W. et al. (2015) Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC: Heart Failure, 3(1), pp. 40-9. (doi: 10.1016/j.jchf.2014.06.014) (PMID:25453534)
Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Wienhues-Thelen, U.-H., Block, D., Zaugg, C. and Gullestad, L. (2015) Predictive value of endostatin in chronic heart failure patients with poor kidney function. Cardiology, 130(1), pp. 17-22. (doi: 10.1159/000368220) (PMID:25428583)
Abdul-Rahim, A. H. et al. (2015) Response to Letter Regarding Article, “Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.”. Circulation, 132(22), e358. (doi: 10.1161/CIRCULATIONAHA.115.018395) (PMID:26621661)
Abualnaja, S., Podder, M., Hernandez, A. F., McMurray, J. J. V. , Starling, R. C., O'Connor, C. M., Califf, R. M., Armstrong, P. W. and Ezekowitz, J. A. (2015) Acute heart failure and atrial fibrillation: insights from the acute study of clinical effectiveness of nesiritide in decompensated heart failure (ASCEND‐HF) trial. Journal of the American Heart Association, 4(8), e002092. (doi: 10.1161/JAHA.115.002092) (PMID:26304935) (PMCID:PMC4599466)
Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina. Circulation: Heart Failure, 8(4), pp. 717-724. (doi: 10.1161/CIRCHEARTFAILURE.114.002024) (PMID:26067854)
Cannon, J. A., McMurray, J. J.V. and Quinn, T. J. (2015) ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure. Alzheimer's Research and Therapy, 7, 22. (doi: 10.1186/s13195-015-0106-5) (PMID:25722749) (PMCID:PMC4342092)
Carson, P. E. et al. (2015) The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC: Heart Failure, 3(6), pp. 429-441. (doi: 10.1016/j.jchf.2014.12.017) (PMID:25982110)
Jackson, C. E. et al. (2015) Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 36(18), pp. 1106-14. (doi: 10.1093/eurheartj/ehu490) (PMID:25616644)
Lam, C. S. P. et al. (2015) Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the valsartan in acute myocardial infarction trial (VALIANT). European Journal of Heart Failure, 17(3), pp. 301-312. (doi: 10.1002/ejhf.238) (PMID:25655011)
Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi: 10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)
McMurray, J. , Zhu, L., McKillop, I. and Chen, H. (2015) Modelling system level health information exchange: an ontological approach. Studies in Health Technology and Informatics, 208, pp. 269-274. (PMID:25676986)
McMurray, J. (2015) Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC: Cardiovascular Imaging, 8(6), pp. 656-665. (doi: 10.1016/j.jcmg.2015.02.014) (PMID:25981507)
McMurray, J. J.V. (2015) Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure, 17(3), pp. 242-7. (doi: 10.1002/ejhf.250) (PMID:25756942)
Roberts, E., Ludman, A. J., Dworzynski, K., Al-Mohammad, A., Cowie, M. R., McMurray, J. J. V. and Mant, J. (2015) The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. British Medical Journal, 350, h910. (doi: 10.1136/bmj.h910) (PMID:25740799) (PMCID:PMC4353288)
Voors, A. A. et al. (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 17(5), pp. 510-517. (doi: 10.1002/ejhf.232) (PMID:25657064)
Badar, A. A. et al. (2014) Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 35(48), pp. 3426-3433. (doi: 10.1093/eurheartj/ehu342)
Damman, K., Tang, W. H. W., Testani, J. M. and McMurray, J. J. V. (2014) Terminology and definition of changes renal function in heart failure. European Heart Journal, 35(48), pp. 3413-3416. (doi: 10.1093/eurheartj/ehu320) (PMID:25157110)
Das, D., Bakal, J. A., Westerhout, C. M., Hernandez, A. F., O'Connor, C. M., Atar, D., McMurray, J. J.V. , Armstrong, P. W. and Ezekowitz, J. A. (2014) The association between meteorological events and acute heart failure: new insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 819-824. (doi: 10.1016/j.ijcard.2014.11.066) (PMID:25465826)
van Diepen, S. et al. (2014) Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 840-846. (doi: 10.1016/j.ijcard.2014.11.007) (PMID:25465830)
McMurray, J. J.V. , Packer, M. and Solomon, S. D. (2014) Neprilysin inhibition for heart failure. New England Journal of Medicine, 371(24), pp. 2336-2337. (doi: 10.1056/NEJMc1412654) (PMID:25494275)
Campbell, R. T., McKean, A. R. and McMurray, J. J.V. (2014) Acute heart failure: have we got it all wrong? European Journal of Heart Failure, 16(12), pp. 1263-1267. (doi: 10.1002/ejhf.197)
Chin, M. P. et al. (2014) Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Journal of Cardiac Failure, 20(12), pp. 953-958. (doi: 10.1016/j.cardfail.2014.10.001) (PMID:25307295)
Cotter, G. et al. (2014) Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure, 16(12), pp. 1362-1371. (doi: 10.1002/ejhf.186) (PMID:25371147)
McMurray, J. J.V. and van Veldhuisen, D. J. (2014) β blockers, atrial fibrillation, and heart failure. Lancet, 384(9961), pp. 2181-2183. (doi: 10.1016/S0140-6736(14)62340-0) (PMID:25625384)
Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi: 10.1111/dom.12320) (PMID:24861892)
Cannon, J. A. and McMurray, J. J.V. (2014) Gut feelings about heart failure. Journal of the American College of Cardiology, 64(18), pp. 1915-1916. (doi: 10.1016/j.jacc.2014.04.088)
Adabag, S., Rector, T. S., Anand, I. S., McMurray, J. J. , Zile, M., Komajda, M., McKelvie, R. S., Massie, B. and Carson, P. E. (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 16(11), pp. 1175-1182. (doi: 10.1002/ejhf.172)
Desai, A. S. et al. (2014) Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure, 7(6), pp. 895-902. (doi: 10.1161/CIRCHEARTFAILURE.114.001567)
Lee, D., Wilson, K., Akehurst, R., Cowie, M.R., Zannad, F., Krum, H., van Veldhuisen, D.J., Vincent, J., Pitt, B. and McMurray, J.J.V. (2014) Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 100(21), pp. 1681-1687. (doi: 10.1136/heartjnl-2014-305673) (PMID:24993605) (PMCID:PMC4215293)
Oluleye, O. W., Rector, T. S., Win, S., McMurray, J. J. V. , Zile, M. R., Komajda, M., McKelvie, R. S., Massie, B., Carson, P. E. and Anand, I. S. (2014) History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulation: Heart Failure, 7(6), pp. 960-966. (doi: 10.1161/CIRCHEARTFAILURE.114.001523)
Patel, P. A. et al. (2014) Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circulation: Heart Failure, 7(6), pp. 918-925. (doi: 10.1161/CIRCHEARTFAILURE.113.000872)
Preiss, D. , McMurray, J. J. and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi: 10.1016/s2213-8587(14)70052-x) (PMID:25439459)
de Barros e Silva, P. G.M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Holman, R., Haffner, S., Thomas, L. and Lopes, R. D. (2014) Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. International Journal of Cardiology, 176(3), pp. 1126-1128. (doi: 10.1016/j.ijcard.2014.07.297) (PMID:25220176)
Wong, C.M. et al. (2014) Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 35(39), pp. 2714-2721. (doi: 10.1093/eurheartj/ehu216)
Dworzynski, K., Roberts, E., Ludman, A., Mant, J. and McMurray, J. (2014) Diagnosing and managing acute heart failure in adults: summary of NICE guidance. British Medical Journal, 349, g5695-g5695. (doi: 10.1136/bmj.g5695) (PMID:25296764)
Shah, A. M. et al. (2014) Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? Journal of the American College of Cardiology, 64(14), pp. 1535-1536. (doi: 10.1016/j.jacc.2014.04.084) (PMID:25277624)
McMurray, J. J.V. , Gerstein, H. C., Holman, R. R. and Pfeffer, M. A. (2014) Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology, 2(10), pp. 843-851. (doi: 10.1016/S2213-8587(14)70031-2)
Rahimi, K., Bennett, D., Conrad, N., Williams, T. M., Basu, J., Dwight, J., Woodward, M., Patel, A., McMurray, J. and MacMahon, S. (2014) Risk prediction in patients with heart failure. JACC: Heart Failure, 2(5), pp. 440-446. (doi: 10.1016/j.jchf.2014.04.008) (PMID:25194291)
Santos, A. B.S. et al. (2014) Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(10), pp. 1096-1103. (doi: 10.1002/ejhf.147) (PMID:25138249)
Damman, K., Perez, A. C., Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Massie, B., Carson, P. E. and McMurray, J. J.V. (2014) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology, 64(11), pp. 1106-1113. (doi: 10.1016/j.jacc.2014.01.087)
Jessup, M., Fox, K. A.A., Komajda, M., McMurray, J. J.V. and Packer, M. (2014) PARADIGM-HF — The experts' discussion. New England Journal of Medicine, 371(11), e15. (doi: 10.1056/NEJMp1410203) (PMID:25184757)
McMurray, J. J.V. et al. (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), pp. 993-1004. (doi: 10.1056/NEJMoa1409077) (PMID:25176015)
van Deursen, V.M. et al. (2014) Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the acute study of clinical effectiveness of nesiritide and decompensated heart failure (ASCEND-HF). Circulation, 130(12), pp. 958-965. (doi: 10.1161/CIRCULATIONAHA.113.003046) (PMID:25074507)
Callender, T. et al. (2014) Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Medicine, 11(8), e1001699. (doi: 10.1371/journal.pmed.1001699) (PMID:25117081) (PMCID:PMC4130667)
Jennings, C. G. et al. (2014) Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 44(1), pp. 25-30. (doi: 10.1016/j.semarthrit.2014.01.004)
Padwal, R. et al. (2014) The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 38(8), pp. 1110-1114. (doi: 10.1038/ijo.2013.203) (PMID:24173404)
Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V. , Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A. and Solomon, S. D. (2014) Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 7(4), pp. 590-595. (doi: 10.1161/CIRCHEARTFAILURE.113.001281)
Böhm, M. et al. (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure, 16(7), pp. 778-787. (doi: 10.1002/ejhf.85)
Campbell, R. T. and McMurray, J. J.V. (2014) Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Failure Clinics, 10(3), pp. 481-501. (doi: 10.1016/j.hfc.2014.04.009)
Holman, R. R. et al. (2014) Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 168(1), 23-29.e2. (doi: 10.1016/j.ahj.2014.03.021)
McMurray, J. J.V. et al. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 16(7), pp. 817-825. (doi: 10.1002/ejhf.115) (PMID:24828035) (PMCID:PMC4312884)
Jhund, P. S. et al. (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. European Journal of Heart Failure, 16(6), pp. 671-677. (doi: 10.1002/ejhf.76)
Rogers, J. K. et al. (2014) Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(3), pp. 289-297. (doi: 10.1016/j.jchf.2013.12.007)
Gori, M. et al. (2014) Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(5), pp. 535-542. (doi: 10.1002/ejhf.67) (PMID:24574260)
Kalogeropoulos, A. P. et al. (2014) High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 20(5), pp. 319-326. (doi: 10.1016/j.cardfail.2014.02.002) (PMID:24530944)
Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved’ [Eur J Heart Fail2014;16:33-40]. European Journal of Heart Failure, 16(5), p. 592. (doi: 10.1002/ejhf.86)
Sliwa, K. et al. (2014) EURObservational research programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure, 16(5), pp. 583-591. (doi: 10.1002/ejhf.68)
Bello, N. A. et al. (2014) Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2(1), e000011. (doi: 10.1136/bmjdrc-2013-000011) (PMID:25452859) (PMCID:PMC4212578)
Butler, J. et al. (2014) Developing therapies for heart failure with preserved ejection fraction. JACC: Heart Failure, 2(2), pp. 97-112. (doi: 10.1016/j.jchf.2013.10.006) (PMID:24720916) (PMCID:PMC4028447)
Huffman, K. M. et al. (2014) Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. Metabolism, 63(4), pp. 554-561. (doi: 10.1016/j.metabol.2014.01.002) (PMID:24559843) (PMCID:PMC4103164)
McMurray, J. J.V. and O'Connor, C. (2014) Lessons from the TOPCAT trial. New England Journal of Medicine, 370(15), pp. 1453-1454. (doi: 10.1056/NEJMe1401231) (PMID:24716685)
Perez-Moreno, A. C. et al. (2014) Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(2), pp. 187-197. (doi: 10.1016/j.jchf.2014.01.001) (PMID:24720928)
Damman, K., Tang, W.H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H. and McMurray, J. J.V. (2014) Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency. Journal of the American College of Cardiology, 63(9), pp. 853-871. (doi: 10.1016/j.jacc.2013.11.031) (PMID:24334210)
Doughty, R. N. et al. (2014) A meta-analysis of echocardiographic measurements of the left heart for the development of normative reference ranges in a large international cohort: the EchoNoRMAL study. European Heart Journal: Cardiovascular Imaging, 15(3), pp. 341-348. (doi: 10.1093/ehjci/jet240) (PMID:24247924)
Moukarbel, G. V., Yu, Z.-F., Dickstein, K., Hou, Y. R., Wittes, J. T., McMurray, J. J.V. , Pitt, B., Zannad, F., Pfeffer, M. A. and Solomon, S. D. (2014) The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure, 16(3), pp. 289-299. (doi: 10.1002/ejhf.11) (PMID:24464979)
Yates, T. et al. (2014) Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet, 383(9922), pp. 1059-1066. (doi: 10.1016/s0140-6736(13)62061-9) (PMID:24361242)
Hijazi, Z. et al. (2014) High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation, 129(6), pp. 625-634. (doi: 10.1161/CIRCULATIONAHA.113.006286) (PMID:24226808)
Kraigher-Krainer, E. et al. (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 63(5), pp. 447-456. (doi: 10.1016/j.jacc.2013.09.052) (PMID:24184245)
Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)
Dalzell, J. R., Seed, A., Berry, C. , Whelan, C. J., Petrie, M. C. , Padmanabhan, N., Clarke, A., Biggerstaff, F., Hillier, C. and McMurray, J. J.V. (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovascular Therapeutics, 32(1), pp. 13-18. (doi: 10.1111/1755-5922.12053) (PMID:24138103)
Perez, A. C., Jhund, P. S. , Stott, D. J. , Gullestad, L., Cleland, J. G.F. , van Veldhuisen, D. J., Wikstrand, J., Kjekshus, J. and McMurray, J. J.V. (2014) Thyroid-stimulating hormone and clinical outcomes. JACC: Heart Failure, 2(1), pp. 35-40. (doi: 10.1016/j.jchf.2013.07.008)
Wikstrand, J., Wedel, H., Castagno, D. and McMurray, J.J.V. (2014) The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. Journal of Internal Medicine, 275(2), pp. 134-143. (doi: 10.1111/joim.12141) (PMID:24118421)
Alexander, J. H. et al. (2014) Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 35(4), pp. 224-232. (doi: 10.1093/eurheartj/eht445) (PMID:24144788)
Damman, K. and McMurray, J. J.V. (2014) Why and when should we worry about worsening renal function? European Journal of Heart Failure, 16(1), pp. 4-5. (doi: 10.1111/ejhf.17) (PMID:24453094)
Gravning, J., Askevold, E.T., Nymo, S.H., Ueland, T., Wikstrand, J., McMurray, J.J.V. , Aukrust, P., Gullestad, L. and Kjekshus, J. (2014) Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation: Heart Failure, 7(1), pp. 96-103. (doi: 10.1161/CIRCHEARTFAILURE.113.000450) (PMID:24284025)
Hijazi, Z. et al. (2014) High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. Journal of the American College of Cardiology, 63(1), pp. 52-61. (doi: 10.1016/j.jacc.2013.07.093) (PMID:24055845)
Jackson, C. E., Myles, R. C. and McMurray, J. J.V. (2014) Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 16(1), p. 113. (doi: 10.1111/ejhf.45) (PMID:24453101)
Nymo, S. H., Hulthe, J., Ueland, T., McMurray, J. , Wikstrand, J., Askevold, E. T., Yndestad, A., Gullestad, L. and Aukrust, P. (2014) Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome: results from CORONA. European Journal of Heart Failure, 16(1), pp. 68-75. (doi: 10.1093/eurjhf/hft125) (PMID:23918775)
Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. European Journal of Heart Failure, 16(1), pp. 33-40. (doi: 10.1002/ejhf.29) (PMID:24453096)
Calvo, G. et al. (2014) Large streamlined trials in cardiovascular disease. European Heart Journal, 35(9), pp. 544-548. (doi: 10.1093/eurheartj/eht535)
Clark, B., DuChane, J., Hou, J., Rubenstein, E., McMurray, J. and Duncan, I. (2014) Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. Journal of Managed Care Pharmacy, 20(2), pp. 141-150. (PMID:24456315)
Eschalier, R. et al. (2014) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function. analyses of the emphasis-hf study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). Rational Pharmacotherapy in Cardiology, 10(1), pp. 106-115. (doi: 10.20996/1819-6446-2014-10-1-106-115)
Gori, M. et al. (2014) Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 35(48), pp. 3442-3451. (doi: 10.1093/eurheartj/ehu254) (PMID:24980489)
Hood, Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R. and McMurray, J. J. (2014) Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews, 2014(4), CD002901. (doi: 10.1002/14651858.CD002901.pub3)
Jhund, P.S. et al. (2014) Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor lcz696. Circulation: Heart Failure, 7(6), pp. 953-959. (doi: 10.1161/CIRCHEARTFAILURE.114.001427)
Kraigher-Krainer, E. et al. (2014) Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456)). Journal of the American College of Cardiology, 64(3), p. 335. (doi: 10.1016/j.jacc.2014.06.011)
MacDonald, T. M. et al. (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 4(7), e005354. (doi: 10.1136/bmjopen-2014-005354)
McMurray, J. et al. (2014) A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 36(7), pp. 434-439. (doi: 10.1093/eurheartj/ehu455) (PMID:25416329) (PMCID:PMC4328198)
Rossignol, P. et al. (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Circulation: Heart Failure, 7(1), pp. 51-58. (doi: 10.1161/CIRCHEARTFAILURE.113.000792) (PMID:24297687)
Santos, A.B.S. et al. (2014) Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 35(1), pp. 42-47. (doi: 10.1093/eurheartj/eht427) (PMID:24164863)
Wallentin, L. et al. (2014) Response to letter regarding article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". Circulation, 129(2), e21-e22. (doi: 10.1161/CIRCULATIONAHA.113.005709)
de Zeeuw, D. et al. (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine, 369(26), pp. 2492-2503. (doi: 10.1056/NEJMoa1306033) (PMID:24206459)
Krum, H., Massie, B., Abraham, W. T., Dickstein, K., Kober, L. and McMurray, J. J.V. (2013) Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. European Journal of Heart Failure, 15(11), pp. 1205-1207. (doi: 10.1093/eurjhf/hft133) (PMID:23989432)
Lambers Heerspink, H.J. et al. (2013) Baseline characteristics in the bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation, 28(11), pp. 2841-2850. (doi: 10.1093/ndt/gft445) (PMID:24169612)
Latini, R. et al. (2013) Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors: a post hoc analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. American Heart Journal, 166(5), 935-940.e1. (doi: 10.1016/j.ahj.2013.08.012) (PMID:24176451)
Wong, C.M. et al. (2013) Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme. Journal of the American College of Cardiology, 62(20), pp. 1845-1854. (doi: 10.1016/j.jacc.2013.05.072)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Journal of the American College of Cardiology, 62(16), pp. 1495-1539. (doi: 10.1016/j.jacc.2013.05.020) (PMID:23741057)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), e147-e239. (doi: 10.1016/j.jacc.2013.05.019) (PMID:23747642)
Dahl, C. P., Aukrust, P., Nymo, S. H., Kjekshus, J., Cleland, J. G.F., McMurray, J. J.V. , Wikstrand, J., Gullestad, L. and Ueland, T. (2013) Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. International Journal of Cardiology, 168(4), pp. 4427-4429. (doi: 10.1016/j.ijcard.2013.05.008) (PMID:23714594)
Eschalier, R. et al. (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survIval study in heart failure). Journal of the American College of Cardiology, 62(17), pp. 1585-1593. (doi: 10.1016/j.jacc.2013.04.086) (PMID:23810881)
Zannad, F. et al. (2013) Clinical outcome endpoints in heart failure trials: a European society of cardiology heart failure association consensus document. European Journal of Heart Failure, 15(10), pp. 1082-1094. (doi: 10.1093/eurjhf/hft095)
Inglis, S.C. et al. (2013) Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology, 168(2), pp. 1094-1101. (doi: 10.1016/j.ijcard.2012.11.033)
Collier, T. J., Pocock, S. J., McMurray, J.J.V. , Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2013) The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal, 34(36), pp. 2823-2829. (doi: 10.1093/eurheartj/eht247) (PMID:23864130)
Ball, J., Carrington, M.J., McMurray, J.J.V. and Stewart, S. (2013) Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. International Journal of Cardiology, 167(5), pp. 1807-1824. (doi: 10.1016/j.ijcard.2012.12.093)
McMurray, J.J.V. et al. (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 15(9), pp. 1062-1073. (doi: 10.1093/eurjhf/hft052)
Mentz, R. J. et al. (2013) The past, present and future of renin–angiotensin aldosterone system inhibition. International Journal of Cardiology, 167(5), pp. 1677-1687. (doi: 10.1016/j.ijcard.2012.10.007) (PMID:23121914) (PMCID:PMC4145865)
Seferović, P. M. et al. (2013) Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 15(9), pp. 947-959. (doi: 10.1093/eurjhf/hft092) (PMID:23787723)
McMurray, J. J.V. and Jhund, P. S. (2013) Cardiovascular risks with azithromycin. New England Journal of Medicine, 369(6), pp. 579-580. (doi: 10.1056/NEJMc1306999)
Swedberg, K., McMurray, J. J.V. and Young, J. B. (2013) Darbepoetin alfa in systolic heart failure. New England Journal of Medicine, 369(5), pp. 487-489. (doi: 10.1056/NEJMc1306321) (PMID:23902504)
Bourge, R. C. et al. (2013) Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. American Journal of Medicine, 126(8), pp. 701-708. (doi: 10.1016/j.amjmed.2013.02.001) (PMID:23490060) (PMCID:PMC3926199)
Lopes, R. D. et al. (2013) Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. American Heart Journal, 166(2), 208-216.e28. (doi: 10.1016/j.ahj.2013.05.005) (PMID:23895802)
Mahaffey, K. W. et al. (2013) Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal, 166(2), 240-249.e1. (doi: 10.1016/j.ahj.2013.05.004) (PMID:23895806)
Bethel, M. A. et al. (2013) A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. American Journal of Cardiology, 112(2), pp. 231-237. (doi: 10.1016/j.amjcard.2013.03.019) (PMID:23608615)
Eapen, Z.J. et al. (2013) Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: findings from ASCEND-HF. Circulation: Heart Failure, 6(4), pp. 727-732. (doi: 10.1161/circheartfailure.112.000265) (PMID:23770519)
Krum, H., Shi, H., Pitt, B., McMurray, J. , Swedberg, K., van Veldhuisen, D.J., Vincent, J., Pocock, S. and Zannad, F. (2013) Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circulation: Heart Failure, 6(4), pp. 711-718. (doi: 10.1161/circheartfailure.112.000173) (PMID:23625945)
Ueland, T. et al. (2013) CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. European Journal of Heart Failure, 15(7), pp. 747-755. (doi: 10.1093/eurjhf/hft031) (PMID:23487539)
Weir, R. A.P. et al. (2013) Response to letter regarding article, "Galectin-3 and cardiac function in survivors of acute myocardial infarction". Circulation: Heart Failure, 6(4), e58. (doi: 10.1161/CIRCHEARTFAILURE.113.000382)
Verheugt, F.W.A. et al. (2013) Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. European Heart Journal, 34(22), pp. 1621-1629. (doi: 10.1093/eurheartj/eht013)
Hijazi, Z. et al. (2013) N-terminal Pro–B-Type natriuretic peptide for risk assessment in patients with atrial fibrillation. Journal of the American College of Cardiology, 61(22), pp. 2274-2284. (doi: 10.1016/j.jacc.2012.11.082)
Wallentin, L. et al. (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation, 127(22), pp. 2166-2176. (doi: 10.1161/circulationaha.112.142158) (PMID:23640971)
Weir, R. A.P. et al. (2013) Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation: Heart Failure, 6(3), pp. 492-498. (doi: 10.1161/CIRCHEARTFAILURE.112.000146) (PMID:23505301)
Al Suhaim, S.A., Lewsey, J.L. , Jhund, P.S. and McMurray, J.J.V. (2013) 129 prescribing multiple classes of evidence based pharmacotherapy in the community is associated with lower mortality. Heart, 99(Sup 2), A77. (doi: 10.1136/heartjnl-2013-304019.129)
Gheorghiade, M. et al. (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 15(5), pp. 551-559. (doi: 10.1093/eurjhf/hft010) (PMID:23355060) (PMCID:PMC3707428)
Pocock, S.J. et al. (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal, 34(19), pp. 1404-1413. (doi: 10.1093/eurheartj/ehs337)
Campbell, R. T. and McMurray, J. J.V. (2013) Reply: Diagnosis of Heart Failure With Preserved Ejection Fraction: Still a Challenge, Journal of the American College of Cardiology, Volume 61, Issue 16, 23 April 2013, Pages 1748-1749. Journal of the American College of Cardiology, 61(16), p. 1749. (doi: 10.1016/j.jacc.2013.01.012)
de Zeeuw, D. et al. (2013) Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). American Journal of Nephrology, 37(3), pp. 212-222. (doi: 10.1159/000346948) (PMID:23467003)
Perez, A.C., Jhund, P. , Preiss, D. , Kjekshus, J. and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi: 10.1016/j.jacc.2012.12.004)
McMurray, J.J.V. et al. (2013) Corrigendum to: ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012’ [Eur J Heart Fail 2012;14: 803-869]. European Journal of Heart Failure, 15(3), pp. 361-362. (doi: 10.1093/eurjhf/hft016)
McMurray, J.J.V. et al. (2013) Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). European Journal of Heart Failure, 15(3), pp. 334-341. (doi: 10.1093/eurjhf/hfs204)
Swedberg, K. et al. (2013) Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 368(13), pp. 1210-1219. (doi: 10.1056/NEJMoa1214865)
Rienstra, M., Damman, K., Mulder, B. A., Van Gelder, I. C., McMurray, J. J.V. and Van Veldhuisen, D. J. (2013) Beta-blockers and outcome in heart failure and atrial fibrillation. JACC: Heart Failure, 1(1), pp. 21-28. (doi: 10.1016/j.jchf.2012.09.002)
Skali, H. et al. (2013) Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm. American Journal of Kidney Diseases, 61(2), pp. 238-246. (doi: 10.1053/j.ajkd.2012.08.043)
Askevold, E. T. et al. (2013) Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation: Heart Failure, 6(1), pp. 91-98. (doi: 10.1161/circheartfailure.112.972653) (PMID:23230311)
van Veldhuisen, D.J. and McMurray, J.J.V. (2013) Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? European Journal of Heart Failure, 15(1), pp. 5-8. (doi: 10.1093/eurjhf/hfs194)
Inglis, S.C., Lewsey, J.D. , Lowe, G.D.O., Jhund, P. , Gillies, M., Stewart, S., Capewell, S., MacIntyre, K. and McMurray, J.J.V. (2013) Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. International Journal of Cardiology, 167(5), pp. 2149-2155. (doi: 10.1016/j.ijcard.2012.05.099)
Jackson, C.E. et al. (2013) Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 15(11), pp. 1253-1261. (doi: 10.1093/eurjhf/hft085)
Jackson, C.E. et al. (2013) Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. European Journal of Heart Failure, 14(6), pp. 676-677. (doi: 10.1093/eurjhf/hfs050)
Jankowska, E.A. et al. (2013) Iron status in patients with chronic heart failure. European Heart Journal, 34(11), pp. 827-834. (doi: 10.1093/eurheartj/ehs377)
MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2013) Letter by MacDonald et al regarding article, "catheter ablation of atrial fibrillation". Circulation, 127(4), e433-e433. (doi: 10.1161/CIRCULATIONAHA.112.137604)
McMurray, J.J.V. et al. (2013) Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation: Heart Failure, 6(3), pp. 451-460. (doi: 10.1161/CIRCHEARTFAILURE.112.000143)
Parving, H.H., Brenner, B.M. and McMurray, J.J. (2013) Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Annals of Internal Medicine, 158(6), JC7. (doi: 10.7326/0003-4819-158-6-201303190-02007)
Pfeffer, M. A., Brenner, B. M. and McMurray, J. J.V. (2013) The author's reply - Aliskirenin Type 2 diabetes and cardiorenal end points. New England Journal of Medicine, 368(11), pp. 1064-1066. (doi: 10.1056/NEJMc1300257)
Poppe, K.K. et al. (2013) Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. European Journal of Heart Failure, 15(11), pp. 1220-1227. (doi: 10.1093/eurjhf/hft101)
Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi: 10.1161/STROKEAHA.113.001177)
Shen, L. et al. (2013) Role of diuretics, blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. British Medical Journal, 2013(347), f6745. (doi: 10.1136/bmj.f6745) (PMID:24322398) (PMCID:PMC3898638)
Wong, Y. W. et al. (2013) Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the nateglinide and valsartan in Impaired Glucose Tolerance Outcomes Research study. Circulation: Heart Failure, 6(2), pp. 203-210. (doi: 10.1161/circheartfailure.112.000086) (PMID:23388113)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), e240-e327. (doi: 10.1161/CIR.0b013e31829e8776) (PMID:23741058)
Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), pp. 1810-1852. (doi: 10.1161/CIR.0b013e31829e8807) (PMID:23741057)
Yancy, C.W. and McMurray, J.J.V. (2013) ECG — still the best for selecting patients for CRT. New England Journal of Medicine, 369, pp. 1463-1464. (doi: 10.1056/NEJMe1310406)
Campbell, R.T., Jhund, P.S. , Castagno, D., Hawkins, N.M., Petrie, M.C. and McMurray, J.J.V. (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? Journal of the American College of Cardiology, 60(23), pp. 2349-2356. (doi: 10.1016/j.jacc.2012.04.064)
Parving, H.-H. et al. (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), pp. 2204-2213. (doi: 10.1056/NEJMoa1208799) (PMID:23121378)
Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S.H., Hulthe, J., Muntendam, P., McMurray, J.J.V. , Wikstrand, J. and Aukrust, P. (2012) The predictive value of galectin-3 for mortality and cardiovascular events in the controlled rosuvastatin multinational trial in heart failure (CORONA). American Heart Journal, 164(6), pp. 878-883. (doi: 10.1016/j.ahj.2012.08.021)
Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi: 10.1136/bmjopen-2012-001925)
Schwartz, G.G. et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine, 367(22), pp. 2089-2099. (doi: 10.1056/NEJMoa1206797)
McMurray, J., J. et al. (2012) Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012'[Eur Heart J 2012;33:1787-1847, doi:10.1093/eurheartj/ehs104. European Heart Journal, 34(2), p. 158. (doi: 10.1093/eurheartj/ehs370)
Felker, G.M. et al. (2012) Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Failure, 14(11), pp. 1257-1264. (doi: 10.1093/eurjhf/hfs110)
Lopes, R.D. et al. (2012) Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, 380(9855), pp. 1749-1758. (doi: 10.1016/S0140-6736(12)60986-6)
Pettit, S.J., Jhund, P.S. , Hawkins, N.M., Gardner, R.S., Haj-Yahia, S., McMurray, J.J.V. and Petrie, M.C. (2012) How small is too small? A systematic review of center volume and outcome after cardiac transplantation. Circulation: Cardiovascular Quality and Outcomes, 5(6), pp. 783-790. (doi: 10.1161/CIRCOUTCOMES.112.966630)
McMurray, J.J.V. , Haffner, S.M., Califf, R.M. and Holman, R.R. (2012) Prediabetes and the risk of diabetes. Lancet, 380(9849), pp. 1225-1226. (doi: 10.1016/S0140-6736(12)61706-1)
McMurray, J.J. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 = Akut ve Kronik Kalp Yetersizligi Tani ve Tedavisine Yönelik 2012 ESC Kilavuzu. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 40(1), pp. 77-137. (PMID:27305718)
Weir, R. A.P., Miller, A. M., Petrie, C. J., Clements, S., Steedman, T., Dargie, H. J., Squire, I. B., Ng, L. L., McInnes, I. B. and McMurray, J. J.V. (2012) Interleukin-21 – a biomarker of importance in predicting myocardial function following acute infarction? Cytokine, 60(1), pp. 220-225. (doi: 10.1016/j.cyto.2012.06.002) (PMID:22748465)
McMurray, J.J.V. , Califf, R.M., Bethel, A.M., Haffner, S.M. and Holman, R.R. (2012) Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. Journal of Clinical Hypertension, 14(10), p. 731. (doi: 10.1111/j.1751-7176.2012.00687.x)
McMurray, J. J.V. et al. (2012) Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012 = ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Revista Española de Cardiología, 65(10), 938.e1-938.e59. (doi: 10.1016/j.recesp.2012.08.003)
Seed, A., Kuc, R.E., Maguire, J.J., Hillier, C., Johnston, F., Essers, H., de Voogd, H.J., McMurray, J.J.V. and Davenport, A.P. (2012) The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sciences, 91(13-14), pp. 743-748. (doi: 10.1016/j.lfs.2012.03.022)
Solomon, S.D. et al. (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 380(9851), pp. 1387-1395. (doi: 10.1016/S0140-6736(12)61227-6)
McMurray, J.J.V. et al. (2012) Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements, 2(4), 279-335-279-335. (doi: 10.1038/kisup.2012.37)
McMurray, J. J.V. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 14(8), pp. 803-869. (doi: 10.1093/eurjhf/hfs105)
Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi: 10.1001/jama.2012.8439)
Lip, G. Y.H. et al. (2012) Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 14(7), pp. 681-695. (doi: 10.1093/eurjhf/hfs073) (PMID:22611046)
McMurray, J.J.V. et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology: developed in collaboration with the heart failure association (HFA) of the ESC. European Heart Journal, 33(14), pp. 1787-1847. (doi: 10.1093/eurheartj/ehs104) (PMID:22611136)
Castagno, D., Skali, H., Takeuchi, M., Swedberg, K., Yusuf, S., Granger, C. B., Michelson, E. L., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. Journal of the American College of Cardiology, 59(20), pp. 1785-1795. (doi: 10.1016/j.jacc.2011.12.044) (PMID:22575317)
Perk, J. et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 33(13), pp. 1635-1701. (doi: 10.1093/eurheartj/ehs092) (PMID:22555213)
Welsh, P. and McMurray, J.J. (2012) B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia, 55(5), pp. 1240-1243. (doi: 10.1007/s00125-012-2515-3)
Castagno, D., Petrie, M.C. , Claggett, B. and McMurray, J. (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal, 33(9), pp. 1137-1141. (doi: 10.1093/eurheartj/ehs004)
Castagno, D., Baird-Gunning, J., Jhund, P. , Zoccai, G. B., MacDonald, M. R., Petrie, M. , Gaita, F. and McMurray, J. (2012) Reply to the letter by Dr Erqou regarding "Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients". American Heart Journal, 163(5), e37. (doi: 10.1016/j.ahj.2012.02.022)
Martínez-Sellés, M. et al. (2012) Gender and survival in patients with heart failure: interactions with diabetes and aetiology: results from the MAGGIC individual patient meta-analysis. European Journal of Heart Failure, 14(5), pp. 473-479. (doi: 10.1093/eurjhf/hfs026) (PMID:22402958)
Meris, A. et al. (2012) Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. Journal of the American Society of Echocardiography, 25(5), pp. 535-542. (doi: 10.1016/j.echo.2012.01.006) (PMID:22305962) (PMCID:PMC3501447)
Nymo, S.H. et al. (2012) The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. Journal of Internal Medicine, 271(5), pp. 436-443. (doi: 10.1111/j.1365-2796.2011.02503.x) (PMID:22211640)
Swedberg, K., Zannad, F., McMurray, J. J.V. , Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study. Journal of the American College of Cardiology, 59(18), pp. 1598-1603. (doi: 10.1016/j.jacc.2011.11.063) (PMID:22538330)
Ezekowitz, J.A., Hernandez, A.F., O'Connor, C.M., Starling, R.C., Proulx, G., Weiss, M.H., Bakal, J.A., Califf, R.M., McMurray, J.J.V. and Armstrong, P.W. (2012) Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. Journal of the American College of Cardiology, 59(16), pp. 1441-1448. (doi: 10.1016/j.jacc.2011.11.061)
MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2012) Catheter ablation for atrial fibrillation. New England Journal of Medicine, 366(11), p. 1060.
Broch, K. et al. (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 14(3), pp. 268-277. (doi: 10.1093/eurjhf/hfs006) (PMID:22302661)
Lowrie, R., Mair, F.S. , Greenlaw, N. , Forsyth, P., Jhund, P.S. , McConnachie, A. , Rae, B. and McMurray, J.J.V. (2012) Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. European Heart Journal, 33(3), pp. 314-324. (doi: 10.1093/eurheartj/ehr433)
McMurray, J.J.V. (2012) Heart failure in 2011: heart failure therapy — technology to the fore. Nature Reviews Cardiology, 9(2), pp. 73-74. (doi: 10.1038/nrcardio.2011.212)
Anker, S.D. and McMurray, J.J.V. (2012) Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? European Heart Journal, 33(22), pp. 2764-2765. (doi: 10.1093/eurheartj/ehs277)
Gullestad, L. et al. (2012) Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 33(18), pp. 2290-2296. (doi: 10.1093/eurheartj/ehs077) (PMID:22513778)
Hawkins, N.M., Jhund, P.S. , McMurray, J.J.M. and Capewell, S. (2012) Heart failure and socioeconomic status: accumulating evidence of inequality. European Journal of Heart Failure, 14(2), pp. 138-146. (doi: 10.1093/eurjhf/hfr168)
Jackson, C.E., Myles, R.C. , Cobbe, S.M., Petrie, M.C. and McMurray, J.J.V. (2012) Microvolt T-wave alternans testing has no role at present in guiding therapy for patients at high risk of ventricular arrhythmias. Journal of the American College of Cardiology, 59(9), p. 856. (doi: 10.1016/j.jacc.2011.10.897)
Jackson, C.E. et al. (2012) Microvolt T-wave alternans (MTWA) testing in 'real world' heart failure (HF): a study of prevalence and incremental prognostic value. Heart, 2012(98), A12. (doi: 10.1136/heartjnl-2012-301877b.17)
Jackson, C.E. et al. (2012) Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 14(6), p. 678. (doi: 10.1093/eurjhf/hfs077)
Jackson, C.E. et al. (2012) Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. European Journal of Heart Failure, 14(4), pp. 377-386. (doi: 10.1093/eurjhf/hfs010)
Lam, C. S. P. et al. (2012) Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation: Heart Failure, 5(5), pp. 571-578. (doi: 10.1161/CIRCHEARTFAILURE.112.970061)
McMurray, J.J.V. (2012) Heart failure in 2011: heart failure therapy—technology to the fore. Nature Reviews Cardiology, 9(2), pp. 73-74. (doi: 10.1038/nrcardio.2011.212)
McMurray, J.J.V. , Abraham, W.T., Dickstein, K., Kober, L., Massie, B.M. and Krum, H. (2012) Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. European Journal of Heart Failure, 14(4), pp. 341-343. (doi: 10.1093/eurjhf/hfs033)
McMurray, J.J.V. et al. (2012) Wytyczne ESC dotycza̧ce rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca na 2012 rok. Kardiologia Polska, 70(S2), pp. 101-175.
Parving, H.-H. et al. (2012) Baseline characteristics in the Aliskiren Trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). Journal of the Renin-Angiotensin-Aldosterone System, 13(3), pp. 387-393. (doi: 10.1177/1470320311434818)
Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi: 10.1093/eurjhf/hfs067)
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J. and McMurray, J.J.V. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine, 9(9), e1001310. (doi: 10.1371/journal.pmed.1001310) (PMID:23028261) (PMCID:PMC3445446)
Rector, T.S., Carson, P.E., Anand, I.S., McMurray, J.J. , Zile, M.R., McKelvie, R.S., Komajda, M., Kuskowski, M. and Massie, B.M. (2012) Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota living with heart failure questionnaire in the Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial. Circulation: Heart Failure, 5(2), pp. 217-225. (doi: 10.1161/CIRCHEARTFAILURE.111.964221)
Rogers, J.K., McMurray, J.J.V. , Pocock, S.J., Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation, 126(19), pp. 2317-2323. (doi: 10.1161/CIRCULATIONAHA.112.110536)
Shah, A.M. et al. (2012) Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. European Journal of Heart Failure, 14(2), pp. 185-192. (doi: 10.1093/eurjhf/hfr125)
Zannad, F., Gattis Stough, W., McMurray, J.J.V. , Remme, W.J., Pitt, B., Borer, J.S., Geller, N.L. and Pocock, S.J. (2012) When to stop a clinical trial early for benefit: lessons learned and future approaches. Circulation: Heart Failure, 5(2), pp. 294-302. (doi: 10.1161/circheartfailure.111.965707)
Zannad, F. et al. (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 33(22), pp. 2782-2795. (doi: 10.1093/eurheartj/ehs257)
Zannad, F. et al. (2012) Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? European Heart Journal, 33(9), pp. 1049-1057. (doi: 10.1093/eurheartj/ehr437) (PMID:22422830)
Zile, M.R., Baicu, C.F., Gottdiener, J.S., Hetzel, S.J., McMurray, J.J. , Komajda, M., McKelvie, R., Massie, B.M. and Carson, P.E. (2012) Response to letters regarding article, "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction". Circulation, 126(5), e64-e65. (doi: 10.1161/CIRCULATIONAHA.112.110809)
Zile, M.R., Gottdiener, J.S., Hetzel, S.J., McMurray, J.J.V. , Komajda, M., McKelvie, R., Baicu, C.F., Massie, B.M. and Carson, P.E. (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation, 124(23), pp. 2491-2501. (doi: 10.1161/CIRCULATIONAHA.110.011031)
Ariti, C. A., Cleland, J. G.F. , Pocock, S. J., Pfeffer, M. A., Swedberg, K., Granger, C. B., McMurray, J. J.V. , Michelson, E. L., Östergren, J. and Yusuf, S. (2011) Days alive and out of hospital and the patient journey in patients with heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 162(5), pp. 900-906. (doi: 10.1016/j.ahj.2011.08.003) (PMID:22093207)
Desai, A.S. et al. (2011) Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKd. American Journal of Kidney Diseases, 58(5), pp. 717-728. (doi: 10.1053/j.ajkd.2011.05.020)
Anand, I. S. et al. (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation: Heart Failure, 4(5), pp. 569-577. (doi: 10.1161/CIRCHEARTFAILURE.111.962654) (PMID:21715583)
Granger, C.B. et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), pp. 981-992. (doi: 10.1056/NEJMoa1107039)
Tendera, M. et al. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 32(22), pp. 2851-2906. (doi: 10.1093/eurheartj/ehr211) (PMID:21873417)
Cleland, J. G.F. et al. (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, 378(9792), pp. 676-683. (doi: 10.1016/S0140-6736(11)61126-4) (PMID:21856481)
Sidik, N. P., Solomon, S. D., Latini, R., Maggioni, A. P., Wright, M., Gimpelewicz, C. R., Pitt, B. and McMurray, J. J. V. (2011) Effect of aliskiren in patients with heart failure according to background dose of ace inhibitor: a retrospective analysis of the aliskiren observation of heart failure treatment (ALOFT) trial. Cardiovascular Drugs and Therapy, 25(4), pp. 315-321. (doi: 10.1007/s10557-011-6319-3)
McMurray, J. and Ponikowski, P. (2011) Heart failure: not enough pump iron? Journal of the American College of Cardiology, 58(5), pp. 481-482. (doi: 10.1016/j.jacc.2011.02.066)
O'Connor, C.M. et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. New England Journal of Medicine, 365(1), pp. 32-43. (doi: 10.1056/NEJMoa1100171)
Verma, A., Pfeffer, M.A., Skali, H., Rouleau, J., Maggioni, A., McMurray, J.J.V. , Califf, R.M., Velazquez, E.J. and Solomon, S.D. (2011) Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. American Heart Journal, 161(6), pp. 1156-1162. (doi: 10.1016/j.ahj.2011.03.024)
Hawkins, N.M., Petrie, M.C. , MacDonald, M.R., Jhund, P.S. , Fabbri, L.M., Wikstrand, J. and McMurray, J.J.V. (2011) Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists. Journal of the American College of Cardiology, 57(21), pp. 2127-2138. (doi: 10.1016/j.jacc.2011.02.020)
MacDonald, M.R. et al. (2011) Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD) study. Diabetes Care, 34(6), pp. 1394-1396. (doi: 10.2337/dc10-2398)
McMurray, J. J.V. (2011) Low Coenzyme Q(10) Levels and the Outcome of Statin Treatment in Heart Failure Reply. Journal of the American College of Cardiology, 57(14), p. 1569. (doi: 10.1016/j.jacc.2010.12.018)
Piepoli, M. F. et al. (2011) Exercise training in heart failure: from theory to practice: a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Heart Failure, 13(4), pp. 347-357. (doi: 10.1093/eurjhf/hfr017) (PMID:21436360)
Teo, K.K. et al. (2011) Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. The ARB Trialists Collaboration. Journal of Hypertension, 29(4), pp. 623-635. (doi: 10.1097/HJH.0b013e328344a7de)
Macpherson, K.J. et al. (2011) Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 11(1), p. 38. (doi: 10.1186/1471-2377-11-38)
Gheorghiade, M., Pang, P.S., O'Connor, C.M., Prasad, K., McMurray, J. , Teerlink, J.R., Fiuzat, M., Sabbah, H. and Komajda, M. (2011) Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 161(2), pp. 224-232. (doi: 10.1016/j.ahj.2010.10.023)
Horowitz, J. D., Rosenson, R. S., McMurray, J. J.V. , Marx, N. and Remme, W. J. (2011) Clinical Trials Update AHA Congress 2010. Cardiovascular Drugs and Therapy, 25(1), pp. 69-76. (doi: 10.1007/s10557-011-6285-9) (PMID:21340529)
Lewis, E.F. et al. (2011) Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of the American Society of Nephrology, 6(4), pp. 845-855. (doi: 10.2215/CJN.06450710)
Castagno, D., Baird-Gunning, J., Jhund, P.S. , Biondi-Zoccai, G., MacDonald, M.R., Petrie, M.C. , Gaita, F. and McMurray, J.J.V. (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 162(5), 938-948.e2. (doi: 10.1016/j.ahj.2011.07.030)
Dickstein, K., Vardas, P.E., Auricchio, A., Daubert, J.-C., Linde, C., McMurray, J. , Ponikowski, P., Priori, S.G. and Sutton, R. (2011) Focused Update Recommendation European Society of Cardiology instrumentation for use in heart failure therapy, 2010 | Cielená aktualizácia Odporúčaní Európskej kardiologickej spoločnosti pre využitie prístrojovej terapie pri srdcovom zlyhávaní 2010. Cardiology Letters, 20(3), pp. 246-253.
Gallanagh, S. et al. (2011) Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). Cardiovascular Drugs and Therapy, 25(1), pp. 77-85. (doi: 10.1007/s10557-011-6284-x)
Jackson, C.E. et al. (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure, 13(7), pp. 746-754. (doi: 10.1093/eurjhf/hfr031)
Jankowska, E.A. et al. (2011) Erratum: Iron deficiency: an ominous sign in patients with systolic chronic heart failure [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. European Heart Journal, 32(9), p. 1054. (doi: 10.1093/eurheartj/ehr115)
Krum, H. et al. (2011) Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation: Heart Failure, 4(5), pp. 561-568. (doi: 10.1161/CIRCHEARTFAILURE.110.960716)
Lowrie, R. et al. (2011) The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. European Journal of Heart Failure, 13(8), pp. 917-924. (doi: 10.1093/eurjhf/hfr083)
MacDonald, M. R. et al. (2011) Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart, 97(9), pp. 740-747. (doi: 10.1136/hrt.2010.207340)
McMurray, J.J.V. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure, 13(9), pp. 929-936. (doi: 10.1093/eurjhf/hfr093)
McMurray, J.J.V. (2011) Heart failure: Acute ischemic events in HF—should we include sudden death? Nature Reviews Cardiology, 8(4), pp. 192-193. (doi: 10.1038/nrcardio.2011.22)
McMurray, J.J.V. and Smith, G.L. (2011) Calcium handling in the failing heart and SUMO — weighing the eviden. New England Journal of Medicine, (doi: 10.1056/NEJMcibr1110758)
McMurray, J.J.V. et al. (2011) Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal, 162(4), 748-755.e3. (doi: 10.1016/j.ahj.2011.07.016)
Milo-Cotter, O. et al. (2011) Neurohormonal activation in acute heart failure: results from VERITAs. Cardiology, 119(2), pp. 96-105. (doi: 10.1159/000330409)
Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Smith, B.A., Wright, M., Prescott, M.F. and McMurray, J.J.V. (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 13(7), pp. 755-764. (doi: 10.1093/eurjhf/hfr034)
Pouleur, A.-C. et al. (2011) Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both". Circulation, 123(18), e586. (doi: 10.1161/CIRCULATIONAHA.111.021600)
Preiss, D. , Sattar, N. and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi: 10.1016/j.ahj.2010.10.019)
Shah, A.M. et al. (2011) Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal, 162(4), pp. 685-691. (doi: 10.1016/j.ahj.2011.07.015)
Skali, H. et al. (2011) Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with aranesp therapy (TREAT) experience. Circulation, 124(25), pp. 2903-2908. (doi: 10.1161/CIRCULATIONAHA.111.030411)
Solomon, S.D. et al. (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 32(10), pp. 1227-1234. (doi: 10.1093/eurheartj/ehq522) (PMID:21317148)
Thune, J. J. et al. (2011) Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarctio. European Journal of Heart Failure, 13(2), pp. 148-153. (doi: 10.1093/eurjhf/hfq194)
Weir, R.A.P., Clements, S., Steedman, T., Dargie, H.J., McMurray, J.J.V. , Squire, I.B. and Ng, L.L. (2011) Plasma TIMP-4 Predicts Left Ventricular Remodeling After Acute Myocardial Infarction. Journal of Cardiac Failure, 17(6), pp. 465-471. (doi: 10.1016/j.cardfail.2011.02.002)
Weir, R.A.P., Tsorlalis, I.K., Steedman, T., Dargie, H.J., Fraser, R., McMurray, J.J.V. and Connell, J.M.C. (2011) Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. European Journal of Heart Failure, 13(12), pp. 1305-1313. (doi: 10.1093/eurjhf/hfr129)
Ye, S. et al. (2011) Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction: Implications for Prevention. Circulation, 123(23), pp. 2674-2680. (doi: 10.1161/CIRCULATIONAHA.110.990655)
Zannad, F., McMurray, J.J.V. and Swedberg, K. (2011) The authors reply. New England Journal of Medicine, 364(14), pp. 1372-1375. (doi: 10.1056/NEJMc1101504)
Lainscak, M. et al. (2010) Self-care management of heart failure practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 13(2), pp. 115-126. (doi: 10.1093/eurjhf/hfq219)
Dickstein, K. et al. (2010) Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 12(4), p. 416. (doi: 10.1093/eurjhf/hfq025)
Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)
Zile, M. R. et al. (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (i-preserve) trial. Circulation, 121(12), pp. 1393-1405. (doi: 10.1161/circulationaha.109.909614) (PMID:20231531)
Preiss, D. , Sattar, N. and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi: 10.1001/jama.2010.137)
McMurray, J.J. (2010) Systolic heart failure. New England Journal of Medicine, 362(3), pp. 228-238. (doi: 10.1056/NEJMcp0909392)
Weir, R.A.P., Miller, A.M., Murphy, G., Clements, S., Steedman, T., Connell, J., McInnes, I. , Dargie, H. and McMurray, J.J. (2010) Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Journal of the American College of Cardiology, 55(3), pp. 243-250. (doi: 10.1016/j.jacc.2009.08.047) (PMID:20117403)
Hawkins, N.M., Jhund, P.S., Simpson, C.R., Petrie, M.C., MacDonald, M.R., Dunn, F.G., MacIntyre, K. and McMurray, J.J.V. (2010) Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 12(1), pp. 17-24. (doi: 10.1093/eurjhf/hfp160)
Lorgelly, P.K. et al. (2010) An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 12(1), pp. 66-74. (doi: 10.1093/eurjhf/hfp172)
Piccini, J.P., Zhang, M., Pieper, K., Solomon, S.D., Al-Khatib, S.M., Van de Werf, F., Pfeffer, M.A., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2010) Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal, 31(2), pp. 211-221. (doi: 10.1093/eurheartj/ehp425)
Castagno, D. et al. (2010) Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure, 12(6), pp. 607-616. (doi: 10.1093/eurjhf/hfq038)
Chang, S. M. et al. (2010) Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 12(7), pp. 738-745. (doi: 10.1093/eurjhf/hfq065)
Cleland, J.G.F., McMurray, J.J.V. and Kjekshus, J. (2010) Statins and Heart Failure - Reply. Journal of the American College of Cardiology, 55(15), p. 1646. (doi: 10.1016/j.jacc.2010.01.018)
Desai, A., Lewis, E., Solomon, S., McMurray, J. J. V. and Pfeffer, M. (2010) Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. European Journal of Heart Failure, 12(9), pp. 936-942. (doi: 10.1093/eurjhf/hfq094)
Dickstein, K. et al. (2010) Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [Eur Heart J 2008;29:2388-2442]. European Heart Journal, 31(5), p. 624. (doi: 10.1093/eurheartj/ehq027)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy * Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Journal of Heart Failure, 12(11), pp. 1143-1153. (doi: 10.1093/eurjhf/hfq192)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy * Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace, 12(11), pp. 1526-1536. (doi: 10.1093/europace/euq392)
Dickstein, K. et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Heart Journal, 31(21), pp. 2677-2687. (doi: 10.1093/eurheartj/ehq337)
Felker, G. M. et al. (2010) Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward. Circulation: Heart Failure, 3(2), pp. 314-325. (doi: 10.1161/CIRCHEARTFAILURE.109.893222)
Gheorghiade, M. et al. (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 12(5), pp. 423-433. (doi: 10.1093/eurjhf/hfq045)
Hawkins, N. M. et al. (2010) Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 12(6), pp. 557-565. (doi: 10.1093/eurjhf/hfq040)
Hogg, K. J. and McMurray, J. J. V. (2010) HEART FAILURE Hospital-at-home care for CHF-verdict, 'not proven'. Nature Reviews Cardiology, 7(2), pp. 63-64. (doi: 10.1038/nrcardio.2009.225)
Hogg, K.J. and McMurray, J.J.V. (2010) Evaluating dyspnoea in acute heart failure: progress at last! European Heart Journal, 31(7), pp. 771-772. (doi: 10.1093/eurheartj/ehq015)
Holman, R. R. et al. (2010) Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), pp. 1463-1476. (doi: 10.1056/NEJMoa1001122)
Hung, C.L. et al. (2010) Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. Journal of the American College of Cardiology, 56(22), pp. 1812-1822. (doi: 10.1016/j.jacc.2010.06.044)
Inglis, S. C. et al. (2010) Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). European Journal of Heart Failure, 12(7), pp. 698-705. (doi: 10.1093/eurjhf/hfq070)
Jankowska, E. A. et al. (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 31(15), pp. 1872-1880. (doi: 10.1093/eurheartj/ehq158)
Komajda, M., Carson, P. E., Hetzel, S., McKelvie, R., McMurray, J. , Ptaszynska, A., Zile, M. R., DeMets, D. and Massie, B. M. (2010) Factors Associated with Outcome in Heart Failure with Preserved Ejection Fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation: Heart Failure, 4(1), pp. 27-35. (doi: 10.1161/CIRCHEARTFAILURE.109.932996)
Komajda, M., McMurray, J. J. V. , Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P. and Home, P. D. (2010) Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal, 31(7), pp. 824-831. (doi: 10.1093/eurheartj/ehp604)
Krum, H. et al. (2010) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to minimize outcomes in patients with heart failure (ATMOSPHERE)study. European Journal of Heart Failure, 13(1), pp. 107-114. (doi: 10.1093/eurjhf/hfq212)
Krum, H., McMurray, J. J. V. , Horton, E., Gerlock, T., Holzhauer, B., Zuurman, L., Haffner, S. M., Bethel, M. A., Holman, R. R. and Califf, R. M. (2010) Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. Cardiovascular Therapeutics, 28(2), pp. 124-132. (doi: 10.1111/j.1755-5922.2010.00146.x)
Langhorne, P. et al. (2010) Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), pp. 1301-1305. (doi: 10.1136/jnnp.2009.195131)
Lewsey, J. et al. (2010) Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 8, p. 23. (doi: 10.1186/1741-7015-8-23)
Lopes, R. D. et al. (2010) Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 159(3), pp. 331-339. (doi: 10.1016/j.ahj.2009.07.035)
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D. , Bhagra, S., Jhund, P. S. , Petrie, M. C., McMurray, J. J. V. , Petrie, J.R. and McAlister, F. A. (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care, 33(6), pp. 1213-1218. (doi: 10.2337/dc09-2227)
McKelvie, R.S., Komajda, M., McMurray, J. , Zile, M., Ptaszynska, A., Donovan, M., Carson, P. and Massie, B.M. (2010) Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 16(2), pp. 128-134. (doi: 10.1016/j.cardfail.2009.09.007)
McMurray, J. J. et al. (2010) Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 362(16), pp. 1477-1490. (doi: 10.1056/NEJMoa1001121)
McMurray, J. J. V. and Swedberg, K. (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure-lessons learnt from a decade of trials. European Journal of Heart Failure, 12(2), pp. 99-103. (doi: 10.1093/eurjhf/hfp197)
McMurray, J.J.V. , Dunselman, P., Wedel, H., Cleland, J.G.F., Lindberg, M., Hjalmarson, Å., Kjekshus, J., Waagstein, F., Apetrei, E. and Barrios, V. (2010) Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart FailureA Pre-Specified Substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). Journal of the American College of Cardiology, 56(15), pp. 1196-1204. (doi: 10.1016/j.jacc.2010.02.075)
McMurray, J. J.V. et al. (2010) Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial’ [Eur J Heart Fail2009;11:795-801]. European Journal of Heart Failure, 12(7), p. 765. (doi: 10.1093/eurjhf/hfq067)
Nilsson, K. R. et al. (2010) Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart, 96(11), pp. 838-842. (doi: 10.1136/hrt.2009.180182)
Park, J.H. , Balmain, S., Berry, C. , Morton, J.J. and McMurray, J.J.V. (2010) Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart, 96(7), pp. 533-538. (doi: 10.1136/hrt.2009.175257) (PMID:20350990)
Pouleur, A.-C. et al. (2010) Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation, 122(6), pp. 597-602. (doi: 10.1161/CIRCULATIONAHA.110.940619)
Rocchiccioli, J.P., McMurray, J.J.V. and Dominiczak, A.F. (2010) Biomarkers in heart failure: a clinical review. Heart Failure Reviews, 15(4), pp. 251-273. (doi: 10.1007/s10741-008-9123-9)
Shah, A. M. et al. (2010) The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. European Journal of Heart Failure, 12(11), pp. 1229-1237. (doi: 10.1093/eurjhf/hfq179)
Shamshad, F., Kenchaiah, S., Finn, P.V., Soler-Soler, J., McMurray, J.J.V. , Velazquez, E.J., Maggioni, A. P., Califf, R.M., Swedberg, K. and Kober, L. (2010) Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal, 160(1), pp. 145-151. (doi: 10.1016/j.ahj.2010.02.037)
Sliwa, K. et al. (2010) Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy A Proof-of-Concept Pilot Study. Circulation, 121(13), pp. 1465-1473. (doi: 10.1161/CIRCULATIONAHA.109.901496)
Sliwa, K. et al. (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121(13), pp. 1465-1473. (doi: 10.1161/circulationaha.109.901496) (PMID:20308616)
Sliwa, K. et al. (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 12(8), pp. 767-778. (doi: 10.1093/eurjhf/hfq120)
Solomon, S.D. et al. (2010) Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 363(12), pp. 1146-1155. (doi: 10.1056/NEJMoa1005109)
Weir, R. A. P., Murphy, C. A., Petrie, C. J., Martin, T. N., Balmain, S., Clements, S., Steedman, T., Wagner, G. S., Dargie, H. J. and McMurray, J. J. V. (2010) Microvascular Obstruction Remains a Portent of Adverse Remodeling in Optimally Treated Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. Circulation: Cardiovascular Imaging, 3(4), pp. 360-367. (doi: 10.1161/CIRCIMAGING.109.897439)
Weir, R.A.P., Murphy, C.A., Petrie, C.J., Martin, T.N., Clements, S., Steedman, T., Wagner, G.S., McMurray, J.J.V. and Dargie, H.J. (2010) Monocyte chemoattractant protein-1: A dichotomous role in cardiac remodeling following acute myocardial infarction in man? Cytokine, 50(2), pp. 158-162. (doi: 10.1016/j.cyto.2010.02.020)
Zannad, F., McMurray, J.J.V. , Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 12(6), pp. 617-622. (doi: 10.1093/eurjhf/hfq049)
Zannad, F., McMurray, J.J.V. , Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J. and Pitt, B. (2010) Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine, 364(1), pp. 11-21. (doi: 10.1056/NEJMoa1009492)
Zile, M. R. et al. (2010) Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial. Circulation, 121(12), pp. 1393-1405. (doi: 10.1161/CIRCULATIONAHA.109.909614)
Freel, E.M., Tsorlalis, I.K., Lewsey, J.D., Latini, R., Maggioni, A.P., Solomon, S., Pitt, B., Connell, J.M.C. and McMurray, J.J.V. (2009) Aldosterone status associates with insulin resistance in patients with heart failure-data from the ALOFT study. Heart, 95(23), pp. 1920-1924. (doi: 10.1136/hrt.2009.173344)
Schwartz, G.G. et al. (2009) Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 158(6), pp. 896-901. (doi: 10.1016/j.ahj.2009.09.017)
Lewsey, J. et al. (2009) Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2(5), pp. 475-483. (doi: 10.1161/CIRCOUTCOMES.108.825968)
Parving, H.-H., Brenner, B. M., McMurray, J. J.V. , de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N. and Pfeffer, M. A. (2009) Dual renin-angiotensin system blockade and kidney disease. Journal of the American College of Cardiology, 54(3), pp. 278-279. (doi: 10.1016/j.jacc.2009.02.074)
Berry, C. , Pieper, K., White, H., Solomon, S., Van de Werf, F., Velazquez, E., Maggioni, A., Califf, R., Pfeffer, M. and McMurray, J. (2009) Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal, 30(12), pp. 1450-1456. (doi: 10.1093/eurheartj/ehp102)
Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi: 10.2337/dc08-1709) (PMID:19196892)
Lewsey, J.D. et al. (2009) Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke, 40(4), pp. 1038-1043. (doi: 10.1161/STROKEAHA.108.542787)
Dickstein, K. et al. (2009) Linee guida ESC per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico 2008 = Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Giornale Italiano di Cardiologia, 10(3), pp. 141-198.
Jhund, P.S. , MacIntyre, K., Simpson, C.R., Lewsey, J.D., Stewart, S., Redpath, A., Chalmers, J.W.T., Capewell, S. and McMurray, J.J.V. (2009) Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation, 119(4), pp. 515-523. (doi: 10.1161/CIRCULATIONAHA.108.812172)
Abrahamsson, P., Dobson, J., Granger, C.B., McMurray, J.J.V. , Michelson, E.L., Pfeffer, M., Pocock, S., Solomon, S.D., Yusuf, S. and Swedberg, K. (2009) Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. European Heart Journal, 30(3), pp. 338-345. (doi: 10.1093/eurheartj/ehn503)
Hawkins, N. M., Petrie, M. C. , Jhund, P. S. , Chalmers, G. W., Dunn, F. G. and McMurray, J. J.V. (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 11(2), pp. 130-139. (doi: 10.1093/eurjhf/hfn013)
Dickstein, K. et al. (2009) Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 11(1), p. 110. (doi: 10.1093/eurjhf/hfn030)
Allen, L. A., Felker, G. M., Pocock, S., McMurray, J. J.V. , Pfeffer, M. A., Swedberg, K., Wang, D., Yusuf, S., Michelson, E. L. and Granger, C. B. (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 11(2), pp. 170-177. (doi: 10.1093/eurjhf/hfn031)
Califf, R., Lokhnygina, Y., Velazquez, E., McMurray, J. , Leimberger, J., Lewis, E., Diaz, R., Murin, J. and Pfeffer, M. (2009) Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). American Journal of Cardiology, 104(2), pp. 151-157. (doi: 10.1016/j.amjcard.2009.03.020)
Cleland, J. et al. (2009) Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Journal of the American College of Cardiology, 54(20), pp. 1850-1859. (doi: 10.1016/j.jacc.2009.06.041)
Dickstein, K. and McMurray, J. J.V. (2009) Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma? Reply. European Heart Journal, 30(10), pp. 1287-1288. (doi: 10.1093/eurheartj/ehp147)
Gheorghiade, M. et al. (2009) Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 157(6), pp. 957-970. (doi: 10.1016/j.ahj.2009.04.010)
Granger, B. B., Ekman, I., Granger, C. B., Ostergren, J., Olofsson, B., Michelson, E., McMurray, J. J.V. , Yusuf, S., Pfeffer, M. A. and Swedberg, K. (2009) Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure, 11(11), pp. 1092-1098. (doi: 10.1093/eurjhf/hfp142)
Hawkins, N. M., Huang, Z., Pieper, K. S., Solomon, S. D., Kober, L., Velazquez, E. J., Swedberg, K., Pfeffer, M. A., McMurray, J. J.V. and Maggioni, A. P. (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure, 11(3), pp. 292-298. (doi: 10.1093/eurjhf/hfp001)
Hawkins, N.M., MacDonald, M.R., Petrie, M.C., Chalmers, G., Carter, R., Dunn, F.G. and McMurray, J.J. (2009) Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure, 11(7), pp. 684-690. (doi: 10.1093/eurjhf/hfp066)
Hawkins, N., Petrie, M. , Burgess, M. and McMurray, J. (2009) Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. Journal of the American College of Cardiology, 53(21), pp. 1944-1959. (doi: 10.1016/j.jacc.2008.11.062)
Hawkins, N., Petrie, M., Jhund, P. , Chalmers, G., Dunn, F. and McMurray, J. (2009) Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 11(6), pp. 632-633.
Hernandez, A. et al. (2009) Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal, 157(2), pp. 271-277. (doi: 10.1016/j.ahj.2008.07.031)
Heymans, S. et al. (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 11(2), pp. 119-129. (doi: 10.1093/eurjhf/hfn043)
Home, P., Pocock, S., Beck-Nielsen, H., Curtis, P., Gomis, R., Hanefeld, M., Jones, N., Komajda, M. and McMurray, J. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373(9681), pp. 2125-2135. (doi: 10.1016/S0140-6736(09)60953-3)
Hood, W.B., Dans, A., Guyatt, G.H., Jaeschke, R. and McMurray, J.J.V. (2009) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews(2), CD002901. (doi: 10.1002/14651858.CD002901.pub2)
Jaarsma, T. et al. (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 11(5), pp. 433-443. (doi: 10.1093/eurjhf/hfp041)
Jackson, C. et al. (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet, 374(9689), pp. 543-550. (doi: 10.1016/S0140-6736(09)61378-7)
Jackson, C.E., Dalzell, J.R., Bezlyak, V., Tsorlalis, I.K., Myles, R.C., Spooner, R., Ford, I., Petrie, M.C., Cobbe, S. and McMurray, J.J. (2009) Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. European Journal of Heart Failure, 11(12), pp. 1152-1154. (doi: 10.1093/eurjhf/hfp157)
MacDonald, M.R., Petrie, M.C., Fisher, M. and McMurray, J.J.V. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 6(2), pp. 126-132. (doi: 10.1007/s11897-009-0019-3)
McMurray, J.J. et al. (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation, 120(22), 2188-2U51. (doi: 10.1161/CIRCULATIONAHA.109.849117)
McMurray, J.J.V. , Granger, C.B., Ostergren, J., Yusuf, S., Pfeffer, M.A. and Swedberg, K. (2009) Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 54(3), p. 278. (doi: 10.1016/j.jacc.2009.02.073)
McMurray, J. et al. (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure, 11(8), pp. 795-801.
McMurray, J. , Jhund, P. , MacIntyre, K. and Stewart, S. (2009) Heart failure in the UK. Heart, 95(2), p. 156.
Meris, A. et al. (2009) Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. European Heart Journal, 30(1), pp. 56-65. (doi: 10.1093/eurheartj/ehn499)
Moukarbel, G., Signorovitch, J., Pfeffer, M., McMurray, J. , White, H., Maggioni, A., Velazquez, E., Califf, R., Scheiman, J. and Solomon, S. (2009) Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal, 30(18), pp. 2226-2232.
Parving, H. et al. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation, 24(5), pp. 1663-1671.
Pfeffer, M.A. et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine, 361(21), pp. 2019-2032. (doi: 10.1056/NEJMoa0907845)
Pfeffer, M.A. et al. (2009) Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 54(1), pp. 59-69. (doi: 10.1053/j.ajkd.2009.04.008)
Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.
Sochalski, J., Jaarsma, T., Krumholz, H., Laramee, A., McMurray, J. , Naylor, M., Rich, M., Riegel, B. and Stewart, S. (2009) What Works In Chronic Care Management: The Case Of Heart Failure. Health Affairs, 28(1), pp. 179-189. (doi: 10.1377/hlthaff.28.1.179)
Somaratne, J., Berry, C. , McMurray, J. , Poppe, K., Doughty, R. and Whalley, G. (2009) The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. European Journal of Heart Failure, 11(9), pp. 855-862. (doi: 10.1093/eurjhf/hfp103)
Stanton, T., Hawkins, N. M., Hogg, K. J., Goodfield, N. E.R., Petrie, M. C. and McMurray, J. J.V. (2009) Three-dimensional echocardiography for optimization of cardiac resynchronization therapy: reply. European Heart Journal, 30(4), pp. 505-506. (doi: 10.1093/eurheartj/ehp002)
Wedel, H. et al. (2009) Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure, 11(3), pp. 281-291. (doi: 10.1093/eurjhf/hfn046)
Weir, R. A.P., Chong, K. S., Dalzell, J. R., Petrie, C. J., Murphy, C. A., Steedman, T., Mark, P.B. , McDonagh, T. A., Dargie, H. J. and McMurray, J. J.V. (2009) Plasma apelin concentration is depressed following acute myocardial infarction in man. European Journal of Heart Failure, 11(6), pp. 551-558. (doi: 10.1093/eurjhf/hfp043)
Weir, R.A.P., Mark, P.B. , Petrie, C.J., Clements, S., Steedman, T., Ford, I. , Ng, L.L., Squire, I.B., Wagner, G.S. and McMurray, J.J.V. (2009) Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect? American Heart Journal, 157(6), pp. 1088-1096. (doi: 10.1016/j.ahj.2009.04.001)
Weir, R., Martin, T., Petrie, C., Murphy, A., Clements, S., Steedman, T., Wagner, G., McMurray, J. and Dargie, H. (2009) Cardiac and Extracardiac Abnormalities Detected by Cardiac Magnetic Resonance in a Post-Myocardial Infarction Cohort. Cardiology, 113(1), pp. 1-8. (doi: 10.1159/000161233)
Dickstein, K. et al. (2008) Corrigendum to 'ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008' * [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 29(24), p. 3069. (doi: 10.1093/eurheartj/ehn528)
Carson, P. et al. (2008) Health related quality of life in I-PRESERVE trial. Journal of Cardiac Failure, 14(6), S73. (doi: 10.1016/j.cardfail.2008.06.200)
Wynn, G. J., Rammohan, H. S., Stephens, B., Hawkins, N. M., McMurray, J. J.V. and Rodrigues, E. (2008) How many patients with heart failure are suitable for combination ACE inhibitor and candesartan therapy? Journal of Cardiac Failure, 14(6), S114. (doi: 10.1016/j.cardfail.2008.06.397)
, (2008) The editorialst replies [Anesthesia awareness and the bispectral index]. New England Journal of Medicine, 359(4), pp. 427-431. (doi: 10.1056/NEJMc086136)
Anavekar, N.S. et al. (2008) Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO study). American Journal of Cardiology, 101(5), pp. 607-612. (doi: 10.1016/j.amjcard.2007.09.115)
Anavekar, N.S., Solomon, S.D., McMurray, J.J. , Maggioni, A., Rouleau, J.L., Califf, R., White, H., Kober, L., Velazquez, E. and Pfeffer, M.A. (2008) Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. American Journal of Cardiology, 101(7), pp. 925-929. (doi: 10.1016/j.amjcard.2007.11.037)
Anderson, R.E. et al. (2008) High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 155(4), pp. 706-711. (doi: 10.1016/j.ahj.2007.11.016)
Berry, C., Brett, M., Stevenson, K., McMurray, J.J. and Norrie, J. (2008) Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart, 94(3), pp. 296-304. (doi: 10.1136/hrt.2006.110999)
Bethel, M., Holman, R., Haffner, S., Califf, R., Huntsman-Labed, A., Hua, T. and McMurray, J. (2008) Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal, 156(4), pp. 633-640. (doi: 10.1016/j.ahj.2008.05.018)
Califf, R., Boolell, M., Haffner, S., Bethel, M., McMurray, J. , Duggal, A. and Holman, R. (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 156(4), pp. 623-632. (doi: 10.1016/j.ahj.2008.05.017)
Carrington, M., Murphy, N.F., Strange, G., Peacock, A., McMurray, J.J. and Stewart, S. (2008) Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 124(2), pp. 183-187. (doi: 10.1016/j.ijcard.2006.12.045)
Clark, A.M., Reid, M.E., Morrison, C.E., Capewell, S., Murdoch, D.L. and McMurray, J.J. (2008) The complex nature of informal care in home-based heart failure management. Journal of Advanced Nursing, 61(4), pp. 373-383. (doi: 10.1111/j.1365-2648.2007.04527.x)
Cleland, J. et al. (2008) The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure (10/8/08). Journal of Cardiac Failure, 14(9), pp. 797-798.
Cohen-Solal, A., McMurray, J. , Swedberg, K., Pfeffer, M., Puu, M., Solomon, S., Michelson, E., Yusuf, S. and Granger, C. (2008) Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity programme. European Heart Journal, 29(24), pp. 3022-3028. (doi: 10.1093/eurheartj/ehn476)
Dickstein, K. et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure, 10(10), pp. 933-989. (doi: 10.1016/j.ejheart.2008.08.005)
Dickstein, K. et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 29(19), pp. 2388-2442. (doi: 10.1093/eurheartj/ehn309)
Dickstein, K. et al. (2008) ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008 = [Guía de práctica clínica de la sociedad europea de cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008)]. Revista Espanola de Cardiología (English Edition), 61(12), p. 1329. (doi: 10.1016/S1885-5857(09)60059-1)
Gerstein, H. C., Swedberg, K., Carlsson, J., McMurray, J. J. V. , Michelson, E. L., Olofsson, B., Pfeffer, M. A. and Yusuf, S. (2008) The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Archives of Internal Medicine, 168(15), pp. 1699-1704. (doi: 10.1001/archinte.168.15.1699)
Jhund, P. and McMurray, J. J.V. (2008) Heart failure after acute myocardial infarction: a lost bBattle in the war on heart failure? Circulation, 118(20), pp. 2019-2021. (doi: 10.1161/circulationaha.108.813493)
Kjekshus, J., McMurray, J.J. and Wikstrand, J. (2008) The authors reply. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine, 358(12), p. 1301. (doi: 10.1056/NEJMc073536)
Kober, L., Torp-Pedersen, C., McMurray, J.J. , Gotzsche, O., Levy, S., Crijns, H., Amlie, J., Carlsen, J. and Dronedarone Study, G. (2008) Increased mortality after dronedarone therapy for severe heart failure. New England Journal of Medicine, 358(25), pp. 2678-2687. (doi: 10.1056/NEJMoa0800456)
Lewis, E.F. et al. (2008) Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal, 29(6), pp. 748-756. (doi: 10.1093/eurheartj/ehn062)
MacDonald, M.R., Hawkins, N.M., Balmain, S., Dalzell, J., McMurray, J.J. and Petrie, M.C. (2008) Transthoracic echocardiography: a survey of current practice in the UK. QJM: An International Journal of Medicine, 101(5), pp. 345-349.
MacDonald, M.R. et al. (2008) Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circulation: Heart Failure, 1(4), pp. 234-241. (doi: 10.1161/CIRCHEARTFAILURE.108.794008)
MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Petrie, J.R. , Fisher, M., McKelvie, R., Aguilar, D., Krum, H. and McMurray, J.J.V. (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal, 29(10), pp. 1224-1240. (doi: 10.1093/eurheartj/ehn156)
MacDonald, M.R. et al. (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 29(11), pp. 1377-1385. (doi: 10.1093/eurheartj/ehn153)
Massie, B. et al. (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 359(23), pp. 2456-2467. (doi: 10.1056/NEJMoa0805450)
McMurray, J.J. (2008) ACE inhibitors in cardiovascular disease - Unbeatable? New England Journal of Medicine, 358(15), pp. 1615-1616. (doi: 10.1056/NEJMe0801925)
McMurray, J.J.V., Pitt, B., Latini, R., Maggioni, A.P., Solomon, S.D., Keefe, D.L., Ford, J., Verma, A. and Lewsey, J. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure, 1(1), pp. 17-24. (doi: 10.1161/CIRCHEARTFAILURE.107.740704)
McMurray, J. , Carson, P., Komajda, M., McKelvie, R., Zile, M., Ptaszynska, A., Staiger, C., Donovan, J. and Massie, B. (2008) Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure, 10(2), pp. 149-156. (doi: 10.1016/j.ejheart.2007.12.010)
Meredith, P. et al. (2008) Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 52(24), pp. 2000-2007. (doi: 10.1016/j.jacc.2008.09.011)
Murphy, C.L. and McMurray, J.j. (2008) Approaches to the treatment of anaemia in patients with chronic heart failure. Heart Failure Reviews, 13(4), pp. 431-438. (doi: 10.1007/s10741-008-9085-y)
Pocock, S. J. et al. (2008) Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 29(21), pp. 2641-2650. (doi: 10.1093/eurheartj/ehn420)
Prisant, L.M., Thomas, K.L., Lewis, E.F., Huang, Z., Francis, G.S., Weaver, W.D., Pfeffer, M.A., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2008) Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Journal of the American College of Cardiology, 51(19), pp. 1865-1871. (doi: 10.1016/j.jacc.2007.12.050)
Radauceanu, A. et al. (2008) Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. Journal of Cardiac Failure, 14(6), pp. 467-474. (doi: 10.1016/j.cardfail.2008.02.014)
Remme, W. J. et al. (2008) Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal, 29(14), pp. 1739-1752. (doi: 10.1093/eurheartj/ehn196)
Rocchiccioli, J.P. and McMurray, J. (2008) Medical management of advanced heart failure. Progress in Palliative Care, 16(5-6), pp. 229-240. (doi: 10.1179/096992608X346233)
Solomon, S.D., Pfeffer, M.A., Pocock, S., Marro, J., McMurray, J.J.V. , Granger, C.B., Yusuf, S., Swedberg, K., Young, J.B. and Michelson, E. (2008) Response to letter regarding article, "Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure". Circulation, 118(1), e8. (doi: 10.1161/circulationaha.107.759662)
Stanton, T., Hawkins, N.M., Hogg, K.J., Goodfield, N.E.R., Petrie, M.C. and McMurray, J.J.V. (2008) How should we optimize cardiac resynchronization therapy? European Heart Journal, 29(20), pp. 2458-2472. (doi: 10.1093/eurheartj/ehn380)
Stewart, S., Wilkinson, D., Hansen, C., Vaghela, V., Mvungi, R., McMurray, J. and Sliwa, K. (2008) Predominance of Heart Failure in the Heart of Soweto Study Cohort Emerging Challenges for Urban African Communities. Circulation, 118(23), pp. 2360-2367. (doi: 10.1161/CIRCULATIONAHA.108.786244) (PMID:19029467)
Tardif, J.C. et al. (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 371(9626), pp. 1761-1768. (doi: 10.1016/S0140-6736(08)60763-1)
Taylor, G.L., Murphy, N.F., Berry, C. , Christie, J., Finlayson, A., MacIntyre, K., Morrison, C. and McMurray, J.J. (2008) Long-term outcome of low-risk patients attending a rapid-assessment chest pain clinic. Heart, 94(5), pp. 628-632. (doi: 10.1136/hrt.2007.125344)
Thomas, K.L., Al Khatib, S.M., Lokhnygina, Y., Solomon, S.D., Kober, L., McMurray, J.J. , Califf, R.M. and Velazquez, E.J. (2008) Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal, 155, pp. 87-93. (doi: 10.1016/j.ahj.2007.09.010)
Thune, J.J. et al. (2008) Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension, 51, pp. 48-54. (doi: 10.1161/HYPERTENSIONAHA.107.093682)
Thune, J.J. et al. (2008) Response to the J-point revisited. Hypertension, 51(5), E35-E35. (doi: 10.1161/HYPERTENSIONAHA.108.109975)
Torp-Pedersen, C., Kober, L., Carlsen, J.E., Akkan, D., Bruun, N.E., Dacoronias, D., Dickstein, K., Haghfelt, T., Ohlin, H. and McMurray, J.J. (2008) A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure, 10, pp. 89-95. (doi: 10.1016/j.ejheart.2007.10.012)
Verma, A. et al. (2008) Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial InfarctionThe VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC: Cardiovascular Imaging, 1(5), pp. 582-591. (doi: 10.1016/j.jcmg.2008.05.012)
Weir, R.A.P. et al. (2008) Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. European Journal of Heart Failure, 10(2), pp. 157-163. (doi: 10.1016/j.ejheart.2007.12.006)
Recio-Mayoral, A., Kaski, J.C., McMurray, J.J. , Horowitz, J., van Veldhuisen, D.J. and Remme, W.J. (2007) Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovascular Drugs and Therapy, 21(6), pp. 459-465. (doi: 10.1007/s10557-007-6069-4) (PMID:17992567)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N. , Vallance, P., Hillis, W. S. and McMurray, J. (2007) Corrigendum to “Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker” [European Journal of Heart Failure 9/4 (2007) 429-434]. European Journal of Heart Failure, 9(10), p. 1074. (doi: 10.1016/j.ejheart.2007.08.003)
Kenchaiah, S. et al. (2007) Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation, 116(6), pp. 627-636. (doi: 10.1161/circulationaha.106.679779) (PMID:17638930)
O'Meara, E. et al. (2007) Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation, 115(24), pp. 3111-3120. (doi: 10.1161/CIRCULATIONAHA.106.673442) (PMID:17562950)
Murphy, C.L., Fitzsimons, E.J., Jardine, A.J. , Sattar, N. and McMurray, J.J.V. (2007) 103 routine assessment of iron status in all patients with heart failure may identify those at risk of developing anaemia. European Journal of Heart Failure, 6(1), p. 24. (doi: 10.1016/s1567-4215(07)60065-4)
McMurray, J.J.V. et al. (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS Randomized controlled trials. JAMA: Journal of the American Medical Association, 298(17), pp. 2009-2019. (doi: 10.1001/jama.298.17.2009)
Petrie, M. C. and McMurray, J. J.V. (2007) Dysglycemia and heart failure hospitalization: what is the link? Circulation, 115(11), pp. 1334-1335. (doi: 10.1161/circulationaha.106.685214) (PMID:17372185)
Amigoni, M. et al. (2007) Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal, 28, pp. 326-333. (doi: 10.1093/eurheartj/ehl464)
Balmain, S., Padmanabhan, N., Ferrell, W., Morton, J. and McMurray, J. (2007) Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. European Journal of Heart Failure, 9, pp. 865-871. (doi: 10.1016/j.ejheart.2007.06.003)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N. , Vallance, P., Hillis, W. and McMurray, J. (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. European Journal of Heart Failure, 9, pp. 429-434. (doi: 10.1016/j.ejheart.2006.10.005)
Berry, C. , Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N., Vallance, P., Hillis, W. and McMurray, J. (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker (vol 9, pg 429, 2007). European Journal of Heart Failure, 9, p. 1074.
Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J. , McMorn, S., Roberts, J., Zambanini, A. and Wilding, J. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. Journal of the American College of Cardiology, 49, pp. 1696-1704. (doi: 10.1016/j.jacc.2006.10.077)
Desai, A. et al. (2007) Incidence and predictors of hyperkalemia in patients with heart failure. Journal of the American College of Cardiology, 50, pp. 1959-1966. (doi: 10.1016/j.jacc.2007.07.067)
Dickstein, K., Drexler, H., Mcmurray, J. and Bohm, M. (2007) Abstracts of the Heart Failure Congress 2007 - Hamburg, Germany, 9-12 June, 2007 - Welcome address. European Journal of Heart Failure, 6, IX-IX.
Felker, G. et al. (2007) Red cell distribution width as a novel prognostic marker in heart failure - Data from the CHARM program and the Duke Databank. Journal of the American College of Cardiology, 50, pp. 40-47. (doi: 10.1016/j.jacc.2007.02.067)
Granger, C. and McMurray, J. (2007) Efficacy and safety in clinical trials - Reply. Journal of the American College of Cardiology, 49(6), p. 729. (doi: 10.1016/j.jacc.2006.11.016)
Hawkins, N. et al. (2007) Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart, 93, pp. 59-64. (doi: 10.1136/hrt.2005.083949)
Hawkins, N. et al. (2007) Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. European Journal of Heart Failure, 9, pp. 510-517. (doi: 10.1016/j.ejheart.2006.11.006)
Home, P., Pocock, S., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N., Komajda, M., McMurray, J. and Grp, R. (2007) Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis. New England Journal of Medicine, 357, pp. 28-38. (doi: 10.1056/NEJMoa073394)
Kjekshus, J. et al. (2007) Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine, 357, pp. 2248-2261. (doi: 10.1056/NEJMoa0706201)
Lewis, E. et al. (2007) Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 9(1), pp. 83-91. (doi: 10.1016/j.ejheart.2006.10.012) (PMID:17188020)
McEntegart, M., Awede, B., Petrie, M. , Sattar, N., Dunn, F., MacFarlane, N. and McMurray, J. (2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European Heart Journal, 28, pp. 829-835. (doi: 10.1093/eurheartj/ehm033)
Metra, M. et al. (2007) Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 9, pp. 684-694. (doi: 10.1016/j.ejheart.2007.04.003)
Murphy, A. and McMurray, J. (2007) Heart failure: are we neglecting the silent majority? European Heart Journal, 28(9), pp. 1047-1048.
Murphy, N., Simpson, C., Jhund, P. , Stewart, S., Kirkpatrick, M., Chalmers, J., MacIntyre, K. and McMurray, J. (2007) A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 93, pp. 606-612. (doi: 10.1136/hrt.2006.107573)
Myles, R., Jackson, C., Tsorlalis, I., Petrie, M. , McMurray, J. and Cobbe, S. (2007) Is microvolt T-wave alternans the answer to risk stratification in heart failure? Circulation, 116, pp. 2984-2991. (doi: 10.1161/CIRCULATIONAHA.107.699918) (PMID:18086940)
Peacock, A., Murphy, N., McMurray, J. , Caballero, L. and Stewart, S. (2007) An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal, 30, pp. 104-109. (doi: 10.1183/09031936.00092306)
Pfeffer, M. et al. (2007) An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine, 356(9), pp. 959-961.
Sampson, U., Pfeffer, M., McMurray, J. , Lokhnygina, Y., White, H., Solomon, S. and Valsartan Acute, M. (2007) Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. European Heart Journal, 28, pp. 685-691. (doi: 10.1093/eurheartj/ehl197)
Seed, A., Gardner, R., Mcmurray, J. , Hillier, C., Murdoch, D., MacFadyen, R., Bobillier, A., Mann, J. and McDonagh, T. (2007) Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. European Journal of Heart Failure, 9(11), pp. 1120-1127. (doi: 10.1016/j.ejheart.2007.09.002) (PMID:17945530)
Solomon, S.D. et al. (2007) Response to letter regarding article, "Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas". Circulation, 115(12), e349. (doi: 10.1161/circulationaha.106.675553)
Solomon, S. et al. (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation, 116, pp. 1482-1487. (doi: 10.1161/CIRCULATIONAHA.107.696906)
Stephenson, K. et al. (2007) Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm, 4, pp. 308-313. (doi: 10.1016/j.hrthm.2006.11.021)
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2007) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK (vol 90, pg 282, 2004). Heart, 93(11), p. 1472. (doi: 10.1136/hrt.2002.008748corr1)
Vahanian, A. et al. (2007) Guía de práctica clínica sobre el tratamiento de las valvulopatías = [Guide of clinical practice on the treatment of the valvulopatías]. Revista Espanola de Cardiología, 60(6), e1-e50. (doi: 10.1157/13107119) (PMID:17580051)
van Veldhuisen, D. and McMurray, J. (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. European Journal of Heart Failure, 9(2), pp. 110-112. (doi: 10.1016/j.ejheart.2007.01.004)
van Veldhuisen, D., McMurray, J. and Comm, R. (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial (vol 9, pg 110, 2007). European Journal of Heart Failure, 9(3), p. 323.
Verma, A., Anavekar, N., Meris, A., Thune, J., Arnold, J., Ghali, J., Velazquez, E., McMurray, J. , Pfeffer, M. and Solomon, S. (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction - The VALIANT Echo study. Journal of the American College of Cardiology, 50, pp. 1238-1245. (doi: 10.1016/j.jacc.2007.06.018) (PMID:17888840)
Hawkins, N. M., Petrie, M. C. , MacDonald, M. R., Hogg, K. J. and McMurray, J. J.V. (2006) QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence? European Heart Journal, 27(24), pp. 3074-3075. (doi: 10.1093/eurheartj/ehl386) (PMID:17121753)
Murphy, N.F., Stewart, S., Hart, C. , MacIntyre, K., Hole, D.J. and McMurray, J.J.V. (2006) A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew–Paisley study. Heart, 92(12), pp. 1739-1746. (doi: 10.1136/hrt.2006.090118)
MacDonald, M. R., Hawkins, N. M., McMurray, J. J.V. , Dargie, H. J. and Petrie, M. C. (2006) Is CHARM-added candesartan tolerated in 'real-life” patients with advanced chronic heart failure? Journal of Cardiac Failure, 12(6), S126. (doi: 10.1016/j.cardfail.2006.06.434)
Massie, B., Carson, P., Komajda, M., McKelvie, R., McMurray, J. , Zile, M., Frangin, G. and Ptaszynska, A. (2006) The baseline characteristics of patients enrolled in the irbesartan in heart failure with preserved systolic function trial are similar to those in the community but differ from charm-preserved. Journal of Cardiac Failure, 12(6), S77. (doi: 10.1016/j.cardfail.2006.06.262)
Verma, A., Anavekar, N.S., Meris, A., Thune, J.J., Arnold, J.M.O., Ghali, J.K., Velazquez, E.J., McMurray, J.J.V. , Pfeffer, M.A. and Solomon, S.D. (2006) Renal function and cardiac structure and function following MI: the VALIANT echo study. Journal of Cardiac Failure, 12(6), S26. (doi: 10.1016/j.cardfail.2006.06.093)
Young, J.B. et al. (2006) Reduction of events with darbepoetin alfa in heart failure (RED-HF)™ trial. Journal of Cardiac Failure, 12(6), S77. (doi: 10.1016/j.cardfail.2006.06.264)
Yerra, L., Anavekar, N., Skali, H., Zelenkofske, S., Velazquez, E., McMurray, J. , Pfeffer, M. and Solomon, S. (2006) Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm, 3(3), pp. 313-316. (doi: 10.1016/j.hrthm.2005.11.024) (PMID:16500304)
Murphy, N.F., MacIntyre, K., Stewart, S., Hart, C., Hole, D. and McMurray, J. (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew–Paisley study). European Heart Journal, 27(1), pp. 96-106. (doi: 10.1093/eurheartj/ehi506)
Berry, C. , Norrie, J., Hogg, K., Brett, M., Stevenson, K. and McMurray, J. (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. American Heart Journal, 151(6), pp. 1313-1321.
Capewell, S., Unal, B., Critchley, J. and McMurray, J. (2006) Over 20 000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart, 92(4), pp. 521-523.
Capewell, S., Murphy, N.F., MacIntyre, K., Frame, S., Stewart, S., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A. and McMurray, J.J.V. (2006) Short-term and long-term outcomes in 133 429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart, 92(11), pp. 1563-1570. (doi: 10.1136/hrt.2005.085399)
Ducharme, A. et al. (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 151(5), pp. 985-991.
Granger, C. and McMurray, J. (2006) Using measures of disease progression to determine therapeutic effect - A sirens' song. Journal of the American College of Cardiology, 48(3), pp. 434-437.
Hawkins, N., Petrie, M., MacDonald, M., Hogg, K. and McMurray, J. (2006) QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence? European Heart Journal, 27(24), pp. 3074-3075.
Hawkins, N., Petrie, M., MacDonald, M., Hogg, K. and McMurray, J. (2006) Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony? European Heart Journal, 27(11), pp. 1270-1281.
Hillege, H. et al. (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation, 113, pp. 671-678. (doi: 10.1161/CIRCULATIONAHA.105.580506)
Hogg, K. and McMurray, J. (2006) The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Failure Reviews, 11, pp. 141-146. (doi: 10.1007/s10741-006-9488-6)
Hogg, K. and McMurray, J. (2006) The treatment of heart failure with preserved ejection fraction ('diastolic heart failure'). Heart Failure Reviews, 11(2), pp. 141-146.
Janardhanan, R. et al. (2006) Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. American Heart Journal, 152, pp. 183-189. (doi: 10.1016/j.ahj.2005.11.013)
Jhund, P. and McMurray, J. J.V. (2006) Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? - Choosing between the scylla of observational studies and the charybdis of subgroup analysis. Circulation, 113(22), pp. 2566-2568. (doi: 10.1161/CIRCULATIONAHA.106.629212)
Kauf, T. et al. (2006) The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. American Heart Journal, 151, pp. 206-212. (doi: 10.1016/j.ahj.2005.02.028)
Kober, L. et al. (2006) Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. European Journal of Heart Failure, 8, pp. 591-598. (doi: 10.1016/j.ejheart.2005.11.007)
MacIntyre, K., Murphy, N., Chalmers, J., Capewell, S., Frame, S., Finlayson, A., Pell, J., Redpath, A. and McMurray, J. (2006) Hospital burden of suspected acute coronary syndromes: recent trends. Heart, 92(5), pp. 691-692.
McMurray, J. et al. (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction - An analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology, 47, pp. 726-733. (doi: 10.1016/j.jacc.2005.09.055)
Mcmurray, J. and Swedberg, K. (2006) Treatment of chronic heart failure: a comparison between the major guidelines. European Heart Journal, 27(15), pp. 1773-1777.
McMurray, J. (2006) Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. European Heart Journal, 27(19), pp. 2257-2259.
McMurray, J. et al. (2006) Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 27(12), pp. 1447-1458.
McMurray, J. , Califf, R. and Pfeffer, M. (2006) Of statistical significance: 'Trends' toward significance and optimism bias - Reply. Journal of the American College of Cardiology, 48(7), p. 1471.
McMurray, J. et al. (2006) Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM)-Added trial. American Heart Journal, 151, pp. 985-991. (doi: 10.1016/j.ahj.2006.02.028)
McMurray, J. J.V. (2006) Beta-blockers and heart failure in older people: reply. European Heart Journal, 27(7), pp. 888-889. (doi: 10.1093/eurheartj/ehi786)
McMurray, J. J.V. (2006) Drug safety in cardiovascular disease: A call to ACTION. Cardiovascular Drugs and Therapy, 20(1), pp. 9-10. (doi: 10.1007/s10557-006-6690-7) (PMID:16552471)
McMurray, J. J.V. (2006) Editorial. Drugs in Context, 2(4), p. 139.
Murphy, N.F., Simpson, C.R., MacIntyre, K., McAlister, F.A., Chalmers, J. and McMurray, J.J.V. (2006) Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart, 92(8), pp. 1047-1054. (doi: 10.1136/hrt.2005.069419)
Murphy, N., MacIntyre, K., Stewart, S., Hart, C., Hole, D. and McMurray, J. (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew-Paisley study). European Heart Journal, 27, pp. 96-106. (doi: 10.1093/eurheartj/ehi506)
Murphy, N., Stewart, S., Hart, C., MacIntyre, K., Hole, D. and McMurray, J. (2006) A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew Paisley study. Heart, 92, pp. 1739-1746. (doi: 10.1136/hrt.2006.090118)
O'Meara, E. et al. (2006) Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure - Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation, 113, pp. 986-994. (doi: 10.1161/CIRCULATIONAHA.105.582577)
Olsson, L., Swedberg, K., Ducharme, A., Granger, C., Michelson, E., McMurray, J. , Puu, M., Yusuf, S., Pfeffer, M. and Investigators, C. (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction - Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program. Journal of the American College of Cardiology, 47, pp. 1997-2004. (doi: 10.1016/j.jacc.2006.01.060)
Pitt, B., Ferrari, R., Gheorghiade, M., van Veldhuisen, D.J., Krum, H., McMurray, J. and Lopez-Sendon, J. (2006) Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology, 29(10), pp. 434-438. (doi: 10.1002/clc.4960291004) (PMID:17063946)
Pocock, S. et al. (2006) Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal, 27, pp. 65-75. (doi: 10.1093/eurheartj/ehi555)
Reed, S. et al. (2006) Geographic variation in the treatment of acute myocardial infarction in the VALsartan in acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 152, pp. 500-508. (doi: 10.1016/j.ahj.2006.02.032)
Reid, M., Clark, A., Murdoch, D., Morrison, C., Capewell, S. and McMurray, J. (2006) Patients strategies for managing medication for chronic heart failure. International Journal of Cardiology, 109, pp. 66-73. (doi: 10.1016/j.ijcard.2005.05.051)
Solomon, S. D. et al. (2006) Effect of Celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114(10), pp. 1028-1035. (doi: 10.1161/CIRCULATIONAHA.106.636746) (PMID:16943394)
Stewart, S., Murphy, N., McMurray, J. , Jhund, P. , Hart, C. and Hole, D. (2006) Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. European Journal of Heart Failure, 8, pp. 856-863. (doi: 10.1016/j.ejheart.2006.02.008)
Stewart, S., Wilkinson, D., Becker, A., Askew, D., Ntyintyane, L., McMurray, J. and Sliwa, K. (2006) Mapping the emergence of heart disease in a black, urban population in Africa: The Heart of Soweto Study. International Journal of Cardiology, 108, pp. 101-108. (doi: 10.1016/j.ijcard.2006.01.001)
Stewart, S. and McMurray, J. J.V. (2006) Chilling findings: The need for winter vigilance in heart failure. Journal of Cardiac Failure, 12(2), pp. 120-121. (doi: 10.1016/j.cardfail.2005.12.004) (PMID:16520259)
Tardif, J.C., Pfeffer, M.A., McMurray, J.J.V. , Klug, E., Scott, R., Smith, D.H.G., Smith, J.A. and Small, R.D. (2006) Th-P16:264 impact of a major randomized clinical trial on LDL cholesterol levels in the aggressive reduction of inflammation stops events (ARISE) trial. Atherosclerosis Supplements, 7(3), p. 551. (doi: 10.1016/s1567-5688(06)82222-1)
Valeur, N., Nielsen, O., McMurray, J. , Torp-Pedersen, C., Kober, L. and Grp, T. (2006) Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. European Journal of Heart Failure, 8, pp. 577-584. (doi: 10.1016/j.ejheart.2005.11.017)
Walker, A., McMurray, J. , Stewart, S., Berger, W., McMahon, A., Dargie, H., Fox, K., Hillis, S., Henderson, N. and Ford, I. (2006) Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart, 92, pp. 619-624. (doi: 10.1136/hrt.2003.026385) (PMID:16614274) (PMCID:PMC1860935)
Weir, R.A.P., McMurray, J.J.V. , Taylor, J. and Brady, A.J.B. (2006) Heart failure in older patients. British Journal of Cardiology, 13(4), pp. 257-266.
Weir, R. and McMurray, J. (2006) Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Current Heart Failure Reports, 3(4), pp. 175-180. (doi: 10.1007/s11897-006-0019-5)
Weir, R., McMurray, J. , Granger, C., Puu, M., Ostergren, J., Yusuf, S., Swedberg, K. and Pfeffer, M. (2006) Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial. European Heart Journal, 27(Suppl.),
Weir, R., McMurray, J. and Velazquez, E. (2006) Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: Prevalence, clinical characteristics, and prognostic importance. American Journal of Cardiology, 97, 13F-25F. (doi: 10.1016/j.amjcard.2006.03.005)
Clark, A.M., McMurray, J.J.V. , Morrison, C.E., Murdoch, D.L., Capewell, S. and Reid, M.E. (2005) A qualitative study of the contribution of pharmacists to heart failure management in Scotland. Pharmacy World and Science, 27(6), pp. 453-458. (doi: 10.1007/s11096-005-1637-9)
Demers, C. et al. (2005) Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA: Journal of the American Medical Association, 294(14), pp. 1794-1798. (doi: 10.1001/jama.294.14.1794)
Anavekar, N., McMurray, J. and Pfeffer, M. (2005) Chronic renal disease and cardiovascular risk - Reply. New England Journal of Medicine, 352(2), p. 200.
Berry, C. , Hogg, K., Norrie, J., Stevenson, K., Brett, M. and McMurray, J. (2005) Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart, 91, pp. 907-913. (doi: 10.1136/hrt.2004.041996)
Berry, C. , Norrie, J. and McMurray, J. (2005) Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. Cardiovascular Drugs and Therapy, 19, pp. 149-151. (doi: 10.1007/s10557-005-3405-4)
Blue, L. and McMurray, J. (2005) How much responsibility should heart failure nurses take? European Journal of Heart Failure, 7, pp. 351-361. (doi: 10.1016/j.ejheart.2005.01.005)
Boehm, M., Hjalmarson, A., Kjekshus, J., Laufs, U., McMurray, J. and van Veldhuisen, D.J. (2005) Heart failure and statins - Why do we need a clinical trial? Zeitschrift für Kardiologie, 94(4), pp. 223-230. (doi: 10.1007/s00392-005-0210-9)
Carson, P., Massie, B., McKelvie, R., McMurray, J. , Komajda, M., Zile, M., Ptaszynska, A., Frangin, G. and Investigators, I. (2005) The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design. Journal of Cardiac Failure, 11, pp. 576-585. (doi: 10.1016/j.cardfail.2005.06.432)
Clark, A., McMurray, J., Morrison, C., Murdoch, D., Capewell, S. and Reid, M. (2005) A qualitative study of the contribution of pharmacists to heart failure management in Scotland. Pharmacy World and Science, 27, pp. 453-458. (doi: 10.1007/s11096-005-1637-9)
Cowie, M., Mcmurray, J. , Cleland, J., McDonagh, T. and Pearson, M. (2005) Question and answer session. Heart, 91, p. 31.
Dargie, H. et al. (2005) Determinants of coronary events in patients with stable angina: Results from the Impact of Nicorandil in Angina Study. American Heart Journal, 150, (doi: 10.1016/j.ahj.2005.03.040)
Granger, B., Swedberg, K., Ekman, I., Granger, C., Olofsson, B., McMurray, J. , Yusuf, S., Michelson, E., Pfeffer, M. and Investigators, C. (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet, 366, pp. 2005-2011. (doi: 10.1016/S0140-6736(05)67760-4)
Hogg, K. and Mcmurray, J. (2005) Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases, 47(6), pp. 357-366.
Kjekshus, J., Dunselman, P., Blideskog, M., Eskilson, C., Hjalmarson, A., McMurray, J. , Waagstein, F., Wedel, H., Wessman, P. and Wikstrand, J. (2005) A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. European Journal of Heart Failure, 7(6), pp. 1059-1069. (doi: 10.1016/j.ejheart.2005.09.005)
MacIntrye, I., Jhund, P. and McMurray, J. (2005) Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovascular Drugs and Therapy, 19, pp. 261-265. (doi: 10.1007/s10557-005-3309-3)
Mcmurray, J. (2005) Baseline left ventricular wall thickness after myocardial infarction predicts death or heart failure: Findings from the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U588.
Mcmurray, J. (2005) Extent of coronary artery disease and cardiovascular outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: Findings from the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U568.
Mcmurray, J. (2005) Possible beneficial interaction between statins and combination anglotensin receptor blocker (ARB) and ACE inhibitor treatment in patients with myocardial infarction: A post hoc analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Circulation, 112(17, Su), U545.
Mcmurray, J. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 26(3), pp. 215-225. (doi: 10.1093/eurheartj/ehi115)
McMurray, J. et al. (2005) Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. European Journal of Heart Failure, 7, pp. 710-721. (doi: 10.1016/j.ejheart.2005.07.002)
McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. and Ford, I. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction - Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 45, pp. 525-530.
McMurray, J. (2005) Optimising the use of angiotensin receptor blockers in the management of chronic heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 6, S2-S5.
McMurray, J. , Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, N. and Ford, I. (2005) Antiarrythmic effect of carvedilol after acute myocardial infarction. Journal of the American College of Cardiology, 45(4), pp. 525-530. (doi: 10.1016/j.jacc.2004.09.076)
McMurray, J. (2005) Angiotensin receptor blockers and myocardial infarction - Analysis of evidence is incomplete and inaccurate. British Medical Journal, 330(7502), p. 1269.
McMurray, J. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International, 68(4), pp. 1419-1426.
McMurray, J. (2005) Making sense of SENIORS. European Heart Journal, 26(3), pp. 203-206.
McMurray, J. (2005) Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy? Nature Clinical Practice Cardiovascular Medicine, 2(3), pp. 128-129.
McMurray, J. (2005) The role of angiotensin II receptor blockers in the management of heart failure. European Heart Journal Supplements, 7, J10-J14. (doi: 10.1093/eurheartj/sui057)
McMurray, J. and Pfeffer, M. (2005) Heart failure. Lancet, 365, pp. 1877-1889.
Miller, P., Drummond, M., Langkilde, L., McMurray, J. and Ogren, M. (2005) Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. European Heart Journal Supplements, 7(C), C41-C54.
Mix, T. et al. (2005) Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 149, pp. 408-413. (doi: 10.7016/j.ahj.2004.09.047)
Murphy, N., MacIntyre, K., Stewart, S., Capewell, S. and McMurray, J. (2005) Reduced between-hospital variation in short term survival after acute myocardial infarction: the result of improved cardiac care? Heart, 91, pp. 726-730. (doi: 10.1136/hrt.2004.042929)
O'Meara, E. et al. (2005) Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 7(4), pp. 650-656.
O'Meara, E. and McMurray, J. (2005) Myocardial metabolic manipulation: a new therapeutic approach in heart failure? Heart, 91(2), pp. 131-132.
Packer, M. et al. (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: Results of a pilot study. Journal of Cardiac Failure, 11, pp. 12-20. (doi: 10.1016/j.cardfail.2004.05.006)
Pfeffer, M., Solomon, S., Singh, A., Ivanovich, P. and McMurray, J. (2005) Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med, 6 Supp, S35-S41.
Reed, S. et al. (2005) Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal, 150, pp. 323-329. (doi: 10.1016/j.ahj.2004.08.037)
Remme, W. et al. (2005) Public awareness of heart failure in Europe: first results from SHAPE. European Heart Journal, 26, pp. 2413-2421. (doi: 10.1093/eurheartj/ehi447)
Solomon, S. et al. (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation, 112, pp. 3738-3744. (doi: 10.1161/CIRCULATIONAHA.105.561423)
Solomon, S. et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 352, pp. 1071-1080.
Solomon, S. et al. (2005) Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation, 111(25), pp. 3411-3419.
Solomon, S., Wittes, J., McMurray, J. and Co, A. (2005) Cardiovascular risk associated with celecoxib - The authors reply. New England Journal of Medicine, 352(25), p. 2649.
Solomon, S. et al. (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. New England Journal of Medicine, 352, pp. 2581-2588.
Stewart, S., McAlister, F. and McMurray, J. (2005) Heart failure management programs reduce readmissions and prolong survival. Arch Intern Med, 165(11), p. 1311.
Stewart, S., McMurray, J. , Hebborn, A., Coats, A., Packer, M. and Grp, C. (2005) Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. International Journal of Cardiology, 100, pp. 143-149. (doi: 10.1016/j.ijcard.2004.12.003)
Szummer, K. et al. (2005) Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal, 26, pp. 2114-2119. (doi: 10.1093/eurheartj/ehi352)
Teerlink, J. et al. (2005) Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 150, pp. 46-53. (doi: 10.1016/j.ahj.2005.04.035)
Voors, A., Petrie, C., Petrie, M. , Charlesworth, A., Hillege, H., Zijlstra, F., McMurray, J. and van Veldhuisen, D. (2005) Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. European Heart Journal, 26, pp. 1759-1764. (doi: 10.1093/eurheartj/ehi270)
Weir, R. and McMurray, J. (2005) Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart, 91, pp. 17-20. (doi: 10.1136/hrt.2005.062042)
White, H. et al. (2005) Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction - Results from the Valsartan in Acute Myocardial Infarc. Circulation, 112, pp. 3391-3399. (doi: 10.1161/CIRCULATIONHA.105.551143)
Yusuf, S. et al. (2005) Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation, 112, pp. 48-53. (doi: 10.1161/CIRCULATIONAHA.104.528166)
Murphy, N.F., Stewart, S., MacIntyre, K., Capewell, S. and McMurray, J.J.V. (2004) Seasonal variation in morbidity and mortality related to atrial fibrillation. International Journal of Cardiology, 97(2), pp. 283-288. (doi: 10.1016/j.ijcard.2004.03.041)
Kober, L., Maggioni, A.P., McMurray, J.J. , Velazquez, E.J., Zelenkofske, S., Zannad, F., Van de Werf, F. and Swedberg, K. (2004) Increased risk of both mortality and morbidity with prior as well as current atrial fibrillation after MI: results of VALIANT. Journal of Cardiac Failure, 10(4), S100. (doi: 10.1016/j.cardfail.2004.06.305)
Lewis, E.F. et al. (2004) Heart failure post-myocardial infarction in the new millennium: how often does it occur, can we predict it, and what are the consequences? Journal of Cardiac Failure, 10(4), S101. (doi: 10.1016/j.cardfail.2004.06.309)
Maggioni, A.P., McMurray, J.J.V. , Rouleau, J.L., Velazquez, E.J., Califf, R.M., White, H., Opolski, G. and Pfeffer, M.A. (2004) Who is at risk of early hypotension and renal dysfunction with an inhibitor of the renin angiotensin system after myocardial infarction? data from VALIANT. Journal of Cardiac Failure, 10(4), S89-S90. (doi: 10.1016/j.cardfail.2004.06.262)
Tang, W.H.W., Velazquez, E.J., Kilaru, R., Maroo, A., White, H., Kober, L., Rouleau, J.L., McMurray, J.J.V. , Califf, R.M. and Francis, G.S. (2004) Patterns and outcomes of revascularization in patients with heart failure and/or left ventricular systolic dysfunction following acute myocardial infarction: observations from the VALIANT registry. Journal of Cardiac Failure, 10(4), S104. (doi: 10.1016/j.cardfail.2004.06.321)
Zelenkofske, S., McMurray, J.J.V. , Califf, R.M., Rouleau, J.L., Pfeffer, M.A., Ertl, G., Harsanyi, A. and Solomon, S.D. (2004) Do sudden cardiac death rates warrant earlier treatment following myocardial infarction? experience from the VALIANT Trial. Journal of Cardiac Failure, 10(4), S71. (doi: 10.1016/j.cardfail.2004.06.196)
McMurray, J. J.V. and O'Meara, E. (2004) Treatment of heart failure with spironolactone — trial and tribulations. New England Journal of Medicine, 351(6), pp. 526-528. (doi: 10.1056/NEJMp048144) (PMID:15295043)
Riegel, B., Naylor, M., Stewart, S., McMurray, J.J.V. and Rich, M.W. (2004) Interventions to prevent readmission for congestive heart failure. JAMA: Journal of the American Medical Association, 291(23), p. 2816. (doi: 10.1001/jama.291.23.2816-a)
McAlister, F.A., Murphy, N.F., Simpson, C.R., Stewart, S., MacIntyre, K., Kirkpatrick, M., Chalmers, J., Redpath, A., Capewell, S. and McMurray, J.J.V. (2004) Influence of socioeconomic deprivation on the primary care burden and treatment of patients with a diagnosis of heart failure in general practice in Scotland: population based study. British Medical Journal, 328(7448), pp. 1110-1113. (doi: 10.1136/bmj.38043.414074.EE)
Berry, C., Hogg, K., Stevenson, K., Norrie, J. and McMurray, J. (2004) Relationship between plasma C-reactive protein concentration on admission and long-term outcome in unselected hospitalized heart failure patients. Journal of the American College of Cardiology, 43(5), A229. (doi: 10.1016/s0735-1097(04)90976-x)
Berry, C. and McMurray, J. (2004) 1069-116 Prevalence and importance of renal dysfunction in hospitalized heart failure patients. Journal of the American College of Cardiology, 43(Sup 1), A181. (doi: 10.1016/s0735-1097(04)90770-x)
McMurray, J. J. et al. (2004) 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). Journal of the American College of Cardiology, 43(5), A197. (doi: 10.1016/s0735-1097(04)90836-4)
McMurray, J. J. , Östergren, J., Olofsson, B., Granger, C. B., Michelson, E., Young, J. B., Dunlap, M., Yusuf, S., Swedberg, K. and Pfeffer, M. A. (2004) 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM). Journal of the American College of Cardiology, 43(5), A206. (doi: 10.1016/s0735-1097(04)90878-9)
Hogg, K. J., Rooney, E., Lundmark, E., Christie, J., Newman, E., Kay, D. and McMurray, J. J.V. (2004) What proportion of patients with heart failure and preserved left ventricular systolic function has an elevated plasma concentration of B-type natriuretic peptide? Journal of the American College of Cardiology, 43(5), A241-A242. (doi: 10.1016/s0735-1097(04)91028-5)
Aguilar, D. et al. (2004) Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction - The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 110, pp. 1572-1578. (doi: 10.1161/01.CIR.0000142047.28024.F2)
Anand, I., McMurray, J. , Cohn, J., Konstam, M., Notter, T., Quitzau, K., Ruschitzka, F., Luscher, T. and Investigators, E. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin(A) Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, 364, pp. 347-354.
Anand, I., McMurray, J. , Whitmore, J., Warren, M., Pham, A., McCamish, M. and Burton, P. (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation, 110, pp. 149-154. (doi: 10.1161/01.CIR.0000134279.79571.73)
Anavekar, N. et al. (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine, 351, pp. 1285-1295.
Bunton, D., Petrie, M. , Hillier, C., Johnston, F. and McMurray, J. (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacology and Therapeutics, 103, pp. 179-201. (doi: 10.1016/j.pharmthera.2004.07.002)
Dargie, H. et al. (2004) Impact of nicorandil in angina: subgroup analyses. Heart, 90, pp. 1427-1430. (doi: 10.1136/hrt.2003.026310)
Hogg, K. and McMurray, J. (2004) Treatment of heart failure with preserved systolic function: a review of the evidence. European Heart Journal Supplements, 6(H), H61-H66.
Hogg, K., Swedberg, K. and McMurray, J. (2004) Heart failure with preserved left ventricular Systolic function - Epidemiology clinical characteristics and prognosis. Journal of the American College of Cardiology, 43, pp. 317-327. (doi: 10.1016/j.jacc.2003.09.046)
Hood, W., Dans, A., Guyatt, G., Jaeschke, R. and McMurray, J. (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: A systematic review and meta-analysis. Journal of Cardiac Failure, 10, pp. 155-164. (doi: 10.1016/j.cardfail.2003.12.005)
Jhund, P. , Dawson, N., Davie, A., Norrie, J., O'Kane, K. and McMurray, J. (2004) 17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenopausal women. Cardiovascular Drugs and Therapy, 18, pp. 31-36.
Lopez-Sendon, J. et al. (2004) Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal, 25(15), pp. 1341-1362.
Lopez-Sendon, J. et al. (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease - The task force on ACE-inhibitors of the European Society of Cardiolgy. European Heart Journal, 25(16), pp. 1454-1470.
Lopez-Sendon, J. et al. (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Revista Espanola de Cardiologia, 57(12), pp. 1213-1232.
Mann, D. et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL). Circulation, 109(13), pp. 1594-1602.
McAlister, F., Stewart, S., Ferrua, S. and Mcmurray, J. (2004) Multidisciplinary strategies for the management of heart failure patients at high risk for admission - A systematic review of randomized trials. Journal of the American College of Cardiology, 44(4), pp. 810-819.
McMurray, J.J. (2004) Angiotensin inhibition in heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 5, S17-S22.
McMurray, J.J. (2004) The optimal management of heart failure - Introduction. Journal of the Renin-Angiotensin-Aldosterone System, 5, S1-S1.
McMurray, J. and O'Meara, E. (2004) Treatment of heart failure with spironolactone - Trial and tribulations. New England Journal of Medicine, 351(6), pp. 526-528.
McMurray, J. and Pfeffer, M. (2004) The year in heart failure. Journal of the American College of Cardiology, 44(12), pp. 2398-2405.
McMurray, J. (2004) What are the clinical consequences of anemia in patients with chronic heart failure? Journal of Cardiac Failure, 10, S10-S12. (doi: 10.1016/j.cardfail.2004.01.001)
McMurray, J., Pfeffer, M., Swedberg, K. and Dzau, V. (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation, 110, pp. 3281-3288. (doi: 10.1161/01.CIR.0000147274.83071.68)
Meredith, P.A., Murray, L.S. and McMurray, J.J. (2004) A putative placebo comparison of the SCOPE and LIFE trials. Journal of the Renin-Angiotensin-Aldosterone System, 5, pp. 59-63.
Murphy, N., McMurray, J. and MacIntyre, K. (2004) Discharge rates for suspected acute coronary syndromes - Clinical assessment tools need improving - Reply. British Medical Journal, 329(7458), p. 173.
Murphy, N., MacIntyre, K., Capewell, S., Stewart, S., Pell, J., Chalmers, P., Redpath, A., Frame, S., Boyd, J. and McMurray, J. (2004) Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis. British Medical Journal, 328, pp. 1413-1414.
Murphy, N., Simpson, C., McAlister, F., Stewart, S., MacIntyre, K., Kirkpatrick, M., Chalmers, J., Redpath, A., Capewell, S. and McMurray, J. (2004) National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart, 90, pp. 1129-1136. (doi: 10.1136/hrt.2003.029553)
O'Meara, E., Murphy, C. and McMurray, J. (2004) Anemia and heart failure. Current Heart Failure Reports, 1(4), pp. 176-182.
O'Meara, E., Solomon, S., McMurray, J. , Pfeffer, M., Yusuf, S., Michelson, E., Granger, C., Olofsson, B., Young, J. and Swedberg, K. (2004) Effect of candesartan on New York Heart Association functional class - Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 25, pp. 1920-1926. (doi: 10.1016/j.ehj.2004.07.025)
Petrie, M. , Hogg, K., Caruana, L. and McMurray, J. (2004) Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart, 90, pp. 511-517. (doi: 10.1136/hrt.2003.011403)
Pfeffer, M., McMurray, J. and Califf, R. (2004) Valsartan, captopril, or both in myocardial infarction - Reply. New England Journal of Medicine, 350(9), pp. 944-945.
Remme, W. et al. (2004) Increasing awareness and perception of heart failure in Europe and improving care - Rationale and design of the SHAPE study. Cardiovascular Drugs and Therapy, 18(2), pp. 153-159.
Solomon, S. et al. (2004) Effect of candesartan on cause-specific mortality in heart failure patients - The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation, 110, pp. 2180-2183. (doi: 10.1161/01.CIR.0000144474.65922.AA)
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2004) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart, 90, pp. 286-292. (doi: 10.1136/hrt.2002.008748)
Swedberg, K. and McMurray, J. (2004) Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT? European Heart Journal, 25(5), pp. 357-358.
Velazquez, E.J., Califf, R.M., White, H., Zelenkofske, S., Francis, G.S., Lewis, E.F., Pfeffer, M.A. and McMurray, J. (2004) Is the combination of valsartan and captopril better than captopril alone in patients with heart failure and left ventricular systolic dysfunction after myocardial infarction? results of VALIANT. Journal of Cardiac Failure, 10(4), S76. (doi: 10.1016/j.cardfail.2004.06.213)
Velazquez, E.J., Moreira, M., Rouleau, J.L., Swedberg, K., Kvasnicka, J., Marin-Neto, J.A., Manes, C., Pfeffer, M.A. and McMurray, J. (2004) Does the gender gap still persist after myocardial infarction? Treatments and outcomes in VALIANT. Journal of Cardiac Failure, 10(4), S114. (doi: 10.1016/j.cardfail.2004.06.357)
Velazquez, E. et al. (2004) An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal, 25, pp. 1911-1919. (doi: 10.1016/j.ehj.2004.08.006)
Young, J. et al. (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction - Results of the CHARM low-left ventricular ejection fraction trials. Circulation, 110, pp. 2618-2626. (doi: 10.1161/01.CIR.0000146819.43235.A9)
Ostergren, J. and McMurray, J. J.V. (2003) Angiotensin receptor blockers in heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 4(3), pp. 171-175. (PMID:14608522)
McMurray, J. , Östergren, J., Pfeffer, M., Swedberg, K., Granger, C., Yusuf, S., Held, P., Michelson, E. and Olofsson, B. (2003) Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 5(3), pp. 261-270. (doi: 10.1016/s1388-9842(03)00052-7) (PMID:12798823)
Gurr, E. et al. (2003) The European register for specialists in clinical chemistry and laboratory medicine: guide to the register version 2-2003 and procedure for re-registration. Clinical Chemistry and Laboratory Medicine, 41(2), (doi: 10.1515/cclm.2003.038)
Dunselman, P., Hjalmarson, A., Kjekshus, J., McMurray, J. , Waagstein, F. and Executive Comm, C. (2003) The statin wars. Lancet, 362(9398), p. 1854.
Fisher, C., Al Benna, S., Kirk, A., Morton, J. and McMurray, J. (2003) Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin. Heart, 89(7), pp. 789-790.
Fisher, C., Berry, C. , Blue, L., Morton, J. and McMurray, J. (2003) N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart, 89, pp. 879-881.
Granger, C., McMurray, J. , Yusuf, S., Held, P., Michelson, E., Olofsson, B., Ostergren, J., Pfeffer, M., Swedberg, K. and CHARM Investigators Comm, (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 362, pp. 772-776.
Mcmurray, J. (2003) Effects of newly diagnosed and previously known diabetes mellitus on 1-year outcomes of acute myocardial infarction: The VALIANT Trial. Circulation, 108(17 Sup), IV-745.
Mcmurray, J. (2003) Influence of renal function on one-year cardiovascular outcomes in the VALIANT trial. Circulation, 108(17 Sup), IV-485.
Mcmurray, J. (2003) One-year mortality, stroke, and myocardial infarction rates remain high in the elderly despite beta-blockade plus angiotensin-converting-enzyme inhibition, angiotensin receptor blockade, or both: The VALIANT Trial. Circulation, 108(17 Sup), IV-695.
Mcmurray, J. (2003) Relationship between left ventricular structure and function and plasma neurohormones in patients with heart failure: Results from the EARTH Trial. Circulation, 108(17 Sup), IV-519.
Mcmurray, J. (2003) SHAPE: A Pan-European general public heart failure awareness and perception survey. Circulation, 108(17 Sup), IV-693.
McMurray, J. et al. (2003) Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program. European Journal of Heart Failure, 5, pp. 261-270. (doi: 10.1016/S1388-9842(03)00052-7)
McMurray, J. and Hillier, C. (2003) The rise and fall of myotrophin in heart failure. Journal of the American College of Cardiology, 42(4), pp. 726-727.
McMurray, J. , Pfeffer, M., Swedberg, K., Granger, C. and Yusuf, S. (2003) The CHARM programme - Reply. Lancet, 362(9396), pp. 1678-1679.
McMurray, J. , Ostergren, J., Swedberg, K., Granger, C., Held, P., Michelson, E., Olofsson, B., Yusuf, S., Pfeffer, M. and Comm, C. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362, pp. 767-771.
McMurray, J. and Stewart, S. (2003) The burden of heart failure. European Heart Journal Supplements, 5, pp. 3-13.
Petrie, M. and McMurray, J. (2003) It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. European Journal of Heart Failure, 5(2), pp. 117-119.
Pfeffer, M. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349, pp. 1893-1906.
Pfeffer, M., Swedberg, K., Granger, C., Held, P., McMurray, J. , Michelson, E., Olofsson, B., Ostergren, J., Yusuf, S. and Comm, C. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362, pp. 759-766.
Senior, R., Galasko, G., McMurray, J. and Mayet, J. (2003) Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Heart, 89, pp. 24-28.
Stewart, S., MacIntyre, K., Capewell, S. and McMurray, J. (2003) Heart failure and the aging population: an increasing burden in the 21st century? Heart, 89, pp. 49-53.
Stewart, S., Murphy, N., Walker, A., McGuire, A. and McMurray, J. (2003) The current cost of angina pectoris to the National Health Service in the UK. Heart, 89, pp. 848-853.
Velazquez, E. et al. (2003) VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 5, pp. 537-544.
Yusuf, S., Pfeffer, M., Swedberg, K., Granger, C., Held, P., McMurray, J. , Michelson, E., Olofsson, B., Ostergren, J. and Comm, C. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 362, pp. 777-781. (doi: 10.1016/s0140-6736(03)14285-7)
McMurray, J. (2002) Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 106(20), 147e. (doi: 10.1161/01.cir.0000037125.61227.68) (PMID:12427668)
McMurray, J.J.V. (2002) Heart failure in 10 years time: Focus on pharmacological treatment. Heart, 88(Suppl2), ii40-ii46. (doi: 10.1136/heart.88.suppl_2.ii40) (PMID:12213800) (PMCID:PMC1876267)
Stewart, S., Hart, C. L. , Hole, D. J. and McMurray, J. J.V. (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. American Journal of Medicine, 113(5), pp. 359-364. (doi: 10.1016/S0002-9343(02)01236-6)
Stewart, S., MacIntyre, K., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J.P. , Capewell, S. and McMurray, J.J.V. (2002) Trends in case-fatality in 22 968 patients admitted for the first time with atrial fibrillation in Scotland, 1986–1995. International Journal of Cardiology, 82(3), pp. 229-236. (doi: 10.1016/s0167-5273(01)00626-x) (PMID:11911910)
Berry, C. and Mcmurray, J. (2002) CHF: a GP guide to management. Practitioner, 246(1639), 669-72, 675.
Berry, C. and McMurray, J. (2002) Editorial comment - Amlodipine for all undergoing PCI? The evidence is unconvincing. International Journal of Cardiology, 84(1), pp. 30-32.
Berry, C., Davie, A., Mcmurray, J. and Schmitz, G. (2002) Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease. HMG-COA Reductase Inhibitors, pp. 135-147.
Byrne, J., Murdoch, D., Morrison, C. and McMurray, J. (2002) An audit of activity and outcome from a daily and a weekly "one stop" rapid assessment chest pain clinic. Postgraduate Medical Journal, 78, pp. 43-46.
Byrne, J., Murdoch, D., Morrison, C. and McMurray, J. (2002) An audit of activity and outcome from a daily and a weekly 'one stop' rapid assessment chest pain clinic. Postgraduate Medical Journal, 78(915), pp. 43-46.
Davie, A. and McMurray, J. (2002) Cost-effectiveness of invasive strategy in unstable coronary disease - what are we waiting for? European Heart Journal, 23(1), pp. 1-3.
Davie, A. and McMurray, J. (2002) Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. British Journal of Clinical Pharmacology, 53, pp. 37-42.
De Vito, G., Galloway, S., Nimmo, M., Maas, P. and McMurray, J. (2002) Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans. Clinical Physiology and Functional Imaging, 22, pp. 32-38.
Fisher, C., MacLean, M., Morecroft, I., Seed, A., Johnston, F., Hillier, C. and McMurray, J. (2002) Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation, 106, pp. 292-295. (doi: 10.1161/01.CIR.0000025630.05387.45)
Fisher, C. and McMurray, J. (2002) Current management of heart failure. Practitioner, 246(1635), pp. 438-443.
Krum, H. and McMurray, J. (2002) Statins and chronic heart failure: Do we need a large-scale outcome trial? Journal of the American College of Cardiology, 39, pp. 1567-1573.
McMurray, J. and Pfeffer, M. (2002) New therapeutic options in congestive heart failure - Part II. Circulation, 105, pp. 2223-2228. (doi: 10.1161/01.CIR.0000014771.38666.22)
McMurray, J. and Pfeffer, M. (2002) New therapeutic options in congestive heart failure: Part I. Circulation, 105, pp. 2099-2106. (doi: 10.1161/01.CIR.0000014763.63528.9D)
McMurray, J. , Struthers, A. and Mcmurray, J. (2002) The role of the specialist nurse - Question and answer session. Heart, 88, p. 35.
McMurray, J. and Pfeffer, M. A. (2002) New therapeutic options in congestive heart failure: part II. Circulation, 105(18), pp. 2223-2228. (doi: 10.1161/01.cir.0000014771.38666.22) (PMID:11994259)
Packer, M., Califf, R., Konstam, M., Krum, H., McMurray, J. , Rouleau, J., Swedberg, K. and Grp, O. (2002) Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation, 106, pp. 920-926. (doi: 10.1161/01.CIR.0000029801.86489.50)
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J. , Rouleau, J.-L. and Swedberg, K. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation, 106(8), pp. 920-926. (doi: 10.1161/01.cir.0000029801.86489.50) (PMID:12186794)
Pell, J. P. , MacIntyre, K., Walsh, D. , Capewell, S., McMurray, J.J. , Chalmers, J.W., Boyd, J.H., Finlayson, A.R., Stewart, S. and Redpath, A.D. (2002) Time trends in survival and readmission following coronary artery bypass grafting in Scotland, 1981-96: retrospective observational study. British Medical Journal, 324, pp. 201-202. (doi: 10.1136/bmj.324.7331.201)
Petrie, M., Caruana, L., Berry, C. and McMurray, J. (2002) 'Diastolic heart failure' or heart failure caused by subtle left ventricular systolic dysfunction? Heart, 87(1), pp. 29-31.
Petrie, M. , Caruana, L., Berry, C. and McMurray, J. (2002) "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart, 87, pp. 29-31.
Pfeffer, M. and McMurray, J. (2002) Myocardial infarct - No one size fits all. Circulation, 105(22), pp. 2577-2579.
Seed, A., Hillier, C., Berry, C., Johnston, F., Brown, A., Petrie, M. and McMurray, J. (2002) Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition. Clinical Science, 103(1), 13P.
Seed, A., Hillier, C., Berry, C., Johnston, F., Petrie, M. and McMurray, J. (2002) Evidence that a novel orally active NEP/ECE inhibitor blocks the vasoconstrictor response to big endothelin in human resistance arteries. Clinical Science, 103(1), 14P.
Stewart, S., Blue, L., Walker, A., Morrison, C. and McMurray, J. (2002) An economic analysis of specialist heart failure nurse management in the UK - Can we afford not to implement it? European Heart Journal, 23, pp. 1369-1378. (doi: 10.1053/euhj.2001.3114)
Stewart, S., Demers, C., Murdoch, D., McIntyre, K., MacLeod, M., Kendrick, S., Capewell, S. and McMurray, J. (2002) Substantial between-hospital variation in outcome following first emergency admission for heart failure. European Heart Journal, 23, pp. 650-657. (doi: 10.1053/euhj.2001.2890)
Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S. and McMurray, J. (2002) The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure, 4, pp. 361-371.
Stewart, S., MacIntyre, K., Chalmers, J., Boyd, J., Finlayson, A., Redpath, A., Pell, J., Capewell, S. and McMurray, J. (2002) Trends in case-fatality in 22,968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. International Journal of Cardiology, 82, pp. 229-236.
Stewart, S., McIntyre, K., Capewell, S. and McMurray, J. (2002) Heart failure in a cold climate - Seasonal variation in heart failure-related morbidity and mortality. Journal of the American College of Cardiology, 39, pp. 760-766.
Stewart, S. and McMurray, J. (2002) Palliative care for heart failure - Time to move beyond treating and curing to improving the end of life. British Medical Journal, 325(7370), pp. 915-916.
Berry, C. and McMurray, J. (2001) Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. American Journal of Medicine, 111(7), p. 587. (doi: 10.1016/S0002-9343(01)00927-5)
Stewart, S., Hart, C.L. , Hole, D.J. and McMurray, J.J.V. (2001) Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart, 86(5), pp. 516-521. (doi: 10.1136/heart.86.5.516)
Capewell, S., MacIntyre, K., Stewart, S., Chalmers, J. W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J. P. and McMurray, J. J.V. (2001) Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986–95: a retrospective cohort study. Lancet, 358(9289), pp. 1213-1217. (doi: 10.1016/s0140-6736(01)06343-7) (PMID:11675057)
Hood, W.B., Dans, A., Guyatt, G.H., Jaeschke, R. and McMurray, J. (2001) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Nursing Times, 97(34), p. 40. (PMID:11957658)
Stewart, S. and McMurray, J.J.V. (2001) Older and more complicated heart failure patients: an increasing challenge to the health care system! Coronary Health Care, 5(3), pp. 121-125. (doi: 10.1054/chec.2001.0115)
McMurray, J. J.V. (2001) Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? Journal of the Renin-Angiotensin-Aldosterone System, 2(2), pp. 89-92. (doi: 10.3317/jraas.2001.017) (PMID:11881104)
Hood, W.B., Dans, A.L., Guyatt, G.H., Jaeschke, R. and McMurray, J.J.V. (2001) Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews, CD002901. (doi: 10.1002/14651858.CD002901) (PMID:11279775)
Jhund, P. S. , Davie, A. P. and McMurray, J. J.V. (2001) Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. Journal of the American College of Cardiology, 37(5), pp. 1234-1238. (doi: 10.1016/S0735-1097(01)01169-X) (PMID:11300428)
Jhund, P. S. , Dawson, N., Davie, A. P., Sattar, N. , Norrie, J., O’Kane, K. P.J. and McMurray, J. J.V. (2001) Attenuation of endothelin-1 induced vasoconstriction by 17β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 37(5), pp. 1367-1373. (doi: 10.1016/s0735-1097(01)01168-8) (PMID:11300448)
Coats, P., Johnston, F., MacDonald, J., McMurray, J. J.V. and Hillier, C. (2001) Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation, 103(12), pp. 1702-1708. (doi: 10.1161/01.CIR.103.12.1702) (PMID:11274000)
Bacquet, P. et al. (2001) Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). European Heart Journal, 22, pp. 1021-1031.
Berry, C. , Anderson, N., Kirk, A., Dominiczak, A. and McMurray, J. (2001) Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart, 86(2), pp. 217-220. (doi: 10.1136/heart.86.2.217)
Berry, C., Brosnan, M., Alexander, M., Hamilton, C., McMurray, J. and Dominiczak, A.F. (2001) Mechanisms of oxidative free radical generation in human arteries. Clinical Science, 101(2), 7P.
Berry, C. and McMurray, J. (2001) Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart, 85(4), E8.
Berry, C. and McMurray, J. (2001) Undertreatment of heart failure has high cost to patients. British Medical Journal, 322(7288), pp. 731-732.
Berry, C. , Murdoch, D. R. and McMurray, J. J.V. (2001) Economics of chronic heart failure. European Journal of Heart Failure, 3(3), pp. 283-291. (doi: 10.1016/S1388-9842(01)00123-4) (PMID:11377998)
Berry, C. , Norrie, J. and McMurray, J. J.V. (2001) Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. American Journal of Cardiology, 87(5), pp. 606-607. (doi: 10.1016/S0002-9149(00)01439-9) (PMID:11230847)
Berry, C. , Stewart, S., Payne, E. M., McArthur, J. D. and McMurray, J. J.V. (2001) Electrical cardioversion for atrial fibrillation: outcomes in 'real-life' clinical practice. International Journal of Cardiology, 81, pp. 29-35. (doi: 10.1016/S0167-5273(01)00522-8) (PMID:11690662)
Blue, L. et al. (2001) Randomised controlled trial of specialist nurse intervention in heart failure. British Medical Journal, 323, pp. 715-718. (doi: 10.1136/bmj.323.7315.715)
Capewell, S., MacIntyre, K., Stewart, S., Chalmers, J., Boyd, J., Finlayson, A., Redpath, A., Pell, J. and McMurray, J. (2001) Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet, 358, pp. 1213-1217.
Caruana, L., Petrie, M. C. , McMurray, J. j. and MacFarlane, N. G. (2001) Altered diaphragm position and function in patients with chronic heart failure. European Journal of Heart Failure, 3(2), pp. 183-187. (doi: 10.1016/S1388-9842(00)00133-1) (PMID:11246055)
Coats, P., Johnston, F., MacDonald, J., McMurray, J. and Hillier, C. (2001) Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries. Cardiovascular Research, 49, pp. 828-837.
Coats, P., Johnston, F., MacDonald, J., McMurray, J. and Hillier, C. (2001) Endothelium-derived hyperpolarizing factor - Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation, 103, pp. 1702-1708.
Davie, A.P., Rumley, A., Lowe, G.D.O. and McMurray, J.J.V. (2001) Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure. Thrombosis and Haemostasis, 86(6), pp. 1585-1586. (PMID:11776334)
Fisher, C., Johnston, F., Hillier, C. and McMurray, J. (2001) Relaxin, a newly described cardiac hormone, is a more potent vasodilator than atrial natriuretic factor in human resistance arteries. Circulation, 104(17 Sup), II.
Hillier, C., Berry, C. , Petrie, M. C. , O'Dwyer, P. J., Hamilton, C., Brown, A. and McMurray, J. (2001) Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103, pp. 1378-1381. (doi: 10.1161/01.CIR.103.10.1378) (PMID:11245639)
Hillier, C., Petrie, M. , Love, M. P., Johnston, F., MacLean, M. R. and McMurray, J. J.V. (2001) Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clinical Science, 101, pp. 45-51. (doi: 10.1042/cs1010045) (PMID:11410113)
Love, M.P. and McMurray, J.J.V. (2001) Endothelin receptor antagonists and cardiovascular diseases of aging. Drugs and Aging, 18(6), pp. 425-440. (PMID:11419917)
Luscher, T.F., Ruschitzka, F., Anand, I., Konstam, M.A., McMurray, J. , Notter, T. and Cohn, J.N. (2001) EARTH: EndothelinA receptor antagonist trial in heart failure. Rationale and design. Heartdrug, 1(6), pp. 294-298. (doi: 10.1159/000048978)
MacIntyre, K., Stewart, S., Capewell, S., Chalmers, J., Pell, J., Boyd, J., Finlayson, A., Redpath, A., Gilmour, H. and McMurray, J. (2001) Gender and survival: A population-based study of 201,114 men and women following a first acute myocardial infarction. Journal of the American College of Cardiology, 38, pp. 729-735.
MacIntyre, K., Stewart, S. and McMurray, J. (2001) Is prognosis improving in heart failure? Cardiology Review, 18(7), pp. 29-35.
MacIntyre, K., Stewart, S., Chalmers, J., Pell, J., Finlays, A., Boyd, J., Redpath, A., McMurray, J. and Capewell, S. (2001) Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. British Medical Journal, 322, pp. 1152-1153. (doi: 10.1136/bmj.322.7295.1152)
McDonagh, T., Cunningham, A., Morrison, C., McMurray, J. , Ford, I. , Morton, J. and Dargie, H. (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart, 86, pp. 21-26.
McDonald, J., Petrie, M., Padmanabhan, N., Hillier, C., Connell, J. and McMurray, J. (2001) Non-ace mediated angiotensin II production. Clinical Science, 100(2), 8P.
McDonald, J., Padmanabhan, N., Petrie, M., Hillier, C., Connell, J. and McMurray, J. (2001) Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(D)(11)-Ala(12)] angiotensin I in human dorsal hand veins - In vivo demonstration of non-ACE production of angiotensin II in humans. Circulation, 104, pp. 1805-1808.
McDonald, J. E., Padmanabhan, N., Petrie, M. C. , Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Vasoconstrictor Effect of the Angiotensin-Converting Enzyme-Resistant, Chymase-Specific Substrate [Pro11D-Ala12] Angiotensin I in Human Dorsal Hand Veins: In Vivo Demonstration of Non-ACE Production of Angiotensin II in Humans. Circulation, 104(15), pp. 1805-1808. (doi: 10.1161/hc4001.097220) (PMID:11591618)
Mcmurray, J. (2001) Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: Evidence from the CAPRICORN study. Circulation, 104(17 Sup), II.
Mcmurray, J. (2001) An economic analysis of specialist heart failure nurse management in the UK: Can we afford not to implement it? Circulation, 104(17 Sup), II.
Mcmurray, J. (2001) Endothelium-derived hyperpolarizing factor in human pressurised small subcutaneous resistance arteries may be a product of phospholipase A2 and cytochrome P450 metabolism. British Journal of Pharmacology, 133(Procee), 67P.
Mcmurray, J. (2001) The incidence and natural history of heart failure during 20-year follow-up of 15,406 men and women: The Renfrew/Paisley Study. Circulation, 104(17 Sup), II.
Mcmurray, J. , Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, R., Maggioni, A., Pina, I., Soler-Soler, J. and Swedberg, K. (2001) Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure, 3(4), pp. 495-502.
McMurray, J. (2001) Reduced costs with bisoprolol treatment for heart failure: An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). European Heart Journal, 22(12), pp. 1021-1031.
McMurray, J. (2001) What is suspected heart failure with preserved left ventricular systolic function? Reply. British Medical Journal, 322(7280), p. 239.
McMurray, J. J.V. (2001) Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart, 86(1), pp. 97-103. (doi: 10.1136/heart.86.1.97) (PMID:11410575) (PMCID:PMC1729819)
Morris, S., McMurray, J. , Spiers, A. and Jardine, A. (2001) Impaired endothelial function in isolated human uremic resistance arteries. Kidney International, 60, pp. 1077-1082.
Murdoch, D. R., McDonagh, T. A., Farmer, R., Morton, J. J., McMurray, J. J.V. and Dargie, H. j. (2001) ADEPT: Addition of the AT(1) receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. American Heart Journal, 141, pp. 800-807. (doi: 10.1067/mhj.2001.114802) (PMID:11320369)
Petrie, M.C. , Hillier, C., Johnston, F. and McMurray, J.J.V. (2001) Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. Hypertension, 38, pp. 412-416. (doi: 10.1161/01.HYP.38.3.412) (PMID:11566914)
Petrie, M.C. , McDonald, J.E., Hillier, C., Morton, J.J. and McMurray, J.J.V. (2001) Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. British Journal of Clinical Pharmacology, 52(2), pp. 165-168. (doi: 10.1046/j.0306-5251.2001.01428.x) (PMID:11488773)
Petrie, M. and McMurray, J. J.V. (2001) Changes in notions about heart failure. Lancet, 358(9280), pp. 432-434. (doi: 10.1016/S0140-6736(01)05664-1) (PMID:11513900)
Petrie, M. C. , Padmanabhan, N., McDonald, J. E., Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. Journal of the American College of Cardiology, 37(4), pp. 1056-1061. (doi: 10.1016/S0735-1097(01)01111-1) (PMID:11263608)
Petrie, M. , Berry, C., Stewart, S. and McMurray, J. (2001) Failing ageing hearts. European Heart Journal, 22, pp. 1978-1990. (doi: 10.1053/euhj.2000.2558)
Seed, A., Love, M. P. and McMurray, J. J.V. (2001) Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Reviews, 6(4), pp. 317-323. (doi: 10.1023/A:1011408425878) (PMID:11447306)
Seed, A. and McMurray, J. (2001) Acute endothelin A receptor blockade in heart failure. Circulation, 103(18), E94-E94. (doi: 10.1161/01.CIR.103.18.e94) (PMCID:11342484)
Stewart, S., Blue, L., Capewell, S., Horowitz, J.D. and McMurray, J.J. (2001) Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. European Journal of Heart Failure, 3(2), pp. 249-255. (doi: 10.1016/S1388-9842(00)00144-6)
Stewart, S., MacIntyre, K., Hole, D.J., Capewell, S. and McMurray, J.J.V. (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure. European Journal of Heart Failure, 3(3), pp. 315-322. (doi: 10.1016/S1388-9842(00)00141-0)
Stewart, S., MacIntyre, K., MacLeod, M.M.C., Bailey, A.E.M., Capewell, S. and McMurray, J.J.V. (2001) Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. European Heart Journal, 22(8), pp. 693-701. (doi: 10.1053/euhj.2000.2511)
Stewart, S., MacIntyre, K., MacLeod, M.M.C., Bailey, A.E.M., Capewell, S. and McMurray, J.J.V. (2001) Trends in hospitalization for heart failure in Scotland, 1990-1996 - An epidemic that has reached its peak? European Heart Journal, 22(3), pp. 209-217. (doi: 10.1053/euhj.2000.2291)
Pfeffer, M. A. et al. (2000) Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. American Heart Journal, 140(5), pp. 727-750. (doi: 10.1067/mhj.2000.108832) (PMID:11054617)
Shah, M. R. et al. (2000) Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. American Journal of Medicine, 109(6), pp. 489-492. (doi: 10.1016/s0002-9343(00)00529-5) (PMID:11042239)
McMurray, J. (2000) AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment. Heart, 84(90001), 42i-45. (doi: 10.1136/heart.84.suppl_1.i42) (PMID:10956322) (PMCID:PMC1766530)
Jhund, P. S. , McMurray, J. J.V. and Davie, A. P. (2000) The acute vascular effects of frusemide in heart failure. British Journal of Clinical Pharmacology, 50(1), pp. 9-13. (doi: 10.1046/j.1365-2125.2000.00219.x)
McMurray, J. (2000) Why we need new strategies in CHF management. Journal of the Renin-Angiotensin-Aldosterone System, 1(1), pp. 12-16. (doi: 10.3317/jraas.2000.027) (PMID:11967787)
McMurray, J. (2000) Digoxin and heart failure. Lancet, 355(9197), p. 69. (doi: 10.1016/s0140-6736(05)72013-4) (PMID:10615915)
Berry, C., Brosnan, M.J., Alexander, Y.M., Hamilton, C.A., Dominiczak, A.F. and McMurray, J.J.V. (2000) Angiotensin II increases superoxide production in human arteries. Heart, 83(S1), p. 6.
Capewell, S., Livingston, B.M., MacIntyre, K., Chalmers, J.W.T., Boyd, J., Finlayson, A., Redpath, A., Pell, J.P., Evans, C.J. and McMurray, J.J.V. (2000) Trends in case-fatality in 117718 patients admitted with acute myocardial infarction in Scotland. European Heart Journal, 21(22), pp. 1833-1840. (doi: 10.1053/euhj.2000.2318)
Capewell, S. and McMurray, J. (2000) "Chest pain---please admit": is there an alternative?. A rapid cardiological assessment service may prevent unnecessary admissions. British Medical Journal, 320(7240), pp. 951-952. (doi: 10.1136/bmj.320.7240.951) (PMID:10753127) (PMCID:PMC1117892)
Caruana, L., Petrie, M.C. , Davie, A.P. and McMurray, J. (2000) Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. British Medical Journal, 321, pp. 215-218. (doi: 10.1136/bmj.321.7255.215)
Dudley, N., Berry, C. and McMurray, J. (2000) Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data. British Medical Journal, 321(7261), p. 638. (doi: 10.1136/bmj.321.7261.638) (PMID:11023330) (PMCID:PMC1118517)
Evans, C., Chalmers, J., Capewell, S., Redpath, A., Finlayson, A., Boyd, J., Pell, J. , McMurray, J. , MacIntyre, K. and Graham, L. (2000) "I don't like Mondays"--day of the week of coronary heart disease deaths in Scotland: study of routinely collected data. British Medical Journal, 320(7229), pp. 218-219. (doi: 10.1136/bmj.320.7229.218) (PMID:10642230) (PMCID:PMC32257)
Galloway, S. D.R., De Vito, G., McClure, S., Nimmo, M. A. and McMurray, J. J.V. (2000) Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans. Clinical Science, 99(3), pp. 223-230. (doi: 10.1042/cs19990329) (PMID:11787475)
Love, M. P., Haynes, W. G., Webb, D. J. and McMurray, J. J.V. (2000) Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 98(1), pp. 65-70. (doi: 10.1042/cs19990174) (PMID:10600660)
McMurray, J. (2000) Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems. European Heart Journal, 21(15), pp. 1214-1215. (doi: 10.1053/euhj.2000.2257) (PMID:10924310)
McMurray, J. (2000) Heart failure: we need more trials in typical patients. European Heart Journal, 21(9), pp. 699-700. (doi: 10.1053/euhj.1999.1974) (PMID:10739720)
McMurray, J. J. and Stewart, S. (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart, 83(5), pp. 596-602. (doi: 10.1136/heart.83.5.596) (PMID:10768918) (PMCID:PMC1760825)
Morris, S. T.W., McMurray, J. J.V. , Rodger, R. S. C., Farmer, R. and Jardine, A. G. (2000) Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney International, 57(3), pp. 1100-1106. (doi: 10.1046/j.1523-1755.2000.00937.x) (PMID:10720962)
Petrie, M. C. , Hillier, C., Morton, J. and McMurray, J. J.V. (2000) Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. Journal of Hypertension, 18(1), pp. 61-64. (doi: 10.1097/00004872-200018010-00009) (PMID:10678544)
Berry, C. and McMurray, J.J.V. (1999) Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. International Journal of Cardiology, 71(3), pp. 263-264. (doi: 10.1016/s0167-5273(99)00170-9)
Berry, C. and McMurray, J. (1999) A review of quality-of-life evaluations in patients with congestive heart failure. PharmacoEconomics, 16(3), pp. 247-271. (doi: 10.2165/00019053-199916030-00003) (PMID:10558038)
Darnley, G. M., Gray, A. C., McClure, S. J., Neary, P., Petrie, M. , McMurray, J. J.V. and MacFarlane, N. G. (1999) Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. European Journal of Heart Failure, 1(3), pp. 297-300. (doi: 10.1016/s1388-9842(99)00027-6) (PMID:10935679)
McMurray, J. (1999) Transmyocardial laser re vascularisation. Lancet, 353(9165), p. 1704. (doi: 10.1016/s0140-6736(99)00087-2) (PMID:10335808)
Petrie, M. C. , Dawson, N. F., Murdoch, D. R., Davie, A. P. and McMurray, J. J.V. (1999) Failure of women's hearts. Circulation, 99(17), pp. 2334-2341. (doi: 10.1161/01.CIR.99.17.2334) (PMID:10226101)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. , Dargie, H. J. and Morton, J. J. (1999) EndothelinB receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology, 33(4), pp. 932-938. (doi: 10.1016/s0735-1097(98)00663-9) (PMID:10091818)
Northridge, D. B., Currie, P. F., Newby, D. E., McMurray, J. J.V. , Ford, M., Boon, N. A. and Dargie, H. J. (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. European Journal of Heart Failure, 1(1), pp. 67-72. (doi: 10.1016/s1388-9842(98)00003-8) (PMID:10937982)
Petrie, M. C. , McClure, S. J., Love, M. P. and McMurray, J. J.V. (1999) Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1(1), pp. 25-29. (doi: 10.1016/s1388-9842(98)00013-0) (PMID:10937975)
Morris, S.T.W., McMurray, J.J.V. , Rodger, R.S.C., Briggs, J.D. and Jardine, A.G. (1999) Impaired vascular responsiveness to nitric oxide in renal transplant recipients. Transplantation Proceedings, 31(1-2), pp. 304-305. (doi: 10.1016/s0041-1345(98)01637-6) (PMID:10083118)
Hillier, C., Cowburn, P.J., Morton, J.J., Dargie, H.J., Cleland, J.G.F., McMurray, J.J.V. and McGrath, J.C. (1999) Structural and functional assessment of small arteries in patients with chronic heart failure. Clinical Science, 97(6), pp. 671-679. (doi: 10.1042/cs19990166) (PMID:10585894)
McMurray, J.J. , Petrie, M.C. , Murdoch, D.R. and Davie, A.P. (1998) Clinical epidemiology of heart failure: public and private health burden. European Heart Journal, 19 Sup, P9-16. (PMID:9886707)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. and Dargie, H. J. (1998) Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet, 352(9123), pp. 201-202. (doi: 10.1016/s0140-6736(05)77807-7) (PMID:9683214)
Davie, A.P., Caesar, D., Caruana, L., Clegg, G., Spiller, J., Capewell, S., Starkey, I.R., Shaw, T.R. and McMurray, J.J.V. (1998) Outcome from a rapid-assessment chest pain clinic. QJM: An International Journal of Medicine, 91(5), pp. 339-343. (doi: 10.1093/qjmed/91.5.339) (PMID:9709467)
Grant, S., McMurray, J. , Aitchison, T., McDonagh, T., Christie, J., Davie, A. and Dargie, H.J. (1998) The reproducibility of symptoms during a submaximal exercise test in chronic heart failure. British Journal of Clinical Pharmacology, 45(3), pp. 287-290. (doi: 10.1046/j.1365-2125.1998.00682.x) (PMID:9517373)
McDonagh, T.A., Morrison, C.E., McMurray, J.J. and Dargie, H.J. (1998) Left-ventricular dysfunction. Lancet, 351(9099), pp. 371-372. (doi: 10.1016/s0140-6736(05)78299-4)
McDonagh, T., Robb, S.D., Murdoch, D.R., Morton, J.J., Ford, I. , Morrison, C.E., Tunstall-Pedoe, H., McMurray, J. and Dargie, H. (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet, 351(9095), pp. 9-13. (doi: 10.1016/S0140-6736(97)03034-1)
Cowburn, P. J., Cleland, J. G.F., McArthur, J. D., MacLean, M. R., McMurray, J. J.V. and Dargie, H. J. (1998) Pulmonary and systemic responses to exogenous endothelin-1 in patients with left ventricular dysfunction. Journal of Cardiovascular Pharmacology, 31(Sup 1), S290-S293. (doi: 10.1097/00005344-199800001-00081) (PMID:9595462)
McMurray, J. , Davie, A.P. and McClure, S.J. (1998) Assessment of heart failure with plasma natriuretic peptides. Lancet, 351(9100), p. 444. (doi: 10.1016/s0140-6736(05)78386-0) (PMID:9482327)
Caro, J., Klittoch, W., McGuire, A., Ford, I. , Norrie, J., Pettitt, D., McMurray, J. and Shepherd, J. (1997) The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. British Medical Journal, 315, pp. 1577-1582. (doi: 10.1136/bmj.315.7122.1577)
Clark, A.L., Galloway, S., MacFarlane, N., Henderson, E., Aitchison, T. and McMurray, J.J.V. (1997) Catecholamines contribute to exertional dyspnoea and to the ventilatory response to exercise in normal humans. European Heart Journal, 18(11), pp. 1829-33. (doi: 10.1093/oxfordjournals.eurheartj.a015179) (PMID:9402459)
McDonagh, T.A., Morrison, C.E., Lawrence, A., Ford, I. , Tunstall-Pedoe, H., McMurray, J.J.V. and Dargie, H.J. (1997) Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet, 350(9081), pp. 829-833. (doi: 10.1016/S0140-6736(97)03033-X)
Garner, M., Reglinski, J., Smith, W. E., McMurray, J. , Abdullah, I. and Wilson, R. (1997) A 1 H spin echo and 51 V NMR study of the interaction of vanadate with intact erythrocytes. Journal of Biological Inorganic Chemistry, 2(2), pp. 235-241. (doi: 10.1007/s007750050129)
McMurray, J. and Murdoch, D. (1997) Calcium-antagonist controversy: the long and short of it? Lancet, 349(9052), pp. 585-586. (doi: 10.1016/s0140-6736(05)61561-9) (PMID:9057725)
McMurray, J. and Davie, A.P. (1997) Digoxin for patients with heart failure in sinus rhythm. Lancet, 350(9076), p. 519. (doi: 10.1016/s0140-6736(05)63111-x) (PMID:9274604)
Murdoch, D. R., Byrne, J., McDonagh, T., Morton, J. J. and McMurray, J. J.V. (1996) Measurement of brain natriuretic peptide. Lancet, 348(9041), p. 1589. (doi: 10.1016/s0140-6736(05)66206-x) (PMID:8950904)
Davie, A. and McMurray, J. (1996) Open-access echocardiography. Lancet, 348(9038), p. 1387. (doi: 10.1016/s0140-6736(05)65456-6) (PMID:8918303)
Love, M. P. and McMurray, J. J.V. (1996) Endothelin in chronic heart failure: current position and future prospects. Cardiovascular Research, 31(5), pp. 665-674. (doi: 10.1016/s0008-6363(96)00055-7) (PMID:8763394)
Laycock, S.K., Kane, K.A., McMurray, J. and Parratt, J.R. (1996) Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. Journal of Cardiovascular Pharmacology, 27(5), pp. 667-672. (doi: 10.1097/00005344-199605000-00008) (PMID:8859936)
Dargie, H.J., McMurray, J.J.V. and McDonagh, T. (1996) Heart failure - implications of the true size of the problem. Journal of Internal Medicine, 239(4), pp. 309-315. (doi: 10.1046/j.1365-2796.1996.461800000.x) (PMID:8774385)
Laycock, S. K., McMurray, J. , Kane, K. A. and Parratt, J. R. (1995) Effects of chronic norepinephrine administration on cardiac function in rats. Journal of Cardiovascular Pharmacology, 26(4), pp. 584-589. (doi: 10.1097/00005344-199510000-00012) (PMID:8569219)
Russell, J., Ness, J., Chopra, M., McMurray, J. and Smith, W.E. (1994) The assessment of the HO· scavenging action of therapeutic agents. Journal of Pharmaceutical and Biomedical Analysis, 12(7), pp. 863-866. (doi: 10.1016/0731-7085(94)e0022-s) (PMID:7981313)
Laycock, S. K., McMurray, J. , Kane, K. A. and Parratt, J. R. (1993) Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. Free Radical Biology and Medicine, 15(3), pp. 249-255. (doi: 10.1016/0891-5849(93)90071-2) (PMID:8406124)
McMurray, J. and McInnes, G. T. (1992) The J-curve hypothesis. Lancet, 339(8792), pp. 561-562. (doi: 10.1016/0140-6736(92)90390-o) (PMID:1346917)
Chopra, M., Beswick, H., Clapperton, M., Dargie, H.J., Smith, W.E. and McMurray, J. (1992) Antioxidant effects of Angiotensin-Converting Enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. Journal of Cardiovascular Pharmacology, 19(3), pp. 330-340. (doi: 10.1097/00005344-199203000-00005)
McMurray, J. , Dargie, H., Hall, A., Tan, L., Gray, D., Ball, S., Cruickshank, J.M., Roy-Chaudhury, P., Khan, I. and Catto, G.D. (1992) ACE inhibitors for myocardial infarction and unstable angina. Lancet, 340(8834-8), pp. 1547-1549. (doi: 10.1016/0140-6736(92)92803-n) (PMID:1361633)
MacFarlane, N., McMurray, J. , O'Dowd, J. J., Dargie, H. J. and Miller, D. J. (1991) Synergism of histidyl dipeptides as antioxidants. Journal of Molecular and Cellular Cardiology, 23(11), pp. 1205-1207. (doi: 10.1016/0022-2828(91)90077-Y) (PMID:1803015)
McMurray, J. , Lang, C.C., MacLean, D., Struthers, A.D. and McDevitt, D.G. (1991) Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. International Journal of Cardiology, 31(3), pp. 295-303. (doi: 10.1016/0167-5273(91)90380-8) (PMID:1679047)
McMurray, J. , MacLenachan, J. and Dargie, H. J. (1991) Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. Journal of Hypertension, 9(5), pp. 393-397. (doi: 10.1097/00004872-199105000-00002)
McMurray, J. , McLenachan, J. and Dargie, H. J. (1991) Angiotensin converting enzyme inhibitors [reply]. Journal of Hypertension, 9(11), pp. 1075-1076. (doi: 10.1097/00004872-199111000-00016)
McMurray, J. J. , Lang, C. C., MacLean, D., McDevitt, D. G. and Struthers, A. D. (1990) Neuroendocrine changes post myocardial infarction: effects of xamoterol. American Heart Journal, 120(1), pp. 56-62. (doi: 10.1016/0002-8703(90)90160-y) (PMID:1972861)
McMurray, J. , McLay, J., Chopra, M., Bridges, A. and Belch, J.J.F. (1990) Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 65(18), pp. 1261-1262. (doi: 10.1016/0002-9149(90)90985-a) (PMID:2337039)
McMurray, J. , Chopra, M., Stewart, J., Blaney, S., Ewen Smith, W. E. and Dargie, H. J. (1990) Does free radical generation occur in unstable angina? Journal of Molecular and Cellular Cardiology, 22(S3), S120. (doi: 10.1016/0022-2828(90)91883-9)
Ray, S., McMurray, J. , Dargie, H. J. and Morton, J. (1990) Dissociation of endothelin and atrial natriuretic factor after acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 22(Sup 3), S34. (doi: 10.1016/0022-2828(90)91629-l)
Reglinski, J., Chopra, M., McMurray, J. , Dargie, H. J. and Smith, W. E. (1990) Demonstration of oxidative stress across cell membranes in chronic heart failure using 1H spin echo NMR spectroscopy of intact erythrocytes. Journal of Molecular and Cellular Cardiology, 22(Sup 3), S99. (doi: 10.1016/0022-2828(90)91820-w)
Chopra, M., McMurray, J. , Dargie, H.J. and Smith, W.E. (1990) Antioxidant potential of -SH containing angiotensin converting enzyme (ACE) inhibitors. Free Radical Biology and Medicine, 9(Sup 1), p. 151. (doi: 10.1016/0891-5849(90)90714-t)
Chopra, M., Reglinski, J., McMurray, J. and Smith, W.E. (1990) Evidence of oxidative stress across membranes in chronic heart failure using 1H spin echo NMR spectroscopy. Free Radical Biology and Medicine, 9(Sup 1), p. 89. (doi: 10.1016/0891-5849(90)90488-5)
McMurray, J. , McFarlane, L., Coutie, W., Balfour, D. and Struthers, A. (1989) Atrial natriuretic factor attenuates prostaglandin E2-stimulated plasma renin activity in humans. Journal of Cardiovascular Pharmacology, 14(2), pp. 326-330. (doi: 10.1097/00005344-198908000-00021) (PMID:2476609)
McMurray, J. J. and Dargie, H. J. (1989) Neurohumoral aspects of heart failure. Current Opinion in Cardiology, 4(3), pp. 355-359. (doi: 10.1097/00001573-198906000-00004)
McMurray, J. , Forsling, M. L. and Struthers, A. D. (1988) Arginine vasopressin dissociates the diuresis and natriuresis due to atrial natriuretic factor in man. European Journal of Clinical Investigation, 18(6), pp. 627-632. (doi: 10.1111/j.1365-2362.1988.tb01278.x) (PMID:2975995)
McMurray, J. , Coutie, W.J.R., McFarlane, L. and Struthers, A.D. (1988) Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man. European Journal of Clinical Pharmacology, 35(4), pp. 409-412. (doi: 10.1007/BF00561373)
McMurray, J. and Struthers, A.D. (1988) Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. European Journal of Clinical Pharmacology, 35(4), pp. 333-338. (doi: 10.1007/BF00561360) (PMID:2973989)
McMurray, J. and Struthers, A.D. (1988) Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man. Clinical Science, 74(4), pp. 419-425. (doi: 10.1042/cs0740419)
McMurray, J. J. and Struthers, A. D. (1988) Captopril in patients with ileus. Lancet, 331(8583), p. 471. (doi: 10.1016/S0140-6736(88)91260-3)
McMurray, J. , Seidelin, P.H. and Struthers, A.D. (1988) Intrarenal sites of action of atrial natriuretic factor in man. British Journal of Clinical Pharmacology, 25(5), 630P.
McMurray, J. and Struthers, A.D. (1988) The place of ACE inhibitors in the current treatment of chronic heart failure. Postgraduate Medical Journal, 64(755), pp. 653-655. (doi: 10.1136/pgmj.64.755.653)
McMurray, J. and Struthers, A.D. (1988) Significance of atrial natriuretic factor in chronic heart failure. British Journal of Hospital Medicine, 40(1), pp. 55-57.
McMurray, J. , Seidelin, P. H., Howey, J. E.A., Balfour, D. J. and Struthers, A. D. (1988) The effect of atrial natriuretic factor on urinary albumin and β2-microglobulin excretion in man. Journal of Hypertension, 6(10), pp. 783-786.
McMurray, J. J. , Seidelin, P. H., Balfour, D. J.K. and Struthers, A. D. (1988) Physiological increases in circulating noradrenaline are antinatriuretic in man. Journal of Hypertension, 6(9), pp. 757-761. (PMID:3183378)
Lawson, A., McMurray, J. and Northridge, D.B. (1987) Association between liberalization of Scotland's liquor licensing laws and admissions for self poisoning. British Medical Journal (Clinical Research Ed.), 294(6568), pp. 371-372. (PMID:3101883) (PMCID:PMC1245373)
McMurray, J. and Matthews, D.M. (1987) Consequences of fluid loss in patients treated with ACE inhibitors. Postgraduate Medical Journal, 63(739), pp. 385-387. (doi: 10.1136/pgmj.63.739.385) (PMID:2823245) (PMCID:PMC2428483)
McMurray, J. and Struthers, A.D. (1987) The role of neuroendocrine abnormalities in the enhanced sodium and water retention of chronic heart failure. Pharmacology and Toxicology, 61(4), pp. 209-214. (doi: 10.1111/j.1600-0773.1987.tb01805.x) (PMID:3324091)
McMurray, J.J. , Fraser, D.M. and Brogan, O. (1987) Fatal Streptococcus pyogenes pneumonia. Journal of the Royal Society of Medicine, 80(8), pp. 525-526. (doi: 10.1177/014107688708000821) (PMID:3309306)
McMurray, J.J. , Northridge, D.B., Abernathy, V.A. and Lawson, A.A.H. (1987) Trends in analgesic self-poisoning in West-Fife, 1971-1985. QJM: An International Journal of Medicine, 65(246), pp. 835-843. (PMID:3449888)
McMurray, J.J. , Seidelin, P.H. and Fraser, D.M. (1987) Hyperglycaemic non-ketotic focal epilepsy. Practical Diabetes, 4(2), pp. 78-79. (doi: 10.1002/pdi.1960040210)
McMurray, J.J. and Struthers, A.D. (1987) Renal effects of angiotensin II, atrial natriuretic peptide and their interaction in man. Journal of Hypertension, 5(S5), S59-S62. (PMID:2965232)
Northridge, D.B., McMurray, J. , Colledge, N.R. and Fraser, D.M. (1987) Hypertensive hypertrophic cardiomyopathy of the elderly. British Journal of Hospital Medicine, 38(6), p. 567. (PMID:3435805)
McMurray, J. and Fraser, D.M. (1986) Captopril, enalapril, and blood glucose. Lancet, 327(8488), p. 1035. (doi: 10.1016/S0140-6736(86)91304-8) (PMID:2871313)
McMurray, J. , Bloomfield, P. and Miller, H.C. (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. British Medical Journal (Clinical Research Ed.), 292(6515), pp. 239-240. (doi: 10.1136/bmj.292.6515.239-a) (PMID:3081088)
McMurray, J. , Bloomfield, P. and Miller, H.C. (1986) Irreversible pulmonary hypertension after treatment with fenfluramine. British Medical Journal (Clinical Research Ed.), 293(6538), pp. 51-52. (doi: 10.1136/bmj.293.6538.51-d) (PMID:3089403)
McMurray, J. and Fraser, D. M. (1986) Pneumonia. Postgraduate Medical Journal, 62(731), p. 895. (doi: 10.1136/pgmj.62.731.895) (PMCID:PMC2422815)
McMurray, J. and Matthews, D. M. (1986) Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. Heart, 56(5), p. 490. (doi: 10.1136/hrt.56.5.490-a) (PMCID:PMC1236903)
Northridge, D.B., McMurray, J. and Lawson, A.A.H. (1986) Association between liberalization of Scotland's liquor licensing laws and admissions for self poisoning in West Fife. British Medical Journal, 293(6560), pp. 1466-1468. (doi: 10.1136/bmj.293.6560.1466) (PMID:3099914) (PMCID:PMC1342238)
McMurray, J. and Matthews, D. M. (1985) Effect of diarrhoea on a patient taking captopril. Lancet, 325(8428), p. 581. (doi: 10.1016/S0140-6736(85)91240-1) (PMID:2857931)
Books
Fisher, M. and McMurray, J. J. eds. (2007) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd. ISBN 9780470862049 (doi: 10.1002/9780470723807)
Book Sections
Khder, Y., Shi, V., McMurray, J. J.V. and Lefkowitz, M. P. (2016) Sacubitril/valsartan (LCZ696) in heart failure. In: Handbook of Experimental Pharmacology. Springer. (doi: 10.1007/164_2016_77)
McMurray, J. J.V. and Pfeffer, M. A. (2012) Heart failure: management and prognosis. In: Goldman, L. and Schafer, A. I. (eds.) Goldman's Cecil Medicine. Elsevier Saunders: Philadelphia, Pa, pp. 303-318. ISBN 9781437716047 (doi: 10.1016/B978-1-4377-1604-7.00059-2)
Hawkins, N. M., Petrie, M. C. and McMurray, J. J.V. (2011) Selecting patients for cardiac resynchronization therapy: Electrical or mechanical dyssynchrony? In: Cardiac Resynchronization Therapy in Heart Failure. Wolters Kluwer Health. ISBN 9780781798440
Rocchiccioli, J. P. and McMurray, J. J.V. (2010) Epidemiology and prevention of heart failure and management of asymptomatic left ventricular systolic dysfunction. In: Yusuf, S., Cairns, J. A., Camm, A. J., Fallen, E. L. and Gersh, B. J. (eds.) Evidence-Based Cardiology. Wiley-Blackwell: Chichester, pp. 735-755. ISBN 9781405159258
Rocchiccioli, J. P. and McMurray, J. J.V. (2008) Heart failure—optimal pharmacological therapy. In: Beattie, J. and Goodlin, S. (eds.) Supportive Care in Heart Failure. Series: Supportive care series. Oxford University Press: Oxford ; New York, pp. 49-74. ISBN 9780198570288 (doi: 10.1093/acprof:oso/9780198570288.003.0004)
Berry, C. , Fisher, M. and McMurray, J. J. (2007) Coronary heart disease and diabetes. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 37-67. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch3)
Berry, C. , Fisher, M. and McMurray, J. J. (2007) Diabetes and acute coronary syndromes. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 69-92. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch4)
MacDonald, M. R., Petrie, M. C. , Hawkins, N. M. and McMurray, J. J. (2007) Diabetes, left ventricular systolic dysfunction and chronic heart failure. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 93-134. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch5)
Conference or Workshop Item
Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Individualised Care from Early Risk of Cardiovascular Disease to Established Heart Failure
Innovate EU Guarantee
2023 - 2028
- Uncovering Patterns in Aggregated Datasets to Accelerate Personalizing Treatment of Heart Failure
American Heart Association (AHA)
2018 - 2019
- The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomized, double blinded active-comparator cardiac-MR based trial
British Heart Foundation
2017 - 2020
- How do arrhythmias and conduction disturbances contribute to death or rehospitalisation in patients discharged following an admission with acute heart failure? A prospective, observational, multi-centre cohort-study
British Heart Foundation
2017 - 2022
- Aggregating Data to Accelerate Personalization of the Treatment of Heart Failure
American Heart Association
2017 - 2019
- British Society for Heart Failure (BSH) Research Fellow
British Society for Heart Failure
2016 - 2018
- Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction
Chief Scientist Office
2016 - 2019
- Trends in infective endocarditis incidence, prevalence, and mortality in Scotland between 1986-2015
NHS Greater Glasgow and Clyde
2016 - 2017
- Longitudinal strain in patients admitted to hospital with heart failure: diagnostic utility and prognosis prediction (G47097 (14REF012CH03 CAMPBELL))
NHS Greater Glasgow and Clyde
2015 - 2016
- BHF centre of excellence
British Heart Foundation
2014 - 2019
- Palliative Care Needs in Patients with Heart Failure
British Heart Foundation
2013 - 2016
- Diuretics, Worsening Renal Function and Cardiorenal Outcomes in Heart Failure
European Society for Cardiology
2013 - 2013
- Clopidogrel compared to Aspirin in Chronic Heart failure (CACHE)"
Department of Health
2010 - 2015
- Effect of metformin on progression of carotid atherosclerosis in non-diabetic patients with CHD optimally treated with conventional risk reducing agents
Scottish Executive Health Department
2008 - 2012
- Microvolt T-wave alternans in chronic heart failure: a study of prevalence and incremental prognostic value.
Scottish Executive Health Department
2007 - 2009
- Microvolt T-wave alternans in chronic heart failure: a study of prevalence and incremental prognostic value.
NHS Endowment Funds
2007 - 2008
- Preventing hospitalisation early death from chronic heart failure in Primary Care:A randomised controlled trial of pharmacist-led medication review
Greater Glasgow Primary Care NHS Trust
2007 - 2009
- Stroke in Scotland 1986-2004:epidemiology and impact on population and health care
Scottish Executive Health Department
2007 - 2009
- Hydralazine in heart failure - a study of the mechanisms of action in human blood vessels
British Heart Foundation
2006 - 2009
- Long term consequences of socioeconomic deprivation on cardiovascular outcomes: a 25 year follow up of the Renfrew / Paisley
Scottish Executive Health Department
2005 - 2008
- High Fidelity Phenotyping combined with genomics, proteomics and metabonomics close to the patient
British Heart Foundation
2004 - 2008
- Can guiding medical treatment by measurement of blood N-terminal pro BNP concentration improve outcome in chronic heart failure?
British Heart Foundation
2004 - 2006
- Muscle wasting in chronic heart failure - a role for cyclin-dependent kinase inhibitors
British Heart Foundation
2003 - 2005
Supervision
